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Chapter 1
Introduction 
Hepatitis is defined as the structural changes in the liver that arise as a result from an 
inflammatory stimulus. Histological, it is characterized by the presence of inflammatory cells 
in the tissue of the liver. Hepatitis runs a dichotomous course. Either it is self-limiting with 
complete reversal of pathological changes or it can progress to fibrosis (scarring) and cirrhosis. 
Hepatitis may occur with limited or no symptoms, but in advanced stages it often leads to 
jaundice, anorexia (poor appetite), and malaise. Persistence of hepatitis for more than six 
months is classified as chronic hepatitis. Hepatitis caused by a hepatitis virus (for example 
hepatitis B, C, and D virus) are responsible for the overall majority of hepatitis cases 
worldwide. Hepatitis may also be caused by toxic substances (for example alcohol and 
medications), other infections, and autoimmune diseases.[1]  
This thesis focuses mainly on autoimmune hepatitis, hepatitis delta, and hepatitis C infection 
and the therapeutic options for these hepatological disorders. The last 20 years have 
witnessed an impressive development of clinical care options for patients with various forms 
of hepatitis. This progress has come through development of drugs but also by improvement 
of non-medical devices such as stents. Especially in the area of chronic hepatitis C the number 
of new antiviral drugs is increasing rapidly.  These new drugs lead to the question how to best 
use them for which patient and for which (phase of the) medical condition. This progress leads 
to many questions and as such clinicians more and more rely on results stemming from 
evidence based medicine. Evidence based medicine is the explicit and judicious use of current 
best evidence and clinical expertise in making decisions about the care of patients. As such, 
it requires the integration of individual clinical expertise with best evidence that is present 
in the literature. The "best evidence" usually stems from randomized clinical trials that 
compare the efficacy of a therapy with standard-of-care or placebo in a well-defined patient 
population.  
There is little doubt that evidence based medicine has its merits. Well executed clinical trials 
provide new evidence that helps decision making in clinical practice. When we are introducing 
new therapies that replace old well known management options we must be certain that these 
options are more powerful, more efficacious, more accurate, and last but not least also safe. 
There is an uneven penetration of evidence based medicine within hepatological disorders. 
For some forms of hepatitis, for example hepatitis C infection, there is a wealth of clinical 
information from well executed randomized trials available that are helpful to assist the 
clinician. For other disorders such as hepatitis D, or autoimmune hepatitis there is a paucity 
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of evidence. In addition, trials have been executed differently and they differ in 
methodological quality which contributes to the lack of powerful data that help us in clinical 
decision making. Most of the executed trials included only few patients. Moreover, trials 
performed decades ago have not used current standardized, universally accepted end-points 
or diagnostic criteria. Without any doubt, most trials included some forms of bias, which lead 
to uncertainties and different treatment results. 
In order to progress it is of eminent importance to start to collect the information that is 
available that best summarizes the current clinical thinking. In this respect, evidence based 
medicine can be used as method for clinical problem solving. It may provide us with ways of 
determining rational practice, methods to integrate service to our patients with training and 
education, and it may act as a model to generate ideas to improve care through research. 
This thesis focuses mainly on a selection of questions in the three types of hepatitis 
mentioned, autoimmune hepatitis, hepatitis delta, and hepatitis C virus infection. In general, 
we addressed these questions by performing systematic reviews. In addition, we collected 
information on the quality of the performed randomized clinical trials which were included in 
our systematic reviews with an aim to make recommendations on how to optimize new clinical 
trials in the hepatitis field in the future. 
 
Autoimmune hepatitis 
Epidemiology/Pathogenesis 
Autoimmune hepatitis is a rare chronic progressive liver disease of unknown etiology.[2] 
Clinical presentation may include fatigue, pain in the right upper quadrant of the abdomen, 
polymyalgia, and arthralgia involving small joints.[2] The disease predominantly affects 
women and occurs in children and adults of all ages. The estimated annual incidence of 
autoimmune hepatitis among Northern Europeans is 1.9 cases per 100,000 persons per year.[2, 
3] The clinical picture is heterogeneous and in absence of a single clinical or biochemical test, 
diagnosis is made according to a set of clinical criteria developed in 1993, which were revised 
in 1999 and simplified in 2008.[4-6] These diagnostic criteria include (1) 
hypergammaglobulinemia; (2) the presence of particular autoantibodies, i.e., antinuclear 
antibodies (ANA), smooth muscle antibodies (SMA) or liver kidney microsomal antibodies (anti-
LKM1); (3) liver histology features similar to chronic hepatitis of other etiology; (4) the 
absence of viral and toxic hepatitis or other conditions that may resemble autoimmune 
hepatitis.[6, 7] According to the presence of autoantibodies, a sub classification into two 
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major types – Type 1 autoimmune hepatitis and type 2 autoimmune hepatitis – has been 
proposed. Type 1 autoimmune hepatitis is the most common form of the disease, it is 
characterized by the presence of ANA and/or SMA. Type 2 autoimmune hepatitis is associated 
with the presence of anti-LKM1.[8] 
The pathogenesis of autoimmune hepatitis is uncertain, but it probably involves a cell-
mediated form of cytotoxicity. An unknown virus, drug or environmental toxin may be the 
triggering factor or the disease may occur spontaneously.[9] 
Treatment 
Ten-year survival has ranged from 85% to 95%.[10-13] Recent long-term studies reporting a 2-
fold higher mortality than that of the general population.[14, 15] Treatment with 
predniso(lo)ne, usually in combination with azathioprine, dramatically improved survival and 
is considered the mainstay of therapy for autoimmune hepatitis.[16] This therapy originates 
from the 1970s, when three randomized clinical trials have established the effect of 
immunosuppressive therapy for autoimmune hepatitis.[16-18] Predniso(lo)ne monotherapy or 
a combination of predniso(lo)ne and azathioprine was superior to other treatment options, 
including titrating prednisone, in improving liver function and life expectancy. [16-18] 
However, in some cases cirrhosis develops despite treatment. In other patients, treatment 
discontinuation or dose reduction is necessary because of intolerable adverse events.  
This thesis addresses the question: what is the optimal induction and subsequent maintenance 
therapy for autoimmune hepatitis? We therefore performed a systematic review and examined 
all randomized clinical trials for treatment of autoimmune hepatitis published from 1950 until 
July 2009 (model). We hypothesized that therapy of predniso(lo)ne with or without 
azathioprine is more effective than other (immunosuppressive) drugs in achieving remission 
and limiting mortality.  
 
Hepatitis delta  
Epidemiology/Pathogenesis 
Hepatitis delta virus was first identified in 1977 in serum of hepatitis B surface antigen (HBsAg) 
carriers, during a major outbreak of hepatitis delta in the Mediterranean basin.[19, 20] 
Hepatitis delta is a parenterally transmitted ribonucleic acid (RNA – HDV RNA) virus that 
requires hepatitis B virus surface proteins to form the viral coat and to infect hepatocytes. 
Worldwide, 15-20 million people are estimated to be anti-hepatitis delta virus positive.[21, 
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22] However, it is possible that these estimates are inaccurate and difficult to determine as 
systematic screening is not performed in hepatitis b-infected individuals, especially if they 
present with normal liver enzymes.[23] The prevalence of hepatitis delta infection in 
industrialized countries has declined as a result of anti-hepatitis B virus vaccination; however, 
epidemiologic data show that hepatitis delta-related diseases persist in several regions of the 
world.[20] Hepatitis delta infection can be distributed in eight genotypes. Each genotype has 
a unique geographical representation.[24-32] 
 
Hepatitis delta is spread and bears the same transmission risk as hepatitis B, through 
parenteral or sexual exposure to blood or body fluids. Infection with hepatitis delta can occur 
in two major patterns: as co-infection and as superinfection. Both patterns of infection may 
lead to chronic liver disease and progression to cirrhosis in 80% of infected patients.[33-39] 
Treatment 
The ultimate goal of treatment is to eradicate hepatitis delta together with hepatitis B. 
Hepatitis delta is considered eradicated when both HDV RNA in the serum and HDAg in the 
liver become persistently undetectably. However, it is only with HBsAg clearance that 
complete and definitive resolution is attained. Viral clearance is accompanied with 
normalization of the alanine aminotransferase (ALT) level, amelioration of liver inflammation, 
while the progression of liver fibrosis stops. This is the ultimate treatment goal, however, 
with current means treatment remains difficult. Interferon-alpha is the only therapy that 
bears some efficacy against hepatitis delta. Indeed anecdotal evidence suggest that in isolated 
cases virological, biochemical, and histological response may be obtained.[40-43] Randomized 
clinical trials conducted so far have failed to show that (combination) therapy with ribavirin, 
famcyclovir, lamivudine, levamisole, and thymosin have an improved efficacy compared to 
interferon-alpha monotherapy.[44-49]  
At the outset of this thesis, high dose of recombinant standard interferon-alpha was the 
preferred option for experts dealing with these patients. Although pegylated interferon-alpha 
(peg interferon-alpha) is significantly superior to standard interferon-alpha for treatment of 
both chronic hepatitis B and C, its superiority has not been elucidated in the hepatitis delta 
therapy.[50, 51] 
Since there appears to be an important therapeutic role or (peg) interferon-alpha therapy in 
the treatment of hepatitis delta, an in depth assessment of the evidence that supports 
efficacy and safety of interferon-alpha based strategies in hepatitis delta is warranted.  
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To this end, we wanted to address the question what the available evidence for interferon-
alpha in hepatitis delta therapy currently is? Therefore, we performed a systematic review 
and examined all randomized clinical trials that investigated interferon-alpha-based 
treatment in hepatitis delta published from 1970 until January 2011 (model). We hypothesized 
that peg interferon-alpha therapy is more effective than treatment with interferon-alpha in 
achieving undetectable levels of HDV RNA and normal levels of ALT.  
 
Hepatitis C infection 
Epidemiology/Pathogenesis 
Hepatitis C virus infection was first described in 1989.[52] Presence of hepatitis C virus RNA 
(HCV RNA) for more than 6 months delineates a chronic hepatitis C infection. It is thought 
that chronic hepatitis C affects around 3%, i.e. 170 million individuals worldwide.[53-55] The 
prevalence in The Netherlands varies between 0.1-0.4%.[56, 57] European prevalence rates, 
especially in southern European countries are somewhat higher (0.4-4%).[58]  
At least 6 different hepatitis C genotypes (1-6) and several subtypes (a, b, etc.) have been 
identified.[59] Globally, genotype 1 to 4 are the most common causes of chronic hepatitis 
C.[59] In The Netherlands, ~50% of chronic hepatitis C is caused by genotype 1a and 1b, ~30% 
by genotype 3, whereas genotype 2 and 4 both account for ~10% of chronic hepatitis C infected 
patients. Genotype 5 and 6 are uncommon in The Netherlands.[60-62] 
Hepatitis C infection is a leading cause of mortality and liver-related morbidity with hepatic 
fibrosis, end-stage liver cirrhosis, and hepatocellular carcinoma as the dominant clinical 
sequelae.[54] Hence, prevention of progression is important. Chronic hepatitis C infection 
progresses slowly, over a time frame of 15 years to 50 years. Around 10-20% of all infected 
individuals will develop end-stage liver disease (cirrhosis).[63-68] In cirrhotic hepatitis C 
infected patients, the annual occurrence of hepatocellular carcinoma is 1% to 4%.[69] 
Treatment 
Prevention of progression to development of cirrhosis is possible with targeted antiviral 
treatment. Successful antiviral treatment is defined as reaching a sustained virological 
response (SVR), that is, clearance of HCV RNA from the blood six months after stopping 
treatment. Unfortunately, current antiviral therapy does not reach SVR in 100% of treated 
patients. 
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According to guidelines, antiviral therapy for chronic hepatitis C infection, consist of a 
combination of peg interferon-alpha and ribavirin for all genotypes.[70, 71] The regimen may 
include either peg interferon-alpha-2b (Peg-Intron®) or peg interferon-alpha-2a (Pegasys®). 
Both agents are administered subcutaneously with weekly intervals.[72] The optimal dose of 
peg interferon-alpha-2b is 1.5 µg/kg/week.[72] Peg interferon-alpha-2a is administered at a 
fixed dose of 180 µg weekly.[72] Ribavirin is an oral therapy with weight-based total daily 
doses between 800 mg and 1200 mg administered twice per day.[73] Forty percent to 80% of 
chronic hepatitis C infected patients without co-infection with hepatitis B virus or human 
immunodeficiency virus will achieve SVR after treatment with peg interferon-alpha and 
ribavirin.[72, 74]  
Treatment for chronic hepatitis C underwent a paradigm shift with the introduction of a new 
class of antiviral drugs for hepatitis C virus genotype 1. These antiviral agents act directly, 
inhibiting the nonstructural (NS) NS3/N4A serine protease and NS5B polymerase of the 
hepatitis C virus. The direct-acting antivirals (DAAs) can alone or in combination with peg 
interferon-alpha and ribavirin (triple therapy) increase sustained virological response rates. 
From April 2012 onwards two DAAs boceprevir (Victrelis®) and telaprevir (Incivo®) have been 
allowed on the market in The Netherlands and are reimbursed by the health insurance 
companies for the treatment of chronic hepatitis C genotype 1 infection in adults with 
compensated liver disease (including cirrhosis). These two DAAs which have to be given in 
combination with peg interferon-alpha and ribavirin, can increase SVR rates considerably, 
from 40-50% to 70% or above.[75-79] Currently, phase III clinical trials with drugs such as 
ledipasvir, daclatasvir, and sofosbuvir have reached the journals.[80-82]  
Success in terms of SVR are influenced by several host dependent factors but also viral factors. 
One of the major elements that influences SVR is viral genotype.[83] Patients infected with 
genotype 2 and 3 respond better to antiviral treatment than patients infected with genotype 
1 and 4.[83] 
Apart from (peg) interferon-alpha and ribavirin, a great number of drugs have been 
investigated in chronic hepatitis C. Aminoadamantanes, another antiviral group, such as 
amantadine and rimantadine, have also been investigated in several trials for treatment of 
patients with chronic hepatitis C.[84, 85] Amantadine, which has been used primarily for the 
prophylaxis and treatment of respiratory tract infections caused by influenza A virus, is 
believed to interfere with early stages of viral replication, uncoating or primary transcription 
of viral RNA.[86, 87] Aminoadamantanes, mostly amantadine, were investigated as oral 
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monotherapy, administered mostly as 100 mg twice a day, and also in combination with 
interferon-alpha or ribavirin, or both.  
With the new DAAs, higher SVR-proportions can be reached, but still not 100%.[75-79]. This 
indicates that there is an unmet need for drugs with better efficacy. The data from 
randomized clinical trials that have been performed so far have created more questions than 
anticipated. For example, are there other drugs available that increase SVR-proportions? Or 
did we overlook drugs that are available and have been investigated in formal randomized 
clinical trials but were disregarded because they failed to increase the overall SVR rates. 
These drugs may be useful and effective for certain subpopulations. Trials investigating 
aminoadamantanes in chronic hepatitis C demonstrated conflicting results. Some trials 
showed a beneficial effect of the addition of the aminoadamantane amantadine. Also, 
different trials demonstrated efficacy in a subgroup with patients who were difficult to treat, 
with interferon non-response.[88, 89] Other trials showed no enhancement of achieving 
SVR.[90, 91]  
We wanted to answer the question whether the administration or addition of 
aminoadamantanes to chronic hepatitis C treatment is beneficial? This is necessary as the 
results from the clinical trials highly varied and its use continued in clinical practice. 
Therefore, we performed a systematic review with meta-analysis aimed at assessing benefits 
and harms of aminoadamantanes (model). We hypothesized that aminoadamantanes improves 
SVR in some subgroups, for example patients with an interferon dependent non-response. 
Furthermore, we wanted to write a new Dutch guideline for hepatitis C virus infection that 
provides recommendations for the management of hepatitis C infection. The last Dutch 
guideline on the treatment of hepatitis C infection stems from 2008.[92] As mentioned, until 
2012 the standard for treatment consisted of peg interferon-alpha and ribavirin. The advent 
of first-generation direct antiviral agents such as boceprevir and telaprevir has changed the 
concept of treatment of adult chronic hepatitis C genotype 1 infected patients. In order to 
guide the clinician through the changed therapeutic environment we want to provide a 
completely revised guideline with concise recommendations for the management and 
treatment of hepatitis C monoinfection in adults. The Dutch guideline serves as a manual for 
physicians for the management and treatment of acute and chronic hepatitis C monoinfection.  
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Research models 
In order to address the abovementioned questions we applied the systematic review as main 
research tool. We performed systematic reviews of randomized clinical trials for the various 
topics that have been published in the international literature. In order to answer a specific 
research question, a systematic review attempts to compare and collect all available 
evidence. In order to minimize bias, we used a systematic method that provides more reliable 
findings. On the basis of these findings it is possible to draw conclusions and provide input for 
clinical decisions.[93, 94] 
Key characteristics of a systematic review are: clear objectives with pre-specified eligibility 
criteria for trials; an explicit, reproducible methodology; a systematic search that attempts 
to identify all trials that would meet the eligibility criteria; an assessment of the validity of 
the findings of the included trials, for example through the assessment of risk of bias; and a 
systematic presentation, and synthesis, of the characteristics and findings of the included 
trials.[95]  
In order to answer our specific research questions we performed four systematic reviews 
following the above mentioned steps. We performed two of these four systematic reviews 
according to the Cochrane systematical review method. This Cochrane method has been 
developed by The  Cochrane Collaboration, which prepares, maintains, and promotes 
systematic reviews to inform healthcare decisions.[95] The Cochrane method distinguishes 
itself by using a uniform format for all Cochrane systematical reviews. Standard headings and 
tables are embedded in the Cochrane Collaboration’s Review Manager (RevMan) software. 
This guides the authors when preparing their report and make it easier for readers to identify 
information that is of particular interest to them. Furthermore, protocols for Cochrane 
reviews are published in the Cochrane Database of Systematic Reviews prior to publication of 
the Cochrane review, which reduces the impact of authors’ bias, promotes transparency of 
methods and processes, reduces the potential for duplication, and allows peer review of the 
planned methods.[95] 
Besides the systematic review as main research tool, the clinical guideline was the other used 
method. Clinicians need simple, patient specific, user friendly guidelines. There are three 
components which are essential building blocks of usable clinical guidelines. The first is the 
explicit identification of the major decisions that are relevant to patients, which have to be 
made, and the possible consequences of these decisions. Weighing the various consequences 
of different treatment options, decisions and their consequences are often difficult to map 
and a flow diagram or algorithm that identifies the key decisions and important outcomes 
relevant to patients and others is crucial. This is a requirement to limit practice variation. 
16
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The second key success parameter involves bringing together the relevant, valid evidence that 
clinicians need to make informed decisions at each of the key decision points. In every field 
there are controversies and gaps in knowledge and sifting through the evidence that is 
inadequate is difficult but a necessity. The final goal is to make explicit statements about the 
benefits and risks of treatment in view of patient preferences and available resources. A third 
essential component of a successful guideline is the presentation of evidence and 
recommendations in a concise, accessible format. Decision makers must be able to retrieve 
and assimilate information quickly. Moreover, information must be presented in a flexible 
format that is applicable to specific patients or circumstances. 
 
Outline of the thesis 
In Chapter 1, ‘the General Introduction’, we provide background information and we describe 
a framework for this thesis. Chapter 2 describes systematically the optimal induction and 
subsequent maintenance therapy for autoimmune hepatitis. In Chapter 3 we will 
systematically review the evidence for interferon-alpha in hepatitis delta virus therapy. We 
will delineate treatment with aminoadamantanes versus placebo or no intervention for 
chronic hepatitis C infection in Chapter 4 according to the Cochrane systematical review 
method. Chapter 5 also follows the Cochrane systematic method and focuses on treatment 
with aminoadamantanes for chronic hepatitis C infection, but in this case compared with other 
antiviral drugs. In Chapter 6 we will describe the current treatment guidelines of chronic 
hepatitis C virus infection. We will complete this thesis by a General Discussion (Chapter 7) 
that summarizes and discusses the main findings of this thesis. 
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Abstract 
Introduction: Predniso(lo)ne with or without azathioprine is considered the mainstay in the 
treatment of autoimmune hepatitis (AIH), but many therapeutic options are available. The 
primary objective of this review was to explore the published literature on the optimal 
induction and subsequent maintenance therapy for AIH.  
Methods: We performed a systematic search on electronic databases MEDLINE (1950-
07.2009), Web of Science and Cochrane and the website www.clinicaltrials.gov. Randomized 
controlled trials (RCTs) on apparent beneficial treatment regimens as induction or 
maintenance treatment in AIH were included. Pediatric studies were excluded. We calculated 
relative risks (RR) for comparison of treatment options on the primary outcome measure, 
which was defined as clinical, biochemical and histological remission. 
Results: Eleven RCTs were included, of which 7 studies evaluated the induction therapy in 
AIH patients: 3 treatment-naive (n = 253), 2 relapse (n = 53), 2 combination of naive and 
relapse (n = 110). The remaining 4 studies (n = 162) assessed maintenance therapy. All but 
one maintenance study (thymostimulin versus no therapy) studied predniso(lo)ne (PRED), 
azathioprine (AZA) or combination PRED+AZA. We found no differences in primary outcome 
between induction therapy with PRED and PRED+AZA in treatment naive patients (RR=0.98; 
95%CI 0.65-1.47). AZA monotherapy as induction was considered as not viable because of a 
high mortality rate (30%). This was similar in AIH patients who relapsed: RR for PRED vs 
PRED+AZA for inducing remission was not different: 0.71 (95%CI 0.37-1.39). PRED+AZA 
maintained remission more often than PRED (RR=1.40; 95%CI 1.13-1.73). Also AZA maintained 
a higher remission rate than PRED (RR=1.35; 95%CI 1.07-1.70). Maintenance of remission was 
not different between PRED+AZA and AZA (RR=1.06; 95%CI 0.94-1.20). 
Conclusions: Based on available RCTs PRED monotherapy and PRED+AZA combination therapy 
are both viable induction therapies for AIH treatment naives and relapsers, while for 
maintenance therapy PRED+AZA and AZA therapy are superior to PRED monotherapy.  
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Background 
Autoimmune hepatitis (AIH) is a rare chronic progressive liver disease of unknown etiology.1 
Clinical presentation may include fatigue, pain in the right upper quadrant of the abdomen, 
polymyalgia, and arthralgia involving small joints.1 The disease predominantly affects women 
and occurs in children and adults of all ages. The estimated annual incidence of AIH among 
Northern Europeans is 1.9 cases per 100,000 persons per year.1,2 The clinical picture is 
heterogeneous and in absence of a single clinical or biochemical test, diagnosis is made 
according to a set of clinical criteria developed in 1993, which were revised in 1999 and 
simplified in 2008.3,4,5 These diagnostic criteria include: 1) hypergammaglobulinemia; 2) the 
presence of particular autoantibodies, i.e. ANA, SMA or anti-LKM1; 3) liver histology features 
similar to chronic hepatitis of other etiology; and 4) the absence of viral and toxic hepatitis 
or other conditions that may resemble AIH.5,6 Based on this set of criteria, the sensitivity of 
the scoring system for AIH ranges from 97%-100%, and its specificity for excluding AIH in 
patients with chronic hepatitis C ranges from 66%-92%.6  
Three randomized controlled trials (RCTs) dating from the 1970’s have established the effect 
of immunosuppressive drugs for AIH.7-9 Predniso(lo)ne monotherapy (PRED) or a combination 
of predniso(lo)ne and azathioprine (PRED+AZA) was superior to other treatment options, 
including titrating PRED, in improving liver function and life expectancy.7-9 The current 
recommendations for AIH therapy originate from this era, and PRED, usually in combination 
with AZA, is considered the mainstay of therapy. In some cases cirrhosis develops despite 
treatment; or treatment discontinuation or dose reduction is necessary because of intolerable 
adverse events. This has fueled the search for treatment alternatives.  
Our primary objective was to explore the published literature on evidence of optimal 
induction and subsequent maintenance therapy for AIH. We therefore performed a systematic 
review and examined all RCTs for treatment of AIH published from 1950 until present. 
 
Methods 
Literature search 
We performed a systematic literature search using a set of electronic databases: MEDLINE 
(1950-07.2009), Web of Science and Cochrane and the website www.clinicaltrials.gov to 
identify all published articles and abstracts, and ongoing studies from 1950 until July 2009. 
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The following terms were used: ‘hepatitis’, ‘autoimmune’ and ‘clinical trial’. All papers 
published before August 2009 were eligible. 
Selection of studies 
We employed a 2-stage approach. First, we excluded all articles that were not written in 
English, German, French or Spanish. We subsequently removed all duplicates, and screened 
remaining articles on basis of title and abstract. Only RCTs were included: case reports, case 
series, review articles, letters and editorials were excluded. Studies not evaluating the 
efficacy of therapy for AIH in adult patients (age ≥18 years) were rejected. Subsequently, full 
text screening was applied to the remaining studies. Articles were systematically reviewed on 
the basis of their inclusion criteria and methodological aspects by two independent reviewers 
(ML, MP). Discrepancies were solved by discussion with a third party (JD). In order to check 
whether our search included all published papers that were possibly relevant for this review, 
we scrutinized reference lists of included articles. This strategy was adopted because of 
evolving definition of AIH prior to 1993.  
Outcomes 
Remission was considered as the primary outcome measure. We defined remission following 
recently published criteria: disappearance of symptoms; normal serum bilirubin and γ-globulin 
levels; serum aminotransferase level normal or less than twice normal; normal hepatic tissue 
or minimal inflammation and no interface hepatitis.10 For each individual article, we 
evaluated all available outcomes that matched the criteria of our user definition of remission. 
For example, if liver biopsy was not an outcome described in a particular article, we applied 
all other presented outcomes, such as clinical and biochemical variables, in order to achieve 
the most appropriate definition of remission for that study.  
The secondary outcome measures included mortality and occurrence of adverse events. All 
outcomes were extracted from the included trials and were assessed at maximum follow-up. 
Clinical trials in the treatment of AIH can be divided in 2 categories: 1) trials that assess the 
effect of induction therapy in newly identified or relapsed AIH patients (induction trials); and 
2) trials that have been performed during remission in order to compare the efficacy of two 
immunosuppressive regimens with maintenance of remission as the primary endpoint 
(maintenance trials). 
Quality of the included studies was assessed, based on a well-established, validated scale 
developed by Jadad et al.11 The Jadad score gives a numerical score between 0-5 as a rough 
measure of clinical trial design/reporting quality (0 being weakest and 5 being strongest).  
Chapter 2
28
Extraction of data 
After inclusion, we extracted data from each article and entered characteristics of trials, 
patients, and interventions, as well as the primary and secondary outcome measures. Trial 
characteristics included the first author’s name, year and journal of publication, study design, 
type, dose and duration of applied therapy and length of follow-up.  Patient characteristics 
comprised inclusion and exclusion criteria, mean age, number of patients randomized, and 
number and reasons for dropouts and withdrawals.  
Data on all patients, irrespective of compliance or follow-up were sought to allow intention-
to-treat analyses. In this analysis the total number of patients randomized is the number of 
patients included in the efficacy analysis. We used data related to initial therapy and relevant 
to maintenance therapy. In case data were recorded immediately at the end of the evaluation 
period, this was preferred to follow-up data. In case of missing outcome values at the end of 
the evaluation period, due to premature withdrawal of therapy in patients with deterioration 
or drug intolerance, last measured values of outcome were substituted for missing values. 
In order to evaluate adverse events related to therapy for AIH, data regarding adverse events 
in patients treated with the interventional drug(s) were extracted. In addition, data about 
deterioration in all patients reported in the included studies, were extracted. 
Synthesis of data and analysis 
In this review, a brief overview of the interventions and number of patients in the trials is 
given for each separate study. In addition, we pooled patient data of all studies and stratified 
them in different subgroups according to induction and maintenance therapy, applied 
intervention and obtaining remission, mortality or complications. This was done in order to 
determine the efficacy of the interventional drugs in terms of induction of favorable outcome 
in each of the different therapy groups.  
We calculated overall frequencies for the primary outcome measure expressed as 
percentages. Furthermore, frequencies and percentages for two of the secondary outcome 
measures, reported mortality and adverse events were calculated. 
Data was stored in Reference Manager 11 and Excel database software for Windows XP. Due 
to heterogeneity of studies, we have focused on descriptive analysis and overall frequencies 
of favorable outcomes were determined by sample sized weighted pooled proportion. In order 
to quantify the differences between frequently studied treatment strategies we pooled the 
data and calculated relative risk with 95% confidence interval. 
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Results 
Literature search and selection of studies 
The results of our systematic literature search and subsequent selection of articles are 
summarized in a flow diagram (Figure 1). The search identified 302 different studies, of which 
we excluded 247 studies due to study aims; 49 studies were rejected because of study design. 
Full text screening was applied for 6 articles, and all fulfilled the selection criteria. Of these 
articles, the reference lists were checked, and this strategy resulted in 5 additional articles 
that fulfilled the inclusion criteria. Thus, a total of 11 RCTs were included for further 
analyses7-9,12-19 of which 7 studies evaluated the induction therapy in AIH patients: 3 
treatment-naive (n = 253), 2 relapse (n = 53), 2 combination of naive and relapse (n = 110). 
The remaining 4 studies (n = 162) assessed maintenance therapy. 
Many drugs were studied and we analyzed the most viable options: PRED, AZA or a combination 
of both. Outcome assessments in patients treated within the different treatment arms were 
made after an evaluation period of >3 months, the mean evaluation period was for the groups 
comparable, and varied between 1-2 years.  
Induction therapy in treatment naive AIH patients 
We retrieved 5 studies, published between 1971 and 1982, that assessed the clinical outcome 
of AIH in drug naive patients (Table 1). These 5 studies included 363 patients in 6 different 
arms, 26% were male.7-9,17,18 The calculated Jadad score of these studies ranged between 1 
and 4. Two studies performed a head-to-head comparison between PRED and AZA.9,17 One 
study evaluated the treatment with PRED, PRED+AZA, titrated PRED and placebo or AZA.18 
Another trial studied the same drugs but titrated PRED.8 One study compared PRED with no 
intervention.7 Applied dosages varied between 10-60 mg daily of PRED (maintenance dose 10-
20 mg/day)7-9,17,18 and between 50-100 mg daily of AZA.8,9,17,18  
Ninety-five patients were treated with PRED (not titrated), remission occurred in 42%.8,17,18 
We were not able to extract remission rates in two studies, as they contained only minimal 
information.7,9 The mortality rate was 15% (21/139) (Figure 2a).7-9,17,18  
Only 14% of 51 AZA treated patients achieved remission,8,17 and 30% deceased (27/89).8,9,17,18 
The therapy of PRED+AZA in 44 patients yielded a remission rate of 43% and a mortality rate 
of 7%.8,18 Remission rates of PRED treated patients versus PRED+AZA treated patients yielded 
a comparable rate (RR=0.98; 95%CI 0.65-1.47). Neither of 33 patients randomized for placebo 
achieved remission, and 13 patients (39%) died.8,18 One study assessed 27 patients with no 
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intervention, the remission rate could not be extracted and the mortality rate was 56%.7 One 
study evaluating the effect of titrated PRED showed no benefit.18  
 
Figure 1. Flowchart of included and excluded articles in the systematic literature search 
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Figure 2a: Induction therapy naive AIH patients 
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Induction therapy in AIH patients who relapsed 
Four studies, with a Jadad score between 2 and 4, assessed the clinical outcome of induction therapy 
in AIH patients who relapsed (Table 2).8,9,14,15 In total, these 4 studies included 163 patients (22% 
males) in 7 different arms. The most important comparators were similar to the studies in naive 
patients: PRED (15-60 mg/day) versus AZA (75-100 mg/day) or a combination of these two (PRED 10-
30 mg/day, AZA 50 mg/day) versus monotherapy.8,9,15 One study compared ursodeoxycholic acid 
(UDCA 13-15 mg/kg/day) with placebo in PRED treated patients, and UDCA showed no additional 
value.14 A total of 32% from 34 PRED treated patients obtained remission,8,14 4% died (Figure 2b).8,9,14 
Twenty-two patients treated with PRED+AZA achieved remission in 45% and had a corresponding 
mortality of 5%.8,15 Treatment with PRED or with PRED+AZA were not different (RR=0.71; 95%CI 0.37-
1.39). Two studies focused on AZA treatment.8,9 Only 7% reached remission 8 and 28% died.8,9 For 
comparison, none of the patients who received placebo came into remission, and there was an 
associated mortality of 41%.8 
 
Figure 2b: Induction therapy relapse AIH patients
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Table 1. Induction therapy in naive patients with autoimmune hepatitis 
 
*Ninety-nine autoimmune patients, information provided for 84 patients only. Thirty-four patients 
prednisone for 1 year, 27 patients azathioprine for 1 year. Thirteen patients who were treated with 
prednisone died before 1 year of treatment, while 10 patients died in the azathioprine group 
 
 
First author, 
journal, year 
Intervention Treatment 
duration 
Patients 
(n) 
Remission 
(%) 
Mortality 
(%) 
Jadad 
score 
Cook, 
Quarterly 
Journal of 
Medicine, 
1971 
Prednisolone 15 mg/day 
 
No intervention 
 
30-72 
months 
22 
 
27 
-  
 
-  
14 
 
56 
2 
Soloway, 
Gastroente- 
rology, 1972 
Prednisone 60 mg/day 1 
week, 40 mg/day 1 week,  
30 mg/day 2 weeks, 20 
mg/day maintenance 
 
Azathioprine 100 mg/day  
 
Prednisone 30 mg/day 1 
week, 20 mg/day 1 week, 15 
mg/day 2 weeks, 10 mg/day 
maintenance +  azathioprine 
50 mg/day 
 
Placebo 
 
3 months - 
3,5 years 
 
 
18 
 
 
 
 
14 
 
14 
 
 
 
 
 
17 
44 
 
 
 
 
7 
 
21 
 
 
 
 
 
0 
6 
 
 
 
 
36 
 
7 
 
 
 
 
 
41 
4 
Murray-Lyon, 
Lancet, 1973 
Prednisone 5mg 3dd 
 
Azathioprine 75 mg 1dd 
2 years 22 
 
25 
 
-  
-  
5 
 
24 
3 
Summerskill, 
Gut, 1975 
Prednisone 60 mg/day 1 
week, 40 mg/day 1 week,  
30 mg/day 2 weeks, 20 
mg/day maintenance 
 
Prednisone 30 mg/day 1 
week, 20 mg/day 1 week, 15 
mg/day 2 weeks, 10 mg/day 
maintenance + azathioprine 
50 mg/day 
 
Prednisone in doses titrated 
given on alternated days 
 
Placebo/azathioprine 100 
mg/day 
 
36 months 30 
 
 
 
 
30 
 
 
 
 
 
31 
 
 
29 
(16/13) 
37 
 
 
 
 
53 
 
 
 
 
 
10 
 
 
-  
10 
 
 
 
 
7 
 
 
 
 
 
7 
 
 
41 
(38/46) 
1 
Tage-Jensen, 
Liver, 1982 
Azathioprine 10 mg/kg/ 
week, first 2 weeks 5 mg/ 
kg/week 
 
Prednisone <70 kg 
10mg/day, ≥70 kg 15mg/day 
 
38 (12-83) 
months 
37* 
 
 
 
47* 
16 
 
 
 
45 
27 
 
 
 
28 
2 
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Table 2. Induction therapy in patients with autoimmune hepatitis who relapsed 
First author, 
journal, year 
Intervention Treatment 
duration 
Patients 
(n) 
Remission 
(%) 
 
Mortality 
(%) 
Jadad 
score 
Soloway, 
Gastroente- 
rology, 1972 
Prednisone 60 mg/day 1 
week, 40 mg/day 1 week, 30 
mg/day 2 weeks, 20 mg/day 
maintenance 
 
Azathioprine 100 mg/day  
 
Prednisone 30 mg/day 1 
week, 20 mg/day 1 week, 15 
mg/day 2 weeks, 10 
mg/day/week + azathioprine 
50 mg/day  
 
Placebo 
 
3 months - 
3,5 years 
18 
 
 
 
 
14 
 
14 
 
 
 
 
 
17 
44 
 
 
 
 
7 
 
21 
 
 
 
 
 
0 
6 
 
 
 
 
36 
 
7 
 
 
 
 
41 
4 
Murray-Lyon, 
Lancet, 1973 
Prednisone 5mg 3dd 
 
Azathioprine 75 mg 1dd 
 
2 years 22 
 
25 
-  
  
-  
5 
 
24 
3 
Czaja, 
Hepatology, 
1993 
Oral pulse prednisone 90 mg/ 
day for 5 consecutive days, 
every 28 days 
 
Prednisone 30 mg/day 1 
week, 20 mg/day 1 week,  
15 mg/day 2 weeks,  
10 mg/day/week + 
azathioprine 50 mg/day 
 
Indefinite 8 
 
 
 
8 
0 
 
 
 
 88 
0 
 
 
 
0 
3 
Czaja, 
Hepatology, 
1999 
UDCA 13-15 mg/kg/day + 
usual corticosteroid schedule 
 
Placebo + usual corticosteroid 
schedule 
 
6 months 21 
 
 
16 
14 
 
 
19 
5 
 
 
0 
2 
 
UDCA = ursodeoxycholic acid 
 
Maintenance therapy in AIH patients 
We identified 4 clinical trials that focused on AIH patients in remission on maintenance 
therapy (Table 3).12,13,16,19 These studies included 162 patients in 6 different arms, of which 
22% were male. Three studies scored 3 on the Jadad scale,12,13,19 one study scored 1.16 One 
study compared AZA (2 mg/kg/day) with PRED (5-12,5 mg/kg/day) + AZA (1 mg/kg/day),13 
another study compared this combination ((PRED 5-10mg/kg/day) + (AZA 50-100 mg/day)) 
with PRED (5-12,5 mg/day).12 Two trials compared either thymostimulin with no intervention 
or PRED (15 mg/day) with D-penicillamine.16,19 Thymostimulin and D-penicillamine had no 
relevant clinical value. PRED+AZA yielded a higher rate of maintaining remission (96%)12,13 
than PRED (68%12,19, RR=1.40; 95%CI 1.13-1.73). A total of 92% of AZA treated patients 
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maintained remission (Figure 2c)13. Maintenance treatment with PRED+AZA is not better than 
with AZA (RR=1.06; 95%CI 0.94-1.20). AZA also maintained a higher remission rate than PRED 
(RR=1.35; 95%CI 1.07-1.70). In all studied treatment groups none deceased.12,13,19  
Figure 2c: Maintenance therapy AIH patients 
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Table 3. Maintenance therapy for autoimmune hepatitis patients in remission 
First author, 
journal, year 
Intervention Treatment 
duration 
Patients 
(n) 
Remission 
(%) 
Mortality 
(%) 
Jadad 
score 
Stern, Gut, 
1977 
D-penicillamine 1.2 g/day 
 
Prednisone 15 mg/day 
 
1 year  18 
 
17 
50 
 
65 
0 
 
0 
3 
Hegarty, 
Gut, 1984 
Thymostimulin 1 mg/kg/day 
i.m. for 7 days; 1 
mg/kg/weekly thereafter 
 
No therapy 
Indefinite 13 
 
 
 
17 
16 
 
 
 
12 
0 
 
 
 
0 
1 
Stellon, 
Lancet, 1985 
Prednisolone 5-10 mg/day + 
Azathioprine 50-100 mg/day 
 
Prednisolone 5-12,5 mg/day 
 
3  years 23 
 
 
27 
96 
 
 
70 
01 
 
 
01 
3 
Stellon, 
Hepatology, 
1988 
Azathioprine 2 mg/kg/day 
 
Azathioprine 1 mg/kg/day + 
Prednisolone 5-12,5 mg/day 
1 year 25 
 
22 
92 
 
100 
0 
 
0 
3 
 
1 One patient died in a road accident, inclusion group unknown 
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 Table 4. Adverse events  
First author, 
journal, year 
Intervention 
 
Treatment 
duration 
Patients 
(n) 
 
Adverse events (n) 
Cook, Quarterly 
Journal of 
Medicine, 1971 
 
 
 
 
Soloway, 
Gastroenterology, 
1972 
 
 
 
Murray-Lyon, 
Lancet, 1973 
 
Summerskill, Gut, 
1975 
 
 
 
 
Summerskill, Gut, 
1975 
 
 
Tage-Jensen, 
Liver, 1982  
 
 
Stellon, Lancet, 
1985 
 
Czaja, Hepatology, 
1993 
 
 
Prednisolone 15 mg 
 
 
 
 
 
 
Prednisone 60 
mg/day 1 week, 
reduction schedule 
to 20 mg/day 
maintenance 
 
Prednisone 5mg  
3 times a day 
 
Prednisone 60 
mg/day 1 week, 
reduction schedule 
to 20 mg/day 
maintenance 
 
Prednisone in doses 
titrated given on 
alternated days 
 
Prednisone <70 kg 
10mg/day, ≥70 kg 
15mg/day 
 
Prednisolone 5-
12,5 mg/day 
 
Oral pulse 
prednisone 90 
mg/day for 5 
consecutive days, 
every 28 days 
 
Indefinite 
 
 
 
 
 
 
3  months - 
3,5 years 
 
 
 
 
2 years 
 
 
36 months 
 
 
 
 
 
36 months 
 
 
 
38 (12-83) 
months 
 
 
3  years 
 
 
Indefinite 
 
 
 
22 
 
 
 
 
 
 
18 
 
 
 
 
 
22 
 
 
30 
 
 
 
 
 
31 
 
 
 
47 
 
 
 
27 
 
 
8 
 
 
 
Severe: osteoprosis + vertebral 
collapse (2), perforated duodenal 
ulcer (1), acute steroid psychosis 
(1), terminal bronchopneumoniae 
(1). Mild: obesity (5), facial 
‘mooning’ (5), acne (4), myositis (1) 
 
Cushingoid appearance (13), 
diabetes requiring insulin (1), GI-
bleeding (1), spinal collapse, aseptic 
necrosis of hip, or cataracts (3) 
 
 
- 
 
 
Severe cosmetic changes, diabetic 
mellitus cataracts, hypertension  
 
 
 
 
Diabetes mellitus, diabetes mellitus 
and hypertension, 
hematemesis/melena 
 
- 
 
 
 
- 
 
 
None 
Soloway, 
Gastroenterology, 
1972 
 
 
 
 
Summerskill, Gut, 
1975 
 
 
 
 
 
Prednisone 30 mg/ 
day 1 wk, 
reduction schedule 
to 10 mg/day/wk + 
azathioprine 50 
mg/day 
 
Prednisone 30 mg/ 
day 1 wk, 
reduction schedule 
to 10 mg/day/wk + 
azathioprine 50 
mg/day 
 
3 months - 
3,5 years 
 
 
 
 
 
36 months 
 
 
 
 
 
 
 
14 
 
 
 
 
 
 
30 
 
 
 
 
 
 
 
Cushingoid appearance (10) 
 
 
 
 
 
 
Diabetes mellitus, hematemesis; 
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 Stellon, Lancet, 
1985 
 
 
 
Stellon, 
Hepatology, 1988 
 
 
 
Czaja, Hepatology, 
1993 
 
 
Prednisolone 5-10 
mg/day + 
azathioprine 50-
100 mg/day 
 
Prednisolone (5-
12,5 mg/day) + 
azathioprine 1 
mg/kg/day 
 
Prednisone 60 
mg/day 1 week, 
reduction schedule 
to 20 mg/day 
maintenance 
 
3 years 
 
 
 
 
1 year 
 
 
 
 
Indefinite 
 
 
23 
 
 
 
 
22 
 
 
 
 
8 
 
 
None 
 
 
 
 
Arthralgias (1) 
 
 
 
 
Severe adverse events of 
azathioprine not observed 
Soloway, 
Gastroenterology, 
1972 
 
 
 
 
Murray-Lyon, 
Lancet, 1973 
 
Summerskill, Gut, 
1975 
 
Tage-Jensen, 
Liver, 1982  
 
 
 
Stellon, 
Hepatology, 1988 
Azathioprine 100 
mg/day  
 
 
 
 
 
Azathioprine 75 mg 
once daily 
 
Azathioprine 100 
mg/day 
 
Azathioprine 10 
mg/kg/week, first 
2 weeks 5 
mg/kg/week 
 
Azathioprine 2 
mg/kg/day 
3 months - 
3,5 years 
 
 
 
 
 
2 years 
 
 
36 months 
 
 
38 (12-83) 
months 
 
 
 
1 year 
14 
 
 
 
 
 
 
25 
 
 
13 
 
 
37 
 
 
 
 
25 
Cushingoid appearance (2), GI-
bleeding (3), spinal collapse, aseptic 
necrosis of hip, or cataracts (1), 
leucopenia/ trombopenia (2), 
ascites + 2x increase in bilirubin 
(>6mg/100ml) (2) 
 
- 
 
 
- 
 
 
- 
 
 
 
 
Arthralgia most hinged joints (14), 
myalgias (7), transient leucopenia 
(1), pancytopenia (2) 
 
Adverse events 
Frequencies and percentages of reported adverse events were not adequately mentioned in 
most studies. Patients receiving PRED had a number of well-known steroid related adverse 
events such as cushingoid appearance, diabetes mellitus, hypertension and cataracts (Table 
4). Adverse events associated with AZA treatment were gastrointestinal bleeding, leucopenia, 
trombopenia, and arthralgia. Cushingoid appearance and diabetes mellitus were adverse 
events associated with the combination therapy PRED+AZA, but in a lower reported frequency 
than PRED monotherapy. We found no differences in adverse event incidence between 
treatment indications (naive, relapse or remission). 
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 Discussion 
This systematic review evaluates the evidence that is available for induction and maintenance 
therapy in AIH. Results from our analysis show that both PRED monotherapy and PRED+AZA 
are better in achieving remission and limiting mortality in treatment naive AIH patients than 
any other treatment option evaluated in the literature between 1950 and July 2009. The 
efficacy of both strategies seems similar, and the lower mortality rate with PRED or PRED+AZA 
is an important additional argument to favor this therapy over AZA monotherapy for the initial 
treatment of both naive and relapsing patients.  
For patients who require maintenance therapy, the combination PRED+AZA and AZA 
monotherapy provides higher maintenance rates of persistent remission compared to PRED 
monotherapy. Testament to this is that mortality was absent with either choice. Although AIH 
is much more prevalent in females, we could not discern a gender difference in efficacy for 
either naives, relapsers or patients in remission. 
Surprisingly, the number of RCTs describing the clinical efficacy of different treatment 
strategies in AIH patients is low. We only found 11 RCTs published between 1950 and July 
2009. For comparison, between July 2008 and July 2009 alone, already around 150 clinical 
trials in hepatitis C were reported in the literature. Moreover, studies were heterogeneous, 
performed decades apart with an evolving set of diagnostic criteria and no proper evidence 
based definition for remission until 1999. In order to offer recommendations for optimal 
induction and maintenance treatment in AIH we performed a descriptive analysis of the 
published RCTs.  
The question is whether we need future RCTs with currently available treatment options in 
AIH. We believe that there is a large unmet need. The trials that established the current 
standard PRED+AZA stem from an era with different, and currently considered suboptimal, 
laboratory diagnostics. In addition, the epidemiology of AIH probably has shifted. Due to 
improved diagnostics AIH is probably diagnosed in a much earlier phase, and patients that 
were considered to have AIH at the time of the earlier trials will currently receive an 
alternative diagnosis. Thus, there is a need for trials that reflects and benefits the current 
AIH patient. This brings us to the design of these future trials. Inclusion of a placebo arm for 
induction treatment of either naive or relapsing AIH is probably unethical. The remission rates 
with placebo are poor (<12%) , and earlier trials have shown that this strategy is associated 
with significant mortality.7,8,16,18 We concur that the therapy of AIH with PRED with or without 
AZA is far from ideal, and the search for drugs with a favorable risk-benefit ratio is ongoing.20 
For most of the alternative approaches in the past, the results have been disappointing and 
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 the adverse effects severe.20 Recently a German study group compared combined budesonide 
and AZA treatment to PRED+AZA in 208 AIH patients. Note that this trial alone includes ~25% 
of all AIH patients included in a RCT to date. The primary endpoint of the study was complete 
remission in absence of typical steroid-induced adverse effects.21,22 Preliminary results 
indicate that budesonide is an efficacious alternative to PRED, with a more favourable side 
effect profile. Less adverse events were experienced compared to the data that we presented 
here. However, results have only been published in abstract-form and long-term results of 
budesonide are awaited.  
In general, the results from our systematic analysis accord with the current guidelines, which 
advises PRED or PRED+AZA for naive AIH patients.1,6,10,20 The combination regimen is the 
preferred treatment because it is associated with a lower occurrence of corticosteroid-related 
adverse events than the higher dose PRED regimen (10% vs 44%).18,20 However in individual 
patients, therapy is best tailored to the patient’s presentation.20 For adults who have relapsed 
more than once the AASLD advises to be treated with PRED+AZA therapy, low dose PRED, or 
AZA only.10 Current maintenance regimens include PRED+AZA or AZA.4,10 Many AIH patients 
who have been in complete remission for at least one year with PRED+AZA can remain in 
remission with a higher dose of AZA alone.23 Altogether, we can conclude that our results in 
all three categories match with the current guidelines.   
This review has some limitations. A standardized, universally accepted definition of remission 
in AIH patients exists since 1999. All articles that are part of this review were published in or 
prior to 1999, and could consequently not match the overall definition.  
Apart from differences in definition of a remission, the trials described in the included articles 
used various doses for PRED and AZA. Therefore, we were not able to abstract the best dose 
for the highest remission rates using a systematic review. 
Thirdly, variations in medication schemes, outcome measures and validity of trials introduced 
heterogeneity between included studies. Another limitation is that only 11 RCTs have been 
published since 1950. The current literature is replete with reviews reflecting personal 
opinion, but lacks well executed RCTs. In addition, most studies include a small number of 
patients. Indeed, current therapy guidelines are based on 11 trials with only 607 patients 
reflecting the perpetual lack of evidence. In the same vein we note that there is also a paucity 
of structured and systematic recording of adverse events with AIH therapy. 
Current literature indicates remission rates of 65-80%24, but we found much lower 
percentages. The early RCTs in the 1970’s that established the efficacy of corticosteroids in 
the treatment of AIH included severe cases of AIH with severe, rapidly progressive disease. 
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 Consequently, these studies contained more patients with cirrhosis, which led to worse 
treatment outcomes and a higher mortality rate. Patients with less severe disease probably 
have not been included in the controlled clinical trials.25 Data on mild AIH are missing from 
the literature, and this introduces a potential source of bias. Furthermore, the hepatitis C 
virus was identified in 1989.21 Thus, AIH patients diagnosed prior to 1989 could have hepatitis 
C, and probably some patients were inadvertently included in the initial trials. This could 
translate in a lower remission rate. In addition, we did not take into account the lead time 
bias, which also may affect the achievement of remission and mortality. 
In conclusion, PRED monotherapy and PRED+AZA combination therapy are equivalent in 
efficacy for induction treatment in naive and relapsing AIH patients. For maintenance therapy 
PRED+AZA combination and AZA monotherapy are superior to PRED monotherapy. Alternative 
proposed strategies in patients who have failed to achieve remission on standard therapy or 
patients with drug toxicity are very welcome to optimize treatment.  
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B Hepatitis Delta
  
3 Interferon-alpha for patients with chronic hepatitis delta; a systematic 
review of randomized clinical trials
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 Abstract 
Background: Hepatitis delta virus (HDV) infection therapy is unclear. 
Aim: This systematic analysis aims to clarify the evidence on the efficacy of interferon alpha 
(IFNα) based therapy in HDV. 
Methods: We performed a systematic search on electronic databases MEDLINE (1970-
01.2011), Web of Science, Cochrane and the website www.clinicaltrials.gov. RCTs comparing 
IFNα based therapy with either another drug, placebo or no intervention were included. We 
excluded pediatric studies. We calculated relative risks (RR) for comparison of treatment 
options on the primary outcome measure, which was defined as undetectable levels of HDV 
RNA and normal ALT at end of treatment (EOT=1-year). 
Results: Nine randomized clinical trials (RCTs) were included. Seven trials evaluated the 
treatment with IFNα (n=132). The remaining 2 trials evaluated treatment with pegylated IFNα 
(peg-IFNα) (n=45). We found that 1-year treatment with high-dose-IFNα achieved better 
primary outcome rates than with peg-IFNα (RR=4.14; 95%CI 1.00-17.14). One year treatment 
with low-dose-IFNα or with peg-IFNα were similar (RR=2.83; 95%CI 0.65-12.40) as were low-
dose-IFNα and high-dose-IFNα (RR=0.68; 95%CI 0.31-1.50). High-dose-IFNα and peg-IFNα 
reached similar HDV RNA suppression 24 weeks after EOT (RR=1.00; 95%CI 0.51-1.97). None of 
the 55 patients assigned to no intervention obtained undetectable levels of HDV RNA and only 
one patient achieved normalization of ALT level.  
Conclusions: Based on available RCTs 1-year high-dose-IFNα monotherapy appears to be 
more effective than peg-IFNα for treatment of HDV patients, with efficacy rates around 30%. 
There is a lack of head-to-head comparisons. Combination therapies and longer treatment 
duration needs to be investigated. 
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 Introduction 
Hepatitis delta virus (HDV) was first identified in 1977 in serum of hepatitis B surface antigen 
(HBsAg) carriers.[1] HDV is a parenterally transmitted RNA virus that requires hepatitis B virus 
(HBV) surface proteins to form the viral coat and to infect hepatocytes. There are 8 genotypes 
that each have a unique geographical representation.[2-10]  
HDV infection occurs as co-infection or superinfection. Co-infection of HBV with HDV is usually 
acute and self-limiting, with a clinical picture that ranges from mild to severe fulminant 
hepatitis. Chronic liver disease is seen in less than 5% of these patients.[11, 12]  Superinfection 
of HDV in HBV carriers is associated with severe acute hepatitis that leads to chronic HDV 
infection in up to 80% of patients.[11-16] All in all, an estimated 10% of chronic HBV infected 
patients have a concomitant HDV infection, with considerable differences between countries, 
regions and risk groups.[12, 17] Eventually, this may lead to chronic liver disease and 
progression to cirrhosis in 80% of patients.[13, 15, 16, 18-21]  
Treatment of chronic HDV remains under debate. Clinical trials dating from the mid-1980s and 
beginning 1990s used interferon alpha (IFNα) based therapy to inhibit HDV replication.[22-27] 
Response with IFNα was not high, but therapeutic efficacy seemed to increase with higher 
IFNα dosages [28, 29] and prolonged therapy.[22, 23, 30, 31] The addition of polyethylene 
glycol to IFNα, which enhances the half-life of IFNα, greatly increased the therapeutic efficacy 
in hepatitis C.[32-34] The effect of pegylated IFNα (peg-IFNα) in HDV treatment has not been 
fully explored.[35, 36] In addition, several oral agents have been proven to be ineffective in 
HDV, including ribavirin, famcyclovir, lamivudine, levamisole and thymosin.[37-42] Since 
there is an important therapeutic role of IFNα therapy in the treatment of HDV, an in depth 
reassessment of the evidence that supports safety and efficacy of IFNα based strategies in 
HDV is warranted.  
Our primary objective was to explore the published literature and clarify the evidence on the 
effects of IFNα in HDV. Therefore we performed a systematic review and examined all 
randomized clinical trials (RCTs) for IFNα based treatment of HDV from 1970 until present. 
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 Methods 
Literature search 
We performed a systematic literature search using a set of electronic databases: PUBMED 
(from 1970 to January 2011), Web of Science, The Cochrane Library and the website 
www.clinicaltrials.gov. We identified all published articles, abstracts, and ongoing studies in 
all languages from 1970 until January 2011. Searches were performed by using the official 
Medical Subject Headings (MeSH): ‘hepatitis’, ‘HDV’, ‘delta’ and ‘clinical trial’. Additional 
articles were obtained through citation snowballing to locate primary sources that were 
referred to in the initial document where necessary. 
Selection of studies 
We included all articles irrespective of language. We included any study that met the following 
criteria: 1) RCT; 2) comparing IFNα based therapy with another drug, placebo, or no 
intervention; 3) outcome measures include levels of HDV RNA and alanine aminotransferase 
(ALT); and 4) treatment duration of 1 year or more. All duplicates and pediatric trials were 
removed. Subsequently, we screened all remaining articles on the basis of title and abstract. 
Studies not evaluating the treatment of chronic HDV were removed from the analysis. Case 
series, cross-sectional studies, cohort studies, review articles and letters were excluded. 
Thereafter, we subjected the remaining studies to full text screening. 
Two reviewers (M.L., O.O.) independently evaluated the eligibility of all studies retrieved 
from the databases on basis of the predetermined selection criteria. Disagreements were 
resolved by discussion with a third party (J.D.). In order to determine whether our search 
included all published articles, we manually searched the reference sections of included 
articles. 
Quality of the included studies was assessed, using a domain-based evaluation, where critical 
assessments are made separately for different domains.[43]  
Outcomes 
The primary outcome measure was: 1) undetectable levels of HDV RNA plus 2) normal levels 
of ALT, both at end of treatment (EOT = 1-year of treatment).  
The secondary outcome measures included undetectable levels of HDV RNA at EOT, normal 
levels of ALT at EOT, both variables at 24 weeks after EOT, mortality, and occurrence of 
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 adverse events. All outcomes were extracted from the included trials and assessed at 
maximum follow-up. 
Data abstraction 
We developed an electronic data extraction form in MS Excel and used this for data entry. 
Extracted data included characteristics of trials, patients and interventions, as well as all 
outcome measures. Trial characteristics comprised the first author’s name, year and journal 
of publication, study design, type, dose and duration of applied therapy and length of follow-
up. Patient characteristics included inclusion and exclusion criteria, mean age, number of 
patients randomized, number of and reasons for dropouts and withdrawals.  
Synthesis of data and analysis 
For each separate study, a brief overview of the interventions and number of patients was 
generated. We pooled patient data from all studies and stratified results in different 
subgroups according to applied intervention. Thereafter, we determined the primary and 
secondary outcome measures to assess the efficacy of the different applied interventions. We 
calculated relative risks (RR) for comparison of treatment options on the primary and 
secondary outcome measures. 
 
Results 
Literature search and selection of studies 
The search of our systematic literature search and subsequent selection of articles is 
summarized in a flow diagram (figure 1). The initial search identified 419 different articles. 
We excluded 356 articles on basis of different study aims and 48 papers were rejected because 
the study design did not meet the inclusion criteria. Full text screening was applied for 15 
articles and ultimately 8 full papers met the selection criteria. We checked the reference lists 
of the first set of 8 articles, and this strategy resulted in one additional article. Thus, a total 
of 9 RCTs were included for further analysis.[23, 28, 29, 31, 36, 38, 44-46] Seven studies 
evaluated the treatment with IFNα (n = 132 patients monotherapy)[23, 28, 29, 31, 38, 44, 45] 
and another 2 studies evaluated treatment with peg-IFNα (n = 45 patients monotherapy).[36, 
46] 
The RCTs evaluated IFNα based therapies in combination with lamivudine, ribavirin, and 
adefovir. Outcome assessments in patients treated within the different treatment arms were 
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 made after an evaluation period of ≥1 year. The mean evaluation period was comparable 
between the different groups, approximately 1 year, except for one article that had a 2 year 
evaluation phase. Most trials used a 6-month follow-up period.  
Interferon alpha based monotherapy 
We retrieved 7 studies, published between 1991 and 2008 which assessed our primary outcome 
of 1-year IFNα therapy in chronic HDV patients. These 7 trials evaluated 253 patients allocated 
to 7 different intervention groups and 73% of participants were male (Table 1).[23, 28, 29, 
31, 38, 44, 45] Two studies compared IFNα, in different dosages ranging from 5 MU/m2 three 
times in a week (t.i.w.) to 10 MU/m2 twice a week, without a comparator.[23, 31] Two studies 
performed a head-to-head comparison between high (9 MU t.i.w. or 18 MU t.i.w.) and low 
dose (3 MU t.i.w. or 3 MU daily) IFNα, while a single study used a non-treated control 
group.[28, 29] One study compared IFNα monotherapy (10 MU t.i.w.) with combination 
therapy of IFNα (10 MU t.i.w.) and lamivudine (100 mg daily).[44] Another trial studied the 
same drugs (IFNα therapy (9 MU t.i.w.), combination therapy of IFNα (9 MU t.i.w.) with 
lamivudine (100 mg daily)) but included a third arm with lamivudine monotherapy (100 mg 
daily).[38] One study performed a comparison between IFNα monotherapy (9 MU t.i.w.) and 
IFNα (9 MU t.i.w.) and ribavirin (1000-1200 mg daily) combination therapy.[45] 
We identified two clinical trials that investigated the efficacy of peg-IFNα therapy in chronic 
HDV patients (Table 2).[36, 46] These studies included 128 patients (62% male) allocated to 4 
different intervention groups.[36, 46] The first study compared peg-IFNα (1.5 µg/kg/week) 
with peg-IFNα (1.5 µg/kg/week) in combination with ribavirin (800 mg daily).[46] The second 
study evaluated peg-IFNα (180 µg/week) and adefovir (10 mg daily) combination therapy, the 
combination of peg-IFNα (180 µg/week) and placebo, and adefovir monotherapy (10 mg 
daily).[36] 
Primary outcome measure: One-hundred-twenty-two patients were treated with IFNα for 1-
year [23, 28, 29, 31, 38, 44], 72 patients were treated with low dose (3-5 MU t.i.w.) IFNα.[23, 
28, 29, 31] The combination of undetectable levels of HDV RNA and normal levels of ALT at 
EOT (1-year treatment) was observed in 20% of patients (figure 2).[28, 29, 31] We were not 
able to extract data on the primary outcome measure from one study as this manuscript 
contained only minimal information.[23]  
Twenty-nine percent of high dose (9-18 MU t.i.w.) IFNα treated patients (n=42) reached both 
undetectable HDV RNA and normal ALT levels.[28, 29, 44] Patients on low dose IFNα had a 
similar response compared with high dose IFNα (RR = 0.68; 95% CI 0.31-1.50).  
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Figure 1. Flowchart of included and excluded articles in the systematic literature search  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forty-five patients were treated with peg-IFNα.[36, 46] Only 7% reached combined 
undetectable levels of HDV RNA and normal levels of ALT at EOT.[36] One year treatment with 
low dose IFNα or with peg-IFNα was not significantly different (RR = 2.83; 95% CI 0.65-12.4). 
One year treatment with high dose IFNα was better compared to peg-IFNα (RR = 4.14; 95% CI 
1.00-17.14). 
Secondary outcome measures: Sixteen of 72 patients (22%) treated with low dose IFNα reached 
undetectable levels of HDV RNA at EOT.[23, 28, 29, 31] Similarly, 22% of peg-IFNα treated 
patients (n=45) achieved HDV RNA negativity.[36, 46] Forty-eight percent of 50 high dose IFNα 
treated patients attained undetectable levels of HDV RNA.[28, 29, 38, 44] High dose IFNα was 
11 duplicates removed  
MEDLINE search:              124 hits 
The Cochrane Library search: 4 hits 
Web of Science search:           24 hits 
Clinicaltrials.gov search:         287 hits  9 articles excluded 
Animal studies 
256 studies excluded 
(based on title) 
Studies not evaluating the 
efficacy of therapy for adult 
HDV patients 
 
48 studies excluded (based 
on abstract) 
14 reviews  
2 case series 
6 cross-sectional 
24 cohort 
1 letter to the editor 
1 no full-text version 
3 studies excluded 
2 presentation of the same 
data, but in a preliminary 
setting 
1 cohort study 
4 studies included for 
screening full text  
Reference lists of 8 articles 
identified by this search 
strategy were checked  
 
419 hits  
Screened on title/abstract  
15 hits 
Screened on full text  
 
9 articles included 
7 studies excluded 
3 cohort studies 
1 presentation of same data, 
but in a preliminary setting 
2 due to a lack of 
information or data were not 
reproducible/interpretable 
1 used other outcome 
measures 
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 more effective than low dose IFNα or peg-IFNα to achieve undetectable HDV RNA (RR = 2.16; 
95% CI 1.28-3.63 / RR = 2.16; 95% CI 1.16-4.01). There was no significant difference between 
low dose IFNα or peg-IFNα (RR = 1.00; 95% CI 0.50-2.01). 
Table 1. Interferon alpha therapy in HDV patients 
 
First 
author, 
journal, 
year 
Intervention Treatment 
duration 
(years) 
Patients 
(n) 
Undetectable 
levels of HDV 
RNA & 
normal levels 
of ALT  
(%) 
Undetectable 
levels of HDV 
RNA 
(%) 
Normal 
levels of 
ALT 
(%) 
Rosina 
Hepatology 
1991 
[23] 
 
Rec IFNα-2b 
3x/w  
5 MU/m² 4 
months 3 MU/m² 
8 months 
 
No intervention 
 
1 
 
31 
 
 
 
30 
 
Unknown 
 
 
 
Unknown 
 
0 
 
 
 
0 
26 
 
 
 
0 
Farci  
NEJM  
1994 
[28] 
Rec IFNα-2a 9 MU 
3x/w 
 
Rec IFNα-2a 3 MU 
3x/w 
 
No intervention 
 
1 
 
14 
 
 
14 
 
 
14 
 
50 
 
 
21 
 
 
0 
71 
 
 
36 
 
 
0 
71 
 
 
29 
 
 
8 
Madejon 
Hepatology
1994 
[29] 
3MU rec IFN/day 
3 months; 1.5MU/ 
day for 9 months 
 
18 MU of rec IFN 
3x/w 6 months,9 
MU 3x/w 1 
month,  
6 MU 3x/w 1 
month, 3 MU 
3x/w 4 months 
 
1 
 
16 
 
 
 
16 
 
6 
 
 
 
6 
25 
 
 
 
31 
12 
 
 
 
31 
Gaudin 
Liver  
1995 
[31] 
IFNα-2b; 5 MU 
3x/w 4 months, 3 
MU 3x/w 8 
months  
 
No intervention 
 
1 
 
11 
 
 
 
 
11 
 
36 
 
 
 
 
0 
64 
 
 
 
 
0 
36 
 
 
 
 
0 
Gunsar 
Antiviral 
Therapy 
2005 
[44] 
IFNα-2a 9 MU 
3x/w 2 years 
 
IFNα-2a 9 MU 
3x/w + Ribavirin 
1000-1200 
mg/day 
 
2 
 
10 
 
 
21 
 
50 
 
 
unknown 
50 
 
 
52 
50 
 
 
57 
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 a Treatment-naive patients (n=25). b Previously treated with interferon (IFN; n=14). ALT, alanine 
aminotransferase; IFNα, interferon alpha; HDV, hepatitis delta virus; 3x/w, three times a week; MU, 
million units; 1dd, once daily 
 
 
 
Figure 2: HDV RNA negativity and normal alanine aminotransferase at end of treatment 
The comparison of high-dose IFNα versus 
PEG-IFNα was clinically significant. Values 
above bars represent comparisons 
between the treatment groups with 
associated risk ratios.  
 
 
ALT, alanine aminotransferase; HDV, 
hepatitis delta virus; PEG-IFNα, pegylated 
interferon alpha 
virus; RR, relative risk 
Canbakan 
Gastroente
rol & 
Hepatology 
2006 
[45] 
 
IFNα-2b 10 MU 
3x/w 
 
IFNα-2b 10 MU 
3x/w + 
Lamivudine 100 
mg/day 
 
1 12 
 
 
14 
 
33 
 
 
50 
42 
 
 
64 
42 
 
 
57 
Yurdaydın 
Viral 
Hepatitis 
2008 
[38] 
Lamivudine 100 
mg 1dda 
 
IFNα-2a 9 MU 
3x/wa 
 
Lamivudine (2 
months alone, 
100 mg 1dd) + 
Lamivudine and 
IFNα-2a 10 
monthsa 
 
Lamivudine 100 
mg 1ddb 
 
Lamivudine (2 
months alone, 
100 mg 1dd) + 
Lamivudine and 
IFNα-2a 10 
monthsb 
1 
 
9 
 
 
8  
  
 
8 
 
 
 
 
 
 
8 
 
 
6 
Unknown 
 
 
Unknown 
 
 
Unknown 
 
 
 
 
 
 
Unknown 
 
 
Unknown 
11 
 
 
50 
 
 
50 
 
 
 
 
 
 
13 
 
 
50 
22 
 
 
63 
 
 
75 
 
 
 
 
 
 
13 
 
 
50 
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 Table 2. Peg interferon alpha therapy in HDV patients 
 
 
Treatment with low dose IFNα resulted in normal levels of ALT in 25% of 72 patients.[23, 28, 
29, 31] Normalization of ALT was reached in 25 of 50 high dose IFNα treated patients.[28, 
29, 38, 44] Thirty-one percent of 45 patients achieved normal ALT levels with peg-IFNα.[36, 
46] High dose IFNα was more effective in reaching normal levels of ALT than low dose IFNα 
(RR = 2.00; 95% CI 1.23-3.25). Furthermore, the efficacy of low and high dose IFNα was not 
different from that of peg-IFNα (RR = 0.80; 95% CI 0.45-1.45 / RR = 1.61; 95% CI 0.96-2.69).  
Because none of the manuscripts contained information on the primary outcome measure 
after EOT (for example at 24 weeks after EOT) we were not able to extract these data. Four 
of the 72 patients (6%) treated with low dose IFNα had undetectable HDV RNA 24 weeks after 
EOT.[23, 28, 29, 31] Twenty-nine percent of 38 high dose IFNα treated patients maintained 
undetectable levels of HDV RNA at follow-up week 24.[28, 29, 38] Thirteen of 45 peg-IFNα 
treated patients (29%) achieved negative HDV RNA levels.[36, 46] High dose IFNα and peg-
IFNα were better than low dose IFNα in reaching undetectable HDV RNA 24 weeks after EOT 
(RR = 6.00; 95% CI 0.06-0.49 / RR = 5.99; 95% CI 2.08-17.31). High dose IFNα and peg-IFNα 
were similarly effective (RR = 1.00; 95% CI 0.51-1.97). 
First author, 
journal, year 
 
Intervention Treatment 
duration 
(years) 
Patients 
(n) 
Undetectable 
levels of HDV 
RNA & normal 
levels of ALT  
(%) 
Undetectable 
levels of HDV 
RNA 
(%) 
Normal 
levels of 
ALT 
(%) 
Niro 
Hepatology 
2006 
[46] 
Peg-IFNα-2b 
1.5µg/kg/week 
 
Peg-IFNα-2b 
1.5µg/kg/week 
+ Ribavirin; 800 
mg/day 48 
weeks; Peg-
IFNα-2b 24 
weeks 
monotherapy 
 
1½  
 
16 
 
 
22 
Unknown 
 
 
Unknown 
19 
 
 
9 
37 
 
 
41 
Wedemeyer 
NEJM 2011 
[36] 
Peg-IFNα-2a 
180 µg/week + 
Adefovir 10 mg 
daily 
 
Peg-IFNα-2a 
180 µg/week + 
Placebo 
 
Adefovir 10 mg 
daily 
1 31 
 
 
 
 
29 
 
 
 
30 
 
7 
 
 
 
 
7 
 
 
 
0 
23 
 
 
 
 
24 
 
 
 
0 
32 
 
 
 
 
28 
 
 
 
7 
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 Normal ALT levels 24 weeks after EOT were achieved in 6% of 72 patients treated with low 
dose IFNα.[23, 28, 29, 31] Moreover, 32% of 38 high dose IFNα and 38% of 45 peg-IFNα treated 
patients reached normal levels of ALT.[28, 29, 36, 38, 46] High dose IFNα and peg-IFNα were 
more successful in obtaining normal ALT levels than low dose IFNα at 24 weeks after EOT (RR 
= 5.68; 95% CI 1.97-16.43 / RR = 6.8; 95% CI 2.44-18.92). High dose IFNα and peg-IFNα were 
similarly effective in this respect (RR = 0.84; 95% CI 0.49-1.52).  
For comparison, none of the 55 patients who received placebo or no intervention obtained 
undetectable levels of HDV RNA and ALT levels normalized only in a single patient. There was 
no mortality in patients assigned to no intervention.[23, 28, 31] This contrasts with one 
patient in the high dose IFNα group who died due to liver decompensation in the 5th month 
of therapy[44] and one patient in the low dose IFNα group who committed suicide.[31] 
Five of the 10 patients who were treated for 2 years with high dose IFNα reached undetectable 
HDV RNA and normal ALT levels. One patient obtained normal ALT, but failed to reach 
undetectable HDV RNA.[45] IFNα treatment for 1-year or 2 years was not different (RR = 0.45; 
95%CI 0.17-1.22). The article describing the trial gave no information on mortality.[45] 
IFN alpha based combination therapy and other monotherapies 
A total of 57% of 28 patients on IFNα and lamivudine reached undetectable levels of HDV RNA 
[38, 44], 61% achieved normalization of ALT levels [38, 44], and 50% attained both.[44] IFNα 
monotherapy and IFNα in combination with lamivudine were similarly effective (RR = 0.45; 
95%CI 0.19-1.07). Lamivudine monotherapy was investigated in 17 patients. Undetectable HDV 
RNA was seen in 12%, while 18% reached normal ALT levels.[38] 
One trial studied the combination of IFNα and ribavirin for 2 years. Fifty-two percent of 21 
patients achieved undetectable HDV RNA levels and 57% reached normal ALT levels.[45] Peg-
IFNα in combination with ribavirin resulted in undetectable HDV RNA levels in 9% (2/22 
patients) and in 9/41 patients (41%) normal levels of ALT were obtained.[46] Thirty-one 
patients were treated with peg-IFNα and adefovir, 23% achieved undetectable levels of HDV 
RNA, 32% reached normalization of ALT levels and 7% reached both outcome measures.[36] 
Treatment with peg-IFNα or combination therapy with peg-IFNα and adefovir was not different 
(RR = 1.07; 95%CI 0.16 – 7.10). Thirty patients were treated with adefovir monotherapy, 7% 
reached normal ALT levels, none obtained undetectable HDV RNA levels.[36] 
Adverse events 
Frequencies and percentages of reported adverse events were not always adequately 
documented. Patients receiving IFNα based therapy had a number of well-known adverse 
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 events such as flu-like syndrome, leucopenia, thrombocytopenia and fatigue (Table 3). We 
found no differences in adverse events incidence between the different IFNα based therapies. 
Both in the low dose [23, 28, 29, 31] and high dose IFNα group [28, 29, 38, 44] one patient 
died. None of the patients treated with peg-IFNα [36, 46] or who received no intervention 
deceased.[23, 28, 31] 
Table 3. Adverse events 
 
First author 
journal 
 year 
Intervention Treatment 
duration 
(years) 
 
Patients 
(n) 
Adverse events  
(n) 
Rosina 
Hepatology 
1991 
 
Rec IFNα-2b 
3x/w, 
5 MU/m² 4 
months, 3 
MU/m² 8 
months 
 
1  
 
31 
 
 
 
Flu-like symptoms (31), fatigue (31), 
weight loss (31), alopecia (6), nausea and 
anorexia (4), vomiting (2), impaired 
consciousness (1), rhinorrhea (1), ulcer 
at the injection site (1), acute icteric 
hepatitis (1)  
 
Farci 
NEJM 1994 
 
Rec IFNα-2a 9 
MU 3x/w 
 
1 14 
 
Flu-like symptoms, asthenia (10), 
alopecia (8), anemia (1) 
 
Farci 
NEJM 1994 
 
Rec IFNα-2a 3 
MU 3x/w 
1  14 Flu-like symptoms, asthenia (4) , 
alopecia (4) 
Madejon 
Hepatology 
1994 
3MU rec 
IFN/day 3 
months; 
1.5MU/day for 
9 months 
 
1 
 
16 
 
Asthenia (7), anorexia (7), fever (5), 
weight loss (6), arthralgias (5), hair loss 
(4), headache (5), itching (2) 
Madejon  
Hepatology 
1994 
 
18MU of rec 
IFN 3x/w 6 
months, 9MU 
3x/w 1 month, 
6MU 3x/w 1 
month, 3MU 
3x/w 4 months 
 
1 
 
16 
 
Asthenia (11), anorexia (9), fever (10), 
weight loss (9), arthralgias (8), hair loss 
(8), headache (7), itching (2) 
Gaudin  
Liver 1995 
IFN α-2b 5MU 
3x/w 4 
months, 3MU 
3x/w 8 months  
 
1  11 
 
Flu-like syndrome(11), hyperthyroidism 
(1), death by suicide (1), attempted 
suicide (1), leucopenia, 
thrombocytopenia 
Gunsar 
Antiviral 
Therapy 
2005 
 
IFNα-2a 9 MU 
3x/w  
 
2  10 
 
 
 
Leucopenia (1) 
 
 
 
Gunsar IFNα-2a 9 MU 
3x/w +  
2 21 
 
Leucopenia (3), anemia (2) 
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 Antiviral 
Therapy 
2005 
 
Ribavirin 
1000-1200 
mg/day 
Canbakan 
Gastroentero
logy and 
Hepatology 
2006 
 
IFNα-2b 10 MU 
3x/w 
 
 
1 
 
12 Fatigue (5), fever (4), nausea-vomiting 
(4), abdominal pain (2), myalgia (2), 
headache (1), Hair loss (2), influenza-like 
symptoms (1) 
Canbakan 
Gastroentero
logy and 
Hepatology 
2006 
 
IFNα-2b 10 MU 
3x/w +  
Lamivudine 
100 mg/day 
 14 
 
Fatigue (7), fever (4), nausea-vomiting 
(3), abdominal pain (2), myalgia (1), 
headache (1), depression (1), influenza-
like symptoms (1) 
Yurdaydın 
Viral 
Hepatitis 
2008 
 
naive patients 
(25) 
 
previously 
used IFN (14) 
1  25 
  
14 
 
Not mentioned 
Niro 
Hepatology 
2006 
Peg-IFNα-2b 
1.5 µg/ 
kg/week   
1½  
 
16 
 
 
 
Thrombocytopenia (6), neutropenia (2), 
fatigue, headache, insomnia and 
irritability, arthralgia, cellulitis, urinary 
and respiratory infections, nausea, 
injection site reactions, depression 
 
Niro 
Hepatology 
2006 
Peg-IFNα-2b 
1,5µg/kg/ 
week + Riba-
virin; 800 mg/ 
day 48 weeks;  
Peg-IFNα-2b 
24 weeks 
monotherapy 
 
1½  
 
 
22 Thrombocytopenia (7) , neutropenia (6), 
anemia (4), gammaglutamyltransferase 
elevation (1) fatigue, headache, 
insomnia and irritability, arthralgia, 
cellulitis, urinary and respiratory 
infections, generalized itching, nausea, 
injection site reactions, depression 
 
Wedemeyer 
NEJM 2011 
Peg-IFNα-2a 
180 µg/week + 
adefovir 10 
mg daily 
 
 
 
 
1 31 
 
 
Loss of appetite (3), influenza-like 
symptoms (6), fatigue (8), pyrexia (6), 
sexual (2), headache (8), cough (3), 
nausea (3), abdominal pain (7), pruritus 
(2), rash or rashlike event (8), hair loss 
(6), psychiatric (2), insomnia (2), myalgia 
(7), arthralgia (4), neutropenia (3), 
thrombocytopenia (5) 
 
Wedemeyer 
NEJM 2011 
Peg-IFNα-2a 
180 µg/week + 
placebo 
 
1 29 
 
Loss of appetite (3), influenza-like 
symptoms (2), fatigue (8), pyrexia (2), 
dry mouth (6), sexual (1), headache (9), 
dizziness (1), cough (3), nausea (4), 
abdominal pain (7), pruritus (4), rash or 
rashlike event (3), hair loss (2), 
psychiatric (5), insomnia (4), myalgia (8), 
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 arthralgia (6), neutropenia (2), 
thrombocytopenia(2) 
 
Wedemeyer 
NEJM 2011 
Adefovir 10 
mg daily 
1 30 Loss of appetite (3), influenza-like 
symptoms (3), fatigue (4), headache (5), 
dizziness (3), cough (2), nausea (2), 
abdominal pain (5), pruritus (2), rash or 
rashlike event (4), hair loss (1), 
psychiatric (1), insomnia (1), myalgia (1), 
arthralgia (1) 
 
Flu-like syndrome = fever, arthralgia, etc.; 3x/w, three times a week; MU, million units 
 
Discussion 
In general, we found efficacy rates of 10-30% in achieving both undetectable levels of HDV 
RNA and normal levels of ALT. These rates indicate that this is an area of clear unmet need. 
No specific HDV inhibitors have been developed so far. Based on our current knowledge of 
HDV replication, HBV therapies would be theoretically attractive only if they 1) cleared HBV 
entirely or 2) reduced levels of HBsAg, on which HDV depends.  
The use of HBV inhibitors in HDV has been disappointing and these drugs appear to have no or 
little effect on HDV replication.[48] Combination of IFNα with nucleoside or nucleotide 
analogous did not improve virological response rates. However, combination of peg-IFNα and 
adefovir was superior in reducing quantitative HBsAg levels and induces more often HBsAg 
seroconversion. As a consequence, combination therapies of peg-IFNα with more potent HBV 
polymerase inhibitors aiming to induce clearance of both HBsAg and HDV RNA should be 
explored in HDV.[36] 
There is a lack of RCTs in HDV treatment that are useful for the clinician in making evidence 
based decisions. The number of RCTs describing the clinical efficacy of different treatment 
strategies in HDV patients is low. We only found 13 RCTs published between 1970 and January 
2011. Only 2 of them were RCTs evaluating the efficacy of peg-IFNα.[36, 46] For comparison, 
between April 2010 and April 2011 alone, already some 20 RCTs in HBV were reported in the 
literature. An explanation for this difference could be a reduced interest in HDV therapy by 
pharmaceutical companies because of the relative low burden of HDV infection in western 
countries.[49-51] 
Obviously, new treatment strategies for HDV are needed. Future trials should be powered to 
detect meaningful differences in the primary outcome, which in this era will be tested with 
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 more reliable and optimal laboratory diagnostics. Furthermore, trials should differentiate 
between naive and previously treated patients and ideally a long term follow-up is needed to 
evaluate different treatment outcomes of equal duration.  
A new upcoming class of antiviral agents are prenylation inhibitors. These agents block HDAg 
prenylation, an essential step in the assembly of HDV.[52] Prenylation inhibitors clear HDV 
from experimental mouse models and are obviously agents that should be tested in a clinical 
setting.[53] Indeed, clinical trials with these agents have started.[54]  
Another issue that requires further investigation concerns the length of treatment. As 
mentioned, 2 years of IFNα treatment seems better than 1-year.[45] Recently, a Turkish study 
group retrospectively analyzed standard (<18 months; n = 47) or long term (>18 months; n = 
34) conventional or peg-IFNα treatment. The primary endpoint of this study was ALT 
normalization for at least 6 months post-treatment and undetectable HDV RNA. Preliminary 
results suggested that standard 1-year course of treatment with IFNα is most likely not enough 
to achieve ALT normalization in the majority of patients with HDV, and that prolongation of 
treatment is critical. However, results have only been published in abstract-form.[55] 
Moreover, in the reviewed trials most patients relapsed after stopping therapy, suggesting 
that longer treatment might be beneficial.  
This review has some limitations. There is no standardized, universally accepted definition of 
remission in HDV patients. Each described trial used their private end points. For example ALT 
which was used as end point in all included trials.[23, 28, 29, 31, 36, 38, 44-46] One article 
described normalization of ALT as ‘normalization of ALT levels’ [28], whereas another trial 
described it as ‘a decrease of ALT that was greater than or equal to 50% from baseline to a 
less than 1,5 times the upper limit of normal’.[23] Furthermore, other endpoints of relevance 
to HDV, such as histological grading and staging, HBV DNA, and HBsAg could not be 
investigated here. These variables should also be considered in treatment decisions. 
One of the most important limitations of this study is the problem with HDV RNA assays. Earlier 
studies may have used less sensitive HDV RNA assays and thus overestimated virological 
response rates as compared to more recent trials investigating peg-IFNα.[56] The limit of 
detection used in the early studies varied between 10 and 100 viral particles per ml [29, 31], 
compared to 1 to 10 viral particles per ml in the latest studies.[36, 46] 
In addition, peg-IFNα may be associated with some increase in ALT levels despite virological 
response. This phenomenon has been described for HCV infection.[57] Therefore the use of 
ALT levels as the only outcome measure might underestimate the effect of peg-IFNα.  
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 Another limitation is the short follow-up duration. The majority of studies provided results at 
EOT and some also at 24 weeks after treatment discontinuation. To be sure that a virologic 
response is achieved, a longer follow-up would be necessary taking into account that HDV RNA 
concentrations fluctuate spontaneously.[58] 
Furthermore, the trials used various doses of IFNα. Therefore, we were not able to extract 
the best dose needed for the most optimal response rates. Unfortunately, we were also not 
able to distinct between naive and treatment experienced patients. There is definitively a 
need for trials that distinguish between these two categories of patients. Moreover, variations 
in medication schemes, IFNα based therapy (for example peg-IFNα 2a or 2b), outcome 
measures, and validity of trials introduced heterogeneity between included studies. Although 
high dose IFNα seemed more effective than peg-IFNα no formal head-to-head studies have 
been performed and results are based upon indirect comparisons. In addition, most studies 
include a small number of patients. Indeed, current therapy is based on 13 trials published 
since 1970 with only 457 patients, reflecting the paucity of evidence. We also noted some 
redundancy in the literature. There are a number of articles that report on similar dataset 
and seem to reuse data from the same patient cohort in subsequent articles.[23, 24, 31, 59, 
60] We have excluded these articles from our analysis. In the same context we note that there 
is also an absence of structured and systematic recording of adverse events in HDV therapy.  
In conclusion, one year high dose IFNα monotherapy appears to be more effective than peg-
IFNα for treatment of HDV patients. Unfortunately, efficacy rates are only ~ 30% at EOT. 
Ideally, a long-term follow-up is needed to evaluate different outcomes of equal duration for 
IFNα and peg-IFNα with the same test used to detect HDV RNA and a comparable long term 
histological evaluation. Alternative proposed strategies are very welcome to improve the 
current treatment armamentarium.
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Abstract 
Background: Around 3% of the world's population (approximately 160 million people) are 
chronically infected with hepatitis C virus. The proportion of infected people who develop 
clinical symptoms varies between 5% and 40%. Combination therapy with pegylated interferon-
alpha plus ribavirin eradicates the virus from the blood six months after treatment (sustained 
virological response) in approximately 40% to 80% of infected patients, depending on the viral 
genotype. New antiviral agents, such as boceprevir and telaprevir, in combination with 
standard therapy, can increase sustained virological response in genotype 1 infected patients 
to at least 70%. There is therefore an unmet need for drugs that can achieve a higher 
proportion of sustained virological response. Aminoadamantanes are antiviral drugs used for 
treatment of patients with chronic hepatitis C. 
Objectives: To assess the beneficial and harmful effects of aminoadamantanes for patients 
with chronic hepatitis C infection by conducting a systematic review with meta-analyses of 
randomised clinical trials, as well as trial sequential analyses. 
Search methods: We conducted electronic searches of the Cochrane Hepato-Biliary Group 
Controlled Trials Register (1996 to December 2013), the Cochrane Central Register of 
Controlled Trials (CENTRAL) 2013, Issue 11 of 12 (1995 to December 2013), MEDLINE (1946 to 
December 2013), EMBASE (1974 to December 2013), Science Citation Index EXPANDED (1900 
to December 2013), the WHO International Clinical Trials Registry Platform 
(www.who.int/ictrp), Google Scholar, and Eudrapharm up to December 2013 and checked the 
reference lists of identified publications. 
Selection criteria: Randomised clinical trials assessing aminoadamantanes in patients with 
chronic hepatitis C infection. 
Data collection and analysis: Two authors independently extracted data. We assessed for 
risks of systematic errors ('bias') using the 'Risk of bias' tool. We analysed dichotomous data 
with risk ratio (RR) and continuous data with mean difference (MD) or standardised mean 
difference (SMD), both with 95% confidence intervals (CI). We used trial sequential analysis to 
assess the risk of random errors ('play of chance'). We assessed quality using the GRADE 
system. 
Main results: We included 41 randomised clinical trials with 6193 patients with chronic 
hepatitis C. All trials had high risk of bias. All included trials compared amantadine versus 
 68
Chapter 4
 placebo or no intervention. Standard antiviral therapy was administered equally to the 
intervention and the control groups in 40 trials. The standard antiviral therapy, which was 
administered to both intervention groups, was interferon-alpha, interferon-alpha plus 
ribavirin, and peg interferon-alpha plus ribavirin, depending on the time when the trial was 
conducted. 
When we meta-analysed all trials together, the overall results demonstrated no significant 
effects of amantadine, when compared with placebo or no intervention, on our all-cause 
mortality or liver-related morbidity composite outcome (5/2353 (0.2%) versus 6/2264 (0.3%); 
RR 0.90, 95% CI 0.38 to 2.17; I² = 0%; 32 trials; very low quality). There was also no significant 
effect on adverse events (288/2869 (10%) versus 293/2777 (11%); RR 0.98, 95% CI 0.84 to 1.14; 
I² = 0%; 35 trials; moderate quality). We used both fixed-effect and random-effects meta-
analyses. Amantadine, when compared with placebo or no intervention, did not significantly 
influence the number of patients who failed to achieve a sustained virological response 
(1821/2861 (64%) versus 1737/2721 (64%); RR 0.98, 95% CI 0.95 to 1.02; I² = 35%; 35 trials; 
moderate quality). However, in the subgroup using interferon plus ribavirin, amantadine 
decreased the number of patients who failed to achieve a sustained virological response 
(422/666 (63%) versus 447/628 (71%); RR 0.89, 95% CI 0.83 to 0.96; I² = 41%; 11 trials; low 
quality). Similar results were found for failure to achieve an end of treatment virological 
response. Amantadine, when compared with placebo or no intervention, significantly 
decreased the number of patients without normalisation of alanine aminotransferase (ALT) 
serum levels at the end of treatment (671/1141 (59%) versus 732/1100 (67%); RR 0.88, 95% CI 
0.83 to 0.94; I² = 47%; 19 trials; low quality). Amantadine, when compared with placebo or 
no intervention, did not significantly influence the end of follow-up biochemical response 
(1133/1896 (60%) versus 1151/1848 (62%); RR 0.95, 95% CI 0.91 to 1.00; I² = 49%; 21 trials; 
low quality). 
The observed beneficial effects could be true effects but could also be due to both systematic 
errors (bias) and random errors (play of chance). The latter is due to the fact that trial 
sequential analyses could not confirm or refute our findings. We were not able to perform 
meta-analyses for failure of histological improvement or quality of life due to a lack of valid 
data. 
Authors' conclusions: This systematic review does not demonstrate any significant effects 
of amantadine on all-cause mortality or liver-related morbidity composite outcome and on 
adverse events in patients with hepatitis C; however, the median trial duration was 12 
months, with a median follow-up of six months, which is not long enough to assess the 
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 composite outcome sufficiently. Overall, we did not see an effect of amantadine on failure to 
achieve a sustained virological response. Subgroup analyses demonstrated that the 
combination of amantadine plus interferon-alpha and ribavirin seems to increase the number 
of patients achieving a sustained virological response. This finding may be caused by both 
systematic errors (bias) and risks of random errors (play of chance), but it could also be real. 
Based on the results of the overall evidence, it appears less likely that future trials assessing 
amantadine for patients with chronic hepatitis C will show strong benefits. Therefore, it is 
probably advisable to wait for the results of trials assessing other direct-acting antiviral drugs. 
In the absence of convincing evidence of benefit, the use of amantadine is justified in the 
context of randomised clinical trials assessing the effects of combination therapy. We found 
a lack of evidence on other aminoadamantanes than amantadine. 
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 Summary of findings 
Summary of findings for the main comparison. 
Aminoadamantanes compared with placebo or no intervention for hepatitis C 
Patient or population: patients with chronic hepatitis C 
Settings: mainly outpatients in tertiary and teaching hospitals 
Intervention: aminoadamantanes 
Comparison: placebo or no intervention 
Outcomes Illustrative comparative risks*  
(95% CI) 
Relative 
effect 
(95% CI) 
No of 
participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Assumed risk Corresponding 
risk 
Placebo or no 
intervention 
Aminoadamant
anes 
All-cause 
mortality or 
liver-related 
morbidity 
Follow-up: 12 to 
30 months 
Study population RR 0.90 
(0.38 to 
2.17) 
4617 
(32 trials) 
⊕⊝⊝⊝ 
very low 1 3 per 1000 3 per 1000  
(2 to 8) 
Adverse 
events 
Follow-up: 12 to 
30 months 
Study population RR 0.98 
(0.84 to 
1.14) 
5646 
(35 trials) 
⊕⊕⊕⊝ 
moderate
2 
106 per 1000 101 per 1000  
(87 to 118) 
Failure of end 
of treatment 
virological 
response 
Absence of 
clearance of 
HCV RNA from 
the blood at 
end of 
treatment 
Follow-up: 6 to 
12 months 
Study population RR 0.95 
(0.90 to 
1.00) 
4861 
(30 trials) 
⊕⊕⊕⊝ 
moderate
2 
534 per 1000 519 per 1000  
(492 to 547) 
Failure of 
sustained 
Study population RR 0.98 
(0.95 to 
1.02) 
5582 
(35 trials) 
⊕⊕⊕⊝ 
moderate
2 
639 per 1000 637 per 1000  
(618 to 663) 
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 virological 
response 
Absence of 
clearance of 
HCV RNA from 
the blood 6 
months after 
treatment 
Follow-up: 12 to 
30 months 
Quality of life 
Different QoL 
scales 
Follow-up: 12 to 
30 months 
See comment See comment   1181 
(6 trials) 
⊕⊝⊝⊝ 
very 
low3,4 
Failure of 
normalisation 
of ALT at end 
of treatment 
Follow-up: 6 to 
12 months 
Study population RR 0.88 
(0.83 to 
0.94) 
2241 
(19 trials) 
⊕⊕⊝⊝ 
low2 666 per 1000 589 per 1000  
(556 to 629) 
Failure of 
normalisation 
of ALT at end 
of follow-up 
Follow-up: 12 to 
30 months 
Study population RR 0.95 
(0.91 to 
1.00) 
3744 
(21 trials) 
⊕⊕⊝⊝ 
low2 623 per 1000 598 per 1000  
(573 to 630) 
*The basis for the assumed risk (e.g., the median control group risk across studies) is 
provided in footnotes. The corresponding risk (and its 95% confidence interval) is based 
on the assumed risk in the comparison group and the relative effect of the intervention 
(and its 95% CI). 
ALT: alanine aminotransferase; CI: confidence interval; HCV: hepatitis C virus; QoL: 
quality of life; RNA: ribonucleic acid; RR: risk ratio. 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of 
effect. 
Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
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 Background 
Description of the condition 
Hepatitis C virus was first described in 1989 (Choo 1989). Around 3% of the world's population 
is affected by chronic hepatitis C infection: on average approximately 160 million people (Sy 
2006; Lavanchy 2011). Hepatitis C is a leading cause of liver-related morbidity and mortality, 
with hepatic fibrosis, end-stage liver cirrhosis, and hepatocellular carcinoma being the 
dominant clinical sequelae (Sy 2006). 
Chronic hepatitis C infection progresses slowly, over a time frame of 15 to 50 years. Both 
prospective or retrospective studies, following cohorts of patients for decades, suggest that 
less than 10% of all infected individuals will develop end-stage liver disease. However, there 
are also publications that have reported on patients who developed cirrhosis two to three 
decades after infection, with a range of 0.5% to 39% (Koretz 1993; Kenny-Walsh 1999; Rodger 
2000; Wiese 2000; Thein 2008; Seeff 2009). The incidence rate of hepatocellular carcinoma is 
3 patients per 100,000 person-years in the USA (El-Serag 2003). Hepatitis C is responsible for 
one-third of hepatocellular carcinomas (El-Serag 2003). In cirrhotic hepatitis C patients, the 
annual occurrence of hepatocellular carcinoma is 1% to 4% (Lauer 2001). Furthermore, chronic 
hepatitis C infection is the most common indication for orthotopic liver transplantation (Kim 
2009). 
Hepatitis C is divided into six genotypes (Simmonds 2005). Genotypes 1 to 4 are the most 
common (Simmonds 2005). Several factors have an influence on achieving a sustained 
virological response to antiviral drugs; genotype is one of these factors (Asselah 2010). 
Genotypes 2 and 3 respond better to antiviral treatment than genotypes 1 and 4 (Asselah 
2010). 
In 1990, the antiviral drug interferon-alpha was approved for the treatment of chronic 
hepatitis C as monotherapy (Tine 1991). Interferon-alpha was administered subcutaneously in 
doses of more than or equal to 3 million units (MU) in the induction phase (over one to three 
months) and less than 3 MU in the maintenance phase (Tine 1991). Only 10% to 17% of patients 
achieved sustained virological response, compared to 1% to 3% of the patients receiving no 
intervention (Davis 1989; Myers 2002). 
Antiviral drugs for patients with hepatitis C-related liver disease have improved considerably 
during the past two decades (Ghany 2009). In 1998, trials assessed the combination of 
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 interferon-alpha and ribavirin (Davis 1998; McHutchison 1998; Poynard 1998). This 
combination treatment resulted in an improved antiviral response in treatment-naive chronic 
hepatitis C-infected patients (Brok 2010) and in previously treated patients who had failed to 
respond to interferon-alpha monotherapy, compared with interferon-alpha alone (Brok 2010). 
The success of antiviral therapy has been assessed by 'sustained virological response', that is 
clearance of hepatitis C ribonucleic acid (RNA) from the blood six months after treatment. 
Observational studies suggest that people with achieved sustained virological response have 
less disease progression and lower risk of hepatocellular carcinoma (Ueno 2009). Based on 
systematic reviews of randomised clinical trials comparing ribavirin plus interferon-alpha 
versus interferon-alpha alone, the combination of drugs seems to result in more patients with 
achieved sustained virological response, but we do not know if this results in less mortality or 
morbidity (Brok 2010). Accordingly, sustained virological response is a non-validated, 
putative, surrogate outcome measure (Gluud 2007). Furthermore, a recent trial has shown 
that there is increased mortality in patients who were retreated with interferon-alpha 
compared with non-treated patients (Di Bisceglie 2011). Other trials cannot confirm or 
invalidate this finding (Di Martino 2011). 
The standard of treatment of chronic hepatitis C infection, according to guidelines, is a 
combination of pegylated interferon-alpha (peg interferon-alpha) and ribavirin (Ghany 2009; 
EASL 2011). The regimen can include either peg interferon-alpha-2b (Peg-Intron®, Schering 
Plough Corp., Kenilworth, NJ) or peg interferon-alpha-2a (Pegasys®, Hoffmann-La Roche, 
Nutley, NJ), both of which are administered subcutaneously (Awad 2010). The optimal dose 
of peg interferon-alpha-2b is 1.5 µg/kg/week (Awad 2010). Peg interferon-alpha-2a is 
administered at a fixed dose of 180 µg weekly (Awad 2010). Ribavirin is administered orally 
with weight-based total daily doses between 800 mg and 1200 mg (Brok 2009). Some 40% to 
80% of chronic hepatitis C patients without co-infection with hepatitis B virus or human 
immunodeficiency virus (HIV) will achieve a sustained virological response after treatment 
with peg interferon-alpha and ribavirin (Simin 2007; Awad 2010). 
Recently, a new class of drugs for hepatitis C genotype 1 has emerged. These drugs have to 
be given together with the current standard treatment. They are antiviral agents that inhibit 
the NS3/N4A serine protease of hepatitis C. This triple therapy can increase sustained 
virological response proportions to reach 70% to 80% (Bacon 2011; Jacobson 2011; Poordad 
2011; Sherman 2011; Zeuzem 2011). 
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 During the 1990s and 2000s, ribavirin was tested as monotherapy for chronic hepatitis C 
infection (Brok 2009). Ribavirin does not seem to have any major effect on the course of 
hepatitis C infection (Brok 2009). 
Description of the intervention 
Aminoadamantanes, such as amantadine and rimantadine, are another antiviral drug group 
and have also been investigated in several studies for treatment of patients with chronic 
hepatitis C (Brillanti 1999; Smith 2004). Aminoadamantanes have been investigated as oral 
monotherapy, administered mostly at a dose of 100 mg twice a day, and also in combination 
with interferon-alpha or ribavirin, or both. The benefits and harms of amantadine in patients 
with chronic hepatitis C infection have been explored previously in a meta-analysis (Deltenre 
2004). The authors concluded that amantadine therapy had no effect in naive patients or 
relapsers. However, combination therapy of amantadine with interferon-alpha and ribavirin 
did improve sustained virological response proportions in non-responder patients. 
How the intervention might work 
Aminoadamantanes have been used for many years to prevent infection with influenza and 
have been shown to have activity against Flaviviridae, encompassing hepatitis C infection 
(Koff 1980). Known mechanisms of action of aminoadamantanes include inhibition of an early 
step in viral replication, most likely viral uncoating and interaction with the influenza A viral 
matrix protein (M2), which is important in virion budding (De Clercq 2001). The 
aminoadamantane amantadine acts in a similar way to ribavirin, which in monotherapy often 
improves liver biochemistry (Reichard 1991; Brok 2009). However, it is unclear whether 
aminoadamantanes reduce the hepatitis C viral load or improve liver biochemistry (Reichard 
1993). Furthermore, it is unclear whether aminoadamantanes affect patient-relevant 
outcomes. 
Why it is important to do this review 
The combination therapy of peg interferon-alpha and ribavirin achieves virus eradication of 
approximately 40% to 80% (Simin 2007; Awad 2010). This indicates that there is an unmet need 
for drugs which can achieve a higher proportion of sustained virological response. With the 
new direct antiviral agents, higher proportions can be reached, but still not 100% (Bacon 2011; 
Jacobson 2011; Poordad 2011; Sherman 2011; Zeuzem 2011). Several studies have so far been 
published regarding the effects of aminoadamantanes. Our systematic review aims to assess 
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 the benefits and harms of aminoadamantanes. This systematic review may have practical 
implications for the way patients with chronic hepatitis C are treated. 
We are aware of a meta-analysis by Deltenre 2004, who studied the benefits and harms of 
aminoadamantanes for patients with chronic hepatitis C. A total of 31 randomised clinical 
trials including 4831 patients with chronic hepatitis C infection were included in this meta-
analysis. Since 2004, new randomised clinical trials of aminoadamantanes have been 
conducted and our review therefore includes all the trials identified both before and after 
this meta-analysis. 
Objectives 
To assess the beneficial and harmful effects of aminoadamantanes for patients with chronic 
hepatitis C infection by conducting a systematic review with meta-analyses of randomised 
clinical trials, as well as trial sequential analyses. 
 
Methods 
Criteria for considering studies for this review 
Types of studies 
Randomised clinical trials assessing aminoadamantanes in patients with chronic hepatitis C 
infection irrespective of duration of treatment, language, publication type or status, and 
blinding. We excluded quasi-randomised studies or other observational studies captured 
during the search process from the reporting of benefit but they were included for the 
reporting of harm. However, we did not conduct specific searches for the latter studies. 
Types of participants 
We included patients with chronic hepatitis C. The diagnosis was based on the presence of 
serum hepatitis C RNA plus elevated transaminases for more than six months, or chronic 
hepatitis documented by liver biopsy. We also included patients diagnosed with 'non-A, non-
B' chronic hepatitis as some trials may have been conducted before hepatitis C RNA analyses 
were widely available. 
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 Based on the existence of and response to previous antiviral treatment, we classified the 
included patients as naive (not previously treated with antivirals), relapsers (patients with a 
transient serological viral response to previous treatment with antivirals), or non-responders 
(patients without a serological viral response to previous treatment with antivirals). 
We excluded patients with chronic hepatitis C who had undergone liver transplantation. 
Types of interventions 
We aimed to perform the following comparisons. 
• Aminoadamantanes versus placebo or no intervention. 
• Aminoadamantanes plus standard antiviral therapy versus standard antiviral therapy 
alone. 
• High-dose aminoadamantanes versus low-dose aminoadamantanes. 
• Long-duration aminoadamantanes versus short-duration aminoadamantanes. 
Co-interventions were allowed if administered equally to the intervention groups. 
Types of outcome measures 
Primary outcomes 
1. All-cause mortality or liver-related morbidity as a composite outcome: number of patients 
who died or who developed, for example, cirrhosis (compensated or decompensated), 
ascites, hepatic encephalopathy, or hepatocellular carcinoma during treatment. 
2. Adverse events (according to the Code of Federal Regulations and ICH guidelines (ICH-
GCP)): number of patients with either serious adverse events or treatment discontinuation 
due to any adverse event. An adverse event is defined as "Any untoward medical 
occurrence in a patient or clinical investigation subject administered a pharmaceutical 
product and which does not necessarily have to have a causal relationship with this 
treatment" (ICH-GCP 1997). 
3. Quality of life (as reported in the trials). 
Secondary outcomes 
1. Failure of serum (or plasma) sustained virological response: number of patients with 
detectable hepatitis C RNA at least six months after treatment. 
2. Failure of end of treatment virological response: number of patients with detectable 
hepatitis C RNA at the end of treatment. 
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 3. Failure of histological response: number of patients without improvement of histology 
(inflammation score (grading) or fibrosis score (staging) as defined by the individual trials). 
4. Number of patients without normalisation of alanine aminotransferase (ALT) or aspartate 
transaminase (AST) serum levels or both (defined by the individual trials) at end of 
treatment and end of follow-up. 
Search methods for identification of studies 
Electronic searches 
We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (1996 to December 
2013) (Gluud 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 
11 of 12 (1995 to December 2013), MEDLINE (1946 to December 2013), EMBASE (1974 to 
December 2013), and Science Citation Index EXPANDED (1900 to December 2013) (Royle 2003). 
We also searched the WHO International Clinical Trials Registry Platform 
(www.who.int/ictrp), Google Scholar, and Eudrapharm. We have provided the search 
strategies in Appendix 1. We performed the latest search in December 2013. We will improve 
the searches for any later updates, if necessary. 
Searching other resources 
We searched for further trials by reading the reference lists of the identified publications. We 
checked the retrieved review articles and meta-analyses in order to find randomised clinical 
trials not identified by the electronic searches. We searched the journals Hepatology and 
Journal of Hepatology for abstracts from various gastrointestinal meetings. We wrote to the 
principal authors of the identified randomised clinical trials to request additional information. 
Data collection and analysis 
Selection of studies 
Two authors (ML, MB) independently inspected each reference identified by the searches and 
applied the inclusion criteria. For possibly relevant publications, or in cases of disagreement, 
we obtained the full article and inspected this independently. In cases where ML and MB still 
disagreed, CG was consulted. 
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 Data extraction and management 
Two authors (ML, MB) extracted data independently. In case of disagreement between the 
two authors, a third author (CG) arbitrated. We discussed the data extraction, documented 
decisions and, where necessary, contacted the authors of trials for clarification. Trials were 
identified by the name of the first author and year in which the trial was published in full and 
ordered chronologically. 
We extracted, checked, and recorded the following data: 
• Characteristics of trials: date, location and setting; publication status; sponsor (specified, 
known, or unknown); duration of follow-up; bias domains; sample size calculation. 
• Characteristics of participants: number of participants in each group; age; sex; ethnicity; 
weight or body mass index; viral load at the beginning of treatment; degree of fibrosis at 
the beginning of treatment. 
• Characteristics of interventions: dose and duration of aminoadamantanes, and any co-
interventions. 
• Characteristics of outcome measures: whenever possible, we recorded the number of 
events listed under 'outcomes' in each group of the trial; we extracted information about 
harms from observational studies. 
We incorporated cross-over trials in meta-analysis by using the end of first period strategy, 
which indicates that the analysis is based on only the first period of the included trial. 
Assessment of risk of bias in included studies 
Methodological quality is defined as confidence that the design and reporting of a randomised 
clinical trial will restrict bias in the comparison of the intervention (Moher 1998). According 
to empirical evidence, risk of bias in a trial can be assessed using 'Risk of bias' domains (Schultz 
1995; Moher 1998; Kjaergard 2001; Wood 2008; Lundh 2012; Savović 2012; Savović 2012a). 
These are the following. 
Allocation sequence generation 
• Low risk of bias: sequence generation was achieved using computer random number 
generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and 
throwing dice are adequate if performed by an independent research assistant not 
otherwise involved in the trial. 
• Uncertain risk of bias: the method of sequence generation was not specified. 
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 • High risk of bias: the sequence generation method was not random. 
Allocation concealment 
• Low risk of bias: the participant allocations could not have been foreseen in advance of, 
or during, enrolment. Allocation was controlled by a central and independent 
randomisation unit. The allocation sequence was unknown to the investigators (for 
example, if the allocation sequence was hidden in sequentially numbered, opaque, and 
sealed envelopes). 
• Uncertain risk of bias: the method used to conceal the allocation was not described so 
that intervention allocations may have been foreseen in advance of, or during, enrolment. 
• High risk of bias: the allocation sequence was likely to be known to the investigators who 
assigned the participants. 
Blinding of participants and personnel 
• Low risk of bias: it was described that both the participants and the personnel were 
blinded, and the method of blinding was described, so that knowledge of group assignment 
was adequately prevented during the trial. 
• Uncertain risk of bias: it was not described if the trial was blinded, or the trial was 
described as blind but the method of blinding was not described, so that knowledge of 
group assignment was possible during the trial. 
• High risk of bias: the trial was not blinded, so that the group assignment was known during 
the trial. 
Blinded outcome assessment 
• Low risk of bias: outcome assessment was done blinded for all relevant outcomes, and the 
method of blinding was described, so that knowledge of group assignment was adequately 
prevented. 
• Unclear: it was not described if outcome assessment was blinded, or the outcome 
assessment was described as blind, but the method of blinding was not described, so that 
knowledge of group assignment was possible. 
• High risk of bias: outcome assessment was not blinded, so that the group assignment was 
known for outcome assessors. 
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 Incomplete outcome data 
• Low risk of bias: missing data were unlikely to make treatment effects depart from 
plausible values. Sufficient methods, such as multiple imputation, have been employed to 
handle missing data. 
• Uncertain risk of bias: there was insufficient information to assess whether missing data 
in combination with the method used to handle missing data were likely to induce bias on 
the results. 
• High risk of bias: the results were likely to be biased due to missing data. 
Selective outcome reporting 
• Low risk of bias: all outcomes were predefined (for example, in a published protocol) and 
reported, or all clinically relevant and reasonably expected outcomes were reported, 
which included all primary and secondary outcome measures as stated under 'Types of 
outcome measures'. 
• Uncertain risk of bias: it is unclear whether all predefined and clinically relevant and 
reasonably expected outcomes were reported, which included all primary and secondary 
outcome measures as stated under 'Types of outcome measures'. 
• High risk of bias: one or more clinically relevant and reasonably expected outcomes, which 
included all primary and secondary outcome measures as stated under 'Types of outcome 
measures', were not reported, and data on these outcomes were likely to have been 
recorded. 
Vested interest bias 
• Low risk of bias: if the trial's source(s) of funding did not come from any parties that might 
have conflicting interests (e.g., an amantadine manufacturer), or if any academic, 
professional, financial, or other benefits to the person responsible for the trial were 
independent of the direction or statistical significance of the trial results. 
• Uncertain: if the source of funding was not clear, or if it was unclear if the person 
responsible for the trial stands to benefit according to the direction or statistical 
significance of the trial results. 
• High risk of bias: if the trial's source of funding had a conflict of interest, or if any 
academic, professional, financial, or other benefits to the person responsible for the trial 
were dependent of the direction or statistical significance of the trial results. 
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 We assessed all trials for risk of bias. If we judged the risk of bias in a trial as 'uncertain' or 
'high' for a domain, then we considered the trial to have 'high risk of bias'. If we judged a trial 
as low risk of bias in all seven domains, then we considered the trial as 'low risk of bias'. If we 
judged a trial as low risk of bias in at least the four domains random sequence generation, 
allocation concealment, blinding of participants and personnel, and blinding of outcome 
assessment, then we judged it to have 'lower risk of bias'. By using the term 'lower risk of 
bias', we wished to signal that we were well aware that such trials might indeed have risk of 
bias. 
We handled reporting biases following the recommendations of The Cochrane Collaboration 
(Higgins 2011). We assessed funnel plot asymmetry (Higgins 2011), even though asymmetric 
funnel plots are not necessarily caused by publication bias and publication bias does not 
necessarily cause asymmetry in a funnel plot (Egger 1997). 
Measures of treatment effect 
The treatment effects in this meta-analysis are dichotomous or continuous. We expressed 
dichotomous data as risk ratio (RR) with 95% confidence intervals (CI). We derived the number 
needed to treat to benefit (NNTB) from the risk difference (RD) in case it was significant. For 
continuous data, we used the mean difference if the outcomes of the trials were measured in 
the same way. Where appropriate, we used the standardised mean difference to combine 
trials that measured the same outcome but using different methods. 
Unit of analysis issues 
As unit of analysis we used the reported outcomes per intervention group within the 
randomised clinical trials. In case no randomised clinical trials were identified, the results of 
the prospective cohort studies obtained with the search were to be presented in a narrative 
way in the 'Discussion' section of the review. 
Dealing with missing data 
We did the following to deal with missing data. 
• We contacted the original investigators to request missing data. 
• We performed sensitivity analyses to assess how sensitive our results were to reasonable 
changes in the assumptions that were made. We performed our analyses based on the 
intention-to-treat principle using imputation for the outcomes. We used the following 
scenarios (Hollis 1999). 
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 o Carry forward analysis: if participants had missing outcome data, we used the last 
reported observed response ('carry forward') in the nominator, and included all 
randomised participants in the denominator. 
o Extreme case analysis favouring the experimental intervention ('best-worst' case 
scenario): none of the drop-outs and participants lost from the experimental group 
but all of the drop-outs and participants lost from the control group experienced 
the outcome, including all randomised participants in the denominator. 
o Extreme case analysis favouring the control ('worst-best' case scenario): all drop-
outs and participants lost from the experimental group but none from the control 
group experienced the outcome, including all randomised participants in the 
denominator. 
Assessment of heterogeneity 
We assessed heterogeneity using the Chi2 test of heterogeneity and quantified inconsistency 
with the I2 statistic (Higgins 2002). In cases of substantial heterogeneity, as measured by a 
Chi2 test with a P value less than 0.1 or an I2 statistic value greater than 70%, we did not 
conduct meta-analysis. We assessed sources of clinical, methodological, and statistical 
heterogeneity in subgroup analyses. 
Assessment of reporting biases 
This is described under 'Assessment of risk of bias in included studies'. 
Data synthesis 
For the statistical analyses, we used Review Manager 5.2 (RevMan 2012). We meta-analysed 
the data with both a random-effects model (DerSimonian 1986) and a fixed-effect model 
(DeMets 1987) to ensure the robustness of the results. In case of differences in the results 
that the two models may have produced, we presented the results using both methods. If 
there were no differences in the results, we presented the results of the fixed-effect model 
only (Higgins 2011). If there was considerable variation in the results, and particularly if the 
direction of effect was inconsistent, it may be misleading to quote the average value for the 
intervention effect; we therefore interpreted the meta-analyses with utmost care. 
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 Trial sequential analysis 
Trial sequential analysis is a tool for quantifying the statistical reliability of data in cumulative 
meta-analysis, adjusting for sparse data, and repetitive testing of accumulating data (Brok 
2008; Wetterslev 2008; Brok 2009a; Thorlund 2009, Wetterslev 2009; Thorlund 2010). Trial 
sequential analysis is a methodology that combines the calculation of a required information 
size (the sample sizes of the trials in the meta-analysis ought to answer a research question 
reliably) with the threshold of statistical significance (CTU 2011; Thorlund 2011). 
Our intention was to perform trial sequential analysis primarily on the data from the trials 
with low risk of bias (Brok 2008; Wetterslev 2008). However, we chose to carry out trial 
sequential analysis on all trials because there were only a few trials with lower risk of bias. 
We analysed the outcome measures using trial sequential analysis no matter whether they 
yielded a statistically significant result in the meta-analysis or not. We used the meta-analytic 
estimate of the control event proportions of all trials, independent of risk of bias, as the 
control event proportion in the trial sequential analysis. We used the intervention effect 
estimated in the meta-analysis using all trials or used an a priori intervention effect of 20% 
risk ratio reduction. The unit of the intervention effect was risk ratio reduction for all 
dichotomous data. 
For each trial sequential analysis performed, we calculated a diversity-adjusted required 
information size based on the intervention effect suggested by the trials with low risk of bias 
(LBHIS) or an a priori intervention effect of 20% risk ratio reduction, a risk of type I error of 
5% and a risk of type II error of 20% or 10% (Wetterslev 2009). We performed the diversity 
adjustment using the observed diversity adjustment factor (1/(1-D2)) where D2 is the 
estimated heterogeneity among all trials and with an a priori assumed final diversity of 50% 
(Wetterslev 2009). 
Subgroup analysis and investigation of heterogeneity 
We planned the following subgroup analyses. 
• Trials with low risk of bias compared to trials with high risk of bias. 
• Type of patients, regarding previous antivirals, naives, relapsers, and non-responders as 
three separate groups, e.g., naives compared to relapsers. 
• Type of patients, regarding genotype: genotype 1 compared to genotype non-1. 
• Type of patients, regarding degree of liver disease (inflammation score (grading) or fibrosis 
score (staging)). 
84
Chapter 4
 • Type of patients, regarding HIV or hepatitis B co-infection compared to patients without 
co-infection. 
• Type of patients, regarding age: children compared to adults. 
• Intervention: according to the type, dose, and duration of aminoadamantanes and other 
antiviral drugs. 
We compared subgroups with a test of interaction (Altman 2003). 
Sensitivity analysis 
We identified suitable sensitivity analyses during the review process. For example, we used a 
sensitivity analysis when imputing missing data with replacement values. 
Data analysis in the included trials was according to the intention-to-treat principle as well 
as 'as treated' (per protocol) analysis. 
Summary of findings 
We created a 'Summary of findings' table, presenting the results of our review outcomes 
(GRADEpro). 
 
Results 
Description of studies 
See: Characteristics of included studies; Characteristics of excluded studies. 
Results of the search  
Our search strategy identified 639 publications of potential interest. After filtering for 
duplicates 290 publications remained. Of the remaining 290 publications, we excluded 214 
after screening the title and abstract, among other reasons because they were reviews or 
because they did not describe a randomised clinical trial investigating the effect of 
aminoadamantanes in patients with chronic hepatitis C. The remaining 76 references 
described 41 unique randomised clinical trials (Figure 1). 
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 Figure 1. Flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Twenty-five of the included trials were published in more than one publication. Six out of 41 
randomised clinical trials were published as abstracts only (Cornberg 2000; Shakil 2000; Jorge 
2001; Vardar 2001; Teuber 2002; Calay 2005). 
When necessary, we contacted the primary or last authors for further information and data 
relating to the trials. We searched for ongoing trials in the WHO International Clinical Trials 
Registry Platform (www.who.int/ictrp), Google Scholar, and Eudrapharm, but we did not 
identify any registered ongoing or planned trials. 
Included studies 
The included trials were 41 in total. Thirteen trials were conducted in Italy (Brillanti 1999; 
Brillanti 2000; Gaeta 2001; Mangia 2001; Tabone 2001; Bacosi 2002; Adinolfi 2003; Baisini 
2003; Piai 2003; Angelico 2004; Ciancio 2006; Gramenzi 2007; Angelico 2008), seven trials 
638 records identified through 
database searching 
290 records after duplicates 
removed 
18 publications excluded  
- 7 not found 
-  5 did not report one of our 
outcome measures 
- 3 not randomised 
- 1 comparison of amantadine 
plus peg interferon-alpha and 
ribavirin versus amantadine 
and peg interferon-alpha 
- 1 did not describe how many 
patients were randomised to 
each arm 
- 1 data in text and table are 
not comparable and 
reproducible 
 
1 additional record identified 
through other sources  
196 records excluded  
290 records screened on title 
and/or abstract  
94 publications assessed for 
eligibility 
76 publications included in 
qualitative synthesis (41 trials) 
41 trials included in quantitative 
synthesis (meta-analysis) 
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 were conducted in Germany (Cornberg 2000; Zeuzem 2000; Teuber 2001; Teuber 2002; Berg 
2003; Teuber 2003; von Wagner 2008), four trials were conducted in the USA (Shakil 2000; 
Smith 2004; Thuluvath 2004; Herrine 2005), three trials were conducted in Switzerland (Sax 
2001; Helbling 2002; Wenger 2007), and two trials were conducted both in France and the UK 
(Caronia 2001; Caronia 2001a; Calay 2005; Maynard 2006). Other trials were conducted in each 
of the following different countries: Argentina, Austria, Belgium, Brazil, Kuwait, Mexico, The 
Netherlands, Spain, Taiwan, and Turkey (see Characteristics of included studies). 
The first of the included trials was published in 1999 (Brillanti 1999) and the last in 2012 
(Pessoa 2012). Thirty-six trials had a parallel-group design with two intervention groups. Two 
trials included three intervention groups (Bacosi 2002; Gramenzi 2007) and two trials included 
four intervention groups (Herrine 2005; Salmeron 2007). One trial had a cross-over group 
design (Smith 2004). 
A total of 6193 patients with chronic hepatitis C were randomised to an amantadine arm or a 
control arm in the 41 clinical trials. 
Only one trial compared amantadine monotherapy with placebo without additional antiviral 
drugs (Smith 2004). Seventeen trials compared amantadine plus interferon-alpha versus 
placebo or no intervention plus interferon-alpha (Characteristics of included studies). One out 
of these 17 trials also compared amantadine plus interferon-alpha and ribavirin versus placebo 
or no intervention plus interferon-alpha and ribavirin (Salmeron 2007). Eleven trials reported 
on the comparison of amantadine plus interferon-alpha plus ribavirin versus placebo or no 
intervention plus interferon-alpha plus ribavirin (Characteristics of included studies). Twelve 
trials compared amantadine plus peg interferon-alpha plus ribavirin versus placebo or no 
intervention plus peg interferon-alpha plus ribavirin (Characteristics of included studies). 
The amantadine dose was the same in each trial: 200 mg daily, except for one trial, which 
prescribed 400 mg per day (von Wagner 2008). The treatment duration of the trials varied 
from 6 to 12 months. A six-month post-treatment duration of follow-up was used in all trials, 
except for four trials which applied 12 months of post-treatment follow-up (Bacosi 2002; 
Adinolfi 2003; Yang 2003; van Soest 2010) and one trial which applied 18 months of post-
treatment follow-up (Ciancio 2006). The details are displayed in Table 1. 
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 Table 1. Summary of characteristics of the included trials 
Trial Risk of bias Trial duration (months) Follow-up duration (months) 
Amantadine versus placebo 
Smith 2004 Lower 6 6 
 
Amantadine plus interferon versus placebo or no intervention plus interferon 
Angelico 2004 High 12 6 
Bacosi 2002 High 12 12 
Baisini 2003 High 12 6 
Caronia 2001 High 12 6 
Caronia 2001a High 12 6 
Gaeta 2001 High 6 6 
Helbling 2002 High 12 6 
Jorge 2001 High 12 6 
Mangia 2001  High 12 6 
Salmeron 2007 High 12 6 
Sax 2001 High 12 6 
Shakil 2000 High 6 6 
Tabone 2001 High 12 6 
Teuber 2001 High 12 6 
Vardar 2001 High 6 6 
Yang 2003 High 6 12 
Zeuzem 2000 High 12 6 
 
Amantadine plus interferon plus ribavirin versus placebo or no intervention plus interferon plus 
ribavirin 
Adinolfi 2003 High 12 12 
Berg 2003 Lower 12 6 
Brillanti 1999 High 6 6 
Brillanti 2000 High 12 6 
Cornberg 2000 High 12 6 
Gramenzi 2007 High 12 6 
Piai 2003 High 12 6 
Salmeron 2007 High 12 6 
Teuber 2002 High 12 6 
Teuber 2003 High 12 6 
Thuluvath 2004  High 12 6 
Wenger 2007 High 12 6 
 
Amantadine plus peg interferon plus ribavirin versus placebo or no intervention plus peg 
interferon plus ribavirin 
Angelico 2008 High 12 6 
Calay 2005 High 12 6 
Ciancio 2006 High 12 18 
Ferenci 2006 High 12 6 
Hasan 2004 High 12 6 
Herrine 2005 High 12 6 
Langlet 2009  High 6/12 6 
Maynard 2006  High 12 6 
Mendez-Navarro 2010 High 12 6 
Pessoa 2012 High 12 6 
van Soest 2010 High 12 12 
von Wagner 2008 High 12 6 
None of the trials compared one amantadine dose versus another. None of the trials 
compared head-to-head long-duration amantadine versus short-duration amantadine. 
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 From the publications which reported the sex of the participants, more than 63% were males. 
All trials included adult patients, except for one trial which included children of one year or 
older (Smith 2004). Only one trial included HIV co-infected patients (Sax 2001). None of the 
trials included patients co-infected with hepatitis B. 
Excluded studies 
The excluded studies are listed under Characteristics of excluded studies and the reasons for 
exclusion are given there. 
Risk of bias in included studies 
We assessed risk of bias according to seven domains: random sequence generation; allocation 
concealment; blinding of participants and personnel; blinding of outcome assessment; 
handling of incomplete outcome data; selective outcome reporting; and vested interest bias. 
Other potential sources of bias for the individual trial, but not for the meta-analyses of such 
trials, were: baseline imbalance and early stopping. 
We considered all included trials to have high risk of bias. We considered only two out of 41 
trials as having lower risk of bias (Berg 2003; Smith 2004). Our statistical analyses are, 
therefore, based mainly on trials with high risk of bias. None of them had low risk of bias. For 
details of the judgements made for the individual trials, please see Figure 2 and Figure 3. 
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies.
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 Figure 3. 'Risk of bias' summary: review authors' 
judgements about each risk of bias item for each included 
study. 
 
Allocation 
The generation of the allocation sequence was adequately 
described in 20 trials (Characteristics of included studies). 
The remaining 21 trials were described as randomised but 
the method of random sequence generation was not 
described (Characteristics of included studies). 
The method used to conceal allocation was adequately 
described in 14 trials (Characteristics of included studies). 
We judged the method for allocation concealment as 
unclear in 25 trials (Characteristics of included studies) and 
as high risk of bias in two trials (Caronia 2001; Caronia 
2001a). 
Blinding 
The method of blinding of participants and personnel was 
adequately described in only eight trials (Zeuzem 2000; 
Teuber 2001; Helbling 2002; Berg 2003; Smith 2004; 
Thuluvath 2004; Ferenci 2006; van Soest 2010). We 
considered 33 trials as high risk of bias regarding blinding of 
participants and personnel (Characteristics of included 
studies). Three trials adequately described the method of 
blinding of outcome assessment (Caronia 2001a; Berg 2003; 
Smith 2004). Thus, the other 38 trials had high risk of bias 
(Characteristics of included studies). Only two trials had low 
risk of bias, with both blinding of participants and personnel 
and blinding of outcome assessments (Berg 2003; Smith 
2004). 
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 Incomplete outcome data 
Incomplete data were addressed adequately in 15 trials (Brillanti 1999; Brillanti 2000; 
Cornberg 2000; Zeuzem 2000; Caronia 2001; Gaeta 2001; Mangia 2001; Sax 2001; Tabone 2001; 
Teuber 2001; Piai 2003; Yang 2003; Wenger 2007; Mendez-Navarro 2010; Pessoa 2012). In 26 
trials there were risks of incomplete outcome data (Characteristics of included studies). 
Selective reporting 
Predefined, clinically relevant and reasonably expected primary and secondary outcomes 
were adequately assessed in only six clinical trials (Brillanti 2000; Zeuzem 2000; Teuber 2001; 
Berg 2003; Hasan 2004; Maynard 2006). Accordingly, there were risks of selective reporting of 
outcomes in 35 trials (Characteristics of included studies). 
Other potential sources of bias 
Five trials did not receive funding and were at low risk of bias regarding vested interests 
(Mangia 2001; Sax 2001; Tabone 2001; Teuber 2003; Ciancio 2006). Seventeen trials received 
funding from the medical industry. It was unclear whether trials received funding from the 
medical industry in 19 trials. We considered these last 36 trials as having high risk of bias 
because industrial sponsorship could introduce bias. 
There were no baseline differences in any of the trials, except for two in which baseline 
imbalance was unknown (Sax 2001; Piai 2003). One trial stopped early due to poor results 
(Salmeron 2007). 
Effects of interventions 
See: Summary of findings for the main comparison 
Amantadine versus placebo or no intervention 
Primary outcomes 
All-cause mortality or liver-related morbidity (composite outcome) 
Thirty-two trials provided information on all-cause mortality or liver-related morbidity and 
could be included in the analyses. These 32 trials included one trial comparing amantadine 
versus placebo (Smith 2004), 14 trials comparing amantadine plus interferon-alpha versus 
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 placebo or no intervention plus interferon-alpha, 10 trials comparing amantadine plus 
interferon-alpha and ribavirin versus placebo or no intervention plus interferon-alpha and 
ribavirin, and eight trials comparing amantadine plus peg interferon-alpha and ribavirin versus 
placebo or no intervention plus peg interferon-alpha and ribavirin. It should be noted that one 
trial included four treatment groups and was part of two treatment subgroups (Salmeron 2007) 
(Analysis 1.1). The included trials reported five deaths or liver-related morbidities in 2353 
(0.2%) participants in the amantadine group versus six out of 2264 (0.3%) patients in the 
control group (Analysis 1.1). Meta-analyses with both the fixed-effect model and random-
effects model showed no significant effect of amantadine, when compared with placebo or 
no intervention, on all-cause mortality or liver-related morbidity (fixed-effect model: risk 
ratio (RR) 0.90, 95% confidence interval (CI) 0.38 to 2.17; I² = 0%) (Analysis 1.1). 
The subgroup analyses stratifying the trials according to risk of bias and according to previous 
treatment and treatment response with antivirals (for example, naive or non-responder 
patients) did not reveal any significant subgroup differences in effect estimates for the risk 
of all-cause mortality or liver-related morbidity (Analysis 2.1; Analysis 4.1). 
Inspection of the funnel plot did not suggest bias (Figure 4). 
Figure 4. Funnel 
plot 
Subgroup: trials at 
lower risk versus high 
risk of bias.  
Outcome: 4.1 All-
cause mortality or 
liver-related 
morbidity. 
 
 
Fourteen trials provided information on all-cause mortality or liver-related morbidity in 
patients treated with amantadine plus interferon-alpha versus placebo or no intervention plus 
interferon-alpha. In the amantadine group, two out of 813 (0.2%) patients died or experienced 
a liver-related morbidity and in the control group two out of 758 (0.3%) patients died or had 
a liver-related morbidity. Meta-analysis showed no significant effect of amantadine plus 
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 interferon-alpha when compared to placebo or no intervention plus interferon-alpha (fixed-
effect model: RR 1.01, 95% CI 0.26 to 3.98; I² = 0%) (Analysis 1.1). 
Zero deaths or liver-related morbidities were reported in 10 trials which conducted treatment 
with amantadine plus interferon-alpha and ribavirin compared with placebo or no intervention 
plus interferon-alpha and ribavirin (Analysis 1.1). 
Eight trials reported on all-cause mortality or liver-related morbidity in patients treated with 
amantadine plus peg interferon-alpha and ribavirin versus placebo or no intervention plus peg 
interferon-alpha and ribavirin (Analysis 1.1). Three out of 933 (0.3%) patients treated with 
amantadine plus peg interferon-alpha and ribavirin, and three out of 897 (0.3%) patients 
treated with placebo or no intervention plus peg interferon-alpha and ribavirin, died or 
experienced liver-related morbidities. The risk ratio for this event was statistically non-
significant when comparing amantadine plus peg interferon-alpha and ribavirin with placebo 
or no intervention plus peg interferon-alpha and ribavirin (fixed-effect model: RR 0.97, 95% 
CI 0.28 to 3.39; I² = 0%) (Analysis 1.1). 
We considered only two trials as lower risk of bias, therefore we deemed it unnecessary to 
perform trial sequential analysis with these two trials only. Consequently, we performed trial 
sequential analysis on all included trials that reported on the composite outcome 'all-cause 
mortality or liver-related morbidity'. Due to lack of accurate reporting on all-cause mortality 
and liver-related morbidity in a number of trials, we were not able to gather enough 
information to support or refute the effect of amantadine on all-cause mortality or liver-
related morbidity (see Figure 5). 
Adverse events 
We classified adverse events into two groups: number of patients with serious adverse events 
or number of patients with treatment discontinuation due to any adverse event. 
Two-hundred and eighty-eight patients out of 2869 (10.0%) in the amantadine group with or 
without additional therapy versus 293 patients out of 2777 (10.6%) in the control placebo or 
no intervention group with or without additional therapy were reported to have either serious 
adverse events or treatment discontinuation due to any adverse event (Analysis 1.2). 
The risk ratio for both events as a composite outcome was statistically non-significant when 
comparing amantadine with or without additional intervention versus placebo or no 
intervention with or without the same additional intervention (fixed-effect model: RR 0.98, 
95% CI 0.84 to 1.14; I² = 0%; 5646 participants, 35 trials) (Analysis 1.2). 
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 As there were no trials with low risk of bias, we performed trial sequential analysis on all 
included trials reporting on adverse events. Trial sequential analysis of these data supports 
the statistically non-significant finding (Figure 6). 
 
Figure 5. Trial sequential analysis on all-cause mortality or liver-related morbidity 
All cause mortality or liver related morbidity DARIS Pc 2%, RRR 20%, a 5%, b 20%, D 0% in a 
Two-sided graph. 
 
Figure 5: Trial sequential analysis of the random-effects meta-analysis of the effect of amantadine 
versus placebo or no intervention on all-cause mortality or liver-related morbidity in patients with 
chronic hepatitis C infection. The trial sequential analysis is performed with a type 1 error of 5% (two-
sided), a power of 80%, an assumed control proportion of death or liver-related morbidity of 2%, and 
an anticipated relative risk reduction (RRR) of 20%. The diversity-adjusted required information size 
(DARIS) to detect or reject a RRR of 20%, with a between-trial heterogeneity of 0%, is estimated at 
34,685 participants. The number of participants actually accrued is 2196, which is only 6% of the 
required information size. The blue cumulative Z-curve does not cross the red trial sequential 
monitoring boundaries for benefit or harm. Therefore, there is no evidence to support or refute the 
assumption that amantadine influences all-cause mortality or liver-related morbidity. The cumulative 
Z-curve does not reach the futility area (which is not even drawn by the program), demonstrating 
that further randomised trials may be needed. 
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 Figure 6. Trial sequential analysis on serious adverse events or patients discontinuation 
treatment due to an adverse event 
SAE or AE discontinuation DARIS Pc 11%, RRR 20%, a 5%, b 20%, D 0% in a Two-sided graph. 
  
Figure 6: Trial sequential analysis of the random-effects meta-analysis of the effect of amantadine 
versus placebo or no intervention, in chronic hepatitis C-infected patients, on the number of patients 
experiencing a serious adverse event or the number of patients who had to discontinue treatment due 
to an adverse event. The trial sequential analysis is performed with a type 1 error of 5% (two-sided), 
a power of 80%, an assumed control proportion of number of patients experiencing a serious adverse 
event or who had to discontinue treatment due to an adverse event of 10%, and an anticipated relative 
risk reduction (RRR) of 20%. The diversity-adjusted required information size (DARIS) to detect or 
reject a RRR of 20%, with a between-trial heterogeneity of 0%, is estimated at 5787 participants. The 
number of participants actually accrued is 5272, which is 91% of the required information size. The 
blue cumulative Z-curve does not cross the red trial sequential monitoring boundaries for benefit or 
harm. Therefore, there is no evidence to support the assumption amantadine influences the number 
of patients experiencing a serious adverse event or who have to discontinue treatment due to an 
adverse event. The cumulative Z-curve does cross the trial sequential beta-spending monitoring 
boundaries and reach the futility area, demonstrating that no further randomised trials may be 
needed. 
Inspection of the funnel plot did not suggest bias (Figure 7). 
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Figure 7. Funnel plot 
Subgroup: trials at lower 
risk versus high risk of 
bias. Outcome: 4.2 
Adverse events. 
 
 
 
 
Quality of life 
Only six trials reported on quality of life (Zeuzem 2000; Teuber 2001; Helbling 2002; Berg 
2003; Smith 2004; Ferenci 2006). Three trials applied the 'Profile of Mood Status' scale (POMS) 
and the 'Everyday Life' questionnaire (EDLQ) (Zeuzem 2000; Teuber 2001; Berg 2003). The 
other three trials used a health-related quality of life (HRQoL) score (Ferenci 2006), VAS score 
(Helbling 2002), or the McMaster Quality of Life Survey (Smith 2004). We were not able to 
perform meta-analyses on quality of life due to a lack of valid data. Overall, we found no 
significant differences between treatment with amantadine when compared with placebo or 
no intervention in each separate trial. 
Secondary outcomes 
Failure of serum (or plasma) sustained virological response  
Thirty-five trials provided information on patients who failed to achieve a sustained virological 
response. In the amantadine group, 1821 out of 2861 (63.6%) patients did not achieve a 
sustained virological response versus 1737 out of 2721 (63.8%) patients in the control group. 
Meta-analyses with both the fixed-effect model and random-effects model showed no 
significant effect of amantadine on failure to achieve a sustained virological response (fixed-
effect model: RR 0.98, 95% CI 0.95 to 1.02; I² = 35%) (Analysis 1.4). 
Thirteen trials reported on failure to achieve a sustained virological response in patients 
treated with amantadine plus interferon-alpha versus placebo or no intervention plus 
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 interferon-alpha (Analysis 1.4). Five-hundred and sixty-four patients failed to achieve a 
sustained virological response out of 687 patients (82.1%) in the amantadine group versus 514 
patients out of 626 patients (82.1%) in the control group. Meta-analysis showed no significant 
effect of amantadine plus interferon-alpha compared with placebo or no intervention plus 
interferon-alpha (fixed-effect model: RR 0.99, 95% CI 0.94 to 1.04; I² = 37%) (Analysis 1.4). 
Eleven trials provided information on failure to achieve a sustained virological response in 
patients treated with amantadine plus interferon-alpha and ribavirin versus placebo or no 
intervention plus interferon-alpha and ribavirin (Analysis 1.4). Four-hundred and twenty-two 
patients failed to achieve a sustained virological response out of 666 (63.4%) patients in the 
amantadine group versus 447 out of 628 (71.2%) patients in the control group. Meta-analysis 
with both the fixed-effect model and random-effects model showed a significant effect of 
amantadine plus interferon-alpha and ribavirin when compared with placebo or no 
intervention plus interferon-alpha and ribavirin (fixed-effect model: RR 0.89, 95% CI 0.83 to 
0.96; I² = 41%) (Analysis 1.4). 
We analysed the missing data using a best-worst case scenario (assuming that participants 
receiving amantadine with an unknown status for achieving a sustained virological response 
did achieve this and that all participants from the control group with an unknown status for 
achieving a sustained virological response did not). This reveals a statistically significant 
effect favouring amantadine in patients treated with amantadine plus interferon-alpha and 
ribavirin (best-worst case scenario: RR 0.69, 95% CI 0.56 to 0.85; 1294 participants, 11 trials) 
(Analysis 5.1). We also analysed the missing data using a worst-best case scenario (assuming 
that participants receiving amantadine with an unknown status for achieving a sustained 
virological response did not achieve this and that all participants from the control group with 
an unknown status for achieving this did). This analysis shows no significant differences (worst-
best case scenario: RR 1.02, 95% CI 0.81 to 1.29; 1294 participants, 11 trials) (Analysis 5.1). 
In 12 trials, 2975 patients were treated with amantadine plus peg interferon-alpha and 
ribavirin versus placebo or no intervention plus peg interferon-alpha and ribavirin (Analysis 
1.4). Eight-hundred and thirty-five out of 1508 patients (55.4%) treated in the amantadine 
group compared with 776 out of 1467 patients (52.9%) in the control group failed to achieve 
a sustained virological response. The risk ratio for this event was statistically non-significant 
when comparing amantadine plus peg interferon-alpha and ribavirin therapy with placebo or 
no intervention plus peg interferon-alpha and ribavirin (fixed-effect model: RR 1.04, 95% CI 
0.97 to 1.10; I² = 3%) (Analysis 1.4). 
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 The subgroup analyses, stratifying the trials according to risk of bias, revealed no statistically 
significant differences in the risk ratio for failure to achieve a sustained virological response, 
with both the fixed-effect model and the random-effects model, when comparing trials with 
lower risk of bias (RR 0.85, 95% CI 0.70 to 1.03; 400 participants; one trial) to trials with high 
risk of bias (fixed-effect model: RR 1.00, 95% CI 0.96 to 1.03; 5182 participants, 35 trials) 
(Analysis 4.3). 
Meta-analysis with both a fixed-effect model and random-effects model resulted in no 
significant difference in the effect estimates for the risk of failure to achieve a sustained 
virological response in the subgroup analysis of trials including genotype 1 patients (RR 1.00, 
95% CI 0.94 to 1.06, I² = 6%) compared to trials including non-genotype 1 patients (RR 0.98, 
95% CI 0.82 to 1.18; I² = 0%) (Analysis 3.1). 
Lastly, subgroup analyses, stratifying the trials according to previous antiviral therapy, 
showed no statistically significant differences with both the fixed-effect model and the 
random-effects model (Analysis 2.3). Subgroup analyses regarding degree of liver disease, HIV 
or hepatitis B co-infection, and age could not be performed due to lack of data. 
Inspection of the funnel plot did indicate bias (Figure 8). 
Figure 8. Funnel plot  
Subgroup: trials at 
lower risk versus high 
risk of bias.  
Outcome: 4.3 Failure 
of sustained virological 
response. 
 
 
 
We performed trial sequential analysis on all trials, because we considered only two trials as 
lower risk of bias trials. Trial sequential analysis of the combined data supports the finding of 
no effect of amantadine, when compared with placebo or no intervention, on failure to 
achieve a sustained virological response (Figure 9). The result of the trial sequential analysis 
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 is shown by the cumulated Z-curve (blue curve), which does not cross the trial sequential 
alpha spending monitoring boundary (red inward sloping curve) and ends up in the futility 
area. This implies that there is no evidence for a beneficial effect of amantadine in preventing 
failure to achieve a sustained virological response. 
Figure 9. Trial sequential analysis on failure to achieve sustained virological response 
Failure SVR DARIS Pc 64%, RRR 7%, a 5%, b 10%, D 35% in a Two-sided graph. 
Figure 9: Trial sequential analysis of the random-effects meta-analysis of the effect of amantadine 
versus placebo or no intervention on the number of patients with chronic hepatitis C virus infection 
who failed to achieve a sustained virological response (SVR). The trial sequential analysis is performed 
with a type 1 error of 5% (two-sided), a power of 90%, an assumed control proportion of number of 
patients who failed to achieve a SVR of 64%, and an anticipated relative risk reduction (RRR) of 7%. 
The diversity-adjusted required information size (DARIS) to detect or reject a RRR of 7%, with a 
between-trial heterogeneity of 35%, is estimated at 7609 participants. The number of participants 
actually accrued is 5328, which is 70% of the required information size. The blue cumulative Z-curve 
does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, there is 
no evidence to support the assumption that amantadine influences the number of patients who fail 
to achieve a SVR and it is likely that a 7% RRR in the number of patients who fail to achieve a SVR can 
be rejected with the chosen error risks. The cumulative Z-curve does reach the futility area, 
demonstrating that no further randomised trials may be needed. 
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 We also performed trial sequential analysis on a subgroup, comparing failure to achieve a 
sustained virological response in patients treated with amantadine plus interferon-alpha and 
ribavirin with patients treated with interferon-alpha and ribavirin (Figure 10). There is no 
evidence to support or refute the assumption that amantadine influences the number of 
patients who fail to achieve a sustained virological response. 
Figure 10. Trial sequential analysis on failure to achieve sustained virological response in 
subgroup treated with amantadine plus interferon-alpha and ribavirin versus placebo or 
no intervention plus interferon-alpha and ribavirin 
Failure SVR subgroup AMA + IFN + RIBA vs IFN + RIBA DARIS Pc 71%, RRR 7%, a 5%, b 10%, D 
12% in a Two-sided graph. 
 
Figure 10: Trial sequential analysis of the random-effects subgroup meta-analysis of the effect of 
amantadine plus interferon-alpha and ribavirin versus placebo or no intervention plus interferon-alpha 
and ribavirin on the number of patients with chronic hepatitis C virus infection who failed to achieve 
a sustained virological response (SVR). The trial sequential analysis is performed with a type 1 error 
of 5% (two-sided), a power of 90%, an assumed control proportion of number of patients who failed 
to achieve a SVR response of 71%, and an anticipated relative risk reduction (RRR) of 7%. The diversity-
adjusted required information size (DARIS) to detect or reject a RRR of 7%, with a between-trial 
heterogeneity of 12%, is estimated at 4171 participants. The number of participants actually accrued 
is 1294, which is only 31% of the required information size. The blue cumulative Z-curve does not 
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 cross the red inward sloping trial sequential alpha-spending monitoring boundaries for benefit or 
harm. Therefore, there is no evidence to support the assumption that amantadine influences number 
of patients who fail to achieve a SVR and it is likely that a 7% RRR in the number of patients who fail 
to achieve a SVR on treatment with amantadine plus interferon-alpha and ribavirin can be rejected 
with the chosen error risks. The cumulative Z-curve does not reach the futility area (which is not even 
drawn by the program), demonstrating that further randomised trials may be needed. 
Failure of end of treatment virological response 
Thirty trials provided information on patients who failed to achieve an end of treatment 
virological response and could be included in the analyses (Analysis 1.3). In the amantadine 
group, 1288 out of 2483 patients (51.9%) did not achieve an end of treatment virological 
response versus 1268 out of 2378 patients (53.3%) in the control group. Meta-analyses with 
both the fixed-effect model and the random-effects model showed no significant effect of 
amantadine on achieving an end of treatment virological response (fixed-effect model: RR 
0.95, 95% CI 0.90 to 1.00; I² = 43%) (Analysis 1.3). 
Ten trials provided information on failure to achieve an end of treatment virological response 
in patients treated with amantadine plus interferon-alpha and ribavirin versus placebo or no 
intervention plus interferon-alpha and ribavirin (Analysis 1.3). Three-hundred and forty-nine 
patients failed to achieve an end of treatment virological response out of 625 patients (39.8%) 
in the amantadine group versus 386 out of 594 patients (65.0%) in the control group. Meta-
analysis with both the fixed-effect model and the random-effects model showed a significant 
effect of amantadine plus interferon-alpha and ribavirin compared with placebo or no 
intervention plus interferon-alpha and ribavirin (fixed-effect model: RR 0.86, 95% CI 0.79 to 
0.94; I² = 66%) (Analysis 1.3). 
We analysed the data in a best-worst case scenario regarding missing data (assuming that 
participants with an unknown status for achieving an end of treatment virological response 
receiving amantadine did achieve this and that all participants from the control group with 
an unknown status for achieving an end of treatment virological response did not). This reveals 
a stronger positive statistical effect estimate favouring amantadine in patients treated with 
amantadine plus interferon-alpha and ribavirin (RR 0.58, 95% CI 0.52 to 0.65; 1219 
participants, 10 trials) (Analysis 5.2). We also analysed the data in a worst-best case scenario 
regarding missing data (assuming that participants with an unknown status for an achieving 
end of treatment virological response receiving amantadine did not achieve this and that all 
participants from the control group with an unknown status for achieving an end of treatment 
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 virological response did). This reveals an effect favouring the control (worst-best case 
scenario: RR 1.20, 95% CI 1.08 to 1.34; 1219 participants, 10 trials) (Analysis 5.2). 
Failure of histological response 
Only three trials provided information on the number of patients without improvement of 
histology (Shakil 2000; Zeuzem 2000; Baisini 2003) (Analysis 1.5). They included 24, 93, and 
119 patients. Only 74 out of these 219 patients underwent a liver biopsy before treatment and 
after treatment. We cannot meta-analyse or draw any conclusions from these data. 
Number of patients without normalisation of serum ALT and/or AST levels at end 
of treatment and at end of follow-up 
All trials that reported on biochemical response reported ALT levels only. Therefore, we have 
chosen only to provide ALT levels in this analysis. 
Nineteen trials provided information on failure to achieve end of treatment biochemical 
response. In the amantadine group, 671 out of 1141 (58.8%) patients did not achieve end of 
treatment biochemical response versus 732 out of 1100 (66.5%) patients in the control group. 
Meta-analyses with both the fixed-effect model and random-effects model showed that 
amantadine significantly decreases the number of patients without normalisation of ALT 
serum levels at the end of treatment compared with placebo or no intervention (fixed-effect 
model: RR 0.88, 95% CI 0.83 to 0.94; I² = 47%) (Analysis 1.6). 
In seven trials, 207 out of 418 (49.5%) patients treated with amantadine plus interferon-alpha 
and ribavirin compared with 247 out of 390 (63.3%) patients in the control group treated with 
placebo or no intervention plus interferon-alpha and ribavirin failed to achieve an end of 
treatment biochemical response (Analysis 1.6). Meta-analysis with both the fixed-effect model 
and the random-effects model showed a significant effect of amantadine plus interferon-alpha 
and ribavirin compared with placebo or no intervention plus interferon-alpha and ribavirin 
(fixed-effect model: RR 0.79, 95% CI 0.70 to 0.89; I² = 70%) (Analysis 1.6). 
Furthermore, 21 trials provided information on patients who failed to achieve an end of 
follow-up biochemical response and could be included in the analyses (Analysis 1.7). In the 
amantadine group, 1133 out of 1896 (59.8%) patients did not achieve an end of follow-up 
biochemical response versus 1151 out of 1848 (62.3%) patients in the control group. Meta-
analyses with both models showed no significant effect of amantadine on achieving an end of 
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 follow-up biochemical response (fixed-effect model: RR 0.95, 95% CI 0.91 to 1.00; I² = 49%) 
(Analysis 1.7). 
Summary of findings 
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
'Summary of findings' table (Guyatt 2008) is shown in Summary of findings for the main 
comparison. We considered all outcomes for the 'Summary of findings' table except failure of 
histological response, due to lack of data. 
 
Discussion 
Summary of main results 
We included 41 trials with a total of 6193 patients, which assessed the benefit and harm of 
amantadine when compared with placebo or no intervention in the treatment of patients with 
chronic hepatitis C. The effect of amantadine was evaluated in four different treatment 
strategies: monotherapy with amantadine, combination therapy of amantadine with 
interferon-alpha, combination therapy of amantadine plus interferon-alpha and ribavirin, and 
combination therapy of amantadine plus peg interferon-alpha and ribavirin. We carried out 
subgroup analyses according to a classification based on whether a patient had already 
received treatment for hepatitis C before and if so which treatment he/she had received, 
e.g., naive patients, relapsers, or non-responders. The present systematic review did not 
demonstrate any benefit of amantadine on all-cause mortality or liver-related morbidity for 
any of these treatment regimens or types of patients. 
Our systematic review also showed that concomitant use of amantadine in the treatment of 
chronic hepatitis C is not associated with either an increase or a reduction in adverse events, 
defined as the number of patients who experienced a serious adverse event or had to 
discontinue treatment due to an adverse event. We confirmed these results by applying trial 
sequential analysis. 
Moreover, amantadine did not decrease the overall proportion of patients who failed to 
achieve a sustained virological response. This finding was confirmed by a trial sequential 
analysis. However, in subgroup analysis we demonstrated that patients treated with a 
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 combination therapy of amantadine plus interferon-alpha and ribavirin had statistically 
significant less failure in achieving a sustained virological response. However, trial sequential 
analysis could not exclude risks of random errors (play of chance) and all trials had risks of 
systematic errors (bias). When applying further subgroup analysis with both the fixed-effect 
model and the random-effects model, stratifying trials according to previous antiviral therapy 
or genotype, there were no significant differences in the effect estimates for the risk of failure 
to achieve a sustained virological response. 
Unfortunately, we were not able to identify any convincing benefits of amantadine when 
assessing histology, because only three trials reported failure of histological improvement. 
For quality of life, we also could not identify any convincing benefits because only six trials 
reported this outcome. We found a significant benefit of adding amantadine to interferon-
alpha-based therapy for biochemical response at the end of treatment, but not for end of 
follow-up response. 
Overall completeness and applicability of evidence 
This systematic review examined the evidence from 41 randomised clinical trials on the 
treatment of hepatitis C. Despite efforts to obtain additional information from the authors 
we could not obtain all relevant data, hence not all trials reported on all of our predefined 
outcomes. 
Thirty-two trials reported adequately on our primary outcomes of all-cause mortality or liver-
related morbidity, and 35 trials reported on serious adverse events and treatment 
discontinuation due to an adverse event. Only six trials provided information on quality of 
life. Thirty-six trials reported on our first secondary outcome measure: failure to achieve a 
sustained virological response. Twenty-nine trials reported on failure of end of treatment 
virological response. Only two trials provided information on failure of histological 
improvement, another 17 trials reported on failure of biochemical response at the end of 
treatment, and 19 trials reported on failure of biochemical response at the end of follow-up. 
It is questionable whether the included patients are representative of current practice. All 
trials included patients with positive serum hepatitis C RNA. However, there was 
heterogeneity among the trials due to the different disease severity of the patients at trial 
entry, differences in genotype (35 trials included a mixture of genotypes), and differences 
regarding previous antiviral treatment. Concerning sex and age, the trials seem representative 
of current clinical care: more than 63% of the included patients were male and all included 
adult patients, except for one trial which included children of one year or older (Smith 2004). 
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However, only one trial included HIV co-infected patients (Sax 2001). None of the trials 
included patients co-infected with hepatitis B. There are therefore insufficient data on co-
infected patients. 
Quality of the evidence 
We conducted this review according to the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins 2011) and the Cochrane Hepato-Biliary Group Module (Gluud 2014). The 
results of our meta-analysis, however, are only as strong as the primary trials included. 
The main limitation in the design and implementation of trials was the lack of clarity about 
the generation of the allocation sequence, concealment of allocation, and blinding. Of the 41 
included trials, only 20 (49%) reported adequate allocation sequence generation, only 14 (35%) 
adequately reported allocation concealment, and only two (5%) reported blinding. Fifteen 
trials (37%) adequately addressed incomplete data, but only six trials (15%) reported all 
clinically relevant and reasonably expected outcomes. Also, only five trials (12%) appeared to 
be free of other components that could put them at risk of bias. Accordingly, 95% of trials 
were at high risk of bias. It is surprising to see that so many trials had high risk of bias, despite 
the repeated calls for improved trial quality both within and outside hepatology (Schultz 1995; 
Gluud 1998; Kjaergard 1999; Needleman 1999; Kjaergard 2001; Wood 2008; Savović 2012; 
Savović 2012a). 
Regarding the precision of our results, some outcomes in our meta-analysis include few 
patients and few events, and thus have wide confidence intervals around the estimate of 
effect. 
Potential biases in the review process 
In this systematic review we performed a comprehensive literature search. As far as we know, 
we have found all the evidence available. A potential limitation of our literature search may 
be that we have not specifically searched for trials in the grey literature, which may have 
introduced a slight risk of bias into our meta-analysis (Egger 2003). However, this bias is 
unlikely to influence our results in a beneficial way as trials found in the grey literature rarely 
report beneficial effects. 
Most of the included trials are of a relatively small size, especially those performed in the 
early 2000s. This increases the risk of an unrealistic estimate of the intervention effects due 
to bias (systematic errors) or chance (random errors). Risk of bias is known to have an impact 
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 on the estimated intervention effect, with trials at high risk of bias overestimating beneficial 
intervention effects and underestimating harmful effects (Schultz 1995; Moher 1998; 
Kjaergard 2001; Wood 2008; Lundh 2012; Savović 2012; Savović 2012a). We divided the 
analysis for all outcomes into trials with high risk of bias and trials with lower risk of bias trials 
to reveal any influence of bias on the effect estimates of our outcomes. Of the 41 included 
trials, only two had lower risk of bias. We did not observe an influence of bias on any of our 
analyses, but due to there being few trials with lower risk of bias these analyses do not have 
sufficient power. The estimated intervention effects for all significant beneficial findings may 
therefore possibly be due to systematic errors. 
No statistical signs of publication bias or other bias were observed. 
This review pooled data for all-cause mortality or liver-related morbidity from 32 trials 
involving 4617 patients. We also pooled data for serious adverse events or treatment 
discontinuation due to an adverse event from 35 trials involving 5646 patients. The median 
trial duration was 12 months, with a median follow-up of six months (four trials had a follow-
up of 12 months, one trial had a follow-up of 18 months). For our primary outcome measure, 
all-cause mortality or liver-related morbidity, this is not sufficiently long, considering that 
the estimated median time in which hepatitis C progresses to cirrhosis is 15 years to 50 years 
(Koretz 1993; Kenny-Walsh 1999; Seeff 2009). Therefore, it is difficult to detect a significant 
difference in all-cause mortality and liver-related morbidity based on these trials. If 
aminoadamantanes have an effect on morbidity and mortality one prerequisite would be that 
they significantly affect virological load. However, we were unable to provide viral data to 
demonstrate that this was the case. 
We used trial sequential analysis to cope with the risk of random error, which is higher when 
information sizes are small (Wetterslev 2008). Trial sequential analysis of the primary 
outcomes, all-cause mortality or liver-related morbidity and serious adverse events or 
treatment discontinuation due to an adverse event, and of the secondary outcome measure, 
sustained virological response, showed no significant effect estimates when we applied both 
the random-effects and fixed-effect models in patients treated with amantadine. 
Heterogeneity among the trials might be due to differences in dose, duration, and type of 
interferon-alpha or peg interferon-alpha. Both evaluation of this and long-term follow-up 
studies could be useful. Also different definitions of non-responders were used in the trials, 
such as non-responder to previous interferon-alpha therapy alone or non-responder to 
combination therapy of interferon-alpha with ribavirin. Furthermore, there could be 
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 heterogeneity among trials due to the disease severity of patients at entry and differences in 
genotype, which can both affect the sustained virological response rates. To reflect our 
concern about heterogeneity, we conducted all analyses using both the fixed-effect model 
and the random-effects model. We only presented the results of the fixed-effect model if the 
results of the two models did not differ. We also considered other important and predefined 
trial-level covariates, including trial risk of bias, genotype distribution, and previous antiviral 
treatment. Subgroup analyses of other predefined covariates, such as degree of liver disease, 
could not be performed because of the lack of trials reporting on this outcome. 
Lastly, we did not analyse the two amantadine modalities, amantadine hydrochloride and 
amantadine sulphate. 
Agreements and disagreements with other studies or reviews 
It is likely that less than 10% of all infected patients will develop end-stage liver disease. 
Overall, we found that amantadine did not show any benefit for all-cause mortality or liver-
related morbidity. Most trials reported on the surrogate outcome measure sustained 
virological response, but as already mentioned, we do not know whether a sustained 
virological response results in less mortality or morbidity (Gluud 2007). An observation was 
that, while those treated with interferon-alpha and ribavirin were allegedly more likely to 
develop a sustained virological response if amantadine was added, there was no difference in 
all-cause mortality or liver-related morbidity (although this observation is certainly limited by 
the short follow-up periods). This is in accordance with a number of findings in patients with 
chronic hepatitis C showing that a sustained virological response may not be a valid surrogate 
marker of clinical outcomes for a number of antiviral drugs (Brok 2010; Koretz 2013; Gurusamy 
2013; Hauser 2014; Hauser 2014a). 
Considering failure to achieve a sustained virological response, we also found that amantadine 
did not show any benefit, except for in the subgroup patients treated with the combination 
therapy of amantadine plus interferon-alpha and ribavirin, in which amantadine seems to 
complement the lack of efficacy of interferon-alpha compared with peg interferon-alpha. 
However, this finding was not supported by the trial sequential analyses. This result is in 
accordance with the main findings of a recently published meta-analysis (Chen 2012), which 
suggests that there is no beneficial effect of adding amantadine to peg interferon-alpha plus 
ribavirin in naive hepatitis C genotype 1 patients. Our findings are contrary to the main 
findings of another meta-analyses (Deltenre 2004), which suggested a role for amantadine in 
non-responder patients. Furthermore, our results are also in contrast with another review, 
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 which suggests that there may be a limited role of combination therapy in naive patients (Lim 
2005). 
We have no evidence from randomised clinical trials on the long-term effects (more than one 
year) of amantadine on our primary outcomes. Long-term effects would be relevant in 
particular for outcomes such as all-cause mortality or liver-related morbidity. 
Amantadine was generally well tolerated. We observed that amantadine was associated with 
non-serious adverse events and almost all trials in general reported similar frequencies and 
severities of adverse events in both amantadine groups versus control groups. This result is in 
accordance with a recently published Cochrane review of amantadine and rimantadine for 
influenza A in children and the elderly (Alves Galvão 2012). The result is also somewhat 
comparable to two other Cochrane reviews. The review of amantadine and rimantadine in 
influenza A in adults showed significantly more adverse effects in patients receiving 
amantadine compared with placebo, but no increased risk of serious adverse events (Jefferson 
2012). The second review reported on amantadine in Parkinson's disease and found that there 
is not enough evidence from trials about the effects of amantadine for people with Parkinson's 
disease, but that adverse events in trials so far have not been severe (Crosby 2009). In our 
analysis, amantadine was administered with interferon-alpha or peg interferon-alpha with or 
without ribavirin, except for in one trial. Interferon-alpha-based therapy is typically 
associated with haematologic complications (i.e., neutropenia, thrombocytopenia), 
neuropsychiatric complications (i.e., memory and concentration loss, visual disturbances, 
headaches, depression, irritability), flu-like symptoms, hormonal complications (i.e., 
hypothyroidism, hyperthyroidism), gastrointestinal complications (i.e., nausea, vomiting, 
weight loss), and dermatologic complications (i.e., eczema, alopecia). The most well-known 
adverse effect of ribavirin is dose-dependent haemolytic anaemia but gastrointestinal adverse 
effects such as nausea are also reported (Chutaputti 2000; Soza 2002; Sulkowski 2004). In 
conclusion, both interferon-alpha and ribavirin are associated with a variety of adverse events 
of different severities, which may make it hard to detect less severe adverse events associated 
with amantadine. We cannot exclude the possibility of less severe adverse events with 
amantadine, for example gastrointestinal symptoms and insomnia. 
Regarding tolerance of amantadine we have to take dosage into consideration. Only one trial 
used an amantadine dose of more than 200 mg per day (von Wagner 2008). One randomised 
clinical trial evaluated the safety and toxicity of amantadine in patients with chronic hepatitis 
C; it also investigated the maximum tolerable dose of amantadine (Smith 2004a). They 
reported an increase in biochemical response with higher daily doses of amantadine from 200 
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 mg per day up to 500 mg per day in monotherapy. However, no statistically significant 
difference was found in alanine aminotransferase (ALT) values between those receiving 300 
mg and those receiving higher doses of amantadine. Also, increasing the amantadine dose did 
not result in more patients achieving a sustained virological response, when comparing 200 
mg per day with 300 mg to 500 mg per day (Smith 2004a). 
 
Authors’ conclusions 
Implications for practice 
This review shows that there seems to be no significant beneficial effect of amantadine on 
all-cause mortality or liver-related morbidity composite outcome, or on adverse events in 
hepatitis C-infected patients; although the timeframe for measuring the composite outcome 
was insufficient in the included randomised clinical trials. Furthermore, amantadine did not 
increase the proportion of patients with a sustained virological response. In the absence of 
convincing evidence of benefit, the use of amantadine is justified in the context of randomised 
clinical trials assessing the effects of combination therapy with peg interferon-alpha and 
ribavirin. We found no randomised clinical trials assessing other aminoadamantanes. 
Implications for research 
Given the results of our analysis, we cannot conclude whether new randomised clinical trials 
will or will not find any beneficial effect of amantadine on patients' survival in chronic 
hepatitis C patients. In subgroup analyses we observed that therapy with amantadine plus 
interferon-alpha and ribavirin compared with interferon-alpha and ribavirin seems to increase 
the number of patients with a sustained virological response, but this effect was not supported 
by our trial sequential analysis. We did not observe a similar finding when examining 
amantadine combined with peg interferon-alpha and ribavirin. Therefore, to prove the former 
effect, further randomised clinical trials would be required. We found no evidence for other 
aminoadamantanes. Based on the overall evidence, future trials assessing amantadine, or 
potentially other aminoadamantanes for patients with chronic hepatitis C, may not show 
strong benefits. Therefore, it is probably advisable to wait for the results of trials assessing 
other direct-acting antiviral drugs. Amantadine and other aminoadamantanes should only be 
used within randomised clinical trials; they do not appear to have a place in usual clinical 
practice. To our knowledge, no ongoing trials are investigating the effects of amantadine in 
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 hepatitis C patients. Any further trials should be designed according to the SPIRIT guidelines 
(SPIRIT 2013; SPIRIT 2013a), and conducted and reported according to the CONSORT 
Statement (Schulz 2012). 
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 Data and analyses 
Comparison 1. Amantadine versus placebo or no intervention 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical 
method 
Effect size 
1 All-cause mortality or liver-related 
morbidity 
32 4617 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.90 [0.38, 
2.17] 
1.1 Amantadine versus placebo or no 
intervention 
1 152 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.36 [0.01, 
8.71] 
1.2 Amantadine plus interferon-alpha 
versus placebo or no intervention plus 
interferon-alpha 
14 1571 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.26, 
3.98] 
1.3 Amantadine plus interferon-alpha 
and ribavirin versus placebo or no 
intervention plus interferon-alpha and 
ribavirin 
10 1064 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.4 Amantadine plus peg interferon-
alpha and ribavirin versus placebo or 
no intervention plus peg interferon-
alpha and ribavirin 
8 1830 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.97 [0.28, 
3.39] 
2 Adverse events 35 5646 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.98 [0.84, 
1.14] 
2.1 Amantadine versus placebo or no 
intervention 
1 152 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.22 [0.01, 
4.43] 
2.2 Amantadine plus interferon-alpha 
versus placebo or no intervention plus 
interferon-alpha 
14 1571 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.07 [0.73, 
1.56] 
2.3 Amantadine plus interferon-alpha 
and ribavirin versus placebo or no 
intervention plus interferon-alpha and 
ribavirin 
11 1289 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.78 [0.61, 
1.00] 
2.4 Amantadine plus peg interferon-
alpha and ribavirin versus placebo or 
no intervention plus peg interferon-
alpha and ribavirin 
10 2634 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.12 [0.90, 
1.40] 
3 Failure of end of treatment 
virological response 
30 4861 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.90, 
1.00] 
3.1 Amantadine plus interferon-alpha 
versus placebo or no intervention plus 
interferon-alpha 
11 1129 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.94 [0.88, 
1.01] 
3.2 Amantadine plus interferon-alpha 
and ribavirin versus placebo or no 
intervention plus interferon-alpha and 
ribavirin 
10 1219 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.86 [0.79, 
0.94] 
3.3 Amantadine plus peg interferon-
alpha and ribavirin verus placebo or no 
intervention plus peg interferon-alpha 
and ribavirin 
10 2513 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.03 [0.94, 
1.13] 
4 Failure of sustained virological 
response 
35 5582 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.98 [0.95, 
1.02] 
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 4.1 Amantadine plus interferon-alpha 
versus placebo or no intervention plus 
interferon-alpha 
13 1313 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.99 [0.94, 
1.04] 
4.2 Amantadine plus interferon-alpha 
and ribavirin versus placebo or no 
intervention plus interferon-alpha 
and ribavirin 
11 1294 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.89 [0.83, 
0.96] 
4.3 Amantadine plus peg interferon-
alpha and ribavirin versus placebo or 
no intervention plus peg interferon-
alpha and ribavirin 
12 2975 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.04 [0.97, 
1.10] 
5 Failure of histological response 3 236 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.93, 
1.09] 
5.1 Amantadine plus interferon-alpha 
versus placebo or no intervention plus 
interferon-alpha 
3 236 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.93, 
1.09] 
6 Failure of normalisation of ALT at 
end of treatment 
19 2241 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.88 [0.83, 
0.94] 
6.1 Amantadine versus placebo or no 
intervention 
1 152 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.82 [0.70, 
0.94] 
6.2 Amantadine plus interferon-alpha 
versus placebo or no intervention plus 
interferon-alpha 
9 1018 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.87, 
1.04] 
6.3 Amantadine plus interferon-alpha 
and ribavirin versus placebo or no 
intervention plus interferon-alpha 
and ribavirin 
7 808 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.79 [0.70, 
0.89] 
6.4 Amantadine plus peg interferon-
alpha and ribavirin versus placebo or 
no intervention plus peg interferon-
alpha and ribavirin 
2 263 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.96 [0.78, 
1.18] 
7 Failure of normalisation of ALT at 
end of follow-up 
21 3744 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.91, 
1.00] 
7.1 Amantadine plus interferon-alpha 
versus placebo or no intervention plus 
interferon-alpha 
8 994 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.88, 
1.01] 
7.2 Amantadine plus interferon-alpha 
and ribavirin versus placebo or no 
intervention plus interferon-alpha 
and ribavirin 
6 784 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.82 [0.74, 
0.92] 
7.3 Amantadine plus peg interferon-
alpha and ribavirin versus placebo or 
no intervention plus peg interferon-
alpha and ribavirin 
7 1966 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.03 [0.95, 
1.11] 
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 Analysis 1.1. Comparison 1 Amantadine versus placebo or no intervention, Outcome 1 All-
cause mortality or liver-related morbidity. 
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 Analysis 1.2. Comparison 1 Amantadine versus placebo or no intervention, Outcome 2 Adverse 
events. 
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 Analysis 1.3. Comparison 1 Amantadine versus placebo or no intervention, Outcome 3 
Failure of end of treatment virological response. 
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 Analysis 1.4. Comparison 1 Amantadine versus placebo or no intervention, Outcome 4 
Failure of sustained virological response.
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 Analysis 1.5. Comparison 1 Amantadine versus placebo or no intervention, Outcome 5 
Failure of histological response.
Analysis 1.6. Comparison 1 Amantadine versus placebo or no intervention, Outcome 6 
Failure of normalisation of ALT at end of treatment.
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 Analysis 1.7. Comparison 1 Amantadine versus placebo or no intervention, Outcome 7 
Failure of normalisation of ALT at end of follow-up.
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 Comparison 2. Subgroup: naives, relapsers, non-responders 
Outcome or subgroup 
title 
No. of 
studies 
No. of 
participants 
Statistical method Effect size 
1 Mortality or liver-
related morbidity 
32 4617 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.90 [0.38, 2.17] 
1.1 Naives 17 3230 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.83 [0.27, 2.59] 
1.2 Relapsers 2 101 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.3 Non-responders 12 1057 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.00 [0.14, 7.05] 
1.4 Trials without 
differentiation according 
to previous antiviral 
treatment  
2 229 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.05 [0.15, 7.47] 
2 Adverse events 35 5646 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.98 [0.84, 1.14] 
2.1 Naives 16 3141 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.02 [0.85, 1.22] 
2.2 Relapsers 2 101 Risk Ratio (M-H, 
Fixed, 95% CI) 
3.90 [0.46, 33.30] 
2.3 Non-responders 14 1482 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.77 [0.54, 1.10] 
2.4 Trials without 
differentiation according 
to previous antiviral 
treatment  
4 922 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.05 [0.71, 1.54] 
3 Failure of sustained 
virological response 
35 5582 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.99 [0.95, 1.02] 
3.1 Naives 17 3804 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.96, 1.06] 
3.2 Relapsers 4 219 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.93 [0.71, 1.21] 
3.3 Non-responders 13 1412 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.97 [0.92, 1.02] 
3.4 Trials without 
differentiation according 
to previous antiviral 
treatment  
3 147 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.81 [0.64, 1.03] 
4 Failure of end of 
treatment virological 
response 
30 4861 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.91, 1.00] 
4.1 Naives 12 2571 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.97 [0.90, 1.04] 
4.2 Relapsers 2 101 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.78 [0.49, 1.23] 
4.3 Non-responders 13 1412 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.89, 1.02] 
4.4 Trials without 
differentiation according 
4 777 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.91 [0.75, 1.11] 
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 to previous antiviral 
treatment  
5 Failure of histological 
response 
3 236 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.93, 1.09] 
5.1 Naives 3 236 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.93, 1.09] 
6 Failure of normalisation 
of ALT at end of 
treatment  
19 2241 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.88 [0.83, 0.94] 
6.1 Naives 7 1246 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.90 [0.83, 0.99] 
6.2 Relapsers 1 24 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.8 [0.50, 1.28] 
6.3 Non-responders 9 742 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.87 [0.79, 0.97] 
6.4 Trials without 
differentiation according 
to previous antiviral 
treatment  
2 229 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.82 [0.71, 0.96] 
7 Failure of normalisation 
of ALT at end of follow-up 
21 3744 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.91, 1.00] 
7.1 Naives 8 2050 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.89, 1.02] 
7.2 Relapsers 1 77 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.97 [0.66, 1.43] 
7.3 Non-responders 10 847 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.88, 1.03] 
7.4 Trials without 
differentiation according 
to previous antiviral 
treatment  
3 770 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.81, 1.12] 
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 Analysis 2.1. Comparison 2 Subgroup: naives, relapsers, non-responders, Outcome 1 
Mortality or liver-related morbidity. 
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 Analysis 2.2. Comparison 2 Subgroup: naives, relapsers, non-responders, Outcome 2 Adverse 
events. 
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 Analysis 2.3. Comparison 2 Subgroup: naives, relapsers, non-responders, Outcome 3 Failure 
of sustained virological response. 
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 Analysis 2.4. Comparison 2 Subgroup: naives, relapsers, non-responders, Outcome 4 Failure 
of end of treatment virological response.
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 Analysis 2.5. Comparison 2 Subgroup: naives, relapsers, non-responders, Outcome 5 Failure 
of histological response.
 
Analysis 2.6. Comparison 2 Subgroup: naives, relapsers, non-responders, Outcome 6 Failure 
of normalisation of ALT at end of treatment.
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 Analysis 2.7. Comparison 2 Subgroup: naives, relapsers, non-responders, Outcome 7 Failure 
of normalisation of ALT at end of follow-up.
 
Comparison 3. Subgroup: genotype 1 compared to genotype non-1 
Outcome or subgroup 
title 
No. of 
studies 
No. of 
participants 
Statistical method Effect size 
1 Failure of sustained 
virological response 
35 5582 Risk Ratio (M-H, Fixed, 
95% CI) 
0.99 [0.95, 1.02] 
1.1 HCV genotype 1  13 2350 Risk Ratio (M-H, Fixed, 
95% CI) 
1.00 [0.94, 1.06] 
1.2 HCV genotype 
non-1 
8 731 Risk Ratio (M-H, Fixed, 
95% CI) 
0.98 [0.82, 1.18] 
1.3 Trials without 
differentiation 
according to genotype 
23 2501 Risk Ratio (M-H, Fixed, 
95% CI) 
0.98 [0.94, 1.02] 
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 Analysis 3.1. Comparison 3 Subgroup: genotype 1 compared to genotype non-1, Outcome 1 
Failure of sustained virological response.
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 Comparison 4. Subgroup: trials at lower risk of bias compared to trials at high risk 
of bias 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical method Effect size 
1 All-cause mortality or liver-related 
morbidity 
32 4617 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.90 [0.38, 
2.17] 
1.1 Trials with lower risk of bias 2 552 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.36 [0.01, 
8.71] 
1.2 Trials with high risk of bias 30 4065 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.99 [0.39, 
2.49] 
2 Adverse events 35 5646 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.98 [0.84, 
1.14] 
2.1 Trials with lower risk of bias 2 552 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.72 [0.53, 
0.99] 
2.2 Trials with high risk of bias 33 5094 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.06 [0.89, 
1.26] 
3 Failure of sustained virological 
response 
35 5582 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.99 [0.95, 
1.02] 
3.1 Trials with lower risk of bias 1 400 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.85 [0.70, 
1.03] 
3.2 Trials with high risk of bias 34 5182 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.00 [0.96, 
1.03] 
4 Failure of end of treatment 
virological response 
30 4861 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.91, 
1.00] 
4.1 Trials with lower risk of bias 1 400 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.82 [0.65, 
1.02] 
4.2 Trials with high risk of bias 29 4461 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.96 [0.92, 
1.01] 
5 Failure of histological response 3 236 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.93, 
1.09] 
5.1 Trials with high risk of bias 3 236 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.01 [0.93, 
1.09] 
6 Failure of normalisation of ALT at 
end of treatment  
19 2241 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.88 [0.83, 
0.94] 
6.1 Trials with lower risk of bias 2 552 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.79 [0.68, 
0.91] 
6.2 Trials with high risk of bias 17 1689 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.91 [0.85, 
0.98] 
7 Failure of normalisation of ALT at 
end of follow-up 
21 3744 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.95 [0.91, 
1.00] 
7.1 Trials with lower risk of bias 1 400 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.81 [0.67, 
0.98] 
7.2 Trials with high risk of bias 20 3344 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.97 [0.92, 
1.02] 
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 Analysis 4.1. Comparison 4 Subgroup: trials at lower risk of bias compared to trials at high 
risk of bias, Outcome 1 All-cause mortality or liver-related morbidity.
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 Analysis 4.2. Comparison 4 Subgroup: trials at lower risk of bias compared to trials at high 
risk of bias, Outcome 2 Adverse events.
 
  
130
Chapter 4
 Analysis 4.3. Comparison 4 Subgroup: trials at lower risk of bias compared to trials at high 
risk of bias, Outcome 3 Failure of sustained virological response.
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 Analysis 4.4. Comparison 4 Subgroup: trials at lower risk of bias compared to trials at high 
risk of bias, Outcome 4 Failure of end of treatment virological response.
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 Analysis 4.5. Comparison 4 Subgroup: trials at lower risk of bias compared to trials at high 
risk of bias, Outcome 5 Failure of histological response.
 
 
Analysis 4.6. Comparison 4 Subgroup: trials at lower risk of bias compared to trials at high 
risk of bias, Outcome 6 Failure of normalisation of ALT at end of treatment.
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 Analysis 4.7. Comparison 4 Subgroup: trials at lower risk of bias compared to trials at high 
risk of bias, Outcome 7 Failure of normalisation of ALT at end of follow-up.
 
Comparison 5. Subgroup: sensitivity analysis 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical 
method 
Effect size 
1 Failure of sustained virological 
response 
11 2588 Risk Ratio (M-
H, Random, 
95% CI) 
0.84 [0.71, 
0.98] 
1.1 Best-worst: amantadine plus 
interferon-alpha and ribavirin versus 
placebo or no intervention plus 
interferon-alpha and ribavirin  
11 1294 Risk Ratio (M-
H, Random, 
95% CI) 
0.69 [0.56, 
0.85] 
1.2 Worst-best: amantadine plus 
interferon-alpha and ribavirin versus 
placebo or no intervention plus 
interferon-alpha and ribavirin  
11 1294 Risk Ratio (M-
H, Random, 
95% CI) 
1.02 [0.81, 
1.29] 
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 2 Failure of end of treatment 
virological response 
10 2438 Risk Ratio (M-
H, Fixed, 95% 
CI) 
0.84 [0.78, 
0.91] 
2.1 Best-worst: amantadine plus 
interferon-alpha and ribavirin versus 
placebo or no intervention plus 
interferon-alpha and ribavirin  
10 1219 Risk Ratio (M-
H, Fixed, 95% 
CI) 
0.58 [0.52, 
0.65] 
2.2 Worst-best: amantadine plus 
interferon-alpha and ribavirin versus 
placebo or no intervention plus 
interferon-alpha and ribavirin  
10 1219 Risk Ratio (M-
H, Fixed, 95% 
CI) 
1.20 [1.08, 
1.34] 
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Analysis 5.1. Comparison 5 Subgroup: sensitivity analysis, Outcome 1 Failure of sustained 
virological response.
 
  
 Analysis 5.2. Comparison 5 Subgroup: sensitivity analysis, Outcome 2 Failure of end of 
treatment virological response.
 
Appendices 
Appendix 1. Search strategies 
Database Time span Search strategy 
Cochrane Hepato-Biliary 
Group Controlled Trials 
Register 
1996 to 
December 2013 
(adaman* OR amantadin* OR symmetrel OR symandin* 
OR rimantadin* OR flumadin* OR methenamin*) AND 
('hepatitis C' OR 'hep C' OR HCV) 
Cochrane Central 
Register of Controlled 
Trials (CENTRAL) 
CENTRAL 2013, Issue 11 
of 12, in The Cochrane 
Library (Wiley) 
  
1995 to Issue 11 
of 12, 2013 
#1 MeSH descriptor: [Adamantane] explode all trees 
#2 adaman* OR amantadin* OR symmetrel OR symandin* 
OR rimantadin* OR flumadin* OR methenamin* 
#3 (#1 OR #2) 
#4 MeSH descriptor: [Hepatitis C] explode all trees 
#5 hepatitis C OR hep C OR HCV 
#6 (#4 OR #5) 
#7 (#3 AND #6) 
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 MEDLINE (Ovid SP) 1946 to 
December 2013 
1. exp Adamantane/ 
2. (adaman* or amantadin* or symmetrel or symandin* 
or rimantadin* or flumadin* or methenamin*).mp. 
[mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, 
name of substance word, subject heading word, unique 
identifier] 
3. 1 or 2 
4. exp Hepatitis C/ 
5. (hepatitis C or hep C or HCV).mp. [mp=protocol 
supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of 
substance word, subject heading word, unique 
identifier] 
6. 4 or 5 
7. 3 and 6 
8. (random* or blind* or placebo* or meta-analys*).mp. 
[mp=protocol supplementary concept, rare disease 
supplementary concept, title, original title, abstract, 
name of substance word, subject heading word, unique 
identifier] 
9. 7 and 8 
EMBASE (Ovid SP) 
  
1974 to 
December 2013 
1. exp amantadine/ 
2. exp rimantadine/ 
3. (adaman* or amantadin* or symmetrel or symandin* 
or rimantadin* or flumadin* or methenamin*).mp. 
[mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword] 
4. 1 or 2 or 3 
5. exp hepatitis C/ 
6. (hepatitis C or hep C or HCV).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
7. 5 or 6 
8. 4 and 7 
9. (random* or blind* or placebo* or meta-analys*).mp. 
[mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword] 
10. 8 and 9 
Science Citation Index 
Expanded 
  
1900 to 
December 2013 
#5 #4 AND #3 
#4 TS=(random* or blind* or placebo* or meta-analys*) 
#3 #2 AND #1 
#2 TS=(hepatitis C or hep C or HCV) 
#1 TS=(adaman* or amantadin* or symmetrel or 
symandin* or rimantadin* or flumadin* or methenamin*) 
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ML, MB, JD, and CG were involved in the study concept and design. 
ML and MB screened the literature, selected publications for inclusion and exclusion 
according to the eligibility criteria, extracted data, and made the 'Risk of bias' judgements. 
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ML drafted the manuscript and performed the meta-analyses. 
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content. 
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Differences between protocol and review  
• We conducted sensitivity analysis only on the statistically significant findings and only 
using 'best-worse' case scenario and 'worst-best' case scenario analysis, in order to check 
the robustness of our analysis. We did not use 'poor outcome analysis' and 'good outcome 
analysis' and deleted this from our review. 
• We also assessed the risk of other sources of bias (baseline imbalance bias and early 
stopping bias) and described this in our Characteristics of included studies table. Both may 
bias the individual trial, but are unlikely to bias meta-analysis. Therefore, we reported 
this for the individual trials, but not for our meta-analyses. 
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 • We did not contact pharmaceutical companies who are involved in the production and 
assessment of aminoadamantanes. 
• We included a 'Summary of findings' table.  
 
Characteristics of studies 
Characteristics of included studies [ordered by study ID] 
Adinolfi 2003 
Methods Randomised clinical trial in interferon non-responder patients 
12 months therapy, 12 months follow-up 
Participants Country: Italy 
114 patients were randomized 
 
Inclusion criteria: chronic HCV with presence of serum HCV RNA, serum 
ALT levels persistently greater than 1.5 times the normal value during the 
follow-up period, previously received a course of recombinant or 
lymphoblastoid interferon-alpha 3 to 6 MU 3 times a week for at least 4 
months, were considered as non-responders - that is, on no occasion had 
they had both serum HCV RNA clearance and normalisation of serum 
transaminase levels, liver biopsy in the 24 months before entering the 
study 
Exclusion criteria: decompensated cirrhosis, cirrhosis with signs of portal 
hypertension, serum HIV or HBsAg positivity, serum markers of 
autoimmunity with or without associated disease, alcohol intake, serum 
haemoglobin concentration < 12 g/dl for women and < 13 g/dl for men, 
white cell count < 3000 mm³, platelet count < 100,000 mm³, other 
clinically significant diseases 
Amantadine group: 24 patients, median age 50 (30 to 59) years, 
male/female = 16/8. Median serum ALT 105 (64 to 284) MU/mL, and a 
median basal viral load of 3.2 (0.8 to 28.6) eq/mL x 10⁶ copies per mL. 
Genotype 1 (n = 17) and genotype non-1 (n = 7). Histological staging (HAI): 
median 5.4 (4 to 10), 8 patients cirrhosis 
Control group: 46 patients, median age 51 (30 to 60) years, male/female 
= 31/15. Median serum ALT 98 (62 to 308) MU/mL, and the median basal 
viral load of 3.0 (0.7 to 18.4) eq/mL x 10⁶ copies per mL. Genotype 1 (n = 
33) and genotype non-1 (n = 13). Histological staging (HAI): median 5.3 (4 
to 9), 12 patients cirrhosis 
Interventions Amantadine group: interferon-alpha-2b sc 3 MU daily for the first 4 weeks 
and subsequently 3 times a week, oral ribavirin at a daily dose of 1000 mg 
plus oral amantadine hydrochloride 200 mg/day administered in 2 doses 
of 100 mg 
Control group: interferon-alpha-2b sc 3 MU daily for the first 4 weeks and 
subsequently 3 times a week plus oral ribavirin at a daily dose of 1000 mg 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to 
AE; composite outcome of number of patients with or without hepatitis C 
virus and ALT normalisation at end of treatment and end-of follow-up 
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 Notes   
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Drop-outs not reported separately for 3 groups 
Selective reporting 
(reporting bias) 
High risk Only 1 outcome measure 
Other bias Unclear risk Vested interest bias: insufficient information 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Angelico 2004 
Methods Randomised, open-label, controlled trial in naive patients in 14 centres 
12 months therapy, 6 months follow-up 
Participants Country: Italy 
181 patients were enrolled and started the initial 2-month treatment 
course with interferon-alpha-2a monotherapy. 17 patients dropped out 
within this period. The remaining 164 patients were randomised 
Inclusion criteria: age between 18 and 65 years, presence of anti-HCV 
antibodies, positive serum HCV RNA by PCR, persistent elevation of serum 
ALT (≥ 1.5 times the upper limit of normal) during the 12 months prior to 
the study, and histological diagnosis of chronic hepatitis on liver biopsy 
sample taken in the preceding 6 months 
Exclusion criteria: HBsAg or HIV positivity, recent or active alcohol and/or 
drug abuse, platelet count < 70,000/mL or leucocyte count < 3000/mL, 
histological evidence of cirrhosis, autoimmune or genetic liver diseases, 
other clinically significant diseases. 
Amantadine group: 83 patients, mean age 39 ± 13 years, male/female = 
61/22. Serum ALT 123 ± 73 MU/mL and the basal viral load 766 ± 747 x 10³ 
copies per mL. Genotype 1 (n = 45) and genotype non-1 (n = 38). 
Histological staging: median 1.7 ± 1.3 
Control group: 81 patients, mean age 41 ± 12 years, male/female = 53/28. 
Serum ALT 110 ± 66 MU/mL and the basal viral load 738 ± 585 x 10³ copies 
per mL. Genotype 1 (n = 46) and genotype non-1 (n = 35). Histological 
staging: median 1.5 ± 1.1 
Interventions First there was an initial treatment course of 3 MU of recombinant 
interferon-alpha-2a, sc 3 times weekly for 2 months. Patients were then 
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 divided into 2 groups according to the serum HCV RNA status (HCV RNA-
negative or HCV RNA-positive). Patients in each group were randomly 
assigned to receive: 
Amantadine group: interferon-alpha-2a sc 3 times weekly plus 
amantadine, 200 mg po daily 
Control group: interferon-alpha-2a sc 3 times weekly 
In the HCV RNA-positive group, the dose of interferon-alpha-2a was 
increased to 6 MU 3 times weekly. At the end of month 6 of treatment, 
HCV RNA status was re-assessed. All HCV RNA-positive patients were 
withdrawn from therapy, whereas HCV RNA-negative patients continued 
treatment until month 12 according to their initial randomization 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to 
AE; number of patients without SVR; number of patients with detectable 
HCV RNA at EOT; number of patients without normalisation of ALT at EOT 
and at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer-generated randomisation 
Allocation 
concealment (selection 
bias) 
Low risk Sealed envelopes 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Too many drop-outs, not specified for what reasons and in 
which group: this can influence intervention effect 
Selective reporting 
(reporting bias) 
High risk Outcome measures mentioned, but lack of other outcome 
measures 
Other bias Unclear risk Vested interest bias: insufficient information 
No baseline imbalance; sample size calculation was 
reported and the trial was not stopped early 
Angelico 2008 
Methods Randomised clinical trial in naive patients in 12 centres 
The study was designed in 2001 for 48 weeks of treatment, 24 weeks of follow-
up 
Participants Country: Italy and Sardinia 
230 patients were randomised 
Inclusion criteria: interferon-naive patients with chronic HCV, age 18 to 65 
years, positive serum HCV RNA, elevated serum ALT (≥ 1.5 times the upper 
limit of normal in at least 2 determinations over the previous 6-month period) 
Exclusion criteria: decompensated cirrhosis (presence or a history of ascites, 
gastrointestinal bleeding or hepatic encephalopathy); positive serum HBsAg, 
HIV co-infection; neutrophil count < 1500 cells/mm3; platelet count < 90 000 
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 cells/mm3; haemoglobin levels < 12 g/dl (women) or < 13 g/dl (men); serum 
creatinine levels > 1.5 mg/dl; active alcohol or drug dependence; pregnancy 
or lactation; serological markers of autoimmunity; severe psychiatric 
disorders and cancer or severe pulmonary, renal or cardiac comorbidity. 
Cirrhotic patients were eligible only classified as Child–Pugh A 
Amantadine group: 47 patients 
Control group: 42 patients 
Mean baseline characteristics for the whole group of 89 patients (actually 109, 
because the 20 patients who dropped out during the induction period belonged 
to this group according to ITT). Mean age 47.3 ± 12.1 years, male/female = 
63/46, BMI 25.3 ± 3.5 kg/m2. Serum ALT was 117 ± 87 IU/l and the basal viral 
load was 939 ± 109 x 10³ IU per mL. Genotype 1 and 4 (n = 87) and genotype 
2 and 3 (n = 22). Histological staging (Ishak): 2.3 ± 1.4 
Interventions Randomisation was performed after the assessment of EVR, defined as 
undetectable qualitative serum HCV RNA (< 50 IU/ml) after 12 weeks of 
induction monotherapy with peg interferon-alpha-2a (40 kDa) 180 µg/week sc 
Patients who did not achieve EVR were randomised in a 1:1 ratio to add either: 
Amantadine group: ribavirin, 800 mg/day, in divided doses and oral 
amantadine hydrochloride, 200 mg/day, for 36 additional weeks 
Control group: oral ribavirin 800 mg/day, in divided doses, for 36 additional 
weeks 
Patients who achieved EVR were randomised in a 1:1 ratio either to continue 
peg interferon-alpha-2a monotherapy or to add oral ribavirin, 800 mg/day, for 
36 additional weeks 
Outcomes Mortality; liver-related morbidity; number of patients without SVR; number of 
patients with detectable HCV RNA at EOT 
Notes At 21 January 2012 ML sent email to angelico@med.uniroma2.it about 
treatment discontinuation due to SAE in each group 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Low risk Randomisation was performed centrally using computer-
generated lists and was stratified by individual centres and HCV 
genotypes (genotypes 1/4 versus genotypes non-1/4) 
Allocation 
concealment 
(selection bias) 
Unclear risk Random allocation to treatment groups 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
High risk Drop-outs not described completely 
Selective reporting 
(reporting bias) 
High risk Primary outcome was mentioned, but other reasonably 
expected outcomes are missing 
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 Other bias High risk Vested interest bias: the study medication was provided by 
Roche Pharmaceuticals, Monza, Italy 
No baseline imbalance; sample size calculation was reported; 
the trial was not stopped early 
Bacosi 2002 
Methods Randomised clinical trial in non-responders or relapsers 
12 months therapy, 12 months follow-up 
Participants Country: Italy 
165 patients were screened (females n = 86; males n = 79) for 3 groups 
(55 patients each group) 
Inclusion criteria: detectable, circulating HCV RNA; presence of chronic 
active liver disease already diagnosed on the grounds of laboratory and 
pathologic findings 
Exclusion criteria: Child-Pugh score B or C, previous episode of 
gastrointestinal bleeding, disturbances of cardiac rhythm as determined 
by electrocardiogram and renal failure 
Amantadine group: 38 patients, mean age 67 ± 4 years, male/female = 
17/21. Serum ALT 2.6 ± 1.5-fold the upper limit of normal and the basal 
viral load 585 ± 257 x 10³ copies per mL. Genotype 1b was predominant 
(n = 32) with 4 patients with mixed genotypes. The other 6 patients had 
genotypes 2a (n = 3) and 2a-2c (n = 3). 1 patient cirrhosis 
Control group: 39 patients, mean age 65 ± 2 years, male/female = 21/18. 
Basal viral load was 637 ± 452 x 10³ copies per mL, ALT was not provided. 
Genotype 1b was predominant (n = 31) associated with 1a in 3 cases; the 
remaining 8 patients had genotypes (2a (n=4), 2a-2c (n = 3) and 4 (n = 1). 
No patient with cirrhosis 
Interventions Amantadine group: interferon-alpha-n₃ 6 MU sc every other day until 
return to normal of ALT or a decrease in viral copies of at least 1 log unit 
(however, no longer than 3 months) then followed by 3 MU plus 200 
mg/day amantadine orally 
Control group: interferon-alpha-n₃ 6 MU sc every other day until return 
to normal of ALT or a decrease in viral copies of at least 1 log unit 
(however, no longer than 3 months) then followed by 3 MU 
Another included group received only 100 mg amantadine oral twice daily 
The duration of the trial treatment was 12 months; treatment, however, 
was planned to last for no more than 6 months if there was no significant 
decrease in viral load 
Outcomes Mortality; SAE; treatment discontinue due to AE; number of patients 
without SVR; number of patients with detectable HCV RNA at EOT; number 
of patients without normalisation of ALT at EOT and at EOFU 
Notes ML sent Dr Bacosi an email for additional information on 13 December 
2011 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information 
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 Allocation concealment 
(selection bias) 
Low risk Closed envelopes 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Drop-outs not equally divided. Many patients dropped out 
after randomisation 
Selective reporting 
(reporting bias) 
High risk No clear primary and secondary outcome measures 
mentioned 
Other bias Unclear risk Vested interest bias: insufficient information 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Baisini 2003 
Methods Randomised, open-label, controlled trial in naive patients involving 5 centres 
12 months therapy, 6 months follow-up 
Participants Country: Italy 
93 patients were randomised 
Inclusion criteria: elevation of serum ALT > 2 times the upper limit of normal 
in at least 3 occasions over 12 months and with positive HCV RNA testing, 
histological evidence of chronic hepatitis as judged on liver biopsy performed 
no longer than 6 months prior to enrolment, confirmation of HCV infection 
by PCR 
Exclusion criteria: age < 18 years or > 65 years, pregnancy or lack of 
appropriate contraceptive measures in women of child bearing age, previous 
treatment with antiviral or immunosuppressive drugs, current or previous 
drug addiction, alcoholism, positive HBsAg or HIV testing, histological 
evidence of cirrhosis, concomitant metabolic, autoimmune or neoplastic 
liver diseases, severe concomitant diseases other than liver disease, history 
of depression or psychiatric diseases, leukocyte count < 3000/dL, platelet 
count < 75,000/dL and serum albumin < 3 g/dL 
Amantadine group: 48 patients, mean age 48 ± 1.8 years, male/female = 
24/24. Serum ALT 130 ± 15 U/l and 32 patients had a basal viral load > 1 x 
106 copies per mL. Genotype 1 (n = 22). Histological staging 1.7 ± 0.3 
Control group: 45 patients, mean age 45 ± 1.8 years, male/female = 27/18. 
Serum ALT 115 ± 10 U/l and 32 patients had a basal viral load > 1 x 106 copies 
per mL. Genotype 1 (n = 19). Histological staging 1.3 ± 0.2 
Interventions i) Phase 1 (week 0/4): patients received either interferon-alpha 
lymphoblastoid 6 MU daily plus 100 mg amantadine twice daily; or the same 
dose of interferon-alpha alone (regimen B) 
ii) Phase 2 (week 5/24): all patients in regimen A and in regimen B were 
shifted to receive interferon-alpha 6 MU 3 times a week while maintaining 
the amantadine dose as in phase 1 for patients allocated to regimen A 
iii) Phase 3 (week 25/48): patients with serum ALT level lower than the upper 
limit of the normal range at the end of phase 2 were treated with a reduced 
dose of interferon-alpha dose, 3 MU 3 times a week while maintaining 100 
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 mg twice daily amantadine for patients allocated to regimen A. Patients with 
abnormal ALT levels continued treatment as in phase 2 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients without improvement 
of histology; number of patients without normalisation of ALT at EOTand at 
EOFU 
Notes Additional information requested on 9 February 2012 from the last author 
Prof. Dr. A. Lanzini 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk The method of sequence generation was not specified. 
Carried out using a blocked randomisation technique 
Allocation 
concealment 
(selection bias) 
Unclear risk The method of allocation concealment was not specified. 
Carried out using a blocked randomisation technique 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Patients who terminated prematurely were not equally 
divided over the 2 treatment groups 
Selective reporting 
(reporting bias) 
High risk There was no protocol, but all the authors' study endpoints 
were discussed in the article. Not all reasonably expected 
outcomes were discussed 
Other bias Unclear risk Vested interest bias: unclear 
No baseline imbalance; sample size calculation was reported; 
the trial was not stopped early 
Berg 2003 
Methods Randomised, double-blind, placebo-controlled trial in naive patients in 8 
centres 
Patients were studied between December 1998 and June 2001 
48 weeks therapy, 24 weeks follow-up 
Participants Country: Germany 
400 patients were enrolled 
Inclusion criteria: aged between 18 and 70 years with compensated chronic 
HCV infection who had not been previously treated with interferon-alpha, 
ribavirin, and/or amantadine, positive test for anti-HCV and HCV RNA by 
RT-PCR, elevated serum ALT levels for at least 6 months before initiation 
of treatment, and liver biopsy specimen taken in the preceding year of 
study entry showing chronic hepatitis 
Exclusion criteria: decompensated liver disease, other causes of liver 
disease, hepatitis B infection, HIV infection, autoimmune disorders, 
haemoglobin values < 11 g/dL, white blood cell count < 3/nL, 
thrombocytopenia < 70/nL, other severe concurrent diseases, concurrent 
use of thiazide diuretics, pregnancy, or lactation period, alcohol or drug 
abuse or those unwilling to practice contraception 
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 Amantadine group: 200 patients, mean age 41.7 ± 0.82 (18 to 70) years, 
male/female = 126/74. Mean weight 75.6 ± 1.0 (49 to 115) kg. Mean serum 
ALT 62.4 ± 4.03 (16 to 393) MU/mL and the mean basal viral load 5.99 ± 
0.75 x 10⁶ copies per mL. Genotype 1 (n = 126), genotype 2 (n = 20), 
genotype 3 (n = 48), and genotype 4 (n = 6). Histological staging: F0 (n = 
23), F1 (n = 79), F2 (n = 49), F3 (n = 35), and F4 (n = 14) 
Control group: 200 patients, mean age 40.5 ± 0.79 (18 to 68) years, 
male/female = 127/73. Mean weight 73.7 ± 1.07 (47 to 125) kg. Mean serum 
ALT 62.8 ± 3.72 (16 to 369) MU/mL and the mean basal viral load 4.92 ± 
0.59 x 10⁶ copies per mL. Genotype 1 (n = 129), genotype 2 (n = 12), 
genotype 3 (n = 47), genotype 4 (n = 9), and genotype 5 (n = 1). Histological 
staging: F0 (n = 28), F1 (n = 69), F2 (n = 52), F3 (n = 41), and F4 (n = 10) 
Interventions Amantadine group: total dose of 200 mg amantadine sulphate with 
interferon-alpha-2a plus 1000 to 1200 mg ribavirin per day orally adjusted 
according to body weight (1000 mg for weight < 75 kg and 1200 mg for 
weight ≥ 75 kg) for 48 weeks 
Control group: matched placebo with interferon-alpha-2a plus 1000 to 1200 
mg ribavirin per day orally adjusted according to body weight (1000 mg for 
weight < 75 kg and 1200 mg for weight ≥ 75 kg) for 48 weeks 
For the first 2 weeks, 9 MU interferon-alpha daily, followed by 6 MU 
interferon-alpha daily for an additional 6 weeks, then 6 MU 3 times per 
week until week 24 and then 3 MU thrice weekly for a further 24 weeks 
Psychological states were measured by the German adapted and validated 
version of the 'Profile of Mood States' (POMS) scale, which measures 4 factor 
scores for depression, fatigue, vigour, and anger. Furthermore, QoL was 
assessed by the 'Everyday Life' questionnaire (EDLQ), a German validated 
questionnaire related to the SF-36 Health Survey. The EDLQ assesses the 
following 6 subscales: body (e.g., make demands on body, concentrate on 
a task); mind (e.g., cope with illness, accept oneself); everyday life (e.g., 
solve daily problems, perform personal hygiene); social activity (e.g., get 
along with family, count on partner's help); zest for life (e.g., enjoy life); 
and medical treatment (e.g., believe in success of treatment) 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to 
AE; QoL; number of patients without SVR; number of patients with 
detectable HCV RNA at EOT; number of patients without normalisation of 
ALT at EOT and at EOFU 
Notes Study was supported by Merz + Co, Frankfurt a. M. and Hoffman-La Roche, 
Grenzach, Germany 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Independent central randomisation centre using a random 
number generator in fixed blocks of 4 
Allocation 
concealment 
(selection bias) 
Low risk Independent central randomisation centre using a random 
number generator in fixed blocks of 4 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
Low risk Matched placebo 
Blinding of outcome 
assessment (detection 
Low risk Matched placebo 
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 bias)  
All outcomes 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Each drop-out not explained/mentioned separately 
Selective reporting 
(reporting bias) 
Low risk All important outcome measures reported 
Other bias High risk Vested interest bias: supported by Merz + Co 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
Brillanti 1999 
Methods Randomised clinical trial in interferon-alpha non-responders in 1 centre 
Patients were enrolled between May and July 1996 
6 months therapy, 6 months follow-up 
Participants Country: Italy 
20 adult patients were randomised 
Inclusion criteria: persistent elevations of serum ALT levels for at least the 
previous 6 months; liver biopsy obtained within the last 3 months before 
starting the previous interferon-alpha course, showing histological findings 
compatible with chronic viral hepatitis; the presence of antibodies to HCV by 
ELISA and of serum HCV RNA by PCR; the absence of circulating anti-interferon-
alpha antibodies; no signs or symptoms of decompensated liver disease, other 
serious illnesses, or co-infection with HIV; previously been treated using 3 to 5 
MU of recombinant or lymphoblastoid interferon-alpha on alternate days for 6 
months, but neither biochemical nor virological response had been achieved; 
interferon-alpha had been discontinued at least 6 months before entry into 
study 
Exclusion criteria: active hepatitis B virus infection, autoimmune hepatitis, 
alcoholic liver disease, and other possible causes chronic liver disease 
Amantadine group: 10 patients, mean age 42.8 ± 2.5 years, male/female = 
7/3. Mean weight not provided. Mean serum ALT 159.8 ± 22.9 MU/mL and the 
mean basal viral load 5.53 ± 0.22 x 10⁶ copies per mL. Genotype 1 (n = 4), 
genotype 2 (n = 3), and genotype 3 (n = 3). Histological staging: 5 patients 
cirrhosis 
Control group: 10 patients, mean age 45.5 ± 5.2 years, male/female = 8/2. 
Mean weight not provided. Mean serum ALT 169.5 ± 49.6 MU/mL and the mean 
basal viral load 5.42 ± 0.19 x 10⁶ copies per mL. Genotype 1 (n = 4), genotype 
2 (n = 4), and genotype 3 (n = 2). Histological staging: 4 patients cirrhosis 
Interventions Amantadine group: 100 mg oral amantadine per day plus 3 MU natural human 
leukocyte interferon-alpha-n3 on alternate days, plus 800 mg/day (if body 
weight < 75 kg) or 1000 mg/day (if body weight > 75 kg) ribavirin, given orally 
in 2 daily doses 
Control group: 3 MU natural human leukocyte interferon-alpha-n3 on alternate 
days plus 800 mg/day (if body weight < 75 kg) or 1000 mg/day (if body weight 
> 75 kg) ribavirin, given orally in 2 daily doses 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients with detectable HCV RNA 
at EOT; number of patients without normalisation of ALT at EOT and at EOFU 
Notes   
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
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 Random sequence 
generation 
(selection bias) 
Unclear risk Using restricted randomisation (permuted blocks) with serial 
entry, 10 individuals were randomly selected out of the set of 
20 and allocated to the triple therapy group, and the other 10 
were allocated to the double therapy group 
Allocation 
concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Low risk No drop-outs 
Selective reporting 
(reporting bias) 
High risk No pre-planned outcome measures mentioned 
Other bias Unclear risk Vested interest bias: insufficient information 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
 
Brillanti 2000 
Methods Randomised clinical trial in interferon-alpha non-responders in 1 centre 
Patients were enrolled starting in October 1996 
12 months therapy, 6 months follow-up 
Participants Country: Italy 
60 adult patients were randomised 
Inclusion criteria: persistent elevations of serum ALT levels for at least 
the previous 6 months; liver biopsy obtained within the last 3 months 
before starting the previous interferon-alpha course, showing histological 
findings compatible with chronic viral hepatitis; the presence of 
antibodies to HCV by ELISA and of serum HCV RNA by PCR; the absence of 
circulating anti-interferon-alpha antibodies; previously been treated using 
3 to 6 MU of recombinant or lymphoblastoid interferon-alpha on alternate 
days for 4 months, but neither biochemical nor virological response had 
been achieved; interferon-alpha had been discontinued at least 6 months, 
but not more than 12 months, before entering this study 
Exclusion criteria: signs or symptoms of decompensated liver disease, co-
infection with HIV, active hepatitis B virus infection, autoimmune 
hepatitis, alcoholic liver disease, other possible causes of chronic liver 
disease, other clinically significant diseases, haemoglobin concentration 
of < 12 g/dL in women and <13 g/dL in men, white cell count of < 3000 
mm³, and platelet count of < 100,000 mm³ 
Amantadine group: 40 patients, median age 49 (28 to 70) years, 
male/female = 27/13. Weight not provided. Median serum ALT 124.5 (42 
to 502) IU/L and the basal viral load 5.46 GMT (GMT = geometric mean 
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 titre of circulating HCV RNA as the antilog of the mean of the logarithmic 
transformed values of copies/mL). Genotype 1 (n = 23), genotype 2 (n = 
11), genotype 3 (n = 3), and genotype 4 (n = 3). Histological staging: 10 
patients cirrhosis 
Control group: 20 patients, median age 47 (32 to 70) years, male/female 
= 13/7. Weight not provided. Median serum ALT 133 (58 to 404) IU/L and 
the basal viral load 5.5 GMT. Genotype 1 (n = 11), genotype 2 (n = 6), 
genotype 3 (n = 2), and genotype 4 (n = 1). Histological staging: 5 patients 
cirrhosis 
Interventions Amantadine group: oral amantadine hydrochloride administered twice 
daily at total dose of 200 mg plus 5 MU sc interferon-alpha-2b every other 
day and oral ribavirin 800 mg/day (if body weight < 75 kg) or 1000 mg/day 
(if body weight > 75 kg) ribavirin, given orally in 2 daily doses 
Control group: 5 MU sc interferon-alpha-2b every other day and oral 
ribavirin 800 mg/day (if body weight < 75 kg) or 1000 mg/day (if body 
weight > 75 kg) ribavirin, given orally in 2 daily doses 
Outcomes Mortality; liver-related morbidity. SAE. Treatment discontinuation due to 
AE. Number of patients without SVR; number of patients with detectable 
HCV RNA at EOT; number of patients without normalisation of ALT at EOT; 
at EOFU 
Notes Supported partially by a Research Grant from the Italian Ministry for the 
University and Scientific Research 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk We used a restricted randomisation with a ratio of 2:1 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk Treatment was not discontinued in any patient because of 
adverse events 
Selective reporting 
(reporting bias) 
Low risk All reasonably expected study endpoints were discussed in 
the article 
Other bias Unclear risk Vested interest bias: insufficient information 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
Calay 2005 
Methods Multicentre, randomised, double-blind, placebo-controlled trial in naive 
patients 
48 weeks treatment, 24 weeks follow-up 
Participants Country: France 
269 patients were randomised, 253 really started with treatment 
Patients with chronic HCV (proven by liver biopsy and positive for serum 
HCV RNA), previous treatment naive 
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 Baseline characteristics were comparable in both groups: 
Amantadine group: 128 patients, mean age 44.4 years, male/female = 
78/50, BMI 23 kg/m2. Mean serum ALT was 2.3 times the upper limit of 
normal and the basal viral load was 1.3 MUI/mL. Genotype 1 (n = 88) and 
genotype non-1 (n = 40). Histological staging: 24 patients had extensive 
fibrosis and cirrhosis 
Control group: 125 patients, mean age 45.6 years, male/female = 72/53, 
BMI 24 kg/m2. Mean serum ALT was 2.5 times the upper limit of normal 
and the basal viral load was 1.5 MUI/mL. Genotype 1 (n = 89) and 
genotype non-1 (n = 36). Histological staging: 22 patients had extensive 
fibrosis and cirrhosis 
Interventions Amantadine group: peg interferon-alpha-2b 1.5 μg/kg/week sc, ribavirin 
800 to 1200 mg/day orally, with amantadine 200 mg/day for 48 weeks 
Control group: peg interferon-alpha-2b 1.5 μg/kg/week sc, ribavirin 800 
to 1200 mg/day orally, with placebo for 48 weeks 
Outcomes Number of patients without SVR 
Notes ML sent an email to dom-larrey@chu-montpellier.fr on 23 January 2012 
about baseline characteristics 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
Unclear risk Insufficient information, although placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Insufficient information, although placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Unclear risk Insufficient information 
Selective reporting 
(reporting bias) 
High risk Did not report on all reasonable important outcome 
measures 
Other bias Unclear risk Vested interest bias: research support by Schering-
Plough, Roche 
No baseline imbalance; sample size calculation was not 
reported; unknown if trial was stopped early 
Caronia 2001 
Methods Randomised clinical trial in naive patients in 2 centres 
Between 1997 and 1998 
Treatment duration 48 weeks, follow-up 24 weeks 
Participants Country: United Kingdom 
36 patients were randomised 
Inclusion criteria: age between 18 and 70 years; liver biopsy taken within 
18 months of randomisation showing chronic HCV with significant necro-
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 inflammation (HAI grade > 3/18) and/or fibrosis (stage > 2/6) and ALT > 1.3 
times the upper limit of normal within 6 months of randomisation 
Exclusion criteria: patients with concomitant causes of liver disease, recent 
history of alcohol abuse (> 28 units per week within the last 6 months) or 
active intravenous drug use, and biopsy proven cirrhosis 
Amantadine group: 18 patients, mean age 40 ± 12.2 years, male/female = 
9/9. Serum mean ALT was 69 ± 43.9 U/L, the basal viral load was not 
provided. Genotype 1 (n = 9), genotype non-1 (n = 9). Histological staging 
was not provided, presence of cirrhosis = 0 patients 
Control group: 18 patients, mean age 42 ± 14.3 years, male/female = 9/9. 
Serum ALT was 74 ± 52.6 U/L, the basal viral load was not provided. 
Genotype 1 (n = 10), genotype non-1 (n = 8). Histological staging was not 
provided, presence of cirrhosis = 0 patients 
Interventions Amantadine group: interferon-alpha-2a 4,5 MU sc 3 times weekly and 
amantadine hydrochloride, 200 mg oral daily, both for 48 weeks 
Control group: interferon-alpha-2a 4,5 MU sc 3 times weekly for 48 weeks 
Outcomes Mortality; liver-related morbidity; treatment discontinuation due to AE 
Notes Additional information requested on 26 January 2012 from the last author 
Prof. Dr. G. Foster. Dr. Foster responded on 26January 2012. ML responded 
on 31 January 2012 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer-generated random numbers 
Allocation 
concealment 
(selection bias) 
High risk Sealed envelopes. Not opaque 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk 1 patient in each group withdrew because of side effects 
Selective reporting 
(reporting bias) 
High risk Not clearly mentioned what the primary and secondary 
outcome measures are. All the authors' study endpoints were 
discussed in the article. Not all reasonably expected 
outcomes were discussed 
Other bias High risk Vested interest bias: Roche 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Caronia 2001a 
Methods Randomised clinical trial in naive patients in 14 centres 
Between 1998 and 2000 
Treatment duration 48 weeks, follow-up 24 weeks 
Participants Country: United Kingdom 
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 143 patients were randomised 
Inclusion criteria: age between 18 and 70 years; liver biopsy taken within 18 
months of randomisation showing chronic hepatitis C with significant necro-
inflammation (HAI grade > 3/18) and/or fibrosis (stage >2/6) and ALT > 1.3 
times the upper limit of normal within 6 months of randomisation 
Exclusion criteria: patients with concomitant causes of liver disease, recent 
history of alcohol abuse (> 28 units per week within the last 6 months) or 
active intravenous drug use 
Amantadine group: 72 patients, mean age 43 ± 17.6 years, male/female = 
45/27. Serum median ALT was 76 ± 10.6 U/L, the basal viral load was not 
provided. Genotype 1 (n = 19), genotype non-1 (n = 53). Histological staging 
was not provided, presence of cirrhosis = 6 or 7 patients 
Control group: 71 patients, mean age 42 ± 21.6 years, male/female = 43/37. 
Serum ALT was 80 ± 39 U/L, the basal viral load was not provided. Genotype 
1 (n = 20), genotype non-1 (n = 51). Histological staging was not provided, 
presence of cirrhosis = 7 patients 
Interventions Amantadine group: interferon-alpha-2a 4.5 MU sc 3 times weekly and 
amantadine hydrochloride, 200 mg oral daily, both for 48 weeks 
Control group: interferon-alpha-2a 4.5 MU sc 3 times weekly for 48 weeks 
Outcomes Mortality; liver-related morbidity; treatment discontinuation due to AE 
Notes Additional information requested on 26 January 2012 from the last author 
Prof. Dr. G. Foster. Dr. Foster responded 26 January 2012. ML responded on 
31 January 2012 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer-generated random numbers 
Allocation 
concealment 
(selection bias) 
High risk Sealed envelopes. Not opaque 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
Low risk Independent laboratory performed all the PCR tests and all 
samples were provided to the laboratory in a coded, 
anonymous fashion 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk The exact reasons for patients who terminated prematurely 
were not clearly explained 
Selective reporting 
(reporting bias) 
High risk Not clearly described what the primary and secondary 
outcome measures are. All the authors' study endpoints were 
discussed in the article. Not all reasonably expected 
outcomes were discussed 
Other bias High risk Vested interest bias: Roche 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
 
152
Chapter 4
 Ciancio 2006 
Methods Randomised clinical trial in non-responders 
Between May 2001 and December 2002 patients were included 
12 months therapy, 6 months follow-up 
Participants Country: Italy 
161 patients were randomised 
Inclusion criteria: age > 18 and < 65 years; positive results for HCV RNA by 
PCR; chronic HCV at liver biopsy performed within 1 year before entry; 
previous non-response to combined therapy; abnormal ALT levels (at least 1.5 
times upper limit of normal; range: 0 to 40 IU) 
Exclusion criteria: previous course with peg interferon-alpha-based therapy; 
relapse after 1 or more interferon-alpha plus ribavirin courses; positive HBsAg 
test in serum; positive test for antibody to HIV; alcoholic liver disease; 
haemochromatosis; Wilson's disease; drug related liver disease; autoimmune 
hepatitis; haemoglobin level < 10 g/dL, platelet count < 70,000/mm3, white 
blood cell count < 3000/mm3, or granulocyte count < 1500/mm3; 
decompensated cirrhosis; intravenous drug abuse; abnormal serum uric acid 
level; presence of concomitant significant medical illness; history of 
haemolytic anaemia; a1-antitrypsin deficiency; obesity-induced liver disease; 
haemophilia; seizure disorders; ischaemic cardiovascular disease and severe 
mental depression. Pregnant women and patients unable to practice 
contraception during therapy and follow-up 
Amantadine group: 80 patients, mean age 50 ± 11 (22 to 65) years, 
male/female = 59/21, BMI 24.8 ± 3.4 (17.3 to 33) kg/m2. Mean serum ALT was 
116 ± 85 (43 to 335) IU/L, the basal viral load was 2.1 ± 3.1 (0.01 to 19) x 106 
Eq/mL. Genotype 1 (n = 67), genotype 2 (n = 4), genotype 3 (n = 1), and 
genotype 4 (n = 8). Mean histological staging was 3 ± 1.5 (0 to 6), presence of 
cirrhosis = 11 patients 
Control group: 81 patients, mean age 50 ± 11 (27 to 65) years, male/female 
= 60/21, BMI 24.9 ± 3.5 (17.6 to 34.2) kg/m2. Mean serum ALT was 127 ± 84 
(39 to 770) IU/L, the basal viral load was 1.8 ± 3.1 (0.07 to 18) x 106 Eq/mL. 
Genotype 1 (n = 66), genotype 2 (n = 9), genotype 3 (n = 3), and genotype 4 
(n = 3). Mean histological staging was 3 ± 1.5 (0 to 6), presence of cirrhosis = 
7 patients 
Interventions Amantadine group: 180 μg once weekly of peg interferon-alpha-2a plus 
ribavirin, either 1000 mg/day (body 
weight < 75 kg) or 1200 mg/day (body weight > 75 kg) plus amantadine 200 
mg daily for 12 months 
Control group: 180 μg once weekly of peg interferon-alpha-2a plus ribavirin, 
either 1000 mg/day (body weight < 75 kg) or 1200 mg/day (body weight > 75 
kg) for 12 months 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients with detectable HCV RNA 
at EOT 
Notes ML sent an email to g.saracco@tin.it on 23 January 2012 about treatment 
discontinuation due to AE in both groups. Dr. Saracco answered with 
additional information on 23 January 2012 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Low risk Each patient was allocated through a concealed process, using 
a computerised program with block randomisation at a central 
location 
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 Allocation 
concealment 
(selection bias) 
Low risk Each patient was allocated through a concealed process, using 
a computerised program with block randomisation at a central 
location 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Unclear risk Numbers of patients withdrawn due to adverse events in text 
does not match with number of patients in table. Unknown if 
all patients who withdrew from the study were reported 
Selective reporting 
(reporting bias) 
High risk Primary outcome mentioned, but lack of other outcome 
measures 
Other bias Low risk Vested interest bias: no external funding was received for this 
study 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Cornberg 2000 
Methods Randomised, placebo-controlled trial in interferon non-responders 
12 months therapy, 6 months follow-up 
Participants Country: Germany 
26 patients were randomised 
Amantadine group: 14 patients, mean age 38 years, male/female = 
14/0. Serum ALT was not provided, the mean basal viral load was 
1,099,643 copies per mL. Genotype 1a/b (n = 13), genotype non-1 (n 
= 1). Histological staging was not provided 
Control group: 89 patients, mean age 41 years, male/female = 12/0. 
Serum ALT was not provided, the mean basal viral load was 1,420,417 
copies per mL. Genotype 1a/b (n = 9), genotype non-1 (n = 3). 
Histological staging was not provided 
Interventions Amantadine group: interferon 2 weeks 10 MU daily, 2 weeks 5 MU 
daily, 8 weeks 3 MU daily followed by 3 MU every other day for further 
9 months plus daily 1000 to 1200 mg ribavirin and 200 mg amantadine 
orally once daily 
Control group: interferon 2 weeks 10 MU daily, 2 weeks 5 MU daily, 8 
weeks 3 MU daily followed by 3 MU every other day for further 9 
months plus daily 1000 to 1200 mg ribavirin and placebo orally once 
daily 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation 
due to AE; number of patients without SVR; number of patients with 
detectable HCV RNA at EOT 
Notes ML sent Dr. Cornberg an email on 12 January 202012 about the 
biochemical responses. Dr Cornberg responded the same day 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Insufficient information 
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 Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants and 
personnel (performance 
bias)  
All outcomes 
Unclear risk Insufficient information, although the study is 
placebo-controlled 
Blinding of outcome 
assessment (detection bias)  
All outcomes 
Unclear risk Insufficient information, although the study is 
placebo-controlled 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk 26 patients were enrolled and completed treatment 
Selective reporting 
(reporting bias) 
High risk Only reported virological response 
Other bias Unclear risk Insufficient information 
Ferenci 2006 
Methods Randomised, double-blind, placebo-controlled study in naive patients 
48 weeks therapy, 72 weeks follow-up (24 weeks follow-up also measured) 
Participants Country: Austria 
233 patients screened and received interferon sensitivity test; 211 randomised 
Inclusion criteria: treatment-naive patients with chronic HCV, genotype 1 
infection, liver biopsy findings consistent with diagnosis of chronic HCV (obtained 
within 6 months), and elevated serum ALT activity (> 1.5 times the upper limit 
of normal) in the previous 6 months and during screening; haemoglobin values ≥ 
12 g/dL (women) or ≥ 13 g/dL (men), leukocytes ≥ 3000/mL and platelets ≥ 
100,000/mL 
Exclusion criteria: refusal by women of child-bearing age or by sexually active 
patients to use effective contraception; pregnancy or breastfeeding; 
decompensated liver disease; coronary heart disease; co-infection with HIV or 
hepatitis B; overt psychiatric disorders; active alcohol or drug abuse; diabetes 
mellitus requiring medical therapy; autoimmune disorders and/or any other 
unstable medical condition not due to liver disease. Due to the potential adverse 
effects of amantadine, patients with Parkinson’s disease, narrow angle glaucoma 
or adenoma of the prostate gland 
Amantadine group: 114 patients, mean age 45 ± 11 years, male/female = 68/46, 
mean BMI 25.5 ± 4.2 kg/m2. Median serum ALT was 47 (18 to 313) IU/L, the 
median basal viral load was 0.465 (0.023 to 3.82) x 106 IU/mL. Genotype 1a (n = 
23), genotype 1b (n = 73), and genotype 1a and 1b (n = 18). Histological staging: 
F0-F2 = 83; F3 = 15; F4 = 16 
Control group: 95 patients, mean age 44 ± 10 years, male/female = 65/30, mean 
BMI 25.7 ± 3.9 kg/m2. Median serum ALT was 54 (21 to 208) IU/L, the median 
basal viral load was 0.417 (0.0009 to 4.0) x 106 IU/mL. Genotype 1a (n = 27), 
genotype 1b (n = 43), and genotype 1a and 1b (n = 25). Histological staging: F0-
F2 = 71; F3 = 10; F4 = 14 
Interventions Amantadine group: peg interferon-alpha-2a (40KD) 180 μg/week plus ribavirin 
1000 to 1200 mg/day and oral amantadine 100 mg twice daily 
Control group: peg interferon-alpha-2a (40KD) 180 μg/week plus ribavirin 1000 
to 1200 mg/day and a matched placebo. Compliance was assessed by counting 
unused syringes and tablets at each visit 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
QoL; number of patients without SVR 
Notes — 
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 Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random 
sequence 
generation 
(selection bias) 
Low risk Randomisation was performed centrally using an adaptive biased 
coin design, stratified for study centre, the interferon sensitivity 
stratum, and fibrosis grade (Metavir 0/1/2 versus 3/4). Since this 
was a dynamic unrestricted procedure, the allocation sequence 
was produced during the study and unequal numbers of patients 
per treatment group were considered to be acceptable 
Allocation 
concealment 
(selection bias) 
Unclear risk Not mentioned 
Blinding of 
participants and 
personnel 
(performance 
bias)  
All outcomes 
Low risk Matched placebo 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
Unclear risk Matched placebo, but insufficient information 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
High risk No missing outcome data, but they used the last observation 
carried forward method 
Selective 
reporting 
(reporting bias) 
High risk Outcome measures were reported, but no example histological 
outcomes and outcomes per treatment group (EOT in amantadine 
versus control group) 
Other bias High risk Vested interest bias: high risk: This study reported an unrestricted 
research grant from Roche Austria, Vienna 
No baseline imbalance; sample size calculation was reported; the 
trial was not stopped early 
Gaeta 2001 
Methods Randomised clinical trial in non-responders to interferon 
6 months therapy, 6 months follow-up 
Participants Country: Italy 
40 patients were randomized 
Inclusion criteria: persistent serum ALT levels of > 1.5 times the upper 
normal limit; presence of anti-HCV antibodies and HCV RNA in serum; 
histological features of chronic hepatitis in a liver biopsy obtained in the 
previous 12 months; HCV genotype 1b 
Exclusion criteria: age older than 60 years, decompensated cirrhosis, 
kidney disease, current use of antihistamine drugs, HBsAg or anti-HIV 
positivity and any of the major contraindications to interferon treatment 
Amantadine group: 21 patients, mean age 44.7 ± 9.2 years, 
male/female = 14/7. Serum median ALT was 130 U/L and the basal viral 
load was 1.0 x 10⁶ copies per mL. Genotype 1b (n = 21). Histological 
staging: median 1.5; presence of cirrhosis = 1 
Control group: 19 patients, mean age 48.4 ± 9.3 years, male/female = 
12/7. Serum ALT was 134 U/L and the basal viral load was 1.2 x 10⁶ 
copies per mL. Genotype 1b (n = 19). Histological staging: median 1.5; 
presence of cirrhosis = 2 
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 Interventions Amantadine group: interferon-alpha-2a 4.5 MU sc daily for 4 weeks, 
followed by 6 MU sc thrice weekly for an additional 5 months and 
amantadine sulphate 100 mg orally twice daily for the complete 6 
months 
Control group: interferon-alpha-2a 4.5 MU sc daily for 4 weeks, followed 
by 6 MU sc thrice weekly for an additional 5 months 
Outcomes Mortality; treatment discontinuation due to AE; number of patients 
without SVR; number of patients with detectable HCV RNA at EOT; 
number of patients without normalisation of ALT at EOT and at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer-generated list 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Low risk No missing data 
Selective reporting 
(reporting bias) 
High risk Not clearly stated what the primary and secondary 
outcome measures are 
Other bias Unclear risk Vested interest bias: unclear 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Gramenzi 2007 
Methods Randomised, multicentre study in interferon-alpha non-responders 
Patients were enrolled between September 1998 and April 1999 
48 weeks therapy, 24 weeks follow-up 
Participants Country: Italy 
75 patients were randomised 
Inclusion criteria: histologically proven chronic HCV non-responders to a 
previous course of 3 to 6 MU recombinant interferon-alpha 3 times a week 
for at least 16 weeks with or without ribavirin, failure to clear HCV RNA 
from serum and to normalise serum ALT during treatment period, with 
persistent positivity of HCV RNA for at least 12 months and persistent ALT 
levels greater than 1.5 times the normal value 
Exclusion criteria: aged ≤ 18 and ≥ 64 years; decompensated liver 
disease; co-infection with HIV, HBsAg positivity; evidence of any cause of 
liver disease other than chronic hepatitis C; serum haemoglobin 
concentration of < 12 g/dL for women or < 13 g/dL for men; white cell 
count of < 3000/mm³; neutrophil count of < 1500/mm³; platelet count of 
< 70,000 mm³; presence of haemoglobinopathy or haemolytic anaemia; 
alcohol abuse; drug abuse; pregnancy; other clinically significant diseases 
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 Amantadine group: 25 patients, mean age 50.1 ± 10.0 years, 
male/female = 15/10. Weight was not provided. Mean serum ALT 114.4 ± 
69.8 U/L and mean basal viral load 2.3 ± 2.0 MEq/mL. Genotype 1 (n = 
19), genotype 2 (n = 3), and genotype 3 (n = 3). Histological staging: 7 
patients cirrhosis 
Control group: 24 patients, mean age 49.7 ± 11.3 years, male/female = 
16/8. Weight was not provided. Mean serum ALT 120.8 ± 77.9 U/L and 
mean basal viral load 2.3 ± 2.9 MEq/mL. Genotype 1 (n = 18), genotype 2 
(n = 3), genotype 3 (n = 2), and genotype 4 (n = 1). Histological staging: 5 
patients cirrhosis 
Interventions Amantadine group: oral amantadine hydrochloride administered twice 
daily at a total dose of 200 mg, plus 6 MU sc interferon-alpha-2a every 
other day for the first 4 weeks, followed by a dose of 3 MU per day for 
the remaining 44 weeks, and 15 mg/kg per day of oral ribavirin 
Control group: 6 MU sc interferon-alpha-2a every other day for the first 
4 weeks, followed by a dose of 3 MU per day for the remaining 44 weeks 
and 15 mg/kg per day of oral ribavirin 
There was a third study group in this trial: 6 MU sc interferon-alpha-2a 
every other day for the first 4 weeks, followed by a dose of 3 MU per day 
for the remaining 44 weeks 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to 
AE; number of patients without SVR; number of patients with detectable 
HCV RNA at EOT; number of patients without normalisation of ALT at EOT 
and at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Patients were randomly assigned to one of 3 different 
treatment groups 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Unclear risk Drop-outs mentioned, but not divided by groups 
Selective reporting 
(reporting bias) 
High risk Only 1 study endpoint 
Other bias Unclear risk Vested interest bias: insufficient information 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
Hasan 2004 
Methods Randomised clinical trial in non-responders 
The study was conducted between March 2000 and February 2002 
48 weeks therapy, 24 weeks follow-up 
Participants Country: Kuwait 
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 63 patients were randomised 
Inclusion criteria: age between 18 and 65 years; HCV RNA detectable in serum 
at concentrations > 3200 copies/mL (615 IU/mL) by a branched DNA assay 
within 3 months of enrolment; prior treatment for at least 6 months with a 
combination of unmodified interferon-alpha-2a or alpha-2b plus ribavirin; 
persistence of HCV RNA in serum at the end of combination therapy (non-
responder); and evidence of chronic hepatitis with or without cirrhosis 
Exclusion criteria: transient virological response during or at the end of 
combination therapy, followed by a relapse; clinical or biochemical evidence 
of hepatic decompensation; suspicion of hepatocellular carcinoma; white blood 
cell count < 2.5 × 109/l, haemoglobin < 110 g/l, platelet count < 60 × 109/l; 
serum creatinine > 140 μmol/l; alcohol or drug abuse; and severe comorbid 
medical or psychiatric conditions 
Amantadine group: 42 patients, median age 42 (17 to 56) years, male/female 
= 34/8, BMI not provided. Median serum ALT 90 (62 to 184) IU/L, median basal 
viral load 2.1 (0.3 to 15) x 106 eq/mL. Genotype 1a/1b (n = 8), genotype 4 (n = 
33), and genotype 1 (n = 1). Histological staging: F1/F2 = 22; F3/F4 = 20 
Control group: 21 patients, median age 43 (20 to 61) years, male/female = 
16/5, BMI not provided. Median serum ALT 96 (60 to 201) IU/L, median basal 
viral load 2.3 (0.6 to 17) x 106 eq/mL. Genotype 1a/1b (n = 4), genotype 4 (n = 
17). Histological staging: F1/F2 = 12; F3/F4 = 9 
Interventions Patients were randomised in a 2:1 ratio: 
Amantadine group: peg interferon-alpha-2b sc once weekly, at a dose of 1.5 
μg/kg, ribavirin orally at a dose of 1000 mg or 1200 mg per day for patients 
weighing < 75 kg and ≥ 75 kg, and amantadine 200 mg/day 
Control group: peg interferon-alpha-2b sc once weekly, at a dose of 1.5 μg/kg, 
ribavirin orally at a dose of 1000 mg or 1200 mg per day for patients weighing 
< 75 kg and ≥ 75 kg 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients with detectable HCV RNA 
at EOT; number of patients without normalisation of ALT at EOT and at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Unclear risk Randomly assigned, insufficient information 
Allocation 
concealment 
(selection bias) 
Unclear risk Randomly assigned, insufficient information 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete 
outcome data 
Unclear risk Insufficient information. The number of patients who completed 
the entire scheduled dose was reported, but information about 
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 (attrition bias)  
All outcomes 
withdrawals was missing, only 3 patients withdrew because of 
side effects, so it is not clear what happened to the other 2. 
Selective reporting 
(reporting bias) 
Low risk Reported on all important outcomes 
Other bias Unclear risk Vested interest bias unclear 
No baseline imbalance; sample size calculation was reported; 
the trial was not stopped early 
Helbling 2002 
Methods Double-blind, randomised, placebo-controlled trial in naive patients, in 28 
centres 
12 months therapy, 24 weeks follow-up 
Participants Country: Switzerland 
254 patients were enrolled, 8 patients withdrew informed consent after 
baseline evaluation, but before starting treatment. 246 started treatment 
Inclusion criteria: patients aged 18 to 65 years with biopsy-proven (within ≤ 2 
years) chronic HCV who had never been treated before, exhibited elevated 
ALT within 6 months of entry on at least 2 occasions at least 1 month apart, 
and tested positive for HCV RNA in serum by RT-PCR 
Exclusion criteria: any other cause of liver disease including HBV co-infection, 
and alcohol intake > 20 g/day in females and > 40 g/day in males; history of 
or actual decompensation of liver disease; cirrhosis ≥ 8 Child-Pugh points; 
leucocytes < 2000/μL, neutrophils < 50,000/μL, serum creatinine > 1.5 times 
upper limit of normal 
Amantadine group: 121 patients, age 39 (20 to 66) years, male/female = 
68/53. Serum ALT 101 U/L (34 to 421) and basal viral load 2.16 x 10⁶ copies 
per mL. Genotype 1 (n = 62), genotype 2 (n = 12), genotype 3 (n = 34), genotype 
4 (n = 5), and genotype 6 (n = 1). The other 6 patients had genotypes 2a (n = 
3) and 2a-2c (n = 3). Histological staging: mild = 59, moderate = 43, severe = 
18 
Control group: 125 patients, age 38 (20 to 65) years, male/female = 70/55. 
Serum ALT 111 U/L (30 to 768) and basal viral load 4.72 x 10⁶ copies per mL. 
Genotype 1 (n = 52), genotype 2 (n = 11), genotype 3 (n = 50), and genotype 4 
(n = 6). Histological staging: mild = 29, moderate = 91, severe = 4 
Interventions Amantadine group: interferon-alpha-2a 6 MIU sc thrice weekly for 20 weeks, 
followed by 3 MIU sc thrice weekly for an additional 32 weeks and amantadine 
sulphate 100 mg oral twice daily 
Control group: interferon-alpha-2a 6 MIU sc thrice weekly for 20 weeks, 
followed by 3 MIU sc thrice weekly for an additional 32 weeks and placebo oral 
twice daily 
Treatment was stopped if after 10 weeks HCV RNA in serum remained 
detectable by RT-PCR 
Outcomes Mortality; SAE; treatment discontinuation due to AE; QoL. Number of patients 
without SVR; number of patients with detectable HCV RNA at EOT; number of 
patients without normalisation of ALT at EOT and at EOFU 
Notes ML sent an email to Prof Dr. Renner on 23 December 2011 about the drop-out 
rate. ML forwarded this email on 9 January 2012 to Dr. Helbling 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
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 Random sequence 
generation 
(selection bias) 
Low risk Randomisation was carried out in blocks of 10 using random 
numbers stratified according to the presence/absence of 
cirrhosis 
Allocation 
concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
Low risk Matched placebo 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
Unclear risk HCV RNA was determined centrally. A single pathologist (CG), 
unaware of clinical data including treatment response, scored 
all pretreatment liver biopsies using the extended Knodell score 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
High risk Numbers of patients who withdrew due to adverse events in 
text do not match the numbers of patients in the table. 
Unknown if all patients who withdrew from the study were 
reported 
Selective reporting 
(reporting bias) 
High risk All the authors' study endpoints were discussed in the article. 
Not all reasonably expected outcomes were discussed 
Other bias High risk Vested interest bias: Roche 
No baseline imbalance; sample size calculation was reported; 
the trial was not stopped early 
Herrine 2005 
Methods Randomised, controlled, multicentre trial in relapsers or patients who had 
a viral breakthrough 
48 weeks therapy, 24 weeks follow-up 
Participants Country: United States of America 
124 patients were randomised, 123 received at least 1 dose of study 
medication 
Inclusion criteria: adult patients with serologic evidence of HCV 
infection, by a positive anti-HCV antibody test and detectable HCV RNA in 
serum, who had a virologic response during treatment with standard 
interferon-alpha-2b plus ribavirin and had relapsed after at least 24 weeks 
of treatment or had a virologic breakthrough while still on treatment; 
serum ALT activity above the upper limit of normal during the 6 months 
before entering the study; liver biopsy consistent with chronic HCV 
infection in the previous 36 months; and a minimum of 24 weeks since 
cessation of standard interferon-alpha-2b plus ribavirin treatment, with 
no interferon therapy during this time 
Exclusion criteria: had received any systemic antiviral therapy within 24 
weeks of the start of the study or were expected to need any systemic 
antiviral therapy during the study or had acute hepatitis A or B infection, 
HIV infection, decompensated liver disease, neutropenia (< 1500 
neutrophils/mm³), anaemia (haemoglobin < 12 g/dL in women and < 13 
g/dL in men), thrombocytopenia (platelets, < 90,000/mm3), serum 
creatinine level higher than 1.5 times the upper limit of normal, history 
of alcohol or drug abuse within 1 year of entry, history of severe 
psychiatric disease, serum α-fetoprotein level > 100 ng/mL, or substantial 
coexisting medical conditions 
Amantadine group: 31 patients, mean age 46 years, male/female = 
20/11, BMI not provided. Mean serum ALT 67 SE 9 U/L, mean AST 45 SE 6 
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 U/L, basal viral load ≤ 800,000 IU/mL: 12, and > 800,000IU/mL: 19. 
Genotype 1 (n = 25) and genotype non-1 (n = 6). Histological staging: non-
cirrhosis = 27; cirrhosis = 4 
Control group: 32 patients, mean age 48 years, male/female = 24/8, BMI 
not provided. Mean serum ALT 75 SE 10 U/L, mean AST 60 SE 7 U/L, basal 
viral load ≤ 800,000 IU/mL: 14, and > 800,000IU/mL: 18. Genotype 1 (n = 
25) and genotype non-1 (n = 7). Histological staging: non-cirrhosis = 23; 
cirrhosis = 9 
Interventions Patients were randomly assigned at a 1:1:1:1 ratio to: 
Amantadine group: sc weekly injections of 180 μg peg interferon-alpha-
2a plus orally administered ribavirin, 800 mg/day in split doses for patients 
weighing < 75 kg and 1000 mg/day in split doses for those weighing ≥ 75 
kg, and amantadine 200 mg/day for 48 weeks 
Control group: sc weekly injections of 180 μg peg interferon-alpha-2a plus 
orally administered ribavirin for 48 weeks in the same dosage as 
mentioned at the amantadine group 
2 other intervention groups were: peg interferon-alpha-2a plus 
mycophenolate mofetil and peg interferon-alpha-2a plus amantadine, 
both also for 48 weeks in the same dosages as mentioned above, with a 
daily dose of mycophenolate mofetil of 1 g twice daily 
Randomisation was stratified according to HCV genotype (type 1 versus 
non-type 1, with any patient positive for both type 1 and non-type 1 
categorised as type 1), viral load (≤ 800,000 or > 800,000 IU/mL), and 
relapse versus breakthrough 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to 
AE; number of patients without SVR; number of patients with detectable 
HCV RNA at EOT; number of patients without normalisation of ALT at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Unclear risk Insufficient information. Withdrawals mentioned, but not 
the reason for withdrawal in all patients 
Selective reporting 
(reporting bias) 
High risk Not every outcome we would suggest was reported on 
Other bias High risk Vested interest bias: high: research grant from Roche 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
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 Jorge 2001 
Methods Randomised clinical trial in naive patients 
12 months therapy, 24 weeks follow-up 
Participants Country: Argentina 
91 patients were randomized 
 
Amantadine group: 47 patients 
Control group: 44 patients 
Genotype 1 (63%), viral load, ALT, and necro-
inflammatory/fibrosis scores level were similar in both groups 
Interventions Amantadine group: amantadine 200 mg daily and interferon-
alpha-2a 6 MU daily for 4 weeks, 3 MU daily for 8 weeks, and 3 
MU 3 times a week for 12 months 
Control group: interferon-alpha-2a 6 MU daily for 4 weeks, 3 MU 
daily for 8 weeks, and 3 MU 3 times a week for 12 months 
Treatment was discontinued in patients with detectable serum 
HCV RNA after treatment week 24 
Outcomes Number of patients without SVR 
Notes ML sent an email to Dr. Daruich on 12 January 2012 about 
virological EOT and biochemical responses 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Randomly allocated, but method not 
described 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants and 
personnel (performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Unclear risk Insufficient information 
Selective reporting (reporting 
bias) 
Unclear risk Insufficient information 
Other bias Unclear risk Insufficient information 
Langlet 2009 
Methods Multicentre, randomised clinical trial with parallel-group design in naive 
and relapsing patients 
Trial duration: 24 or 48 weeks, follow-up 24 weeks 
Participants Country: Belgium, 37 centres 
Number of patients randomised: 630 (actually 643, but 13 never took any 
study medication) 
Amantadine group: mean age 43.74 ± 12.41 years, male/female: 189/127 
Control group: mean age 45.48 ± 12.19 years, male/female: 173/141 
Inclusion criteria: male and female patients ≥ 18 years of age; serological 
evidence of chronic HCV (anti-HCV antibody test), quantifiable serum HCV 
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 RNA of ≥ 600 IU/mL; elevated serum ALT activity documented on at least 
2 occasions within the 6 months before randomisation; histological liver 
alterations consistent with chronic HCV; in case of cirrhosis, a 
compensated liver disease (Child-Pugh Grade A) 
Exclusion criteria: non-responders to a previous therapy or had a relapse 
during a previous therapy (breakthrough) or after completion of any 
previous treatment other than interferon plus ribavirin; previous 
treatment with any systemic antiviral, anti-neoplastic, or 
immunomodulatory treatment within 6 months prior to the first dose of 
the study drug; chronic liver disease other than HCV; other clinically 
significant medical history or current disease; positive serology for HAV 
IgM, haemoglobin < 11 g/dL, neutrophil count < 1500 cells/mm3, platelet 
count < 90,000 cells/⁄mm3, and serum creatinine level > 1.5 times the 
upper limit of normal; pregnancy 
Interventions Amantadine group: peg interferon-alpha, ribavirin, and amantadine, n = 
316 
Control group: peg interferon-alpha and ribavirin, n = 314 
Peg-INF was given sc at a dose of 180 μg in 0.5 mL, ribavirin was given 
twice daily at a total oral dose of 800 to 1200 mg daily according to body 
weight, amantadine was given orally 100 mg twice daily 
Treatment was given for 24 or 48 weeks according to genotype 
Outcomes Sustained virological response; sustained biochemical response rate; early 
virological response rate; end of treatment virological response rate; 
mean reduction in HCV RNA 
Notes Additional information requested on 23 January 2012 from the last author, 
Prof. Dr. F. Nevens 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Randomisation included a minimisation programme by 
study centre 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Not equally matched drop-outs and insufficient 
information about reasons for drop-outs 
Selective reporting 
(reporting bias) 
High risk All outcome measures reported, but lacking some 
important outcome measures such as EOT ALT 
Other bias High risk Vested interest bias: high: Roche funded 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
Mangia 2001 
Methods Randomised clinical trial in naive patients 
Patients were recruited between June and December 1998 
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 12 months therapy, 6 months follow-up 
Participants Country: Italy 
200 patients were randomised 
Inclusion criteria: raised ALT for at least 6 months, HCV RNA positive by PCR, 
liver biopsy performed within the previous 6 months before entry, consistent 
with chronic HCV 
Exclusion criteria: decompensated cirrhosis, psychiatric conditions, 
diabetes, autoimmune diseases, concurrent hepatitis B or HIV infections, high 
alcohol intake, current intravenous drug use, previous treatment with 
interferon, pregnancy, or concomitant significant medical illness 
Amantadine group: 99 patients, age 46 (19-67) year, male/female = 61/28. 
Serum ALT was not provided and basal viral load was 60 (0.3 to 400) x 10⁶ 
copies per mL. Genotype 1 (n = 52), genotype 2a (n = 34), genotype 3 (n = 7), 
genotype 4 (n = 6). Histological staging: 0/1 = 63, 2/3 = 36 
Control group: 101 patients, mean age 48 (21 to 69) year, male/female = 
71/30. Serum ALT was not provided and basal viral load was 58 (1.9 to 500) x 
10⁶ copies per mL. Genotype 1 (n = 60), genotype 2a (n = 26), genotype 3 (n 
= 11), genotype 4 (n = 4). Histological staging: 0/1 = 52, 2/3 = 49 
Interventions Amantadine group: interferon-alpha-2a 6 MU sc thrice weekly plus 
amantadine 100 mg twice daily orally for 12 months 
Control group: interferon-alpha-2a 6 MU sc thrice weekly for 12 months 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients with detectable HCV RNA 
at EOT; number of patients without normalisation of ALT at EOT and at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Unclear risk Randomisation was performed according to centre, in blocks 
of 10 patients; insufficient information on sequence 
generation 
Allocation 
concealment 
(selection bias) 
Unclear risk Not described 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled. A single pathologist who was unaware 
of the patients' treatment and response to therapy scored the 
pre-therapy liver biopsies for hepatic inflammation and 
fibrosis, according to Scheuer system 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk Follow-up information was available for all patients, including 
those who did not complete the 12-month course of therapy 
Selective reporting 
(reporting bias) 
High risk All the authors' study endpoints were discussed in the article. 
Not all reasonable outcomes were discussed 
Other bias Low risk Invested interest bias: commercial kits for quantitative HCV 
RNA measurements by Roche. No further funding by 
manufacturers of interferon or amantadine 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
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 Maynard 2006 
Methods Multicentre, randomised double-blind, placebo-controlled trial in non-
responders 
Trial duration: 48 weeks, follow-up 24 weeks 
Enrolment began in October 2000 and the trial completed in May 2003 
Participants Country: France, 23 centres 
Number of patients randomised: 200 (actually 202, but 2 patients from the 
control group did not receive any medication) 
 
Amantadine group: mean age 47.1 (27 to 66) years, male/female: 74/27 
Control group: mean age 46.8 (23 to 66) years, male/female: 74/26 
Inclusion criteria: failed to respond to a single previous 24-week cycle of 
interferon/ribavirin combination therapy (at least 3 MIU interferon-alpha 3 
times weekly and ribavirin at a minimum dose of 600 mg/day) (non-
response was defined as persistent HCV RNA in the serum during the last 
month of treatment); elevated serum ALT; detectable HCV RNA; neutrophil 
count ≥ 1000/mm³, platelet count ≥ 100 giga/L, haemoglobin ≥ 10 g/dL; 
post-treatment liver biopsy within a year had to show a METAVIR 
histological score ≥ A1F1 and < F4 
Exclusion criteria: co-infection with HBV or HIV; any other cause of liver 
disease; active drug abuse or alcohol consumption > 40 g/day; other 
clinically significant history or current diseases; previous amantadine use, 
systemic immunosuppressive or antiviral treatment during the last 24 
weeks, and those with a history of interferon and/or ribavirin intolerance 
Interventions Amantadine group: peg interferon-alpha-2b at a dose of 1.5 mg/kg per 
week sc plus oral ribavirin 800 to 1200 mg/day and oral amantadine 
hydrochloride 2 x 100 mg/day for 48 weeks, n = 101 
Control group: the same dose of peg interferon-alpha-2b and ribavirin plus 
a placebo, n = 99 
For both groups, the dose of ribavirin was adjusted according to body 
weight (800 mg up to 65 kg weight, 1000 mg between 65 and 85 kg, and 
1200 mg for weight of 85 kg or more). All drugs were started and stopped 
at the same time. Treatment was administered for 48 weeks regardless of 
the virological response during therapy. At the end of this treatment period, 
patients underwent a liver biopsy and were followed up for 24 weeks 
Outcomes Sustained virological response; biochemical response at week 72 (ALT 
normalisation); histological benefit; tolerance - virological and biochemical 
responses during therapy at weeks 12, 24, and 48 
Notes Additional information requested on 23 January 2012 from the last author 
Prof. Dr. C. Trepo 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Randomisation was done using a random permuted blocks 
method 
Allocation 
concealment 
(selection bias) 
Low risk The randomisation process was generated by the 
Department of Biostatistics, Hospices Civils de Lyon, Lyon, 
France 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
Unclear risk Insufficient information, although placebo-controlled 
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 Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Insufficient information, although placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Withdrawals were reported, but not all the reasons for 
withdrawal 
Selective reporting 
(reporting bias) 
Low risk All outcome measures were reported 
Other bias High risk Vested interest bias: high: supported by Schering-Plough 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
Mendez-Navarro 2010 
Methods Randomised, double-blind, placebo-controlled trial in naive patients 
Trial duration: 48 weeks, follow-up 24 weeks 
Randomisation between March 2003 and June 2005 
Participants Country: Mexico, 1 centre 
Number of patients randomised: 124 
 
Amantadine group: mean age 44 ± 12.29 years, male/female: 29/32 
Control group: mean age 46.2 ± 9.82 years, male/female: 26/37 
Inclusion criteria: men and women age 18 to 65 years with genotype 1 HCV 
infection defined by the presence of an HCV antibody, HCV RNA positive by 
RT-PCR, and genotype 1 infection; elevated serum ALT levels (40 IU/l) for at 
least 6 months; patients with cirrhosis were included only if they were Child-
Pugh Class A (compensated disease); of Latino ethnicity (self identified as 
"Latino or Hispanic") with Spanish as their primary language and were born in 
the Mexican Republic; not previously been treated with interferon, peg 
interferon-alpha, ribavirin, and/or amantadine; pre-treatment liver biopsy 
was encouraged but not required 
Exclusion criteria: other causes of liver disease; HIV infection, hepatitis B 
infection; complication of portal hypertension (variceal bleeding, ascites, 
encephalopathy, Child-Pugh B or C, hepatocellular carcinoma); haemoglobin 
< 12 g/dl, platelets < 70,000 plt/mm3; pregnancy; other clinically significant 
diseases; alcohol or drug abuse; refusal to use contraception during 
treatment 
Interventions Patients were randomly assigned to receive: 
Amantadine group: peg interferon-alpha-2a 180 μg/week plus 1000 to 1200 
mg/day ribavirin according to body weight 
(1000 mg if < 75 kg or 1200 mg if ≥ 75 kg) plus amantadine 200 mg orally daily 
(amantadine hydrochloride 100 mg tablets) for 48 weeks, n = 61 
Control group: the same regimen of peg interferon-alpha-2a plus ribavirin 
for 48 weeks, n = 63 
Outcomes Sustained virological response; early virological response; end of treatment 
response 
Notes Additional information requested on 23 January 2012 from the first author, 
Dr. J. Mendez-Navarro. Dr. Mendez-Navarro responded on 26 January 2012. 
More information was requested on 26 January, and Dr. Mendez responded 
the same day 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
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 Random sequence 
generation (selection 
bias) 
Low risk The randomisation was 1:1 in a balanced design and the 
method for random sequence generation was a computer-
based random number system 
Allocation 
concealment 
(selection bias) 
Low risk Central telephone allocation for concealment 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk Withdrawals reported; no large differences in withdrawals 
between the 2 groups 
Selective reporting 
(reporting bias) 
High risk Outcome measures as described in the methods are reported, 
but some important outcome measures, for example 
biochemical response, are missing 
Other bias High risk Vested interest bias: Chung has received a research grant 
from Roche 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Pessoa 2012 
Methods Randomised, controlled, multicentre trial in non-responders and relapsers 
Trial duration: 48 weeks, follow-up 24 weeks 
First patient enrolled in June 2003 and last patient completed follow-up in 
November 2005 
Participants Country: Brazil 
Number of patients randomised: 186 (106 non-responders and 80 relapsers); 
182 actually received treatment 
The population was predominantly male, of white race, with a mean age of 
± 50 years and a baseline HCV RNA level ≥ 800,00 IU/mL 
Inclusion criteria: adults with a positive anti-HCV antibody test, detectable 
HCV RNA in serum; elevated ALT serum levels on at least 2 occasions during 
the previous 6 months; liver biopsy result within the previous 35 months 
consistent with the diagnosis of chronic HCV; at least 24 weeks of previous 
treatment with interferon-alpha plus ribavirin of which the outcome was 
either virological non-response or virological relapse; previous course 
completed at least 12 weeks prior to enrolment 
Exclusion criteria: co-infection with hepatitis A or B or HIV; neutrophil 
count < 1500 cells/mm³, serum creatinine level > 1.5 times the upper limit 
of normal, or haemoglobin level < 12 g/dL (women) or < 13 g/dL (men); 
serious chronic diseases including severe psychiatric disease or alcohol or 
drug abuse within 1 year; pregnant or breastfeeding women and male 
partners of pregnant women 
Interventions Amantadine group: peg interferon sc 180 μg/week plus oral ribavirin 1000 
mg/day (body weight ≤ 75 kg) or 1200 mg/day (body weight > 75 kg) plus 
oral amantadine 200 mg/day for 48 weeks, n = 94 (n = 92 actually received 
at least 1 dose of treatment) 
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 Control group: peg interferon sc 180 μg/week plus oral ribavirin 1000 
mg/day (body weight ≤ 75 kg) or 1200 mg/day (body weight > 75 kg), n = 92 
(n = 90 actually received at least 1 dose of treatment) 
Outcomes Sustained virological response; sustained biochemical response; early 
virological response; complete early virological response; safety: adverse 
events and laboratory abnormalities 
Notes Additional information requested on 25 January 2012 from second author, 
Prof. Dr. H. Cheinquer. Dr. Cheinquer responded on 25 January with 
information about drop-outs due to AE and information on random sequence 
generation and allocation concealment 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Randomisation was provided by a computerised system 
hosted by the study contract research organisation 
Allocation 
concealment 
(selection bias) 
Low risk Delivered by phone to the site 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk Missing outcome data balanced in numbers across 
intervention groups, with similar reasons for missing data 
across groups 
Selective reporting 
(reporting bias) 
High risk All the outcomes mentioned in methods are reported, but 
information on biochemical EOT response is lacking 
Other bias High risk Vested interest bias: high: Roche funding 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
Piai 2003 
Methods Randomised clinical trial in relapsers in 1 referral hepatologic centre 
Patients were enrolled between January 1999 and May 2000 and were 
followed up until November 2001 
12 months therapy, 6 months follow-up 
Participants Country: Italy 
49 patients entered the first period of the study 
Inclusion criteria: previously received 1 or more course of recombinant or 
lymphoblastoid interferon at a dose ranging from 3 to 6 MU 3 times per 
week for 6 to 12 months and who had normalised serum ALT and cleared 
serum HCV RNA by PCR on therapy but subsequently relapsed within 6 
months after stopping treatment; age between 18 and 65 years; time 
between last course of interferon and the start of combination therapy < 
12 months, liver biopsy before enrolment < 24 months; HCV genotype 1b 
Exclusion criteria: decompensated liver disease; HIV and HBV co-
infection; other clinically significant diseases; haemoglobin < 13 g/dl for 
males and < 12 g/dl for females; platelet count < 100,000 and WBC < 3000 
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 Amantadine group: 12 patients, mean age 51.2 ± 4.4 years, male/female 
= 11/1. Mean BMI 27.5 ± 1.8 kg/m2. Mean serum ALT 195 ± 108 IU/L and 
basal viral load > 1 million n = 4. Genotype 1b (n = 12). Histological staging: 
mean fibrosis score 2.4 ± 1.2 
Control group: 12 patients, mean age 49.3 ± 10.0 years, male/female = 
9/3. Mean BMI 26.7 ± 2.7 kg/m2. Mean serum ALT 184 ± 115 IU/L and basal 
viral load > 1 million n = 4. Genotype 1b (n = 12). Histological staging: 
mean fibrosis score 1.9 ± 1.1 
Interventions In the first part of the study, all 49 relapsers were treated for 6 months 
with recombinant interferon-alpha-2b, administered sc at a dose of 3 MU 
thrice a week, together with ribavirin, given orally twice a day, at a total 
dosage adjusted according to body weight (1000 mg for patients weighing 
≤ 75 kg and 1200 mg for those > 75 kg). During the second part of the study, 
24 patients who showed no biochemical and virological response, were 
randomised to continue treatment for further 6 months in 2 arms: 
Amantadine group: interferon-alpha-2b plus ribavirin in the above 
mentioned dosages, plus oral amantadine hydrochloride 200 mg daily 
Control group: interferon-alpha-2b plus ribavirin in the above mentioned 
dosages 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to 
AE; number of patients without SVR; number of patients with detectable 
HCV RNA at EOT; number of patients without normalisation of ALT at EOT 
Notes On 9 January 2012 ML sent G. Piai an email about the number of patients 
in both groups with normal ALT 6 months after cessation of therapy 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Sealed envelopes; unknown if they were opaque 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled, not mentioned in article 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk All non-responders completed the second part of therapy 
Selective reporting 
(reporting bias) 
High risk All the authors' study endpoints were discussed in the 
article. Not all reasonable outcomes were discussed 
Other bias Unclear risk The study appears to be free of other sources of bias, but 
insufficient information 
Baseline imbalance unknown; sample size calculation was 
reported; the trial was not stopped early 
Salmeron 2007 
Methods Randomised, parallel-group trial in interferon non-responder patients in 36 
centres 
Patients were recruited between 1999 and 2001 and the follow-up finished in 
March 2003 
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 48 weeks therapy, 24 weeks follow-up 
Participants Country: Spain 
378 patients were randomized 
 
Inclusion criteria: serum HCV RNA positivity by PCR before the beginning of 
the treatment and serum ALT activity above the upper limit of normal with 
at least 1 value during the 6-month period preceding the initiation of test 
drug dosing. All patients had chronic hepatitis without cirrhosis in the biopsy. 
The biopsies had been carried out up to a maximum of 3 years before entering 
the study. A treatment-free interval of at least 6 months was necessary 
between the first and the second course 
Exclusion criteria: age 60 years or older, evidence of any cause of liver 
disease other than chronic HCV (co-infection with hepatitis B virus or HIV, 
concomitant autoimmune disease or metabolic disease). Clinically significant 
cardiovascular, renal, haematological, rheumatological, neurological or 
psychiatric disease, systemic infections, neoplastic disease, organ grafts and 
systemic immunosuppressive treatment. Active alcohol (alcohol intake > 40 
g/day in females and > 60 g/day in males) or drug abuse within the previous 
year. Pregnancy or lactation period. Haemoglobin levels < 12 g/dL, white cell 
count < 3000/mm³, granulocyte count < 1500/mm³ or platelet count < 
100,000/mm³ 
Amantadine group + interferon: 111 patients, mean age 44.7 ± 9 years, 
male/female = 87/24. Mean weight 78 ± 13 kg. Mean serum ALT 133 ± 90 UI/L, 
mean serum AST 94 ± 81 UI/L, and high serum HCV RNA titre > 8 x 105 UI/mL 
was detected in 34 out of 78 patients. Genotype 1: 72 out of 88, genotype 
non-1: 16 out of 88. Histological staging was not provided 
Control group (interferon): 53 patients, mean age 45 ± 8 years, male/female 
= 40/13. Mean weight 74 ± 11 kg. Mean serum ALT 135 ± 89 UI/L, mean serum 
AST 103 ± 88 UI/L, and high serum HCV RNA titre > 8 x 105 UI/mL was detected 
in 12 out of 43 patients. Genotype 1: 40 out of 44, genotype non-1: 4 out of 
44. Histological staging was not provided 
Amantadine group + interferon + ribavirin: 108 patients, mean age 45.3 ± 8 
years, male/female = 87/21. Mean weight 78 ± 13 kg. Mean serum ALT 125 ± 
80 UI/L, mean serum AST 97 ± 76 UI/L, and high serum HCV RNA titre > 8 x 
105 UI/mL detected in 27 out of 80 patients. Genotype 1: 74 out of 82, 
genotype non-1: 8 out of 82. Histological staging was not provided 
Control group (interferon + ribavirin): 106 patients, mean age 46 ± 9 years, 
male/female = 85/21. Mean weight 77 ± 13 kg. Mean serum ALT 124 ± 92 UI/L, 
mean serum AST 79 ± 75 UI/L, and high serum HCV RNA titre > 8 x 105 UI/mL 
was detected in 29 out of 81 patients. Genotype 1: 74 out of 85, genotype 
non-1: 11 out of 85. Histological staging was not provided 
Interventions Amantadine group + interferon: interferon-alpha-2a, 9 MUI/day sc for 4 
weeks and 3 MUI 3 times a week for a further 44 weeks plus amantadine 
chloride, 100 mg twice per day 
Control group (interferon): interferon-alpha-2a, 9 MUI/day sc for 4 weeks 
and 3 MUI 3 times a week for a further 44 weeks 
Amantadine group + interferon + ribavirin: the same doses of interferon-
alpha-2a plus amantadine 100 mg twice per day, and ribavirin 1000 to 1200 
mg per day according to weight 
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 Control group (interferon + ribavirin): the same doses of interferon-alpha-
2a and ribavirin 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients with detectable HCV RNA 
at EOT 
Notes ML sent an email to Dr. Salmeron about the ALT values at EOT and at 6 months 
follow-up on 10 January 2012 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Unclear risk Patients were selected randomly by central telephone 
Allocation 
concealment 
(selection bias) 
Low risk Patients were selected randomly by central telephone 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk All drop-outs were discussed, but not equally divided over 
groups 
Selective reporting 
(reporting bias) 
High risk Not all of the study's prespecified primary outcomes have been 
reported. The biochemical response (normalisation of serum 
ALT) was not reported 
Other bias High risk Vested interest bias: Roche  
No baseline imbalance; sample size calculation was reported; 
the trial was stopped early at 378 patients randomised (instead 
of 1100 patients calculated) due to poor results 
Sax 2001 
Methods Randomised clinical trial in patients co-infected with HIV 
Patients were recruited at 2 university outpatient clinics and were 
enrolled within a 4-month period 
Trial duration: 12 months, follow-up 6 months 
Participants Country: Switzerland 
7 patients were randomised: 3 female; mean age 40 years, range 28 to 
54 years 
Inclusion criteria: patient's triple antiretroviral treatment was 
unchanged for at least 2 months; > 200 CD4+ lymphocytes/l; < 50,000 
HIV-1 RNA copies/mL; elevated transaminases for at least 6 months; 
biopsy results were compatible with HCV infection 
Exclusion criteria: decompensated liver cirrhosis; additional liver 
diseases; ongoing illicit drug use; contraindications for interferon 
Interventions Amantadine group: interferon-alpha, 6 MU/day for 1 month and 6 MU 
thrice weekly for the remaining 11 months combined with amantadine 
sulphate 100 mg bid orally, n = 3 
Control group: interferon-alpha, 6 MU/day for 1 month and 6 MU thrice 
weekly for the remaining 11 months alone, n = 4 
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 Outcomes Mortality; number of patients without SVR 
Notes The trial stopped early due to important toxicities and low tolerability 
of interferon-alpha 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk No missing data 
Selective reporting 
(reporting bias) 
High risk Endpoint not clearly stated. Not all reasonably expected 
outcomes were discussed 
Other bias Low risk No vested interest bias (low risk of bias regarding vested 
interest) 
Baseline imbalance unknown; sample size calculation 
was not reported; the trial was not stopped early 
Shakil 2000 
Methods Randomised clinical trial in naive patients 
Trial duration: 24 weeks of therapy, 24 weeks follow-up 
Participants Country: United States of America 
24 patients were randomised 
Inclusion criteria: ≥ 18 years, elevated serum ALT levels, positive anti-
HCV and HCV RNA in serum, and chronic hepatitis on liver biopsy 
Exclusion criteria: HBsAg positivity, HIV, Child's B or C cirrhosis 
Amantadine group: 12 patients, mean age 46 years, mean serum ALT 87 
IU/L, mean viral load 83 x 105 eq/mL, and histological staging was 1.2. 
Genotype and male/female ratio were not provided 
Control group: 12 patients, mean age 46 years, mean serum ALT levels 
were 72 IU/L, mean viral load was 76 x 105 eq/mL, and histological staging 
was 1.4. Genotype and male/female ratio were not provided 
Interventions Amantadine group: interferon-alpha-2a 3 MU sc 3 times a week, and 
amantadine 100 mg orally twice a day for 24 weeks 
Control group: interferon-alpha-2a 3 MU sc 3 times a week for 24 weeks 
Outcomes Mortality; treatment discontinuation due to AE; number of patients 
without SVR; number of patients with detectable HCV RNA at EOT; number 
of patients without normalisation of ALT at EOT 
Notes ML sent an email to Dr. Shakil on 12 January 2012 about biochemical 
responses, SVR, and EOT response. Dr. Shakil responded on 13 January 
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 2012. ML sent another email on 26January 2012 about SAE and death. Dr. 
Shakil responded on 3 1January 2012 (no SAE, no death) 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
Unclear risk Insufficient information, although trial was placebo-
controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Insufficient information, although trial was placebo-
controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Insufficient information: 2 patients in the amantadine 
group withdrew, 4 in the placebo group withdrew; reasons 
unknown 
Selective reporting 
(reporting bias) 
Unclear risk Insufficient information 
Other bias Unclear risk Insufficient information 
Smith 2004 
Methods Randomised, double-blind, placebo-controlled, cross-over trial in interferon 
failures or those not candidates for interferon 
48 weeks therapy, 24 weeks follow-up 
Participants Country: United States of America 
152 patients were enrolled in the study 
Inclusion criteria: previous failed interferon, intolerant of interferon side 
effects, or not candidates for interferon therapy due to either depression, 
neutropenia, or thrombocytopenia. In patients who had previously been 
treated with interferon, a period of 6 months off therapy and a liver biopsy 
were required for enrolment; age between 1 and 65 years; patiens over the 
age of 65 years were eligible if chest x-ray, electrocardiogram, and creatinine 
clearance were normal prior to enrolment; abnormal liver enzymes, 
detectable HCV RNA; inflammation by liver biopsy; females of childbearing 
potential were required to use medially accepted contraceptive regimens if 
sexually active; normal laboratory values for albumin, prothrombin time, 
creatinine, haemoglobin, leukocyte count, antinuclear antibody, platelet 
count, and alpha-fetoprotein 
Exclusion criteria: evidence of decompensated liver disease; other forms of 
liver disease; active HIV infection; other serious medical conditions; active 
using illicit drugs or alcohol; antiviral medications, oral steroids, 
immunosuppressive medications, or anticoagulation therapy 
Amantadine group: 73 patients, age > 50 years, n = 13, male/female = 52/21. 
Serum ALT not provided and the viral load > 200 MEq/mL, n = 21. Genotype 1 
(n = 57), genotype 2 (n = 9), genotype 3 (n = 6), and genotype 4 (n = 1). 
Histological staging: severe liver histology stage 3/4 = 34 
Control group: 79 patients, age > 50 years, n = 18, male/female = 50/29. 
Serum ALT not provided and the viral load > 200 MEq/mL, n = 22. Genotype 1 
(n = 59), genotype 2 (n = 9), genotype 3 (n = 5), and genotype 4 (n = 4), 2 
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 patients could not be genotyped by 2 separate laboratories. Histological 
staging: severe liver histology stage 3/4 = 39 
Interventions Amantadine group: amantadine 100 mg by mouth twice daily 
Control group: placebo twice daily 
Both groups received amantadine or placebo for 6 months. After 6 months, 
patients receiving the placebo were crossed over to amantadine therapy for 6 
months, while those on amantadine continued on this treatment for 6 
additional months 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
QoL; number of patients without normalisation of ALT at EOT 
Notes Amantadine was supplied by Endo Pharmaceuticals Inc. (Chadds Ford, Pa) 
This trial used a 5-way stratification; with this amount of patients this could 
lead to over-stratification 
ML sent an email to Dr. Smith on 9 January 2012 about exact biochemical and 
virological responses 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Low risk A stratified randomised scheme was invoked. SAS statistical 
software was used to generate the treatment codes within 
each of the 32 strata for implementation by the pharmacy 
Allocation 
concealment 
(selection bias) 
Low risk SAS statistical software was used to generate the treatment 
codes within each of the 32 strata for implementation by the 
pharmacy 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
Low risk Identical ghost capsules were filled by the pharmacist with 
amantadine and sucrose, so that neither staff nor patients 
could distinguish between placebo and active drug 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
Low risk Identical ghost capsules were filled by the pharmacist with 
amantadine and sucrose, so that neither staff nor patients 
could distinguish between placebo and active drug 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Unclear risk All drop-outs were mentioned, but uncertain if they were 
equally divided 
Selective reporting 
(reporting bias) 
High risk All the authors' study endpoints were discussed in the article. 
Not all reasonably expected outcomes were discussed 
Other bias Unclear risk Vested interest bias: unclear 
No baseline imbalance; sample size calculation was reported; 
the trial was not stopped early 
Tabone 2001 
Methods Randomised clinical trial in 9 different medical centres in naive patients 
Patients were enrolled between September 1998 and April 1999 
12 months therapy, 6 months follow-up 
Participants Country: Italy 
180 patients were randomised 
Inclusion criteria: positive for anti-HCV and for HCV RNA, liver biopsy 
within a year before entry in the study showing chronic hepatitis without 
cirrhosis, and serum ALT levels elevated at least 1.5 times the upper limit 
of normal (40 IU/L) on 3 determinations before enrolment 
Exclusion criteria: chronic alcohol abuse, active drug addiction, hepatitis 
B or HIV co-infection, evidence of autoimmune disease, platelet count < 
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 100,000/µL, leukocyte count < 2500/µL, other clinically significant 
diseases, and pregnancy 
Amantadine group: 90 patients, mean age 42 ± 12 years, male/female = 
62/28. Serum ALT 103 (56 to 400) U/L and median basal viral load 2.4 (0.2 
to 32). Genotype 1 + 4 (n = 47), genotype 2 + 3 (n = 43). Histological 
staging: mean 3.4 ± 0.3 
Control group: 90 patients, mean age 44 ± 12 years, male/female = 67/23. 
Serum ALT 114 (65 to 274) U/L and median basal viral load 2.54 (0.2-26). 
Genotype 1 + 4 (n = 53), genotype 2 + 3 (n = 37). Histological staging: mean 
3.2 ± 0.3 
Interventions Amantadine group: interferon-alpha-2a 6 MU sc every other day for 6 
months and then 3 MU sc every other day for the other 6 months plus 
amantadine 100 mg twice daily oral for 12 months 
Control group: interferon-alpha-2a 6 MU sc every other day for 6 months 
and then 3 MU sc every other day for the other 6 months 
Outcomes Mortality; SAE; treatment discontinuation due to AE 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Randomisation was centralised with a 1:1 ratio 
Allocation concealment 
(selection bias) 
Low risk Randomisation was centralised with a 1:1 ratio 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk Drop-outs mentioned; 5 in control group 8 in amantadine 
group 
Selective reporting 
(reporting bias) 
High risk All the authors' study endpoints were discussed in the 
article. Not all reasonably expected outcomes were 
discussed 
Other bias Low risk Vested interest bias: no support 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
Teuber 2001 
Methods Randomised, placebo-controlled, double-blind trial in primary interferon-
alpha in primary interferon-alpha non-responders 
48 weeks therapy, 24 weeks follow-up 
Participants Country: Germany 
55 patients were randomised 
Inclusion criteria: non-response to previous interferon-alpha 
monotherapy with persistence of serum HCV RNA and a treatment-free 
interval of at least 24 weeks; elevated ALT levels; positive anti-HCV test; 
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 detectable serum HCV RNA; compensated liver disease; leukocyte count 
≥ 2500/μL, platelet count ≥ 70,000/μL; aged between 18 and 70 years 
Exclusion criteria: co-infection with hepatitis B and HIV, concomitant 
autoimmune disease, other clinically significant disease. Average daily 
intake of alcohol exceeding 50 g of ethanol or drug abuse within the 
previous year. Pregnancy and lactation period 
Amantadine group: 59 patients, mean age 47.7 ± 10.5 years, 
male/female = 19/7. Serum ALT 73 ± 54 U/L, serum AST 38 ± 28 U/L, and 
basal viral load 630 ± 567 x 10³ copies per mL. Genotype 1 (n = 22), 
genotype non-1 (n = 4). Histological staging: non = 2, mild = 7, moderate 
= 10, severe = 7 
Control group: 29 patients, mean age 45.7 ± 10.3 years, male/female = 
17/12. Serum ALT 64 ± 44 U/L, serum AST 37 ± 25 U/L, and basal viral 
load 890 ± 823 x 10³ copies per mL. Genotype 1 (n = 27), genotype non-1 
(n = 2). Histological staging: non = 2, mild = 9, moderate = 12, severe = 6 
Interventions Amantadine group: interferon-alpha-2a 6 MU sc thrice weekly for 24 
weeks, followed by 3 MU sc thrice weekly for an additional 24 weeks and 
oral amantadine sulphate 100 mg twice daily 
Control group: interferon-alpha-2a 6 MU sc thrice weekly for 24 weeks, 
followed by 3 MU sc thrice weekly for an additional 24 weeks and oral 
placebo twice daily 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to 
AE; QoL; number of patients without SVR; number of patients with 
detectable HCV RNA at EOT; number of patients without normalisation of 
ALT at EOT and at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Random number generator in fixed blocks of 4 with a ratio 
of 1:1 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
Low risk Placebo-controlled with a matched placebo 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Placebo-controlled, but insufficient information 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk Drop-outs reported and equally divided over 2 groups 
Selective reporting 
(reporting bias) 
Low risk All important outcome measures were mentioned 
Other bias Unclear risk Vested interest bias: insufficient information 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Teuber 2002 
Methods Randomised clinical trial in relapsing patients 
48 weeks therapy, 24 weeks follow-up 
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 Participants Country: Germany 
75 patients were randomised. 46 males, 29 females, mean age 43 
years 
Inclusion criteria: relapsing after primary successful antiviral 
treatment 
Amantadine group: 41 patients, mean age, male/female, serum 
ALT, and viral load were not provided. Genotype distribution and 
histological staging also were not provided 
Control group: 34 patients, mean age, male/female, serum ALT, 
and viral load were not provided. Genotype distribution and 
histological staging also were not provided 
Interventions Amantadine group: interferon-alpha-2b 5 MU daily for 4 weeks, 5 
MU 3 times a week for 20 weeks followed by 3 MU 3 times a week 
for another 24 weeks in combination with daily 1000 to 1200 mg 
ribavirin plus 100 mg amantadine twice daily for 48 weeks 
Control group: interferon-alpha-2b 5 MU daily for 4 weeks, 5 MU 3 
times a week for 20 weeks followed by 3 MU 3 times a week for 
another 24 weeks in combination with daily 1000 to 1200 mg 
ribavirin for 48 weeks 
Treatment was discontinued in patients with detectable serum HCV 
RNA after treatment week 24 
Outcomes Number of patients without SVR 
Notes ML sent an email to Dr. Teuber on 12 January 2012 about virological 
EOT and biochemical responses 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants and 
personnel (performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Unclear risk Insufficient information 
Selective reporting (reporting 
bias) 
Unclear risk Insufficient information 
Other bias Unclear risk Insufficient information 
Teuber 2003 
Methods Randomised controlled trial in non-responders to previous antiviral treatment 
in 10 centres 
Patients were enrolled between July 1998 and September 1999 
48 weeks therapy, 24 weeks follow-up 
Participants Country: Germany 
225 patients were randomised 
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 Inclusion criteria: chronic HCV not responding to 1 or more courses of 
interferon-alpha with a minimal total dose of at least 108 MU for 12 weeks 
(e.g., at least 3 x 3 MIU tiw) alone or in combination with ribavirin and/or 
amantadine; documented non-response with persistently detectable serum 
HCV RNA during the entire, most recent antiviral treatment; treatment-free 
interval of at least 6 months; positive anti-HCV antibody test; detectable 
serum HCV-RNA; elevated ALT levels; compensated liver disease; leucocyte 
count ≥ 2500/μl, platelet count ≥ 70,000/μl, haemoglobin ≥12.0 g/dL in 
females and haemoglobin ≥13.0 g/dL in males; and patient's age ≥18 years 
Exclusion criteria: co-infection with hepatitis B virus or HIV types 1 and 2, 
concomitant autoimmune disease, 
clinically significant cardiovascular, metabolic, renal, haematological, 
rheumatological, neurological or psychiatric disease, systemic infections, 
neoplastic disease, organ grafts, systemic immunosuppressive treatment, 
active alcohol or drug-abuse within the previous year, pregnancy or lactation 
period 
Amantadine group: 115 patients, age 48 (20 to 72) year, male/female = 74/41. 
Median serum ALT 49 (19 to 254) U/l, median serum AST 27 (10 to 212) U/l, 
and median basal viral load 1.0 (0.04 to 268) x 10⁶ copies per mL. Genotype 1 
(n = 102) and genotype non-1 (n = 13). Histological staging (n=110): mild = 56, 
moderate = 40, severe = 5, and cirrhosis = 9 
Control group: 110 patients, age 46 (24 to 71) year, male/female = 69/41. 
Median serum ALT 50 (18 to 762) U/l, median serum AST 28 (10- to 1206) U/l, 
and median basal viral load 1.0 (0.02 to 22.7) x 10⁶ copies per mL. Genotype 1 
(n = 97) and genotype non-1 (n = 13). Histological staging (n=105): mild = 57, 
moderate = 29, severe = 12, and cirrhosis = 7 
Interventions Amantadine group: 5 MU interferon-alpha-2b daily for the initial 4 weeks, 
followed by 5 MU interferon-alpha-2b thrice weekly sc for further 20 weeks 
and subsequently 3 MU interferon-alpha-2b thrice weekly sc for additional 24 
weeks plus ribavirin 1000 to 1200 mg/day combined with amantadine sulphate 
200 mg/day 
Control group: 5 MU interferon-alpha-2b daily for the initial 4 weeks, followed 
by 5 MU interferon-alpha-2b thrice weekly sc for further 20 weeks and 
subsequently 3 MU interferon-alpha-2b thrice weekly sc for additional 24 weeks 
plus ribavirin 1000 to 1200 mg/day 
After treatment week 24, antiviral treatment was only continued in patients 
with undetectable serum HCV RNA at treatment week 20 
Outcomes Mortality; treatment discontinuation due to AE; number of patients without 
SVR; number of patients with detectable HCV RNA at EOT; number of patients 
without normalisation of ALT at EOT and at EOFU 
Notes ML sent an email to Dr. Teuber on 11 January 2012 about SAE distribution, 
liver-related morbidity, and baseline characteristics 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Unclear risk Not mentioned 
Allocation 
concealment 
(selection bias) 
Unclear risk Not mentioned 
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 Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
High risk Patients lost to follow-up were not equally divided over the 2 
treatment groups. Not described why they were lost to follow-
up 
Selective reporting 
(reporting bias) 
High risk There was no protocol, but all the authors' study endpoints were 
discussed in the article. Not all reasonably expected outcomes 
were discussed nor clearly stated which groups the patients 
were in (for example, SAE distribution) 
Other bias Low risk Vested interest bias: no support from pharmacy 
No baseline imbalance; sample size calculation was reported; 
the trial was not stopped early 
Thuluvath 2004 
Methods Randomised, double-blind, placebo-controlled trial in naive patients in 9 centres 
48 weeks therapy, 24 weeks follow-up 
Participants Country: United States of America 
171 patients were randomised into the study 
Inclusion criteria: adult patients with chronic HCV who had no previous 
treatment for HCV; HCV RNA detectable by PCR, evidence of liver disease ALT 
or AST above the upper limit of normal, liver biopsy (within 3 months), and no 
known contraindications to treatment with interferon, ribavirin, or amantadine. 
Stress testing was required for patients at high risk for coronary artery disease, 
and only patients demonstrating euthyroid state were enrolled 
Exclusion criteria: haemolytic anaemia, hepatocellular carcinoma, renal 
failure, and seizure disorders; concomitant hepatitis B virus or HIV infection, 
immunosuppressed state, active substance abuse, decompensated liver disease, 
major psychiatric disorders, life expectancy less than 5 years, or daily alcohol 
intake over 10 g/day; haemoglobin < 12 g/dl, white blood cell count < 3000, 
platelet count < 70,000, serum bilirubin > 3 mg/dl, serum creatinine > 1.2 mg/dl, 
and a positive pregnancy test. Women and men of childbearing age were 
required to practice medically acceptable methods of contraception 
Amantadine group: 85 patients, age < 50 years: 70, age > 50 years: 15; 
male/female = 45/40. Serum ALT was 103 ± 126 U/L and viral load < 1 x 106 
copies per mL: 51, viral load > 1 x 106 copies per mL: 34. Genotype 1a/b (n = 
74), genotype 2/3 (n = 9), unable to genotype (n = 2). Histological staging: 
minimal/no fibrosis = 69, cirrhosis/septate fibrosis = 16 
Control group: 86 patients, age < 50 years: 65, age > 50 years: 21; male/female 
= 55/31. Serum ALT was 90 ± 66 U/L and viral load < 1 x 106 copies per mL: 49, 
viral load > 1 x 106 copies per mL: 37. Genotype 1a/b (n = 71), genotype 2/3 (n 
= 13), unable to genotype (n = 2). Histological staging: minimal/no fibrosis = 64, 
cirrhosis/septate fibrosis = 22 
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 Interventions Amantadine group: interferon-alpha-2b sc 3 million units 3 times a week, 
ribavirin 1000 to 1200 mg (based on body weight) daily in divided doses, and 
amantadine hydrochloride 100 mg twice daily 
Control group: interferon-alpha-2b sc 3 million units 3 times a week, ribavirin 
1000 to 1200 mg (based on body weight) daily in divided doses, and placebo 
twice daily 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients with detectable HCV RNA 
at EOT 
Notes ML sent an email to Dr Thuluvath about the biochemical response on 10 January 
2012 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Unclear risk Not mentioned 
Allocation 
concealment 
(selection bias) 
Low risk Patients were randomly assigned (central randomisation at Johns 
Hopkins University) 
Blinding of 
participants and 
personnel 
(performance 
bias)  
All outcomes 
Low risk The pharmacy department at the Johns Hopkins Hospital was 
responsible for randomisation and supplying amantadine or 
identical placebo to all centres. Unblinding of amantadine was 
done only when all patients completed treatment or if any patient 
experienced unexpected side effects (this was not necessary as 
there were no serious adverse events) 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
Unclear risk Insufficient information, although placebo-controlled 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Unclear risk All drop-outs were discussed, but not clearly mentioned which 
patients in each group stopped for which reason 
Selective 
reporting 
(reporting bias) 
High risk Not all the secondary outcome measures are well described; very 
sober description of ALT normalisation, no description of 
histological findings 
Other bias High risk Vested interest bias: Schering-Plough 
No baseline imbalance; sample size calculation was reported; the 
trial was not stopped early 
van Soest 2010 
Methods Randomised, double-blind, placebo-controlled trial in naive patients 
Trial duration: 52 weeks, follow-up 52 weeks 
Conducted from January 2001 to July 2007 
Participants Country: the Netherlands, 26 centres 
Number of patients randomised: 321, only 297 really received allocated 
intervention 
Amantadine group: mean age 42.6 ± 9.1 years, male/female: 108/32 
Control group: mean age 43.8 ± 9.2 years, male/female: 105/48 
Inclusion criteria: previously untreated adult patients who tested positive 
for serum HCV antibodies and HCV RNA; ALT and/or AST elevated at least 
once within 6 months before inclusion; liver biopsy (performed within 1 year 
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 before entry) consistent with chronic viral hepatitis; minimal baseline 
haematological values were: haemoglobin 6.5 mmol/L, white blood cells 
2.5 × 109 L−1, 
neutrophils 1.5 × 109 L−1, platelets 70 × 109 L−1 and serum creatinine < 150 
mol/L 
Exclusion criteria: Child-Pugh classification B or C; HIV co-infection; active 
uncontrolled psychiatric disorders; significant dysfunction of the central 
nervous system; chemotherapy and/or systemic antiviral treatment in the 
preceding 6 months; other serious disease; pregnancy or intention to get 
pregnant or unwillingness to use contraception; (former) drug users could 
be included if stable psychosocial situation, support and housing were 
available 
Interventions Amantadine group: peg interferon-alpha-2b, ribavirin, plus amantadine 
hydrochloride for 48 weeks, n = 144 
Control group: peg interferon-alpha-2a, ribavirin, plus oral placebo of 
identical shape and taste was added for 48 weeks, n = 153 
Both treatment groups received the same interferon-alpha induction 
therapy (from day 1 combined with ribavirin), consisting of interferon-
alpha-2b 10 MIU/day sc during the first 6 days, followed by 5 MIU/day for 
the next 6 days, followed by peg interferon-alpha-2b 1.5 g/kg/week sc up 
to 26 weeks and 1.0 g/kg/week from week 26 to week 52. Oral ribavirin was 
given during the entire 52-week treatment period in 2 different doses: 1000 
mg/day for body weight < 75 kg and 1200 mg/day for body weight ≥ 75 kg. 
In the triple therapy group, oral amantadine hydrochloride 100 mg twice 
daily was added 
Outcomes Sustained virological response, 1 year after cessation of the study 
medication; virologic response rates (negative HCV RNA at week 24); 
breakthrough rates (negative HCV RNA at week 24 and positive HCV RNA at 
week 52); relapse rates (negative HCV RNA at week 24 and 52; positive HCV 
RNA at week 104) 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Central randomisation was implemented by the pharmacist 
of the co-ordinating academic centre using a block size of 4 
Allocation 
concealment 
(selection bias) 
Low risk Central randomisation was implemented by the pharmacist 
of the co-ordinating academic centre using a block size of 4 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
Low risk Oral placebo of identical shape and taste 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Investigators and patients were blinded to treatment 
assignment during the entire study and follow-up period 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Unclear risk Patient withdrawal is mentioned, but the reason for 
withdrawal is not stated clearly for every patient 
Selective reporting 
(reporting bias) 
High risk All outcome measures reported; lack of biochemical 
response 
Other bias High risk Vested interest bias: Schering-Plough 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
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 Vardar 2001 
Methods Randomised controlled trial in naive patients in Turkey 
6 months therapy, 6 months follow-up 
Participants Country: Turkey 
33 patients were randomised. They had biopsy-proven chronic HCV 
with raised ALT values equal to or greater than 1.5 times the upper 
normal limit, positive serum HCV RNA by PCR testing, and 
compensated liver disease 
Amantadine group: 19 patients, mean age, male/female, serum 
ALT, viral load, and histological staging were not provided. All 
patients had genotype 1b 
Control group: 14 patients, mean age, male/female, serum ALT, 
viral load, and histological staging were not provided. All patients 
had genotype 1b 
There was no difference in the means for age, sex, and initial 
serum transaminase values between the 2 groups 
Interventions Amantadine group: interferon 3 MU 3 times per week plus 
amantadine 200 mg per day combination therapy for 6 months 
Control group: interferon 3 MU 3 times per week for 6 months 
Follow-up period was 6 months 
Outcomes Number of patients without SVR; number of patients with 
detectable HCV RNA at EOT 
Notes ML sent an email to Dr. Vardar on 12 January 2012 about 
biochemical responses 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Insufficient information 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants and 
personnel (performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of outcome 
assessment (detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete outcome data 
(attrition bias)  
All outcomes 
Unclear risk Insufficient information 
Selective reporting (reporting 
bias) 
High risk Only virological response 
Other bias Unclear risk Insufficient information 
von Wagner 2008 
Methods Randomised, double-blind, placebo-controlled trial in naive patients 
Trial duration: 48 weeks, follow-up 24 weeks 
Participants Country: Germany, 5 centres 
Number of patients randomised: 705 
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 Amantadine group: mean age 46.3 ± 12.0 years, male/female: 185/167 
Control group: mean age 45.4 ± 12.2 years, male/female: 183/169 
Inclusion criteria: male and female patients older than 18 years with 
compensated chronic genotype HCV-1-infection not previously treated with 
interferon-alpha or ribavirin; positive anti-HCV antibody and HCV RNA (600 
IU/mL by quantitative RT-PCR); liver biopsy taken within 24 months before 
the screening visit showing chronic hepatitis; at least 1 serum ALT level 
elevated during the screening period; baseline neutrophil and platelet 
counts ≥ 1500/L and 90,000/L; haemoglobin values ≥ 12 g/dL for females 
and ≥ 13 g/dL for males 
Exclusion criteria: any other cause of liver disease or other relevant 
disorders including HIV or hepatitis B virus co-infection; other clinically 
significant disease; excessive daily intake of alcohol, or drug abuse within 
the past year; pregnancy and lactation, and male partners of pregnant 
women; higher degree of atrioventricular block, bradycardia (heart rate 55 
beats/minute), an implanted pacemaker, prolonged Q-T-interval, or a U 
wave in electrocardiogram, or concomitant intake of medication with long 
Q-T-interval as a known side effect, concomitant medication with thiazides, 
known history of severe ventricular arrhythmia 
Interventions Patients were randomly assigned to receive: 
Amantadine group: amantadine-sulphate 400 mg/day orally in combination 
with peg interferon-alpha-2a 180 μg once per week sc plus ribavirin 1000 to 
1200 mg/day orally according to body weight (75 kg: 1000 mg; 75 kg: 1200 
mg), n = 353 
Control group: placebo plus the same regimen peg interferon-alpha-2a plus 
ribavirin for 48 weeks, n = 352 
Before onset of antiviral treatment with peg interferon-alpha-2a and 
ribavirin, amantadine/placebo was dose escalated within 2 weeks in 100 mg 
steps weekly starting at 200 mg/day 
Outcomes Sustained virological response 
Notes Additional information requested on 23 January 2012 from the last author, 
Prof. Dr. S. Zeuzem. Prof Zeuzem answered on 24 January with information 
about random sequence generation and allocation concealment. ML sent 
another email requesting the number of patients with liver-related 
morbidity. Prof. Zeuzem answered on 26 January 2012 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer random number generator 
Allocation 
concealment 
(selection bias) 
Low risk Central allocation using telephone 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
Unclear risk Placebo-controlled, but insufficient information 
Blinding of outcome 
assessment 
Unclear risk Placebo-controlled, but insufficient information 
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 (detection bias)  
All outcomes 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Withdrawals/loss to follow-up not equally divided 
Selective reporting 
(reporting bias) 
Unclear risk Only 1 outcome measure, but more outcome measures 
reported in results. No information about histological 
improvement 
Other bias High risk Vested interest bias: high: Roche 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Wenger 2007 
Methods Randomised controlled study in interferon-alpha non-responders on behalf of 
the Swiss Association of the Study of the Liver in 11 centres 
Patients were recruited between August 1999 and June 2001 
48 weeks therapy, 6 months follow-up 
Participants Country: Switzerland 
32 patients were recruited for the pilot phase, of whom 2 (1 in the triple, 1 in 
the combination therapy group) withdrew written consent after baseline 
evaluation but before starting treatment. 30 patients started the pilot phase 
Inclusion criteria: patients of both genders, aged 18 to 65 years, with chronic 
HCV who had previously failed to respond to interferon-alpha-2a or -2b given 
in a dose of 3 to 6 MU 3 times weekly for at least 12 weeks, elevated ALT 
within 12 months of entry on at least 2 occasions, positive HCV RNA test in 
serum by RT-PCR within 2 months of entry, and a liver biopsy within 5 years 
before entry consistent with chronic HCV 
Exclusion criteria: any other cause of liver disease including hepatitis B virus 
co-infection (HBsAg positive) and alcohol intake (> 20 g/day in females and > 
40 g/day in males); a history of or actual decompensation of liver disease 
(ascites, variceal bleeding or encephalopathy); cirrhosis ≥ 8 Child-Pugh points; 
other clinically relevant disorders including cardiovascular, pulmonary, renal, 
metabolic, haematological, rheumatologic, neurological and psychiatric 
diseases, autoimmune disorders, HIV infection, immunosuppression within 12 
months of entry, organ transplantation, malignant neoplastic disease within 2 
years of study entry, illicit drug use within 1 year of study entry or psychosocial 
instability, pregnancy or lactation, refusal to practice effective contraception 
during treatment and follow-up, or treatment with any investigational drug 
within 6 months of study entry; leucocytes < 2000/µL, neutrophils < 1000/µL, 
platelets < 50,000/µL, serum creatinine > 1.5 times upper limit of normal, 
elevated thyroid-stimulating hormone, alfa-fetoprotein above normal limits 
and/or focal lesion on ultrasound performed within 1 month of study entry. 
Amantadine group: 16 patients, median age 47 (28 to 65) years, male/female 
= 13/3, BMI 25 (20 to 33) kg/m2. Median serum ALT was 77 (48 to 567) U/l and 
the median basal viral load was 4.3 (0.16 to 25) x 10⁶ copies per mL. Genotype 
1 + 4 (n = 9) and genotype 2 + 3 (n = 7). Histological staging: 3 patients had 
cirrhosis 
Control group: 14 patients, median age 45 (23 to 59) years, male/female = 
12/2, BMI 26 (21 to 40) kg/m2. Median serum ALT was 89 (53 to 397) U/l and 
the median basal viral load was 2.0 (0.12 to 26.2) x 10⁶ copies per mL. 
Genotype 1 + 4 (n = 11) and genotype 2 + 3 (n = 3). Histological staging: 1 
patient had cirrhosis 
Sample size calculation was not mentioned 
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 Interventions Amantadine group: interferon-alpha-2a 6 MIU sc daily for 4 weeks, followed 
by 6 MIU sc tiw for an additional 44 weeks, ribavirin (< 75 kg: 1000, ≥ 75 kg: 
1200 mg), plus amantadine sulphate 100 mg po twice daily 
Control group: interferon-alpha-2a plus ribavirin in the above mentioned 
doses 
Treatment was stopped, if after 4 weeks HCV RNA in serum remained 
detectable by RT-PCR (detection limit: 1000 copies/mL) 
Patients were followed for 24 weeks after stopping therapy 
Outcomes Mortality; liver-related morbidity; SAE; treatment discontinuation due to AE; 
number of patients without SVR; number of patients with detectable HCV RNA 
at EOT; number of patients without normalisation of ALT at EOT and at SVR 
Notes ML sent an email about the biochemical response at EOT and 24 weeks after 
stopping therapy to Dr. Beat Mullhaupt on10 January 2012. Dr. Mullhaupt 
responded on 11 January 2012 with the following information: biochemical 
response at EOT in the triple therapy 4 out of 16, sustained biochemical 
response 3 out of 16. In the double therapy arm EOT was 3 out of 14, as well 
as the sustained biochemical response 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Low risk Patients were randomised with a ratio of 1:1. Randomisation 
was carried out in blocks of 10 using random numbers 
Allocation 
concealment 
(selection bias) 
Unclear risk Insufficient information, method is not described 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not placebo-controlled 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not placebo-controlled 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Low risk Drop-outs were discussed 
Selective reporting 
(reporting bias) 
High risk No ALT description and no QoL description, although mentioned 
as endpoint in the methods section 
Other bias High risk Vested interest bias: interferon-alpha-2a (Roferon® A), 
ribavirin and amantadine sulphate (PK Merz®) were provided by 
Roche Pharma (Schweiz) AG, Reinach, Switzerland 
Baseline balance is questionable: baseline variables were 
similar in both groups, except genotype 1 and 4 infection and 
cirrhosis tended to be slightly more prevalent in the double and 
triple therapy group. 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
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 Yang 2003 
Methods Randomised, double-blind, placebo-controlled trial in naive patients 
Patients were studied between October 1996 and October 1998 
24 weeks therapy, 1 year follow-up 
Participants Country: Taiwan, 1 centre 
Number of patients randomised: 30 
Amantadine group n = 15: age 42 ± 9 years, male/female: 12/3 
Control group n = 15: age 38 ± 7 years, male/female: 12/3 
Inclusion criteria: naive patients aged between 20 and 55 years; positive for 
anti-HCV antibodies; abnormal serum ALT levels for more than 6 months, at 
least 3 documented occasions higher than twice the upper limit of normal (< 
3 IU/L) with 1 month apart, within 6 months prior to enrolment; liver biopsy, 
within 1 month before start of treatment, to confirm chronic hepatitis 
without cirrhosis 
Exclusion criteria: alcoholic, no intravenous drug abusers or homosexuals; 
hepatotoxic drugs, herb medicine, and immunosuppressive therapy within 
the past 6 months; decompensated liver function, cirrhosis; other diseases, 
i.e., chronic renal failure, neurological disorders, chronic hepatitis B, 
autoimmune; pregnancy; white cells and platelet abnormalities 
Interventions Patients were randomly assigned to receive: 
Amantadine group: 4.5 MU recombinant interferon-alpha-2a sc thrice 
weekly and oral amantadine twice daily 100 mg, n = 15 
Control group: 4.5 MU recombinant interferon-alpha-2a sc thrice weekly and 
oral placebo twice daily for 24 weeks, n = 15 
Outcomes Complete response: normalisation of serum ALT levels together with the 
absence of serum HCV RNA by the end of treatment = composite outcome; 
sustained complete response: the continuation of the remission 12 months 
after the end of treatment 
Notes Additional information requested on 23 January 2012 to the first author Dr. 
S. Yang. Dr. Yang answered on 27 January 2012 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer random number generator 
Allocation 
concealment 
(selection bias) 
Low risk By pharmacy. Only the pharmacologist in charge knew the 
sequence. The patients received amantadine or placebo from 
the pharmacy 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
Unclear risk Insufficient information, although placebo-controlled 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
Unclear risk Insufficient information, although placebo-controlled 
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 Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk 1 patient lost to follow-up 2 months after treatment. All 
others finished follow-up period 
Selective reporting 
(reporting bias) 
High risk No information about separate biochemical outcome 
Other bias Unclear risk Vested interest bias: unknown 
No baseline imbalance; sample size calculation was not 
reported; the trial was not stopped early 
Zeuzem 2000 
Methods Randomised, double-blind, placebo-controlled trial in naive patients in 
Germany 
Patients were enrolled between March and October 1997 
48 weeks therapy, 24 weeks follow-up 
Participants Country: Germany 
120 patients were enrolled, 1 patient did not receive treatment. 119 
started treatment 
Inclusion criteria: patients aged 18 to 70 years with compensated 
chronic, HCV infection not previously treated with interferon, ribavirin, 
and/or amantadine. Tested positive for anti-HCV and HCV RNA by RT-PCR. 
A liver biopsy within a year of study entry showing chronic hepatitis, and 
had elevated serum ALT levels for at least 6 months before initiation of 
treatment. Entry leucocyte count had to be ≥ 2500/μL, platelets > 
70,000/μL 
Exclusion criteria: any other cause of liver disease or other relevant 
disorders, including HIV or hepatitis B co-infection. Evidence or history of 
autoimmune disease. Other clinically significant diseases. Average daily 
intake of alcohol exceeding 50 g of ethanol or drug abuse within the 
previous year. Pregnancy and lactation period 
Amantadine group: 26 patients, mean age 42.1 ± 12.9 years, 
male/female = 37/22. Serum ALT was 57.5 ± 39.0 U/L and the basal viral 
load was 7.8 ± 8.5 x 10⁶ copies per mL. Genotype 1 (n = 42), genotype 2 
(n = 3), genotype 3 (n = 13), genotype 4 (n = 1). Histological staging: non 
= 8, mild = 25, moderate = 18, severe = 8 
Control group: 60 patients, mean age 41.6 ± 10.3 years, male/female = 
36/24. Serum ALT was 59.6 ± 36.0 U/L and the basal viral load was 7.4 ± 
9.8 x 10⁶ copies per mL. Genotype 1 (n = 40), genotype 2 (n = 3), genotype 
3 (n = 15), genotype 4 (n = 1). Histological staging: non = 2, mild = 28, 
moderate = 22, severe = 8 
Interventions Amantadine group: interferon-alpha-2a 6 MU sc thrice weekly for 24 
weeks, followed by 3 MU sc thrice weekly for an additional 24 weeks and 
amantadine sulphate 100 mg po twice daily 
Control group: interferon-alpha-2a 6 MU sc thrice weekly for 24 weeks, 
followed by 3 MU sc thrice weekly for an additional 24 weeks and placebo 
po twice daily 
Outcomes Mortality; SAE; treatment discontinuation due to AE; QoL; number of 
patients without SVR; number of patients with detectable HCV RNA at 
EOT; number of patients without improvement of histology; number of 
patients without normalisation of ALT at EOTand at EOFU 
Notes — 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
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 Random sequence 
generation (selection 
bias) 
Low risk Random number generator in fixed blocks of 4 with a ratio 
of 1:1 
Allocation concealment 
(selection bias) 
Unclear risk Insufficient information 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
Low risk Placebo-controlled with matched placebo 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
Unclear risk Placebo-controlled, but insufficient information 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk No missing data, equally divided 
Selective reporting 
(reporting bias) 
Low risk No selective reporting 
Other bias High risk Vested interest bias: Merz + Roche 
No baseline imbalance; sample size calculation was 
reported; the trial was not stopped early 
AE: adverse event 
ALT: alanine aminotransferase 
AST: aspartate transaminase 
bid: twice a day 
BMI: body mass index 
EDLQ: everyday life questionnaire 
ELISA: enzyme-linked immunosorbent assay 
EOFU: end of follow-up 
EOT: end of treatment 
EVR: early virological response 
HAI: histology activity index 
HAV: hepatitis A virus 
HBsAg: hepatitis B surface antigen 
HBV: hepatitis B virus 
HCV: hepatitis C virus 
HIV: human immunodeficiency virus 
HRQoL: health-related quality of life 
ITT: intention-to-treat 
MIU: million international units 
MU: million units 
NS: non-significant 
PCR: polymerase chain reaction 
po: orally 
POMS: profile of mood status scale 
QoL: quality of life 
RNA: ribonucleic acid 
RT-PCR: real-time polymerase chain reaction 
SAE: serious adverse event 
sc: subcutaneous 
SVR: sustained virological response 
tiw: three times weekly 
U/L: units per liter 
VAS: visual analogue scale 
WBC: white blood cells 
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 Characteristics of excluded studies [ordered by study ID] 
Study Reason for exclusion 
Buggisch 2009 Unknown how many patients were randomised to each group 
Di Bisceglie 2001 Compared amantadine plus peg interferon-alpha and ribavirin with amantadine 
and peg interferon-alpha 
Mendez-Navarro 
2010a 
Not randomised: erratum 
Nakamura 2003 Not randomised 
Popovic 2000 Data in text and table are not comparable and reproducible 
Quarantini 2006 Does not report one of our outcome measures 
Schories 2003 Does not report one of our outcome measures 
Torre 1999 Does not report one of our outcome measures 
Zilly 2002 Not randomised 
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 Abstract 
Background: Hepatitis C virus infection affects around 3% of the world population or 
approximately 160 million people. A variable proportion (5% to 40%) of the infected people 
develop clinical symptoms. Hence, hepatitis C virus is a leading cause of liver-related 
morbidity and mortality with hepatic fibrosis, end-stage liver cirrhosis, and hepatocellular 
carcinoma as the dominant clinical sequelae. Combination therapy with pegylated (peg) 
interferon-alpha and ribavirin achieves sustained virological response (that is, undetectable 
hepatitis C virus RNA in serum by sensitivity testing six months after the end of treatment) in 
approximately 40% to 80% of treated patients, depending on viral genotype. Recently, a new 
class of drugs have emerged for hepatitis C infection, the direct acting antivirals, which in 
combination with standard therapy or alone can lead to sustained virological response in 80% 
or more of treated patients. Aminoadamantanes, mostly amantadine, are antiviral drugs used 
for the treatment of patients with chronic hepatitis C. We have previously systematically 
reviewed amantadine versus placebo or no intervention and found no significant effects of 
the amantadine on all-cause mortality or liver-related morbidity and on adverse events in 
patients with hepatitis C. Overall, we did not observe a significant effect of amantadine on 
sustained virological response. In this review, we systematically review aminoadamantanes 
versus other antiviral drugs. 
Objectives: To assess the beneficial and harmful effects of aminoadamantanes versus other 
antiviral drugs for patients with chronic hepatitis C virus infection by conducting a systematic 
review with meta-analyses and trial sequential analyses of randomised clinical trials. 
Search methods: The Cochrane Hepato-Biliary Group Controlled Trials Register (1996 to 
December 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11 of 
12, 2013), MEDLINE (1946 to December 2013), EMBASE (1974 to December 2013), Science 
Citation Index EXPANDED (1900 to December 2013), the WHO International Clinical Trials 
Registry Platform (www.who.int/ictrp), Google Scholar, and Eudrapharm up to December 
2013. Furthermore, full text searches were conducted until December 2013. 
Selection criteria: Randomised clinical trials assessing aminoadamantanes in participants 
with chronic hepatitis C virus infection. 
Data collection and analysis: Two authors independently extracted data. RevMan Analysis 
was used for statistical analysis of dichotomous data using risk ratio (RR) with 95% confidence 
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 intervals (CI). Methodological domains were used to assess the risk of systematic errors ('bias'). 
We used trial sequential analysis to assess risk of random errors ('play of chance'). 
Main results: Six randomised clinical trials with 581 participants with chronic hepatitis C 
were included. All trials had high risk of bias. The included trials compared amantadine versus 
other antiviral drugs: ribavirin, mycophenolate mofetil, interferon-alpha, or interferon-
gamma. Standard antiviral therapy (interferon-alpha, interferon-alpha plus ribavirin, or peg 
interferon alpha) was administered equally to the intervention and the control groups in five 
trials, depending on when the trial was conducted. Four trials compared amantadine versus 
ribavirin. There were no deaths or liver-related morbidity in the two intervention groups 
(0/216 (0%) versus 0/211 (0%); 4 trials; very low quality of the evidence). The lower estimated 
risk for (serious) adverse events leading to treatment discontinuation with amantadine was 
imprecise (RR 0.56, 95% CI 0.27 to 1.16; based on 10/216 (5%) versus 18/211 (9%) participants 
in 4 trials; very low quality of the evidence). There were more participants with failure of 
sustained virological response in the amantadine group than in the ribavirin group (206/216 
(96%) versus 176/211 (84%); RR 1.14, 95% CI 1.07 to 1.22, 4 trials; low quality of the evidence). 
Amantadine versus ribavirin more often failed to achieve end-of follow-up biochemical 
response (41/46 (89%) versus 31/46 (67%); RR 1.31, 95% CI 1.05 to 1.63; 2 trials; very low 
quality of the evidence). One trial compared amantadine versus mycophenolate mofetil. 
There were no significant differences between the two treatment groups, except that 
amantadine was inferior to mycophenolate mofetil regarding the outcome failure to achieve 
end-of treatment virological response (low quality of evidence). One trial each compared 
amantadine versus interferon-alpha or interferon-gamma. Both comparisons showed no 
significant differences in the treatment outcomes (very low quality of the evidence). The 
observed effects could be due to real effects, systematic errors (bias), or random errors (play 
of chance). This possible influence on the observed effect by play of chance is due to the fact 
that trial sequential analyses could not confirm our findings. We were not able to perform 
meta-analyses on failure of histological improvement and quality of life due to lack of valid 
data in all trial comparisons. 
Authors' conclusions: This systematic review has identified evidence of very low quality for 
the key outcomes of all-cause mortality or liver-related morbidity and adverse events in 
people with chronic hepatitis C when treated with amantadine compared with ribavirin, 
mycophenolate, interferon-alpha, or interferon-gamma. The timeframe for measuring the 
composite outcome was insufficient in the included trials. There was low quality evidence 
that amantadine led to more participants who failed to achieve sustained virological response 
compared with ribavirin. This observation may be real or caused by systematic errors (bias), 
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 but it does not seem to be caused by random error (play of chance). Due to the low quality of 
the evidence, we are unable to determine definitively whether amantadine is less effective 
than other antivirals in patients with chronic hepatitis C. As it appears less likely that future 
trials assessing amantadine or potentially other aminoadamantanes for patients with chronic 
hepatitis C would show strong benefits, it is probably better to focus on the assessments of 
other direct acting antiviral drugs. We found no evidence assessing other aminoadamantanes 
in randomised clinical trials in order to recommend or refute their use. 
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 Summary of findings 
Summary of findings for the main comparison. 
Aminoadamantanes compared with ribavirin for chronic hepatitis C 
Patient or population: patients with chronic hepatitis C. 
Settings: mainly outpatients in tertiary and teaching hospitals. 
Intervention: aminoadamantanes. 
Comparison: ribavirin. 
Outcomes Illustrative comparative risks* 
(95% CI) 
Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Assumed 
risk 
Corresponding risk 
Ribavirin Aminoadamantanes 
All-cause 
mortality or 
liver-related 
morbidity 
Follow-up: 12-24 
months 
Study population RR 0.98 
(0.00 to 
248.89) 
427 
(4 trials) 
⊕⊝⊝⊝ 
very low1 0 per 
1000 
0 per 1000  
(0 to 0) 
Adverse events 
Follow-up: 12-24 
months 
Study population RR 0.56 
(0.27 to 
1.16) 
427 
(4 trials) 
⊕⊝⊝⊝ 
very low1 86 per 
1000 
47 per 1000  
(23 to 98) 
Failure of 
sustained 
virological 
response 
Absence of 
clearance of HCV 
RNA from the 
blood 6 months 
after treatment 
Follow-up: 12-24 
months 
Study population RR 1.14 
(1.07 to 
1.22) 
427 
(4 trials) 
⊕⊕⊕⊝ 
low2 835 per 
1000 
954 per 1000  
(896 to 1021) 
Failure of end 
of treatment 
Study population RR 1.20 309 
(3 trials) 
⊕⊕⊝⊝ 
low2 678 per 
1000 
816 per 1000  
(714 to 925) 
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 virological 
response 
Absence of 
clearance of HCV 
RNA from the 
blood at end of 
treatment 
Follow-up: 12-24 
months 
(1.05 to 
1.36) 
Failure of 
normalisation 
of ALT at end 
of treatment 
Follow-up: 12-24 
months 
Study population RR 2.02 
(1.07 to 
3.82) 
29 
(1 trial) 
⊕⊝⊝⊝ 
very low1 429 per 
1000 
867 per 1000  
(460 to 1640) 
Failure of 
normalisation 
of ALT at end 
of follow-up 
Follow-up: 12-24 
months 
Study population RR 1.31 
(1.05 to 
1.63) 
92 
(2 trials) 
⊕⊝⊝⊝ 
very low1 674 per 
1000 
892 per 1000  
(715 to 1110) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is 
provided in footnotes. The corresponding risk (and its 95% confidence interval) is based 
on the assumed risk in the comparison group and the relative effect of the intervention 
(and its 95% CI). 
ALT: alanine aminotransferase; CI: confidence interval; HCV: hepatitis C virus; RNA: 
ribonucleic acid; RR: risk ratio. 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of 
effect. 
Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
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 Background 
Description of the condition 
Hepatitis C virus was first described in 1989 (Choo 1989). It affects around 3% of the world 
population, thus affecting approximately 160 million people (Sy 2006; Lavanchy 2011). 
Hepatitis C virus is a leading cause of mortality and liver-related morbidity with hepatic 
fibrosis, liver cirrhosis, and hepatocellular carcinoma as the dominant clinical sequelae (Sy 
2006). Hepatocellular carcinoma occurs in 3 per 100,000 persons in the United States of 
America (El-Serag 2003). Hepatitis C virus is responsible for one-third of these hepatocellular 
carcinomas (El-Serag 2003). In cirrhotic hepatitis C virus patients, the annual occurrence of 
hepatocellular carcinoma is 1% to 4% (Lauer 2001). Furthermore, hepatitis C virus infection is 
the most common indication for orthotopic liver transplantation (Kim 2009). 
Chronic hepatitis C virus progresses slowly, over a time frame of 15 years to 50 years. 
Prospective and retrospective studies following cohorts of patients for decades suggested that 
less than 10% of all infected individuals would develop end-stage liver disease. However, there 
are also publications reporting on patients who had developed cirrhosis two or three decades 
after infection with a range of 0.5% to 39% (Koretz 1993; Kenny-Walsh 1999; Rodger 2000; 
Wiese 2000; Thein 2008; Seeff 2009). 
Hepatitis C virus is divided into six genotypes (from 1 to 6) (Simmonds 2005). Genotypes 1 to 
4 are the most common genotypes (Simmonds 2005). Several factors have an influence on 
achieving a sustained virological response to antiviral drugs (that is, undetectable hepatitis C 
virus ribonucleic acid (RNA) in serum by sensitivity testing six months after the end of 
treatment); genotype is one of these factors (Asselah 2010). Genotypes 2 and 3 respond better 
to treatment than genotypes 1 and 4 (Asselah 2010). 
In 1990, interferon-alpha, an antiviral drug, was approved for the treatment of chronic 
hepatitis C virus as monotherapy (Tine 1991). Interferon-alpha was administered 
subcutaneously in doses of equal to or more than three million units (MU) in the induction 
phase (during one to three months) and less than three MU in the maintenance phase (Tine 
1991). Results of studies showed that only 10% to 17% of patients responded to interferon-
alpha monotherapy in achieving a sustained virological response compared with 1% to 3% of 
participants on no intervention (Davis 1989; Myers 2002). 
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 Antiviral drugs for patients with hepatitis C virus-related liver disease have improved 
considerably during the past two decades (Ghany 2009). In 1998, trials assessed the 
combination of interferon-alpha and ribavirin compared with interferon alpha alone (Davis 
1998; McHutchison 1998; Poynard 1998). This combination treatment resulted in an improved 
antiviral response in naive, chronic hepatitis C virus-infected patients compared with 
interferon-alpha alone (Brok 2010), and in previously treated patients who had failed to 
respond to interferon-alpha monotherapy (Brok 2010). 
The success of antiviral therapy is usually defined as the proportion of patients who achieve 
sustained virological response, that is, clearance of hepatitis C virus RNA from the blood six 
months after treatment. Observational studies have suggested that people with sustained 
virological response have less disease progression and less risk of hepatocellular carcinoma 
(Ueno 2009). However, following a systematic review of meta-analyses with randomised 
clinical trials comparing ribavirin plus interferon-alpha versus interferon-alpha alone, this 
drug therapy combination seemed to result in more patients with a sustained virological 
response, but no conclusion could be made if this combination results in less mortality or 
morbidity (Brok 2010). Sustained virological response is still a non-validated putative 
surrogate outcome measure (Gluud 2007). 
A recent trial showed that there was an increased mortality in patients who were retreated 
with interferon-alpha compared with non-treated patients (Di Bisceglie 2011) and that was 
supported in a Cochrane systematic review (Koretz 2013). 
The current standard of treatment for chronic hepatitis C virus infection, according to 
guidelines, is a combination of pegylated interferon-alpha (peg interferon-alpha) and ribavirin 
(Ghany 2009; EASL 2014). The regimen can include either peg interferon-alpha-2b (Peg-
Intron®, Schering Plough Corp., Kenilworth, NJ) or peg interferon-alpha-2a (Pegasys®, 
Hoffmann-La Roche, Nutley, NJ), both of which are administered subcutaneously (Awad 2010). 
The optimal dose of peg interferon-alpha-2b is 1.5 µg/kg/week (Awad 2010; Hauser 2014a). 
Peg interferon-alpha-2a is administered at a fixed dose of 180 µg weekly (Awad 2010). 
Ribavirin is an oral therapy with weight-based total daily doses between 800 mg to 1200 mg 
administered twice per day (Brok 2009). Between 40% and 80% of chronic hepatitis C virus 
patients without co-infection with hepatitis B virus or human immunodeficiency virus (HIV) 
will achieve a sustained virological response after treatment with peg interferon-alpha and 
ribavirin (Simin 2007; Awad 2010; Hauser 2014; Hauser 2014a). 
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 Recently, a new class of antiviral drugs for hepatitis C virus have emerged on the market. 
These antiviral agents act directly, inhibiting the nonstructural (NS) NS3/N4A serine protease 
and NS5B polymerase inhibitors of hepatitis C virus. The direct acting antivirals can alone, or 
in concert with peg interferon-alpha and ribavirin (triple therapy) increase sustained 
virological response proportions to 80% or above (Bacon 2011; Jacobson 2011; Poordad 2011; 
Sherman 2011; Zeuzem 2011; Lawitz 2013; Lawitz 2014; Sulkowski 2014). The effects they 
show on sustained virological response will hopefully lead to comparable clinical responses. 
Description of the intervention 
Aminoadamantanes is another antiviral drug group which includes amantadine and 
rimantadine. The drugs have been investigated in several studies for treatment of patients 
with chronic hepatitis C virus (Brillanti 1999; Smith 2004). These aminoadamantanes were 
investigated as oral monotherapy, administered mostly as 100 mg twice a day, and also in 
combination with interferon-alpha or ribavirin, or both. The benefits and harms of 
aminoadamantanes compared with placebo in patients with chronic hepatitis C virus infection 
have been explored in a meta-analysis by Deltenre 2004 and in a recent Cochrane systematic 
review (Lamers 2014). 
How the intervention might work 
Aminoadamantanes have been used for many years to prevent infection with influenza and 
have been shown to have activity against Flaviviridae, a family of viruses, encompassing 
hepatitis C virus infection (Koff 1980). Known mechanisms of action of aminoadamantanes 
include inhibition of an early step in viral replication, most likely viral uncoating and 
interaction with the influenza A viral matrix protein (M2), which is important in virion budding 
(De Clercq 2001). The aminoadamantane such as amantadine acts similar to ribavirin; ribavirin 
in monotherapy often improves liver biochemistry (Reichard 1991; Reichard 1993), but seems 
to have no major effect in the course of hepatitis C virus infection on its own (Brok 2009). 
However, it is unclear whether aminoadamantanes may reduce the hepatitis C virus viral load 
or improve liver biochemistry (Lamers 2014). 
Why it is important to do this review 
The combination therapy of peg interferon-alpha and ribavirin yields sustained virological 
response in approximately 40% to 80% of treated patients (Simin 2007; Awad 2010). This 
indicates an unmet need for drugs in order to reach higher proportions of sustained virological 
response. With the new direct antiviral agents, higher proportions can be achieved (Bacon 
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 2011; Jacobson 2011; Poordad 2011; Sherman 2011; Zeuzem 2011). Several studies have been 
published regarding the effect of aminoadamantanes. Our systematic review is aimed at 
assessing the benefits and harms of aminoadamantanes versus other antiviral drugs. This 
systematic review may have practical implications on the way patients with chronic hepatitis 
C virus should be treated. 
The benefits and harms of aminoadamantanes compared with placebo and other antiviral 
drugs in patients with chronic hepatitis C virus infection have been explored earlier in a meta-
analysis by Deltenre 2004. A recent Cochrane systematic review compared aminoadamantanes 
with placebo for chronic hepatitis C (Lamers 2014). We found no significant effect of 
amantadine when compared with placebo or no intervention on sustained virological response 
or clinical outcomes (Lamers 2014). 
Objectives 
To explore the beneficial and harmful effects of aminoadamantanes versus other antiviral 
drugs for patients with chronic hepatitis C virus infection in a systematic review with meta-
analysis and trial sequential analysis of randomised clinical trials. 
 
Methods 
Criteria for considering studies for this review 
Types of studies 
Randomised clinical trials assessing aminoadamantanes compared with other antiviral drugs 
in participants with chronic hepatitis C virus infection irrespective of duration of treatment, 
language, publication type and status, and blinding. Quasi-randomised studies or other 
observational studies captured during the search process were excluded for the report of 
benefit but were reported in a narrative way for the data on harm from such studies. 
Types of participants 
We included participants with chronic hepatitis C virus. The diagnosis was based on the 
presence of serum hepatitis C virus RNA (HCV RNA) plus elevated transaminases for more than 
six months, or chronic hepatitis documented on liver biopsy. We also included participants 
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 diagnosed with ’non-A, non-B’ chronic hepatitis as some trials may have been conducted 
before HCV RNA analyses were widely available. 
Based on the existence of, and response to previous antiviral treatment, we classified the 
included participants as naive (not previously treated with antivirals), relapsers (participants 
with a transient serological viral response to previous treatment with antivirals), or non-
responders (patients without serological viral response to previous treatment with antivirals). 
We excluded participants who had undergone liver transplantation. 
Types of interventions 
Aminoadamantanes versus other antiviral drugs. 
Co-interventions were allowed if administered equally to the intervention groups being 
compared. 
Types of outcome measures 
Primary outcomes 
1. All-cause mortality or liver-related morbidity as a composite outcome: number of patients 
who died or who developed, for example, cirrhosis, ascites, hepatic encephalopathy, or 
hepatocellular carcinoma. 
2. Adverse events: number of patients with either serious adverse events or treatment 
discontinuation due to any adverse event. Serious adverse events are defined according to the 
International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice as "any 
untoward medical occurrence that at any dose resulted in death, was life-threatening, 
required inpatient hospitalisation or prolongation of existing hospitalisation, or resulted in 
persistent or significant disability or incapacity, or was a congenital anomaly/birth defect, or 
any medical event that might have jeopardised the patient, or required intervention to 
prevent it" (ICH-GCP 1997). All other adverse events (that is, any medical occurrence not 
necessarily having a causal relationship with the treatment but that did, however, cause a 
dose reduction or discontinuation of the treatment) were considered as being non-serious 
(ICH-GCP 1997). 
3. Quality of life (as reported in the trials). 
 
 
213
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C
5
 Secondary outcomes 
1. Failure of serum (or plasma) sustained virological response: number of patients with 
detectable HCV RNA at least six months after treatment. 
2. Failure of end-of treatment virological response: number of patients with detectable HCV 
RNA at the end of treatment. 
3. Failure in histological response: number of patients without improvement of histology 
(inflammation score (grading) or fibrosis score (staging) as defined by the individual trials). 
4. Number of participants without normalisation of alanine aminotransferase (ALT) or 
aspartate transaminase (AST) serum levels or both (defined by the individual trials) at end of 
treatment and end of follow-up. 
Search methods for identification of studies 
Electronic searches 
We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (1996 to December 
2013) (Gluud 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 11 of 
12, 2013), MEDLINE (1946 to December 2013), EMBASE (1974 to December 2013), and Science 
Citation Index EXPANDED (1900 to December 2013) (Royle 2003). We also searched the WHO 
International Clinical Trials Registry Platform (www.who.int/ictrp), Google Scholar, and 
Eudrapharm. We have given the search strategies in Appendix 1 with the time spans of the 
searches. 
Searching other resources 
We identified further trials by reading the reference lists of the identified studies. We checked 
review articles and meta-analyses in order to find randomised trials not identified by the 
electronic searches. We searched for abstracts from various gastrointestinal meetings. We 
wrote to the principal authors of the identified randomised trials and to the researchers active 
in the field to enquire about additional randomised trials they might know of. In order to 
obtain unpublished trials, we contacted pharmaceutical companies involved in the production 
and assessment of aminoadamantanes. 
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 Data collection and analysis 
Selection of studies 
Two review authors (ML, MB) independently inspected each reference identified by the 
searches and applied the inclusion criteria. For possible relevant publications, or in cases of 
disagreement between the two review authors, the full article was obtained and inspected 
independently by the two authors. If the two review authors still disagreed, a third review 
author (CG) was consulted. 
Data extraction and management 
Two review authors (ML, MB) independently extracted data. In case of disagreement between 
the two review authors, a third review author (CG) arbitrated. The data extraction was 
discussed, decisions documented, and, where necessary, we contacted trial authors for 
clarification. Trials were identified by the name of the first author and year in which the study 
was published in full and ordered chronologically. 
The following data were extracted, checked, and recorded. 
• Characteristics of trials: date, location and setting; publication status; sponsor (specified, 
known or unknown); duration of follow-up; bias-domains; sample size calculation. 
• Characteristics of participants: number of participants in each group; age; sex; ethnicity; 
weight or body mass index; viral load at the beginning of treatment; degree of fibrosis at 
the beginning of treatment. 
• Characteristics of interventions: dose and duration of aminoadamantanes and any co-
interventions. 
• Characteristics of outcome measures: whenever possible, the number of events previously 
listed under 'outcome measures' were recorded in each group of the trial; information 
about harms were extracted in observational studies. 
Assessment of risk of bias in included studies 
According to empirical evidence (Schultz 1995; Moher 1998; Kjaergard 2001; Wood 2008; 
Lundh 2012; Savović 2012; Savović 2012a), risk of bias in a trial can be assessed using 'Risk of 
bias' domains. We have used the following domains with definitions to assess the risk of bias 
of the trials included in the review. 
 
215
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C
5
 Allocation sequence generation 
• Low risk of bias: sequence generation was achieved using computer random number 
generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and 
throwing dice are adequate if performed by an independent person not otherwise involved 
in the trial. 
• Uncertain risk of bias: the method of sequence generation was not specified. 
• High risk of bias: the sequence generation method was not random. 
Allocation concealment 
• Low risk of bias: the participant allocations could not have been foreseen in advance of, 
or during, enrolment. Allocation was controlled by a central and independent 
randomisation unit. The allocation sequence was unknown to the investigators (for 
example, if the allocation sequence was hidden in sequentially numbered, opaque, and 
sealed envelopes). 
• Uncertain risk of bias: the method used to conceal the allocation was not described so 
that intervention allocations may have been foreseen in advance of, or during, enrolment. 
• High risk of bias: the allocation sequence was likely to be known to the investigators who 
assigned the participants. 
Blinding of participants, personnel, and outcome assessors 
• Low risk of bias: blinding was performed adequately, or the assessment of outcomes was 
not likely to be influenced by lack of blinding. 
• Uncertain risk of bias: there was insufficient information to assess whether blinding was 
likely to induce bias on the results. 
• High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes was 
likely to be influenced by lack of blinding. 
Incomplete outcome data 
• Low risk of bias: missing data were unlikely to make treatment effects depart from 
plausible values. Sufficient methods, such as multiple imputation, have been employed to 
handle missing data. 
• Uncertain risk of bias: there was insufficient information to assess whether missing data 
in combination with the method used to handle missing data were likely to induce bias on 
the results. 
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 • High risk of bias: the results were likely to be biased due to missing data. 
Selective outcome reporting 
• Low risk of bias: all outcomes were pre-defined and reported, or all clinically relevant and 
reasonably expected outcomes were reported. 
• Uncertain risk of bias: it is unclear whether all pre-defined and clinically relevant and 
reasonably expected outcomes were reported. 
• High risk of bias: one or more clinically relevant and reasonably expected outcomes were 
not reported, and data on these outcomes were likely to have been recorded. 
For a trial to be assessed with low risk of bias in the selective outcome reporting domain, the 
trial should have been registered either on the www.clinicaltrials.gov web site or a similar 
register, or there should be a protocol, for example published in a paper journal. In the case 
where the trial was run and published in the years when trial registration was not required, 
we carefully scrutinised all publications reporting on the trial to identify the trial objectives 
and outcomes. If usable data on all outcomes specified in the trial objectives were provided 
in the publication's results section, then the trial can be considered low risk of bias in the 
'Selective outcome reporting' domain. 
For-profit bias 
• Low risk of bias: the trial appeared to be free of industry sponsorship or other kind of for-
profit support that might have result in manipulation of the trial design, conduct, or results 
of the trial. 
• Uncertain risk of bias: the trial might or might not be free of for-profit bias as no 
information on clinical trial support or sponsorship is provided. 
• High risk of bias: the trial was sponsored by industry or had received other kinds of for-
profit support. 
All trials were assessed for risk of bias. If the risk of bias in a trial was judged as 'low' in all 
the above listed domains, then the trial was considered at 'low risk of bias'. If the risk of bias 
was judged as 'uncertain' or 'high', then the trial was considered at 'high risk of bias'. 
Reporting bias was handled following the recommendations of The Cochrane Collaboration 
(Higgins 2011). Subgroup analyses (see below) and funnel plot asymmetry were assessed 
(Higgins 2011), even though asymmetric funnel plots are not necessarily caused by publication 
bias and publication bias does not necessarily cause asymmetry in a funnel plot (Egger 1997). 
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 Measures of treatment effect 
The treatment effects in this meta-analysis are dichotomous or continuous. The dichotomous 
data were expressed with risk ratio (RR) and 95% confidence intervals (CI). The number needed 
to treat (NNT) was derived from the risk difference (RD), in case the intervention effect was 
considered significant and valid. For continuous data, we planned to use the mean difference 
when outcomes of the trials were measured in the same way. Where appropriate, we would 
have used the standardised mean difference to combine trials that measured the same 
outcome but used different methods. 
Unit of analysis issues 
We used the intervention groups of participants in randomised clinical trials as our unit of 
analysis. Three included trials used a two-armed parallel group design; the other three trials 
used a multiple-armed parallel group design. We present those additional treatment arms in 
the 'Summary of characteristics of included studies', see Table 1. Where the additional 
treatment arms were not relevant, we did not use these data. 
Table 1. Summary of characteristics of the included trials 
Trial Risk of bias Trial duration 
(months) 
Follow-up duration 
(months) 
         
Amantadine versus ribavirin       
Khalili 2000 High 6 6 
Younossi 2001 High 6 6 
Herrine 2005 High 12 6 
Salmeron 2007 High 12 6 
        
Amantadine versus mycophenolate mofetil       
Herrine 2005 High 12 6 
        
Amantadine versus interferon-alpha       
Bacosi 2002 High 12 12 
        
Amantadine versus interferon-gamma       
Abbas 2012 High 12 6 
Dealing with missing data 
We contacted the original investigators to request missing data that we expected to have 
been measured but were not reported. 
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 We performed all analyses according to the intention-to-treat method, including all 
participants irrespective of compliance or follow-up. 
Regarding our primary outcomes, we included patients with incomplete or missing data in 
sensitivity analyses by imputing them according to the following two extreme scenarios (Hollis 
1999; Gluud 2014). 
• Extreme case analysis favouring the experimental intervention ('best-worse' case 
scenario): none of the dropouts/participants lost from the experimental arm, but all of 
the dropouts/participants lost from the control group experienced the outcome, including 
all randomised participants in the denominator. 
• Extreme case analysis favouring the control ('worst-best' case scenario): all 
dropouts/participants lost from the experimental arm, but none from the control arm 
experienced the outcome, including all randomised participants in the denominator. 
Assessment of heterogeneity 
We assessed heterogeneity using the chi-squared statistic test of heterogeneity and quantity 
of heterogeneity by the I2 measure of inconsistency (Higgins 2011). In case of substantial 
heterogeneity as measured by a chi-square test P value less than 0.1 or an I2 measure greater 
than 70%, we considered not to conduct the meta-analysis. We assessed sources of clinical, 
methodological, and statistical heterogeneity in subgroup analyses. 
Assessment of reporting biases 
Described under 'Assessment of risk of bias in included studies'. 
Data synthesis 
Meta-analysis 
For the statistical analyses, we used Review Manager 5.2 (RevMan 2012). We meta-analysed 
the data with both a random-effects model (DerSimonian 1986) and a fixed-effect model 
(DeMets 1987) to ensure robustness of the results. In case of statistically significant 
differences of the results that the two methods produced, we presented the results with both 
methods. If there were no differences in the results, we presented the results of the fixed-
effect model only (Higgins 2011). If there was considerable variation in the results, and 
particularly if the direction of effect was inconsistent, it may be misleading to quote the 
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 average value for the intervention effect; we therefore interpreted the meta-analyses with 
utmost care. 
Trial sequential analysis 
We applied trial sequential analysis (CTU 2011; Thorlund 2011) as cumulative meta-analyses 
are at risk of producing random errors due to sparse data and repetitive testing of the 
accumulating data (Brok 2008; Wetterslev 2008; Brok 2009). To minimise random errors, we 
calculated the required information size (i.e., the number of participants needed in a meta-
analysis to detect or reject a certain intervention effect) (Wetterslev 2008). The required 
information size calculation should also account for the heterogeneity or diversity present in 
the meta-analysis (Wetterslev 2008; Wetterslev 2009). In our meta-analysis, the diversity-
adjusted required information size was based on the event proportion in the control group; 
assumption of a plausible RR reduction of 20% or the RR reduction observed in the included 
trials with low risk of bias; a risk of type I error of 5%; a risk of type II error of 20%; and the 
assumed diversity of the meta-analysis (Wetterslev 2009). We added the trials according to 
the year of publication, and if more than one trial was published in a year, trials were added 
alphabetically according to the last name of the first author. On the basis of the required 
information size, trial sequential monitoring boundaries were constructed (Lan 1983; 
Wetterslev 2008; Thorlund 2011). These boundaries determine the statistical inference one 
may draw regarding the cumulative meta-analysis that has not reached the required 
information size; if the trial sequential monitoring boundary for benefit or harm is crossed 
before the required information size is reached, firm evidence may perhaps be established 
and further trials may turn out to be superfluous. On the other hand, if the boundary is not 
surpassed, it is most probably necessary to continue doing trials in order to detect or reject 
a certain intervention effect. This can be determined by assessing if the cumulative Z-curve 
crosses the trial sequential boundaries for futility. If futility boundaries are crossed, then 
further trials may be unnecessary (CTU 2011). 
We conducted trial sequential analyses using software from The Copenhagen Trial Unit (CTU 
2011). 
Subgroup analysis and investigation of heterogeneity 
Subgroup analyses were performed to compare the following. 
• Trials with low risk compared to trials with high risk of bias. 
• Type of patients regarding previous antivirals: naives, relapsers, and non-responders. 
• Type of patients regarding genotype: genotype 1 compared to genotype non-1. 
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 • Type of patients regarding degree of liver disease (inflammation score (grading) or fibrosis 
score (staging)). 
• Type of patients regarding HIV or hepatitis B co-infection. 
• Type of patients regarding age: children compared to adults. 
• Intervention: according to the type, dose and duration of aminoadamantanes, and other 
viral drugs. 
Subgroups were compared with test of interaction (Altman 2003). 
Sensitivity analysis 
Suitable sensitivity analyses were identified during the review process, e.g., a sensitivity 
analysis was used when imputing missing data with replacement values. 
Data analysis in included trials: according to intention-to-treat principle as well as 'as treated' 
(per protocol) analysis. 
'Summary of findings' table 
We used the principles of the GRADE system to assess the quality of the body of evidence 
associated with all outcomes mentioned in our review and constructed 'Summary of findings' 
table using the GRADE software (ims.cochrane.org/revman/gradepro). 
We assessed five factors referring to limitations in the study design and implementation of 
available studies suggesting high likelihood of bias; indirectness of evidence (population, 
intervention, control, outcomes); unexplained heterogeneity or inconsistency of results 
(including problems with subgroup analyses); imprecision of results (wide confidence 
intervals); and high probability of publication bias. 
We defined the levels of evidence as: 
• high-quality evidence when all bias domains were assessed with low risk of bias and there 
were consistent findings that were generalisable to most of the population of interest; 
there were sufficient data, with narrow confidence intervals; there were no known or 
suspected reporting biases; in such a case, "further research is very unlikely to change our 
confidence in the estimate of effect"; 
• moderate-quality evidence when "further research is likely to have an important impact 
on our confidence in the estimate of effect, and may change the estimate"; 
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 • low-quality evidence when the following statement applies: "further research is very likely 
to have an important impact on our confidence in the estimate of effect, and is likely to 
change the estimate"; 
• very low-quality evidence when the following statement applies: "we are very uncertain 
about  
• the estimate". 
 
Results 
Description of studies 
See: Characteristics of included studies; Characteristics of excluded studies. 
Results of the search   
We identified 639 references through the electronic searches. After filtering for duplicates, 
290 publications remained. Of the remaining 290 publications, 281 were excluded after 
screening the title and abstract, among others because they were reviews or because they 
did not describe a randomised clinical trial investigating the effect of aminoadamantanes in 
patients with chronic hepatitis C virus. The remaining nine references described six unique 
randomised clinical trials (Figure 1). 
Two of these six included trials were published in more than one publication (Khalili 2000; 
Younossi 2001). All six trials were published in full paper articles (Khalili 2000; Younossi 2001; 
Bacosi 2002; Herrine 2005; Salmeron 2007; Abbas 2012). 
When necessary, the primary or last authors were contacted for further information and data 
relating to the trials. 
We did not identify any registered ongoing or planned trials when we searched the WHO 
International Clinical Trials Registry Platform (www.who.int/ictrp), Google Scholar, and 
Eudrapharm. 
Included studies   
We included six trials in total. Three trials were conducted in the USA (Khalili 2000; Younossi 
2001; Herrine 2005). The other three trials were conducted each in different countries: Italy 
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(Bacosi 2002), Pakistan (Abbas 2012), and Spain (Salmeron 2007) (see Characteristics of 
included studies). 
The included trials were published from 2000 (Khalili 2000) to 2012 (Abbas 2012). Three trials 
had a parallel group design with two intervention groups (Khalili 2000; Younossi 2001; Abbas 
2012). One  
trial included three intervention groups (Bacosi 2002) and two trials included four intervention 
groups (Herrine 2005; Salmeron 2007). 
Figure 1. Flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The six randomised clinical trials randomised 581 patients with chronic hepatitis C virus to 
amantadine versus control. The control arms consisted of ribavirin, mycophenolate mofetil, 
interferon-alpha, or interferon-gamma. 
270 records excluded  
638 records identified 
through database searching 
290 records after duplicates 
removed 
11 publications excluded  
- 5 did not report one of our 
outcome measures 
- 3 data in text and table are not 
comparable and reproducible 
- 2 both intervention arms were 
treated with amantadine 
- 1 no separate outcome 
measures 
 
1 additional record identified 
through other sources  
290 records screened on 
title and/or abstract  
20 publications assessed for 
eligibility 
9 publications included in 
qualitative synthesis  
(6 trials) 
6 trials included in 
quantitative synthesis 
(meta-analysis) 
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 Three trials compared amantadine plus interferon-alpha versus ribavirin plus interferon-alpha 
(Khalili 2000; Younossi 2001; Salmeron 2007). One trial compared amantadine monotherapy 
with interferon-alpha without additional antiviral drugs (Bacosi 2002). One trial reported on 
amantadine plus interferon-alpha plus ribavirin versus interferon-gamma plus interferon-
alpha plus ribavirin (Abbas 2012). Another trial compared amantadine plus peg interferon-
alpha versus mycophenolate mofetil plus peg interferon-alpha (Herrine 2005). This trial also 
reported on the comparison of amantadine plus peg interferon-alpha versus ribavirin plus peg 
interferon-alpha (Herrine 2005). 
Amantadine dose was the same in each trial, 200 mg daily. The treatment duration of the 
trials varied from six to 12 months. A six-month post-treatment duration of follow-up was 
used in all trials, except for one trial which applied 12 months of post-treatment follow-up 
(Bacosi 2002). The details are displayed in Table 1. 
All publications reported the sex of the participants; more than 67% were men. All trials 
included adult patients. None of the trials included patients co-infected with HIV or hepatitis 
B virus infection. 
Excluded studies   
The eight excluded studies are listed under 'Characteristics of excluded studies', and the 
reasons for exclusion are given there. 
Risk of bias in included studies 
Risk of bias was assessed according to six domains: allocation sequence generation; allocation 
concealment; blinding of participants, personnel, and outcome assessors; handling of 
incomplete outcome data; selective outcome reporting; and for-profit bias. All included trials 
were considered to have high risk of bias. Our statistical analysis are, therefore, based on 
trials with a high risk of bias. For details of the judgements made for the individual trials, 
please see Figure 2 and Figure 3. 
Allocation (selection bias)   
The generation of the allocation sequence was adequately described in only one trial (Younossi 
2001). The remaining five trials were described as randomised, but the method or performing 
random sequence generation was not described or the randomisation was done by the 
principle investigator (Characteristics of included studies). 
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 Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item 
presented as percentages across all included studies.
 
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item 
for each included study. 
 
 
None of the trials adequately described the 
method of blinding of outcome assessment; 
thus, six trials were considered as high risk 
of bias (Characteristics of included 
studies). This also means that none of the 
included trials had a low risk of bias 
according to both blinding of participants 
and personnel and blinding of outcome 
assessments (Characteristics of included 
studies). 
Incomplete outcome data (attrition 
bias)   
Incomplete data were addressed 
adequately in two trials (Khalili 2000; 
Abbas 2012). In the other four trials, there 
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 were risks of incomplete outcome data (Characteristics of included studies). 
Selective reporting (reporting bias)   
There were risks of selective reporting of outcomes in all six trials (Characteristics of included 
studies). 
Other potential sources of bias   
Only one trial did not receive funding or other for-profit support and was therefore of low risk 
of bias regarding for-profit domain (Abbas 2012). Three trials received funding from the 
medical industry (Younossi 2001; Herrine 2005; Salmeron 2007). It was unclear whether the 
remaining two trials received funding from the medical industry or other for-profit support 
(Khalili 2000; Bacosi 2002) (Characteristics of included studies). We considered these last five 
trials as having high risk of bias for the for-profit bias domain (Figure 3). 
There were no baseline differences in any of the trials, except for one in which there was 
baseline imbalance regarding age (Khalili 2000). One trial stopped early due to poor results 
(Salmeron 2007). 
Effects of interventions 
See: Summary of findings for the main comparison 
Amantadine versus ribavirin 
Three trials compared amantadine plus interferon-alpha versus ribavirin plus interferon-
alpha; one trial compared amantadine plus peg interferon-alpha versus ribavirin plus peg 
interferon-alpha. 
Primary outcomes 
The composite outcome of all-cause mortality or liver-related morbidity 
Four trials provided information on all-cause mortality or liver-related morbidity. The 
combined outcome measure was zero in both the 216 participants in the amantadine group 
and the 211 patients in the ribavirin group (Analysis 1.1). We were not able to perform meta-
analyses on these data in RevMan, but with trial sequential analysis and a continuity correction 
of 0.5, we found no significant differences (fixed-effect model: risk ratio (RR) 0.98; 95% 
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 confidence interval (CI) 0.00 to 248.89). The required information size to detect or reject a 
relative risk reduction (RRR) of 20% with a between-trial heterogeneity of 0% is estimated to 
be 140,645 patients. The actually accrued number of patients was 427, which was only 0.3% 
of the required information size. 
Adverse events 
We classified adverse events into two groups: number of patients with serious adverse events 
and number of patients with treatment discontinuation due to any adverse event. 
Ten patients of 216 (5%) in the amantadine group versus 18 patients of 211 patients (9%) in 
the ribavirin group were reported with either serious adverse events or treatment 
discontinuation due to any adverse event (Analysis 1.2). Meta-analyses showed no statistically 
significant difference (fixed-effect model: RR 0.56; 95% CI 0.27 to 1.16; I² = 20%) (Analysis 
1.2). 
As there were no trials with low risk of bias, we performed trial sequential analysis on all 
included trials reporting on adverse events. Trial sequential analysis of these data showed 
there was too little information to draw any firm conclusions (Figure 4). 
Quality of life 
Only one trial reported on quality of life (Younossi 2001). Health-related quality of life (HRQL) 
was assessed at baseline and every three months using the medical outcome study Short Form-
36 (SF-36) and a validated liver disease-specific instrument, Chronic Liver Disease 
Questionnaire (CLDQ). We were not able to perform meta-analyses on quality of life due to a 
lack of valid data. Overall, we found no significant differences between treatment with 
amantadine versus ribavirin in this trial. 
Secondary outcomes 
Failure of serum (or plasma) sustained virological response 
Four trials provided information on patients who failed to achieve a sustained virological 
response. In the amantadine group, 206 of 216 patients (95%) did not achieve sustained 
virological response versus 176 of 211 patients (83%) in the ribavirin group. Meta-analysis with 
the fixed-effect model showed an effect on failure to achieve sustained virological response 
favouring the ribavirin group: RR 1.14; 95% CI 1.07 to 1.22. This estimated RR with a random-
227
Aminoadamantanes versus other antiviral drugs for chronic hepatitis C
5
 effects model was similar, with marginally wider confidence intervals including the null: RR 
1.15; 95% CI 0.99 to 1.32; I² = 78%) (Analysis 1.3). 
Three trials reported on failure to achieve sustained virological response in patients treated 
with amantadine plus interferon-alpha versus ribavirin plus interferon-alpha (Analysis 1.3). 
One-hundred and seventy-eight participants of 185 participants (96%) in the amantadine group 
versus 156 participants of 179 participants (87%) in the ribavirin group failed to achieve 
sustained virological response. This negative effect of amantadine plus interferon-alpha 
compared with ribavirin plus interferon-alpha, shown by the fixed-effect meta-analysis was 
not observed in the random-effects model analysis (fixed-effect model: RR 1.10; 95% CI 1.04 
to 1.18; random-effects model: RR 1.09; 95% CI 0.98 to 1.21; I² = 78%) (Analysis 1.3). 
Figure 4. Trial sequential analysis on serious adverse events or patients discontinuation 
treatment due to an adverse event 
SAE or AE discontinuation DARIS Pc 11%, RRR 20%, a 5%, b 20%, D 0% in a Two-sided graph. 
 
Figure 4: Trial sequential analysis of the random-effects meta-analysis of the effect of amantadine 
versus ribavirin in chronic hepatitis C-infected patients on number of patients experiencing a serious 
adverse event or number of patients who had to discontinue treatment due to an adverse event. The 
trial sequential analysis is performed with a type 1 error of 5% (two-sided), a power of 80%, an 
assumed control proportion of number of patients experiencing a serious adverse events or who had 
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 to discontinue treatment due to an adverse event of 11%, and an anticipated relative risk reduction 
(RRR) of 20%. The diversity-adjusted required information size (DARIS) to detect or reject a RRR of 
20% with a between-trial heterogeneity of 0% is estimated to be 7214 participants. The actually 
accrued number of participants is 398, which is only 6% of the DARIS. The blue cumulative Z-curve 
does not cross the red trial sequential monitoring boundaries for benefit or harm. Therefore, there is 
no evidence to support that amantadine influences number of patients experiencing a serious adverse 
event or who had to discontinue treatment due to an adverse event. The cumulative Z-curve does not 
reach the futility area (which is not even drawn by the program), demonstrating that further 
randomised trials may be needed. 
Sixty-three patients were treated in one trial with amantadine plus peg interferon-alpha 
versus ribavirin plus peg interferon-alpha (Analysis 1.3). Twenty-eight of 31 participants (90%) 
treated in the amantadine group compared with 20 of 32 participants (63%) in the ribavirin 
group failed to achieve sustained virological response. Risk ratio for this event was statistically 
significant comparing amantadine plus peg interferon-alpha therapy with ribavirin plus peg 
interferon-alpha (fixed-effect model: RR 1.45; 95% CI 1.08 to 1.94) (Analysis 1.3). 
Analysing the missing data as the best-worst case scenario in all the four trials comparing 
amantadine with ribavirin (assuming that participants with unknown status of achieving 
sustained virological response receiving amantadine did achieve sustained virological 
response, and that all participants from the ribavirin group with unknown status of achieving 
sustained virological response did not achieve sustained virological response) reveals no 
statistically significant differences in effect of amantadine versus ribavirin (fixed-effect 
model: RR 0.94; 95% CI 0.86 to 1.03; 427 participants, four trials). Analysing the missing data 
as the worst-best case scenario (assuming that participants with unknown status of achieving 
sustained virological response receiving amantadine did not achieve sustained virological 
response and that all participants from ribavirin group with unknown status of achieving 
sustained virological response achieved sustained virological response) shows an effect 
favouring ribavirin (fixed-effect model: RR 1.58; 95% CI 1.41 to 1.77; 427 participants, four 
trials). 
We performed trial sequential analysis on all the trials. The trial sequential analysis of the 
combined data supports the finding that ribavirin is superior to amantadine with less failure 
to achieve sustained virological response (Figure 5). The result of the trial sequential analysis 
is shown by the cumulated Z-curve (blue curve) which crosses the trial sequential boundary 
(red inward sloping curve). 
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 Figure 5. Trial sequential analysis on failure to achieve sustained virological response 
Failure SVR DARIS PC 83%, RRR 20%, a 5%, b 20%, D 78% in a Two-sided graph. 
 
Figure 5: Trial sequential analysis of the random-effects meta-analysis of the effect of amantadine 
versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve a 
sustained virological response (SVR). The trial sequential analysis is performed with a type 1 error of 
5% (two-sided), a power of 80%, an assumed control proportion of number of patients who failed to 
achieve an SVR of 83%, and an anticipated relative risk reduction (RRR) of 20%. The diversity-adjusted 
required information size (DARIS) to detect or reject a RRR of 20% with a between-trial heterogeneity 
of 78% is estimated to be 981 participants. The actually accrued number of participants is 427, which 
is 44% of the DARIS. The blue cumulative Z-curve crosses the red trial sequential monitoring boundary 
for harm. Therefore, there is evidence to support that ribavirin is superior compared with 
amantadine. 
Failure of end-of treatment virological response 
Three trials provided data on participants who failed to achieve end-of treatment virological 
response and could be included in the analyses (Analysis 1.4). In the amantadine group, 128 
of 157 participants (82%) did not achieve end-of treatment virological response versus 103 of 
152 participants (68%) in the ribavirin group. Meta-analysis showed that amantadine showed 
more failure to achieve end-of treatment virological response compared to ribavirin (fixed-
effect model: RR 1.20; 95% CI 1.05 to 1.36; I² = 32%) (Analysis 1.4). 
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 We performed trial sequential analysis on all the three trials. There is no evidence to support 
that amantadine influences the number of participants who failed to achieve an end-of 
treatment virological response (Figure 6). 
Figure 6. Trial sequential analysis end-of treatment virological response 
Failure end-of treatment virological response DARIS Pc 68%, RRR 20%, a 5%, b 20%, D 32% in a 
Two-sided graph.
 
Figure 6: Trial sequential analysis of the random-effects meta-analysis of the effect of amantadine 
versus ribavirin on number of patients with chronic hepatitis C virus infection who failed to achieve 
an end-of treatment virological response. The trial sequential analysis is performed with a type 1 
error of 5% (two-sided), a power of 80%, an assumed control proportion of number of patients who 
failed to achieve an SVR of 68%, and an anticipated relative risk reduction (RRR) of 20%. The diversity-
adjusted required information size (DARIS) to detect or reject a RRR of 20% with a between-trial 
heterogeneity of 32% is estimated to be 594 participants. The actually accrued number of participants 
is 309, which is 52% of the DARIS. The blue cumulative Z-curve does not cross the red trial sequential 
monitoring boundaries for benefit or harm. Therefore, we cannot exclude random error. 
Analysing the data in the best-worst case scenario regarding missing data (assuming that 
participants with unknown status of achieving end-of treatment virological response receiving 
amantadine did achieve end-of treatment virological response, and that all participants from 
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 the ribavirin group with unknown status of achieving end-of treatment virological response 
did not achieve end-of treatment virological response) reveals no differences in effect 
estimate; thus, no negative effect of amantadine (fixed-effect model: RR 0.91; 95% CI 0.78 
to 1.07; 309 participants, three trials). Analysing the data in the worst-best case scenario 
regarding missing data (assuming that participants with unknown status of achieving end-of 
treatment virological response receiving amantadine did not achieve end-of treatment 
virological response, and that all participants from control group with unknown status of 
achieving end-of treatment virological response did achieve end-of treatment virological 
response) reveals a stronger effect favouring ribavirin (fixed-effect model: RR 2.01; 95% CI 
1.64 to 2.46; 309 participants, three trials). 
Failure in histological response 
None of the included trials provided information on the number of participants without 
improvement of histology. 
Failure of normalisation of serum ALT levels at end-of treatment and at end-of 
follow-up 
All trials that reported on biochemical response, only reported on ALT levels. 
Only one trial provided information on failure of normalisation of end-of treatment 
biochemical response. In the amantadine group, 13 of 15 participants (87%) did not achieve 
end-of treatment biochemical response versus 6 of 14 participants (43%) in the ribavirin group. 
Meta-analyses showed that amantadine resulted in more participants without normalisation 
of ALT serum levels at end-of treatment compared with ribavirin (fixed-effect model: RR 2.02; 
95% CI 1.07 to 3.82) (Analysis 1.5). 
In two trials, 41 participants of 46 participants (89%) treated with amantadine compared with 
31 of 46 participants (67%) in the ribavirin group failed to achieve end-of follow-up 
biochemical response (Analysis 1.6). Meta-analysis (fixed-effect model; RR 1.31; 95% CI 1.05 
to 1.63; I² = 12%) showed that amantadine more often failed to achieve end-of follow-up 
biochemical response compared to ribavirin (Analysis 1.6). 
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 Amantadine versus mycophenolate mofetil 
Only one trial provided information on the comparison amantadine versus mycophenolate 
mofetil (Herrine 2005). The included trial reported on 31 participants in the amantadine group 
versus 29 participants in the mycophenolate mofetil group. 
The all-cause mortality or liver-related morbidity was zero in both intervention arms (Analysis 
2.1). 
Five participants of 31 (16%) in the amantadine group versus five participants of 29 
participants (17%) in the mycophenolate mofetil group were reported with either serious 
adverse events or treatment discontinuation due to any adverse event (Analysis 2.2). There 
were no significant differences between the groups (fixed-effect model: RR 0.94; 95% CI 0.30 
to 2.90) (Analysis 2.2). The required information size to detect or reject a RRR of 20% with a 
between-trial heterogeneity of 14% is estimated to be 4093 participants. The actually accrued 
number of participants is 60, which is only 1% of the required information size. 
Twenty-eight participants (90%) failed to achieve sustained virological response in the 
amantadine group versus 24 participants (83%) in the mycophenolate mofetil group. There 
was no significant difference in effect (fixed-effect model: RR 1.09; 95% CI 0.89 to 1.34) 
(Analysis 2.3). The required information size to detect or reject a RRR of 20% with a between-
trial heterogeneity of 87% is estimated to be 1661 participants. The actually accrued number 
of participants is 60, which is only 4% of the required information size. 
There was a significant negative effect of amantadine on failure to achieve end-of treatment 
virological response (fixed-effect model: RR 2.10; 95% CI 1.09 to 4.08). In the amantadine 
group, 18 of 31 participants (58%) did not achieve end-of treatment virological response versus 
8 of 29 participants (28%) in the mycophenolate mofetil group (Analysis 2.4). Trial sequential 
analysis showed a required information size of 4017 participants. The actually accrued number 
of participants is 60, which is only 1% of the required information size. 
The included trial did not provide information on quality of life, histological response, and 
normalisation of ALT at end-of treatment. 
Twenty-six participants treated with amantadine (84%) compared with 23 participants treated 
with mycophenolate mofetil (79%) failed to achieve end-of follow-up biochemical response 
(Analysis 2.5). Meta-analyses showed no statistically significant difference (fixed-effect 
model: RR 1.06; 95% CI 0.83 to 1.35) (Analysis 2.5). 
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 Due to the limited number of participants, we were unable to perform any of the remaining 
planned sensitivity analysis or funnel plot analysis. 
Amantadine versus interferon-alpha 
One trial reported on the comparison amantadine versus interferon-alpha (Bacosi 2002). The 
included trial reported on 42 participants in the amantadine group versus 39 participants in 
the interferon-alpha group. 
The included trial did not provide information on all-cause mortality, liver-related morbidity, 
quality of life, or histological response. 
Zero participants of 42 (0%) in the amantadine group versus 3 participants of 39 participants 
(8%) in the interferon-alpha group were reported with either serious adverse events or 
treatment discontinuation due to any adverse event (Analysis 3.1). The required information 
size to detect or reject a RRR of 20% with a between-trial heterogeneity of 0% is estimated to 
be 8539 participants. The actually accrued number of participants is 81, which is only 1% of 
the required information size. 
Thirty-five participants (83%) failed to achieve sustained virological response in the 
amantadine group versus 30 participants (77%) in the interferon-alpha group, which showed 
no significant difference in effect (fixed-effect model: RR 1.08; 95% CI 0.87 to 1.35) (Analysis 
3.2). The required information size to detect or reject a RRR of 20% with a between-trial 
heterogeneity of 81% is estimated to be 1484 participants. The actually accrued number of 
participants is 81, which is only 5% of the required information size. 
Regarding failure to achieve end-of treatment virological response, there were no significant 
differences in effect between amantadine and interferon-alpha (fixed-effect model: RR 1.25; 
95% CI 0.96 to 1.62). In the amantadine group, 35 of 42 participants (83%) did not achieve 
end-of treatment virological response versus 26 of 39 participants (67%) in the interferon-
alpha group (Analysis 3.3). Trial sequential analysis showed a required information size of 
1745 participants. The actually accrued number of participants is 81, which is only 5% of the 
required information size. 
In the amantadine group, 21 of 42 participants (50%) did not achieve end-of treatment 
biochemical response versus 22 of 39 participants (56%) in the interferon-alpha group. Meta-
analyses showed no significant difference in the number of participants without normalisation 
of ALT serum levels at end-of treatment compared amantadine with interferon-alpha (fixed-
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 effect model: RR 0.89; 95% CI 0.59 to 1.33) (Analysis 3.4). Trial sequential analysis showed a 
required information size of 1252 participants. The actually accrued number of participants 
is 81, which is only 6% of the required information size. 
Twenty-five participants (60%) treated with amantadine compared with 26 participants (67%) 
in the interferon-alpha group failed to achieve end-of follow-up biochemical response 
(Analysis 3.5). Meta-analyses showed no statistically significant difference (fixed-effect 
model: RR 0.89; 95% CI 0.64 to 1.25) (Analysis 3.5). Trial sequential analysis showed a required 
information size of 1074 participants. The actually accrued number of participants is 81, which 
is only 8% of the required information size. 
Due to the limited number of participants, we were unable to perform any of the remaining 
sensitivity analysis, or funnel plot analysis. 
Amantadine versus interferon-gamma 
One trial provided information on the comparison amantadine versus interferon-gamma 
(Abbas 2012). This trial reported on 22 participants in both the amantadine group and the 
interferon-gamma group. 
The all-cause mortality or liver-related morbidity was zero in both intervention arms (Analysis 
4.1). The required information size to detect or reject a RRR of 20% with a between-trial 
heterogeneity of 0% is estimated to be 70,005 participants. The actually accrued number of 
participants is 44, which is only 0.06% of the required information size. 
Two participants in the amantadine group (9%) versus zero participants (0%) in the interferon-
gamma group were reported with either serious adverse events or treatment discontinuation 
due to any adverse event (Analysis 4.2). The required information size to detect or reject a 
RRR of 20% with a between-trial heterogeneity of 50% is estimated to be 140,010 participants. 
The actually accrued number of participants is 44, which is only 0.03% of the required 
information size. 
Sixteen participants failed to achieve sustained virological response in the amantadine group 
versus 11 participants in the interferon-gamma group. There was no significant effect of 
amantadine compared with interferon-gamma (fixed-effect model: RR 1.45; 95% CI 0.89 to 
2.37) (Analysis 4.3). The required information size to detect or reject a RRR of 20% with a 
between-trial heterogeneity of 66% is estimated to be 2288 participants. The actually accrued 
number of participants is 44, which is only 2% of the required information size. 
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 Also, there was no significant effect of amantadine compared with interferon-gamma on 
failure to achieve end-of treatment virological response (fixed-effect model: RR 1.36; 95% CI 
0.82 to 2.26). In the amantadine group, 15 participants (68%) did not achieve end-of treatment 
virological response versus 11 participants (50%) in the interferon-gamma group (Analysis 4.4). 
The required information size to detect or reject a RRR of 20% with a between-trial 
heterogeneity of 63% is estimated to be 2102 participants. The actually accrued number of 
participants is 44, which is only 2% of the required information size. 
The included trial did not provide information on the outcome measures: quality of life and 
histological response. 
In the amantadine group, 15 participants (68%) did not achieve end-of treatment biochemical 
response versus 11 participants (50%) in the interferon-gamma group. Meta-analyses showed 
no significant difference in effect comparing amantadine with interferon-gamma (fixed-effect 
model: RR 1.36; 95% CI 0.82 to 2.26) (Analysis 4.5). Again, trial sequential analysis showed a 
required information size of 2102 participants. The actually accrued number of participants 
is 44. This is only 2% of the required information size. 
Sixteen participants (73%) treated with amantadine compared with 11 participants (50%) in 
the interferon-gamma group failed to achieve end-of follow-up biochemical response (Analysis 
4.6). Meta-analyses showed no differences (fixed-effect model: RR 1.45; 95% CI 0.89 to 2.37) 
(Analysis 4.6). Trial sequential analysis showed a required information size of 2288 
participants. The actually accrued number of participants is 44, which is only 2% of the 
required information size. 
Due to the limited number of participants, we were unable to perform any of the remaining 
planned trial sequential analysis, sensitivity analysis, or funnel plot analysis. 
Amantadine versus other antiviral-drugs 
For completeness we have also meta-analysed data from all comparisons together in order to 
answer the question: which is best, amantadine or other antivirals? The heterogenous group 
of other antivirals seemed superior. 
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 Summary of findings 
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) 
'Summary of findings' table (Guyatt 2008) is shown in Summary of findings for the main 
comparison. 
 
Discussion 
Summary of main results   
We included six randomised clinical trials with 581 participants that assessed the benefits and 
harms of amantadine versus other antiviral drugs for the treatment of chronic hepatitis C 
virus. Amantadine was compared with four other antiviral drugs: ribavirin, mycophenolate 
mofetil, interferon-alpha, or interferon-gamma. The effect of amantadine was evaluated in 
four different treatment strategies: monotherapy of amantadine, combination therapy of 
amantadine with interferon-alpha, combination therapy of amantadine plus interferon-alpha 
and ribavirin, and combination therapy of amantadine plus peg interferon-alpha. All trials had 
high risks of bias. 
This systematic review did not show any benefit of amantadine on all-cause mortality or liver-
related morbidity. 
Furthermore, our systematic review also showed that amantadine for participants with 
chronic hepatitis C virus is not associated with an increase or a reduction of adverse events, 
defined by the number of participants who experienced a serious adverse event or who had 
to discontinue treatment due to an adverse event. These results are confirmed by trial 
sequential analyses. 
When comparing amantadine versus ribavirin, amantadine seems inferior as the proportion of 
participants who failed to achieve sustained virological response was larger in the amantadine 
group. This finding was confirmed by a trial sequential analysis. However, when comparing 
amantadine with the other three antiviral drugs, we did not demonstrate that participants 
treated with amantadine had more failure in achieving sustained virological response. These 
findings could be due to type II errors or bias. Moreover, amantadine did not show to have 
decreased the overall proportion of participants who failed to achieve end-of treatment 
virological response. Again, type II errors or bias should be considered. 
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 Unfortunately, we were not able to identify any benefits of amantadine on quality of life and 
histology because none of the included trials reported on quality of life or failure of 
histological improvement. We found a disadvantage of amantadine compared with ribavirin 
on biochemical end-of treatment and on end-of follow-up responses. 
Overall completeness and applicability of evidence   
This systematic review examined the evidence from six included randomised clinical trials for 
the use of treatment of hepatitis C virus. Despite efforts to obtain additional information from 
the trial authors, we could not obtain all relevant data, hence not all trials reported on all of 
our predefined outcomes. 
Due to the limited number of included trials and participants, we were not able to perform 
subgroup analyses according to whether a patient had already received a previous antiviral 
therapy for hepatitis C virus, e.g., naive participants, relapsers, or non-responders, and if so, 
which treatment he/she had received. Five trials reported adequately on all-cause mortality 
or liver-related morbidity, and all six trials reported on serious adverse events and treatment 
discontinuation due to an adverse event. None of the included trials provided information on 
quality of life. Six trials reported on our first secondary outcome: failure of achieving 
sustained virological response. Five trials reported on failure of end-of treatment virological 
response. No trial provided information on failure in histological improvement, three trials 
reported on failure of biochemical response at end-of treatment, and four trials reported on 
failure of biochemical response at end-of follow-up. 
It is questionable whether the included participants are representative for the current 
practice. All trials included participants with positive serum HCV RNA. However, there is 
heterogeneity among trials due to different disease severity of participants at entry, 
differences according to genotype (five trials included a mixture of genotypes), and 
differences regarding previous antiviral treatment. Concerning sex and age, the trials seem 
representative for current clinical care; more than 67% of the included participants were men 
and all trials included adult participants. None of the trials included participants with 
hepatitis B virus or HIV co-infection. Accordingly, we lack data on co-infected patients. 
Quality of the evidence   
We conducted this review according to The Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins 2011) and the Cochrane Hepato-Biliary Group Module (Gluud 2014). The 
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 results of our meta-analysis, however, are only as strong as the quality of primary trials 
included. 
The main limitation in the design and implementation is the lack of clarity of the generation 
of allocation sequence, concealment of allocation, and blinding. Of the included trials, only 
one (17%) reported adequate allocation sequence generation; only three (50%) adequately 
reported on allocation concealment; and none reported blinding. Two trials (33%) adequately 
addressed incomplete data, but none of the trials reported on all clinically relevant and 
reasonably expected outcomes. Also, one trial (17%) appeared to be free of other components 
that could put them at risk of bias. Accordingly, all trials were with high risk of bias. It is 
surprising to see that none of the trials were considered as having low risk of bias, in spite of 
the repeated calls for improved trial quality both within and outside hepatology (Schultz 1995; 
Gluud 1998; Kjaergard 1999; Needleman 1999; Kjaergard 2001; Wood 2008; Savović 2012). 
Also, other bias domains had high risk of bias. Patients, patient organisations, and other 
stakeholders do not get unbiased research before the several calls for unbiased clinical 
research is followed by physicians, regulatory authorities, and industry. 
Regarding precision of our results, some outcomes of the included trials in our meta-analysis 
include few participants and few events, and thus the confidence intervals around the 
estimate of effect are large. 
All trials measured sustained virological response which is currently the most commonly used 
surrogate outcome measure of benefit. Recent large cohort studies showed a positive 
correlation between the presence of viraemia and mortality (Butt 2009; Uto 2009). However, 
sustained virological response is still only a putative (unvalidated) surrogate outcome for the 
patient-relevant intervention effect of antivirals (Gluud 2007; Gurusamy 2013; Koretz 2013). 
Because randomised clinical trials need to inform clinical practice, clinical outcomes such as 
the risk of liver failure, hepatocellular carcinoma, mortality, and quality of life would be of 
greater interest to patients and clinicians. Such measures nevertheless require a follow-up of 
maybe up to five years. Currently, no randomised clinical trials assessing aminoadamantanes 
are of such long duration. 
Potential biases in the review process   
In this systematic review, a comprehensive literature search was performed. As far as we 
know, we have found all the evidence available. A potential limitation of our literature search 
may be that we have not specifically searched for trials in the grey literature which may have 
introduced a slight risk of bias into our meta-analysis (Egger 2003). However, the bias is 
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 unlikely to influence our results in a beneficial way as trials found in grey literature rarely 
report beneficial effects (Hopewell 2007). 
We only included six trials, in which four different antiviral regimens (ribavirin, 
mycophenolate mofetil, interferon-alpha, or interferon-gamma) were used as comparator 
drugs. Also, most of the included trials are of a relatively small size. This increases the risk of 
providing a more unrealistic estimate of the intervention effects due to bias (systematic 
errors) or chance (random errors) (Keus 2010). Risk of bias is known to have an impact on the 
estimated intervention effect, with trials with high risk of bias tending to overestimate 
beneficial intervention effects and underestimating harmful effects (Schultz 1995; Moher 
1998; Kjaergard 2001; Wood 2008; Lundh 2012; Savović 2012; Savović 2012a). We could not 
divide the analysis for all outcomes into high risk of bias trials and low risk of bias trials to 
reveal any influence of bias on the effect estimates of our outcomes, because all six trials 
were considered to have high risk of bias. 
No statistical signs of publication bias and other bias were observed. 
This review meta-analysed data for all-cause mortality or liver-related morbidity from five 
trials involving 500 participants. We also meta-analysed data for serious adverse events or 
treatment discontinuation due to an adverse event from six trials involving 581 participants. 
The median length of trial duration was 12 months (two trials had a trial duration of six 
months), the median length of follow-up was six months (one trial had a follow-up of 12 
months). For our primary outcome all-cause mortality or liver-related morbidity, this is not 
sufficiently long considering that the estimated median time in which hepatitis C virus 
progresses to cirrhosis is 15 years to 50 years (Koretz 1993; Kenny-Walsh 1999; Seeff 2009). 
Therefore, it is difficult to detect a significant difference on all-cause mortality and liver-
related morbidity based on these trials. If aminoadamantanes should have an effect on 
morbidity and mortality, one prerequisite would be that it significantly affected virological 
load. However, we were unable to extract viral data to show that this was the case. 
We used trial sequential analysis (CTU 2011; Thorlund 2011) to control the risk of random 
errors which is higher when data come from trials with small sample sizes (Wetterslev 2008). 
The trial sequential analysis on the outcome serious adverse events or treatment 
discontinuation due to an adverse event showed no significant effect estimate applying both 
the random-effects and fixed-effect models in participants treated with amantadine. The trial 
sequential analysis on the secondary outcome measure sustained virological response applied 
for amantadine compared with ribavirin demonstrated a negative effect on the number of 
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 participants who failed to achieve sustained virological response in participants treated with 
amantadine. Thus, random errors seem to have been excluded for this comparison, but 
systematic errors may remain. 
Heterogeneity among trials might be due to differences in dose, duration and type of 
interferon-alpha, or peg interferon-alpha. The inclusion of interferon-alpha as well as peg 
interferon-alpha with pharmacokinetic differences might have influenced the observed 
outcomes and comparability of results with earlier publications. Also, different definitions of 
non-responders were used, such as non-responder to previous interferon-alpha therapy alone 
or non-responder to combination therapy of interferon-alpha with ribavirin. Furthermore, 
there could be heterogeneity among trials due to disease severity of participants at entry and 
differences according to genotype, both of which can affect the sustained virological response 
rates. To reflect our concern about heterogeneity, we conducted all analyses using both the 
fixed-effect model and random-effects model. We only presented the results of the fixed-
effect model if the results of the two models did not differ. Subgroup analyses of the pre-
defined covariates trial risk of bias, genotype distribution, previous antiviral treatment, and 
degree of liver disease could not be performed because of the lack of trials that reported on 
these variables. 
Agreements and disagreements with other studies or reviews   
Less than about 10% of all hepatitis C virus infected patients will develop end-stage liver 
disease. Overall, we found that amantadine did not show any benefit on all-cause mortality 
or liver-related morbidity. Most trials report on the surrogate outcome sustained virological 
response, but as already mentioned, we do not know if sustained virological response results 
in less mortality or morbidity (Gluud 2007; Brok 2009; Gurusamy 2013; Koretz 2013; Hauser 
2014; Hauser 2014a). 
Also, considering failure in achieving sustained virological response, we found that 
amantadine did not show any benefit. On the contrary, amantadine showed less effect 
compared with ribavirin, a finding which was supported by the trial sequential analyses. This 
result is in accordance with the main findings of a published meta-analysis (Chen 2012) which 
suggests that there is no beneficial effect of adding amantadine to peg interferon-alpha plus 
ribavirin in naive hepatitis C virus genotype 1 patients. Our findings are contrary to the main 
findings of another meta-analyses (Deltenre 2004) which suggested a role for amantadine in 
non-responder patients. Furthermore, our results are also in contrast with another review 
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 which suggests that there may be a limited role for combination therapy in naive patients 
(Lim 2005). 
We have no evidence from randomised trials on long-term (> one year) effects of amantadine 
on our primary outcomes. Long-term effects would in particular be relevant for outcomes like 
all-cause mortality or liver-related morbidity. 
Amantadine was generally well tolerated. We observed that amantadine was associated with 
non-serious adverse events and almost all trials reported in general similar frequencies and 
severities of adverse events in both amantadine groups versus control groups. This result is in 
accordance with a Cochrane review about amantadine and rimantadine for influenza A in 
children and the elderly (Alves Galvao 2012). This result is also somewhat comparable to two 
other Cochrane reviews. The review on amantadine and rimantadine in influenza A in adults 
showed significantly more adverse effects in patients receiving amantadine compared to 
placebo, but no increased risk of serious adverse events (Jefferson 2012). The second review 
reported on amantadine in Parkinson's disease and found that there is not enough evidence 
from trials about the effects of amantadine for people with Parkinson’s disease, and that 
adverse events in trials so far have not been severe (Crosby 2009). In our analysis, amantadine 
was administered with interferon-alpha or peg interferon-alpha with or without ribavirin, 
except for one trial. Interferon-alpha-based therapy is typically associated with haematologic 
complications (i.e., neutropenia, thrombocytopenia), neuropsychiatric complications (i.e., 
memory and concentration loss, visual disturbances, headaches, depression, irritability), flu-
like symptoms, hormonal complications (i.e., hypothyroidism, hyperthyroidism), 
gastrointestinal complications (i.e., nausea, vomiting, weight loss), and dermatologic 
complications (i.e., eczema, alopecia). The most well-known adverse effect of ribavirin is a 
dose-dependent haemolytic anaemia, but gastrointestinal adverse effects such as nausea are 
also reported (Chutaputti 2000; Soza 2002; Sulkowski 2004). In conclusion, both interferon-
alpha and ribavirin have a variety and severity of adverse events, which may make it hard to 
detect less severe adverse events of amantadine. We cannot exclude less severe adverse 
events from amantadine, for example gastro-intestinal symptoms and insomnia. 
Regarding tolerance of amantadine, we have to take into consideration the doses of 
amantadine. All included trials used an amantadine dose of 200 mg per day. One randomised 
trial that evaluated the safety and toxicity of amantadine in patients with chronic hepatitis C 
virus also investigated the maximum tolerable dose of amantadine (Smith 2004a). They 
reported an increase in biochemical response with higher daily doses of amantadine from 200 
mg per day up to 500 mg per day in monotherapy. However, no statistically difference was 
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 found in ALT values between those receiving 300 mg of amantadine or those receiving higher 
doses of amantadine. Also, increasing the amantadine dose did not result in more patients 
achieving sustained virological response comparing 200 mg per day with 300 mg to 500 mg per 
day (Smith 2004a). 
 
Authors’ conclusions 
Implications for practice 
This review shows that there seems to be no significant benefit of amantadine on hepatitis C 
virus-infected patients for all-cause mortality or liver-related morbidity, or on adverse events 
in hepatitis C-infected patients; although the timeframe for measuring the composite 
outcome was insufficient in the included randomised clinical trials. Furthermore, amantadine 
did not decrease the proportion of patients with failure to achieve sustained virological 
response compared with ribavirin. In the absence of convincing evidence of benefit, the use 
of amantadine seems only justified in the context of randomised clinical trials assessing the 
effects of combination therapy with peg interferon-alpha and ribavirin. We found no 
randomised clinical trials assessing other aminoadamantanes. 
Implications for research 
Given the results of our analysis, we cannot conclude whether new randomised clinical trials 
will or will not find any beneficial effect of amantadine on patients' survival in chronic 
hepatitis C patients. We found no evidence for other aminoadamantanes. Based on the results 
of the overall evidence, it appears less likely that future trials assessing amantadine or 
potentially other aminoadamantanes for patients with chronic hepatitis C would show strong 
benefits. Therefore, it is probably better to focus on the assessments of other direct acting 
antiviral drugs. To our knowledge, no ongoing trials investigate the effects of amantadine in 
hepatitis C-infected patients. Any further trials ought to be conducted and reported according 
to the SPIRIT and CONSORT guidelines (Schulz 2012). 
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Data and analyses 
Comparison 1. Amantadine versus ribavirin 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical 
method 
Effect size 
1 All-cause mortality or liver-
related morbidity 
4 427 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.1 Amantadine plus interferon-
alpha versus ribavirin plus 
interferon-alpha 
3 364 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
2 Adverse events 4 427 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.56 [0.27, 
1.16] 
2.1 Amantadine plus interferon-
alpha versus ribavirin plus 
interferon-alpha 
3 364 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.38 [0.14, 
1.03] 
2.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.03 [0.33, 
3.22] 
3 Failure of sustained virological 
response 
4 427 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.14 [1.07, 
1.22] 
3.1 Amantadine plus interferon-
alpha versus ribavirin plus 
interferon-alpha 
3 364 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.10 [1.04, 
1.18] 
3.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [1.08, 
1.94] 
4 Failure of end of treatment 
virological response 
3 309 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.20 [1.05, 
1.36] 
4.1 Amantadine plus interferon-
alpha versus ribavirin plus 
interferon-alpha 
2 246 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.16 [1.03, 
1.32] 
4.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.43 [0.85, 
2.39] 
5 Failure of normalisation of ALT at 
end of treatment  
1 29 Risk Ratio (M-H, 
Fixed, 95% CI) 
2.02 [1.07, 
3.82] 
5.1 Amantadine plus interferon-
alpha versus ribavirin plus 
interferon-alpha 
1 29 Risk Ratio (M-H, 
Fixed, 95% CI) 
2.02 [1.07, 
3.82] 
6 Failure of normalisation of ALT at 
end of follow-up 
2 92 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.31 [1.05, 
1.63] 
6.1 Amantadine plus interferon-
alpha versus ribavirin plus 
interferon-alpha 
1 29 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.16 [0.91, 
1.48] 
6.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.41 [1.02, 
1.96] 
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 Analysis 1.1. Comparison 1 Amantadine versus ribavirin, Outcome 1 All-cause mortality or 
 liver-related morbidity. 
  
 
Analysis 1.2. Comparison 1 Amantadine versus ribavirin, Outcome 2 Adverse events. 
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 Analysis 1.3. Comparison 1 Amantadine versus ribavirin, Outcome 3 Failure of sustained 
virological response. 
 
Analysis 1.4. Comparison 1 Amantadine versus ribavirin, Outcome 4 Failure of end of 
treatment virological response.
 
Analysis 1.5. Comparison 1 Amantadine versus ribavirin, Outcome 5 Failure of normalisation 
of ALT at end of treatment.
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 Analysis 1.6. Comparison 1 Amantadine versus ribavirin, Outcome 6 Failure of normalisation 
of ALT at end of follow-up.
 
 
Comparison 2. Amantadine versus mycophenolate mofetil 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical 
method 
Effect size 
1 All-cause mortality or liver-related 
morbidity 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.1 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
2 Adverse events 1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.94 [0.30, 
2.90] 
2.1 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.94 [0.30, 
2.90] 
3 Failure of sustained virological 
response 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.09 [0.89, 
1.34] 
3.1 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.09 [0.89, 
1.34] 
4 Failure of end of treatment 
virological response 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
2.10 [1.09, 
4.08] 
4.1 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
2.10 [1.09, 
4.08] 
5 Failure of normalisation of ALT at 
end of follow-up 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.06 [0.83, 
1.35] 
5.1 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.06 [0.83, 
1.35] 
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 Analysis 2.1. Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 1 All-cause 
mortality or liver-related morbidity. 
 
Analysis 2.2. Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 2 Adverse 
events.
 
Analysis 2.3. Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 3 Failure of 
sustained virological response.
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 Analysis 2.4. Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 4 Failure of 
end of treatment virological response.
 
Analysis 2.5. Comparison 2 Amantadine versus mycophenolate mofetil, Outcome 5 Failure of 
normalisation of ALT at end of follow-up.
 
Comparison 3. Amantadine versus interferon-alpha 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical method Effect size 
1 Adverse events 1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.13 [0.01, 
2.49] 
1.1 Amantadine versus 
interferon-alpha 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.13 [0.01, 
2.49] 
2 Failure of sustained 
virological response 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.08 [0.87, 
1.35] 
2.1 Amantadine versus 
interferon-alpha 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.08 [0.87, 
1.35] 
3 Failure of end of treatment 
virological response 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.25 [0.96, 
1.62] 
3.1 Amantadine versus 
interferon-alpha 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.25 [0.96, 
1.62] 
4 Failure of normalisation of 
ALT at end of treatment  
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.89 [0.59, 
1.33] 
4.1 Amantadine versus 
interferon-alpha 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.89 [0.59, 
1.33] 
5 Failure of normalisation of 
ALT at end of follow-up 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.89 [0.64, 
1.25] 
5.1 Amantadine versus 
interferon-alpha 
1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.89 [0.64, 
1.25] 
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 Analysis 3.1. Comparison 3 Amantadine versus interferon-alpha, Outcome 1 Adverse events. 
 
Analysis 3.2. Comparison 3 Amantadine versus interferon-alpha, Outcome 2 Failure of 
sustained virological response. 
 
Analysis 3.3. Comparison 3 Amantadine versus interferon-alpha, Outcome 3 Failure of end 
of treatment virological response. 
 
Analysis 3.4. Comparison 3 Amantadine versus interferon-alpha, Outcome 4 Failure of 
normalisation of ALT at end of treatment. 
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 Analysis 3.5. Comparison 3 Amantadine versus interferon-alpha, Outcome 5 Failure of 
normalisation of ALT at end of follow-up. 
 
Comparison 4. Amantadine versus interferon-gamma 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical 
method 
Effect size 
1 All-cause mortality or liver-related 
morbidity 
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0  
[0.0, 0.0] 
1.1 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 
[0.0, 0.0] 
2 Adverse events 1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
5.0 [0.25, 
98.52] 
2.1 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
5.0 [0.25, 
98.52] 
3 Failure of sustained virological 
response 
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [0.89, 
2.37] 
3.1 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [0.89, 
2.37] 
4 Failure of end of treatment 
virological response 
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.36 [0.82, 
2.26] 
4.1 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.36 [0.82, 
2.26] 
5 Failure of normalisation of ALT at 
end of treatment  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.36 [0.82, 
2.26] 
5.1 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.36 [0.82, 
2.26] 
6 Failure of normalisation of ALT at 
end of follow-up 
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [0.89, 
2.37] 
6.1 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [0.89, 
2.37] 
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 Analysis 4.1. Comparison 4 Amantadine versus interferon-gamma, Outcome 1 All-cause 
mortality or liver-related morbidity.
 
Analysis 4.2. Comparison 4 Amantadine versus interferon-gamma, Outcome 2 Adverse events. 
 
Analysis 4.3. Comparison 4 Amantadine versus interferon-gamma, Outcome 3 Failure of 
sustained virological response. 
 
Analysis 4.4. Comparison 4 Amantadine versus interferon-gamma, Outcome 4 Failure of end 
of treatment virological response. 
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 Analysis 4.5. Comparison 4 Amantadine versus interferon-gamma, Outcome 5 Failure of 
normalisation of ALT at end of treatment. 
 
Analysis 4.6. Comparison 4 Amantadine versus interferon-gamma, Outcome 6 Failure of 
normalisation of ALT at end of follow-up. 
 
Comparison 5. Amantadine versus other antiviral drugs 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical 
method 
Effect size 
1 All-cause mortality or liver-related 
morbidity 
5 531 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.1 Amantadine plus interferon-alpha 
versus ribavirin plus interferon-alpha 
3 364 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.3 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.4 Amantadine versus interferon-alpha 0 0 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
1.5 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.0 [0.0, 0.0] 
2 Adverse events 6 612 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.65 [0.37, 
1.15] 
2.1 Amantadine plus interferon-alpha 
versus ribavirin plus interferon-alpha 
3 364 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.38 [0.14, 
1.03] 
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 2.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.03 [0.33, 
3.22] 
2.3 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.94 [0.30, 
2.90] 
2.4 Amantadine versus interferon-alpha  1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.13 [0.01, 
2.49] 
2.5 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
5.0 [0.25, 
98.52] 
3 Failure of sustained virological 
response 
6 612 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.14 [1.07, 
1.22] 
3.1 Amantadine plus interferon-alpha 
versus ribavirin plus interferon-alpha 
3 364 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.10 [1.04, 
1.18] 
3.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [1.08, 
1.94] 
3.3 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.09 [0.89, 
1.34] 
3.4 Amantadine versus interferon-alpha  1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.08 [0.87, 
1.35] 
3.5 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [0.89, 
2.37] 
4 Failure of end of treatment 
virological response 
5 494 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.27 [1.13, 
1.42] 
4.1 Amantadine plus interferon-alpha 
versus ribavirin plus interferon-alpha 
2 246 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.16 [1.03, 
1.32] 
4.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.43 [0.85, 
2.39] 
4.3 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
2.10 [1.09, 
4.08] 
4.4 Amantadine versus interferon-alpha  1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.25 [0.96, 
1.62] 
4.5 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.36 [0.82, 
2.26] 
5 Failure of normalisation of ALT at 
end of treatment  
3 154 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.19 [0.90, 
1.58] 
5.1 Amantadine plus interferon-alpha 
versus ribavirin plus interferon-alpha 
1 29 Risk Ratio (M-H, 
Fixed, 95% CI) 
2.02 [1.07, 
3.82] 
5.2 Amantadine versus interferon-alpha  1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.89 [0.59, 
1.33] 
5.3 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.36 [0.82, 
2.26] 
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 6 Failure of normalisation of ALT at 
end of follow-up 
4 277 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.14 [0.99, 
1.32] 
6.1 Amantadine plus interferon-alpha 
versus ribavirin plus interferon-alpha 
1 29 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.16 [0.91, 
1.48] 
6.2 Amantadine plus peg interferon-
alpha versus ribavirin plus peg 
interferon-alpha 
1 63 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.41 [1.02, 
1.96] 
6.3 Amantadine plus peg interferon-
alpha versus mycophenolate mofetil 
plus peg interferon-alpha 
1 60 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.06 [0.83, 
1.35] 
6.4 Amantadine versus interferon-alpha  1 81 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.89 [0.64, 
1.25] 
6.5 Amantadine plus interferon-alpha 
and ribavirin versus interferon-gamma 
plus interferon-alpha and ribavirin  
1 44 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.45 [0.89, 
2.37] 
 
Analysis 5.1. Comparison 5 Amantadine versus other antiviral drugs, Outcome 1 All-cause 
mortality or liver-related morbidity. 
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 Analysis 5.2. Comparison 5 Amantadine versus other antiviral drugs, Outcome 2 Adverse 
events. 
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 Analysis 5.3 Comparison 5 Amantadine versus other antiviral drugs, Outcome 3 Failure of 
sustained virological response.  
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 Analysis 5.4. Comparison 5 Amantadine versus other antiviral drugs, Outcome 4 Failure of 
end of treatment virological response. 
 
 
Analysis 5.5. Comparison 5 Amantadine versus other antiviral drugs, Outcome 5 Failure of 
normalisation of ALT at end of treatment. 
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 Analysis 5.6. Comparison 5 Amantadine versus other antiviral drugs, Outcome 6 Failure of 
normalisation of ALT at end of follow-up. 
 
 
Comparison 6. Sensitivity analysis 
Outcome or subgroup title No. of 
studies 
No. of 
participants 
Statistical method Effect size 
1 Failure of sustained 
virological response 
4 854 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.21 [1.13, 
1.30] 
1.1 Best-worst: Amantadine 
versus ribavirin 
4 427 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.94 [0.86, 
1.03] 
1.2 Worst-best: Amantadine 
versus ribavirin 
4 427 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.58 [1.41, 
1.77] 
2 Failure of end of treatment 
virological response 
3 618 Risk Ratio (M-H, 
Fixed, 95% CI) 
1.32 [1.17, 
1.50] 
2.1 Best-worst: Amantadine 
versus ribavirin 
3 309 Risk Ratio (M-H, 
Fixed, 95% CI) 
0.91 [0.78, 
1.07] 
2.2 Worst-best: Amantadine 
versus ribavirin 
3 309 Risk Ratio (M-H, 
Fixed, 95% CI) 
2.01 [1.64, 
2.46] 
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 Analysis 6.1. Comparison 6 Sensitivity analysis, Outcome 1 Failure of sustained virological 
response. 
 
Analysis 6.2. Comparison 6 Sensitivity analysis, Outcome 2 Failure of end of treatment 
virological response. 
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 Appendices 
Appendix 1. Search strategies 
Database Time span Search strategy 
Cochrane 
Hepato-Biliary 
Group 
Controlled 
Trials Register 
1996 to 
December 
2013 
(adaman* OR amantadin* OR symmetrel OR symandin* OR rimantadin* 
OR flumadin* OR methenamin*) AND ('hepatitis C' OR 'hep C' OR HCV) 
Cochrane 
Central 
Register of 
Controlled 
Trials 
(CENTRAL) 
Issue 11 of 
12, 2013 
#1 MeSH descriptor: [Adamantane] explode all trees 
#2 adaman* OR amantadin* OR symmetrel OR symandin* OR 
rimantadin* OR flumadin* OR methenamin* 
#3 (#1 OR #2) 
#4 MeSH descriptor: [Hepatitis C] explode all trees 
#5 hepatitis C OR hep C OR HCV 
#6 (#4 OR #5) 
#7 (#3 AND #6) 
MEDLINE (Ovid 
SP) 
1946 to 
December 
2013 
1. exp Adamantane/ 
2. (adaman* or amantadin* or symmetrel or symandin* or rimantadin* 
or flumadin* or methenamin*).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, original title, 
abstract, name of substance word, subject heading word, unique 
identifier] 
3. 1 or 2 
4. exp Hepatitis C/ 
5. (hepatitis C or hep C or HCV).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, original title, 
abstract, name of substance word, subject heading word, unique 
identifier] 
6. 4 or 5 
7. 3 and 6 
8. (random* or blind* or placebo* or meta-analys*).mp. [mp=protocol 
supplementary concept, rare disease supplementary concept, title, 
original title, abstract, name of substance word, subject heading 
word, unique identifier] 
9. 7 and 8 
EMBASE (Ovid 
SP) 
1974 to 
December 
2013 
1. exp amantadine/ 
2. exp rimantadine/ 
3. (adaman* or amantadin* or symmetrel or symandin* or rimantadin* 
or flumadin* or methenamin*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
4. 1 or 2 or 3 
5. exp hepatitis C/ 
6. (hepatitis C or hep C or HCV).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
7. 5 or 6 
8. 4 and 7 
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 9. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, 
abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
10. 8 and 9 
Science 
Citation Index 
Expanded 
1900 to 
December 
2013 
# 5 #4 AND #3 
# 4 TS=(random* or blind* or placebo* or meta-analys*) 
# 3 #2 AND #1 
# 2 TS=(hepatitis C or hep C or HCV) 
# 1 TS=(adaman* or amantadin* or symmetrel or symandin* or 
rimantadin* or flumadin* or methenamin*) 
 
Contributions of authors 
ML, MB, JD, and CG were involved in the study concept and design. 
ML and MB screened the literature, selected publications for inclusion and exclusion 
according to the eligibility criteria, extracted data, and made the risk of bias judgements. 
ML, MB, and CG analysed and interpreted the data and results. 
ML drafted the manuscript and performed the meta-analyses. 
JD and CG were involved in critical revision of the manuscript for important intellectual 
content. 
All authors approved the review for publication. 
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Joost PH Drenth: no declarations of interest. 
Christian Gluud: no declarations of interest. 
Sources of support 
Internal sources 
• Radboud University Medical Center Nijmegen, Netherlands. 
External sources 
• The Cochrane Hepato-Biliary Group (CHBG), Denmark. 
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 The first author, Mieke H Lamers, worked on the review for three months at the CHBG Editorial 
Team offices. 
 
Differences between protocol and review 
We conducted sensitivity analysis on only the statistical significant findings with only 'best-
worse' case scenario and 'worst-best' case scenario (instead of these two with poor outcome 
analysis and good outcome analysis in both intervention groups) in order to check the 
robustness of our analysis. 
 
Characteristics of studies 
Characteristics of included studies [ordered by study ID] 
Abbas 2012 
Methods Randomised trial in genotype 3 patients, non-responders or relapsers. 
48 weeks therapy, 24 weeks follow-up. 
Participants Country: Pakistan. 
Inclusion criteria: adult male and female patients infected with HCV genotype 
3, ranging in age from 18-70 years, who had previously received standard 
interferon alpha 2a or 2b 3 MU thrice a week in combination with ribavirin (800 
mg to 1200 mg) for 24 weeks and had not shown a response as depicted by 
disappearance of HCV RNA from serum dose in the last month of therapy (non-
responders) or who relapsed at six months post-treatment (relapsers). Hb ≥ 10 
g/dL (females) and ≥ 11 g/dL (males), platelet count ≥ 100 x 10⁹/L, at least one 
abnormal ALT value in the last year, normal TSH, non-pregnant adult females 
and absence of drug or alcohol abuse. 
Exclusion criteria: antiviral therapy in the last three months, hepatitis B or HIV 
co-infection, severe renal dysfunction or creatinine clearance less than 50 
mL/min, pregnant or breast feeding women, suspected hypersensitivity to 
Interferon alpha, gamma or ribavirin, decompensated liver cirrhosis, history or 
any evidence of other concomitant causes of chronic liver disease, active 
malignant disease, any known pre-existing medical condition that could 
interfere with the patient's participation or completion of study. 
Amantadine group: 22 patients, mean age 42.32 ± 8.5 years, male/female = 
13/9. Basal viral load was 947214.6 ± 1266694.8 IU/mL, ALT was 103.05 ± 55.6 
IU/L Genotype 3: 22. Patient with F3 or F4 fibrosis: 7. 
Control group: 22 patients, mean age 44.95 ± 10.1 years, male/female = 15/7. 
Basal viral load was 606691.2 ± 872128.9 IU/mL, ALT was 88.82 ± 65.4 IU/L 
Genotype 3: 22. Patient with F3 or F4 fibrosis: 7. 
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 Interventions Amantadine group: amantadine 100 mg twice a day, interferon-alpha 2b 3 MU 
thrice a week, and ribavirin 800 mg to 1200 mg per day. Patients of less than 
70 kg of weight received 800 mg of ribavirin, while 70 kg or above received 1200 
mg daily. 
Control group: interferon-gamma 200 MU thrice a week in place of amantadine. 
Outcomes Mortality; Liver-related morbidity; SAE; Treatment discontinuation due to AE; 
Number of patients without SVR; Number of patients with detectable HCV RNA 
at EOT; Number of patients without normalisation of ALT at EOT and at EOFU. 
Notes General note for amantadine: ML sent an email to Novartis (a pharmaceutical 
company which produces amantadine) mid.phnlar@novartis.com on 18 
December 2013. They answered that no new research with amantadine has been 
done. 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
High risk Randomisation, enrolment of participants and assignments of 
participants to interventions was done by the principle 
investigator, insufficient information. 
Allocation 
concealment 
(selection bias) 
Low risk Opaque sealed envelope method. 
Blinding of 
participants and 
personnel 
(performance 
bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Low risk No missing data. 
Selective 
reporting 
(reporting bias) 
High risk Only virological response at 72 weeks, biochemical response at 
72 weeks, and safety and tolerance were mentioned in the 
patients and methods session (however, more data were given in 
the results section). Not every outcome we would suggest was 
reported on. 
Other bias Low risk For-profit bias: the study includes the off-label use of the drug. 
The cost of the drugs and the PCR-based investigations were 
funded by the Genetech Biopharm Pakistan. No limitations on 
publication were imposed by the sponsor. 
No baseline imbalance; sample size calculation was not 
reported, the trials was not stopped early. 
Bacosi 2002 
Methods Randomised trial in non-responders or relapsers. 
12 months therapy, 12 months follow-up. 
Participants Country: Italy. 
165 patients were screened (females n = 86; males n = 79) for 3 groups (55 
patients each group). 
Inclusion criteria: detectable, circulating HCV RNA; presence of chronic 
active liver disease already diagnosed on the grounds of laboratory and 
pathologic findings. 
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 Exclusion criteria: Child-Pugh score B or C, previous episode of 
gastrointestinal bleeding, disturbances of cardiac rhythm as determined 
by electrocardiogram and renal failure. 
Amantadine group: 42 patients, mean age 68 ± 3 years, male/female = 
18/24. Serum ALT was not provided and the basal viral load 482 ± 227 x 
10³ copies per mL. Genotype 1b was predominant (n = 39) with three 
patients with mixed genotypes. The other three patients had genotypes 
2a (n = 1), 2a-2b (n = 1) and 2a to 2c (n = 1). 2 patients cirrhosis. 
Control group: 39 patients, mean age 65 ± 2 years, male/female = 18/21. 
Basal viral load was 637 ± 452 x 10³ copies per mL, ALT was not provided. 
Genotype 1b was predominant (n = 31) associated with 1a in three cases; 
the remaining 8 patients had genotypes (2a (n = 4), 2a to 2c (n = 3) and 4 
(n = 1). No patient with cirrhosis. 
Interventions Amantadine group: 100 mg amantadine oral twice daily. 
Control group: interferon-alpha-n₃ 6 MU sc every other day until return 
to normal of ALT or a decrease in viral copies of at least 1 log unit 
(however, no longer than 3 months) then followed by 3 MU. 
Another included group received interferon-alpha-n₃ 6 MU sc every other 
day until return to normal of ALT or a decrease in viral copies of at least 
1 log unit (however, no longer than 3 months) then followed by 3 MU plus 
200 mg/day amantadine orally. 
The duration of the trial treatment was 12 months; treatment, however, 
did not exceed 9 months in those patients who received amantadine and 
who did not show a decrease of at least 1 log unit in viral copies. 
Furthermore, treatment did not exceed 6 months in those patients who 
received interferon-alpha-n₃ if there was no significant decrease in viral 
load. 
Outcomes SAE; Treatment discontinuation due to AE; Number of patients without 
SVR; Number of patients with detectable HCV RNA at EOT; Number of 
patients without normalisation of ALT at EOT and at EOFU. 
Notes ML send Dr Bacosi an email for additional information at 13/12/2011. 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information. 
Allocation concealment 
(selection bias) 
High risk Closed envelopes, although not opaque. 
Blinding of participants 
and personnel 
(performance bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Blinding of outcome 
assessment (detection 
bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Incomplete outcome 
data (attrition bias)  
All outcomes 
High risk Dropouts not equally divided. Many patients dropped out 
after randomisation. 
Selective reporting 
(reporting bias) 
High risk No clear primary and secondary outcome measures 
mentioned. 
Other bias Unclear risk For-profit bias: insufficient information. 
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 No baseline imbalance; sample size calculation was not 
reported, the trial was not stopped early. 
Herrine 2005 
Methods Randomised, controlled, multicentre trial in relapsers or patients who had a 
viral breakthrough. 
48 weeks therapy, 24 weeks follow-up. 
Participants Country: United States of America. 
124 patients were randomised, 123 received at least one dose of study 
medication. 
Inclusion criteria: adult patients with serologic evidence of HCV infection, by 
a positive anti-HCV antibody test and detectable HCV RNA in serum, who had 
a virologic response during treatment with standard interferon-alpha-2b plus 
ribavirin and had relapsed after at least 24 weeks of treatment or had a 
virologic breakthrough while still on treatment; serum ALT activity above the 
upper limit of normal during the 6 months before entering the study; liver 
biopsy consistent with chronic HCV infection in the previous 36 months; and a 
minimum of 24 weeks since cessation of standard interferon-alpha-2b plus 
ribavirin treatment, with no interferon therapy during this time. 
Exclusion criteria: had received any systemic antiviral therapy within 24 weeks 
of the start of the study or were expected to need any systemic antiviral 
therapy during the study or had acute hepatitis A or B infection, HIV infection, 
decompensated liver disease, neutropenia (<1500 neutrophils/mm3), anaemia 
(Hb < 12 g/dL in women and < 13 g/dL in men), thrombocytopenia (platelets, 
< 90,000/mm3), serum creatinine level higher than 1.5 times the upper limit of 
normal, history of alcohol or drug abuse within 1 year of entry, history of severe 
psychiatric disease, serum α-fetoprotein level >100 ng/mL, or substantial 
coexisting medical conditions. 
Amantadine group: 31 patients, mean age 46 years, male/female = 19/12, BMI 
not provided. Mean serum ALT 57 SE 7 IU/L, mean AST 47 SE 8 IU/L, basal viral 
load ≤ 800.000 IU/mL: 14, and > 800.000 IU/mL: 17. Genotype 1 (n = 26) and 
genotype non-1 (n = 5). Histological staging: non-cirrhosis = 27; cirrhosis = 4. 
Control group 1 with ribavirin: 32 patients, mean age 48 years, male/female 
= 24/8, BMI not provided. Mean serum ALT 75 SE 10 IU/L, mean AST 60 SE 7 
IU/L, basal viral load ≤ 800.000 IU/mL: 14, and > 800.000 IU/mL: 18. Genotype 
1 (n = 25) and genotype non-1 (n = 7). Histological staging: non-cirrhosis = 23; 
cirrhosis = 9. 
Control group 2 with mycophenolate mofetil: 29 patients, mean age 48 years, 
male/female = 20/9, BMI not provided. Mean serum ALT 69 SE 9 IU/L, mean 
AST 47 SE 6 IU/L, basal viral load ≤ 800.000 IU/mL: 10, and > 800.000IU/mL: 
19. Genotype 1 (n = 23) and genotype non-1 (n = 6). Histological staging: non-
cirrhosis = 28; cirrhosis = 1. 
Interventions Patients were randomly assigned at a 1:1:1:1 ratio to: 
Amantadine group: sc weekly injections of 180 μg peg interferon-alpha-2a plus 
orally administered amantadine 200 mg/day. 
Control group 1 with ribavirin: peg interferon-alpha-2a plus orally 
administered ribavirin, 800 mg/day in split doses for patients weighing < 75 kg 
and 1000 mg/day in split doses for those weighing ≥ 75 kg, both for 48 weeks. 
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 Control group 2 with mycophenolate mofetil: peg interferon-alpha-2a plus 
mycophenolate mofetil for 48 weeks with a daily dose of mycophenolate 
mofetil of 1 g twice daily. 
Another included group received peg interferon-alpha-2a and orally 
administered ribavirin plus amantadine in the same dosages as mentioned 
above. 
Randomiation was stratified according to HCV genotype (type 1 vs. non-type 1, 
with any patient positive for both type 1 and non-type 1 categorised as type 
1), viral load (≤ 800,000 or > 800,000 IU/mL), and relapse vs. breakthrough. 
Outcomes Mortality; Liver-related morbidity; SAE; Treatment discontinuation due to AE; 
Number of patients without SVR; Number of patients with detectable HCV RNA 
at EOT; Number of patients without normalisation of ALT at EOFU. 
Notes  - 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Unclear risk Insufficient information. 
Allocation 
concealment 
(selection bias) 
Unclear risk Insufficient information. 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Unclear risk Insufficient information. Withdrawals mentioned, but not the 
reason for withdrawal in all patients. 
Selective reporting 
(reporting bias) 
High risk Only virological response at 72 weeks, biochemical response at 
72 weeks, and safety were mentioned in the patients and 
methods session (however, more data were given in the results 
section). Not every outcome we would suggest was reported on. 
Other bias High risk For-profit bias: high: research grant Roche. 
No baseline imbalance; sample size calculation was reported, 
the trial was not stopped early. 
Khalili 2000 
Methods Randomised, clinical trial in patients who had previously failed to respond to 
interferon-alpha monotherapy. 
24 weeks therapy, 24 weeks follow-up. 
Participants Country: United States of America. 
A total of 31 consecutive patients were enrolled. Two of the 31 patients were 
noncompliant and were disenrolled after 1 and 8 wk of treatment. 
 
Inclusion criteria: Abnormal ALT during the last month of interferon 
treatment and persistent elevation for ≥ 6 months before entry; presence of 
HCV RNA at baseline by quantitative branched nucleotide assay (Chiron bDNA 
2.0; Chiron, Emeryville, CA); and a liver biopsy within 18 months before entry 
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 consistent with chronic hepatitis C. All participants had clinically 
compensated liver disease as determined by prothrombin time < 2 sec 
prolonged, serum albumin > 3.5 g/dL, direct bilirubin < 0.3 mg/dL, indirect 
bilirubin < 0.8 mg/dL, absence of ascites, hepatic encephalopathy, or a past 
history of variceal bleeding. Baseline complete blood counts before entry 
required a Hb level > 12 g/dL, white cell count > 3,000/mm3, and platelets 
> 100,000/mm³. 
Exclusion criteria: therapy with antiviral agents or immunosuppressive 
therapy within 6 months before entry, evidence for another possible etiology 
for the liver disease, coinfection with HBV or HIV, pregnancy or inability to 
practice birth control, other significant medical illness, an abnormal a-
fetoprotein level, and active alcohol (> 80 g/day) or substance abuse. 
Amantadine group: 15 patients, mean age 49.2 years, male/female = 9/6, 
BMI not provided. Mean serum ALT 145 IU/L, mean basal viral load 3.48 x 10⁶ 
copies/mL. Genotype 1 = 13, genotype 3 = 1 and indeterminate genotype = 
1. Fibrosis on liver biopsy = 9. 
Control group: 14 patients, mean age 41.3 years, male/female = 12/2, BMI 
not provided. Mean serum ALT 130 IU/L, mean basal viral load 2.22 x 10⁶ 
copies/mL. Genotype 1 = 11, genotype 2 = 1, and genotype 3 = 2. Fibrosis on 
liver biopsy = 5. 
Interventions Amantadine group: a 24-wk course of interferon-alpha-2b given 
subcutaneously three times weekly in combination with amantadine 
hydrochloride, 200 mg daily given in two divided doses. 
Control group: an identical course of interferon-alpha combined with 
ribavirin, 1000 mg daily. 
Outcomes Mortality and liver-related morbidity; SAE; Treatment discontinuation due to 
AE; Number of patients without SVR; Number of patients with detectable 
HCV RNA at EOT; Number of patients without normalisation of ALT at EOT 
and at EOFU. 
Notes The sensitivity limit of the PCR assay was 100 copies/mL. 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Insufficient information. 
Allocation 
concealment 
(selection bias) 
Unclear risk Insufficient information. 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Blinding of outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Incomplete outcome 
data (attrition bias)  
All outcomes 
Low risk In the control group only 1 patient was lost to follow-up. 
Selective reporting 
(reporting bias) 
High risk No clear primary and secondary endpoints were mentioned in 
the 'materials and methods' section. Not every outcome we 
would suggest was reported on. 
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 Other bias Unclear risk For-profit bias: insufficient information. 
There was baseline imbalance regarding age in both groups; 
sample size calculation was not reported, the trial was not 
stopped early. 
Salmeron 2007 
Methods Randomised, parallel-group trial in interferon non-responder patients in 36 
centres. 
Patients were recruited between 1999 and 2001 and the follow-up finished in 
March 2003. 
48 weeks therapy, 24 weeks follow-up. 
Participants Country: Spain. 
378 patients were randomised. 
Inclusion criteria: serum HCV RNA positivity by PCR before the beginning of 
the treatment and serum ALT activity above the upper limit of normal with at 
least one value during the 6-month period preceding the initiation of test drug 
dosing. All patients had chronic hepatitis without cirrhosis in the biopsy. The 
biopsies had been carried out up to a maximum of 3 years before entering the 
study. A treatment-free interval of at least 6 months was necessary between 
the first and the second course. 
Exclusion criteria: age 60 years or older, evidence of any cause of liver disease 
other than chronic HCV (coinfection with hepatitis B virus or HIV, concomitant 
autoimmune disease or metabolic disease). Clinically significant 
cardiovascular, renal, haematological, rheumatological, neurological or 
psychiatric disease, systemic infections, neoplastic disease, organ grafts and 
systemic immunosuppressive treatment. Active alcohol (alcohol intake > 40 
g/day in females and > 60 g/day in males) or drug abuse within the previous 
year. Pregnancy or lactation period. Hb levels < 12 g/dL, white cell count < 
3000/mm3, granulocyte count < 1500/mm3 or platelet count <100 000/mm3. 
Amantadine group + interferon-alpha: 111 patients, mean age 44.7 ± 9 years, 
male/female = 87/24. Mean weight 78 ± 13 kg. Mean serum ALT 133 ± 90 UI/L, 
mean serum AST 94 ± 81 UI/L, and high serum HCV RNA titre > 8 x 105 UI/mL 
was detected in 34 of 78 patients. Genotype 1: 72 of 88, genotype non-1: 16 
of 88. Histological staging was not provided. 
Control group ribavirin + interferon-alpha: 106 patients, mean age 46 ± 9 
years, male/female = 85/21. Mean weight 77 ± 13 kg. Mean serum ALT 124 ± 
92 UI/L, mean serum AST 79 ± 75 UI/L, and high serum HCV RNA titre > 8 x 105 
UI/mL was detected in 29 of 81 patients. Genotype 1: 74 of 85, genotype non-
1: 11 of 85. Histological staging was not provided. 
Interventions Amantadine group + interferon-alpha: interferon a-2a, 9 MU/day sc for 4 
weeks and 3 MU 3 times a week for a further 44 weeks plus amantadine 
chloride, 100 mg twice per day. 
Control group ribavirin + interferon-alpha: the same doses of interferon-a-
2a plus ribavirin 1000 mg to 1200 mg daily in two gifts. 
Two other included groups received: 
Group 1. Interferona-2a, 9 MU/day sc for 4 weeks and 3 MU 3 times a week for 
a further 44 weeks. 
Group 2. The same doses of interferona-2a plus amantadine 100 mg twice per 
day, and ribavirin, 1000 mg to 1200 mg per day according to weight. 
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 Outcomes Mortality; Liver-related morbidity; SAE; Treatment discontinuation due to AE; 
Number of patients without SVR; Number of patients with detectable HCV RNA 
at EOT. 
Notes ML has send an email to Dr. Salmeron about the ALT values at EOT and at 6 
months FU at 10-01-2012. 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Unclear risk Patients were selected randomly by central telephone. 
Allocation 
concealment 
(selection bias) 
Low risk Patients were selected randomly by central telephone. 
Blinding of 
participants and 
personnel 
(performance bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
High risk Not blinded, these interventions were not be delivered in 
identical ways. 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
High risk All dropouts were discussed, but not equally divided over 
groups. 
Selective reporting 
(reporting bias) 
High risk Not all of the study's pre-specified primary outcomes have been 
reported. The biochemical response (normalisation of serum 
ALT) was not reported, although it was mentioned as study end 
point in the article. 
Other bias High risk For-profit bias: Roche. 
No baseline imbalance; sample size calculation was reported, 
the trial was stopped early due to the poor results 
Younossi 2001 
Methods Randomised, double-blind, clinical, multicentre trial. 
24 weeks therapy, 24 weeks follow-up. 
Participants Country: United States of America. 
Inclusion criteria: adult patients with chronic hepatitis C who had previously 
received at least one course of recombinant interferon alpha (interferon alpha-
2b; interferon alpha-2a and interferon n3) at a dose of 3.3 ± 2.0 MU three times 
per week for at least 12 weeks and who showed neither biochemical nor 
virologic response (elevated ALT and HCV RNA positive by PCR) were considered 
for the study. All potential candidates fully consented and those who agreed to 
participate and met all the inclusion and exclusion criteria were offered to enrol 
in the study. 
 
Exclusion criteria: decompensated liver disease, immunocompromised or HIV 
positivity, severe psychiatric conditions, poorly controlled diabetes mellitus, 
active cardiopulmonary disease, renal insufficiency, seizure disorders, 
autoimmune disease, uncontrolled thyroid disease and other liver diseases. 
Those with Hb <13 g/dL for males and < 12 g/dL for females, platelets count 
<100 000/mm3 and WBCs < 3000/mm3. 
Amantadine group + interferon-alpha: 59 patients, mean age 45.6 ± 7.7 years, 
male/female = 36/23. Mean BMI 29.1 ± 6.9 kg/m². Mean serum ALT 121 ± 77.9 
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 IU/L, and serum HCV RNA titre > 2 x 10⁶ UI/mL was detected in 43 of 59 patients. 
Genotype 1: 43 of 59, genotype non-1: 15 of 59. Histological staging: non-
cirrhosis = 49; cirrhosis = 10. Some patient-data are missing. 
Control group ribavirin + interferon-alpha: 59 patients, mean age 46.1 ± 6.8 
years, male/female = 37/22. Mean BMI 28.4 ± 5.1 kg/m². Mean serum ALT 139 
± 11 IU/L, and serum HCV RNA titre > 2 x 10⁶ UI/mL was detected in 40 of 59 
patients. Genotype 1: 49 of 59, genotype non-1: 10 of 59. Histological staging: 
non-cirrhosis = 48; cirrhosis = 10. Some patient-data are missing.. 
Health-related quality of life (HRQL) was assessed at baseline and every 3 
months using the medical outcome study Short Form-36 (SF-36) and a validated 
liver disease-specific instrument, Chronic Liver Disease Questionnaire (CLDQ). 
Interventions Amantadine group: interferon alpha-2b at a dose of 3 MU three times weekly 
and amantadine 200 mg daily in two divided doses. 
Control group: interferon alpha-2b at a dose of 3 MU three times per week and 
ribavirin 800 mg daily in two divided doses. 
Outcomes SAE; Treatment discontinuation due to AE; QoL. 
Notes ML send dr. Younossi an email at 8-1-2013 about the exact numbers of patients 
who achieved virological and biochemical response. 
Risk of bias 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation 
(selection bias) 
Low risk The randomisation process was centrally administered by the 
data manager through telephone contact. Random, permuted 
blocks were used to ensure balance between the number of 
patients assigned to each treatment arm and to make it difficult 
for study personnel to know where blocks started and stopped. 
Allocation 
concealment 
(selection bias) 
Low risk The randomisation process was centrally administered by the 
data manager through telephone contact. 
Blinding of 
participants and 
personnel 
(performance 
bias)  
All outcomes 
Low risk In order to keep the study blinded, patients receiving one 
treatment regimen also received the identical placebos of the 
alternative regimen. Regardless of the treatment arm, each 
patient received identical and equal numbers of pills. 
Blinding of 
outcome 
assessment 
(detection bias)  
All outcomes 
Unclear risk Insufficient information. 
Incomplete 
outcome data 
(attrition bias)  
All outcomes 
Unclear risk Insufficient information. Withdrawals mentioned, but not the 
reason for withdrawal in all patients. What happened to 6 
interferon alpha + amantadine and 5 interferon alpha + ribavirin 
patients? 
Selective 
reporting 
(reporting bias) 
High risk Numbers in table are not corresponding with numbers in text for 
example, patients achieving SVR and biochemical response. No 
histological outcomes. 
Other bias High risk For-profit bias: Unrestricted grant from Integrated Therapeutics, 
Schering-Plough Oncology Biotech. 
No baseline imbalance; sample size calculation was not reported, 
the trial was not stopped early. 
AE: adverse event 
ALT: alanine aminotransferase 
AST: aspartate transaminase 
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 BMI: body mass index 
EOFU: end of follow-up 
EOT: end of treatment 
Hb: haemoglobin 
HBV: hepatitis B virus 
HCV: hepatitis C virus 
HIV: human immunodeficiency virus 
IU/L: international units per litre 
MU: million units 
PCR: polymerase chain reaction 
QoL: quality of life 
RNA: ribonucleic acid 
SAE: serious adverse event 
sc: subcutaneous 
SE: standard error 
SVR: sustained virological response 
TSH: thyroid-stimulating hormone 
U/L: units per litre 
vs: versus 
WBC: white blood cells 
wk: week 
Characteristics of excluded studies [ordered by study ID] 
Study Reason for exclusion 
Bellobuono 
2002 
After three months, all viraemic patients were treated with triple combination 
therapy (addition of amantadine or ribavirin). Groups were equally treated after three 
months and so a separate comparison between amantadine and ribavirin is not 
possible. 
Di Bisceglie 
2001 
Only preliminary findings, no outcome measures we can include. 
Gerardi 
1998 
Unclear study design, no outcome measure, groups not comparable. 
Torre 1999 Outcome measure only after 30 days of therapy, not after 6 or 12 months of therapy. 
Characteristics of studies awaiting assessment [ordered by study ID] 
Ideo 2003 
Methods Randomised, multicentre trial in 49 centres. 
Participants Country: Italy 
784 biopsy-proven chronic hepatitis C, HCV RNA positive, and persistently elevated 
ALT, naive patients. 
Interventions Pegylated interferon-alpha-2a with ribavirin 1 to 1.2 g daily or amantadine 200 mg 
daily for 48 weeks with a 24-week follow-up. 
Outcomes SVR 
Montaser 2003 
Methods Randomised trial. 
Participants Country: Egypt 
Eighty patients with hepatitis C were selected and divided randomly into four equal 
groups. 
Interventions All groups were treated for 12 months. Group 1: dimethyl dimethoxy biphenyl 
dicarboxylate (DDB); Group 2: amantadine; Group 3: DDB and amantadine.Group 4: 
Sylimarine (control group). 
6 months follow-up. 
Outcomes HCV RNA, bilirubin, AST, and alpha fetoprotein levels at unknown time points. 
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 Picciotto 1999 
Methods Randomised trial. 
Participants Country: USA 
Twenty patients with a diagnosis of chronic hepatitis C, based on the consistent 
detection of anti-HCV antibody, raised level of ALT, histological examination, never 
treated before. 
All patients were hepatitis B surface antigen negative and negative for the antibody 
of HIV. 
Interventions Interferon-alpha 3 MU daily or interferon-alpha 3 MU daily plus amantadine 200 mg 
or interferon-alpha 3 MU daily plus ribavirin 1 to 1.2g for 6 months. 
Outcomes HCV RNA and ALT at end of therapy. 
Pimstone 1997 
Methods Randomised trial between July and November 1996. 
Participants Country: USA 
Chronic hepatitis C patients who previously failed interferon-alpha therapy. 
Amantadine group: 11 patients 
Rimantadine group: 9 patients 
Interventions Amantadine or rimantadine, 100 mg oral twice daily for 6 months. 
Outcomes ALT and HCV RNA, both prior to treatment and every three months on treatment. 
 
ALT: alanine aminotransferase    HIV: human immunodeficiency virus 
AST: aspartate aminotransferase   MU: million units 
HCV: hepatitis C virus     SVR: sustained virological response 
HCV RNA: hepatitis C virus ribonucleic acid   USA: United States of America 
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 Abstract  
In this new Dutch guideline for hepatitis C virus infection we provide recommendations for 
the management of hepatitis C infection. Until now the standard for treatment consisted of 
pegylated interferon alpha (peg-IFNα) and ribavirin. The advent of 1st generation direct 
antiviral agents such as boceprevir and telaprevir has changed the concept of treatment of 
adult chronic hepatitis C genotype 1 infected patients.  
There are three benefits of boceprevir and telaprevir. They increase the likelihood of cure in 
(1) naive genotype 1 patients and (2) in patients who did not respond to earlier treatment 
with peg-IFNα and ribavirin, while allowing (3) shortening of treatment duration from 48 
weeks to 24 or 28 weeks which is possible in 40-60% of non-cirrhotic naive (boceprevir and 
telaprevir) and relapsing patients (telaprevir).  
The use of boceprevir and telaprevir is associated with multiple side effects and awareness of 
these side effects is needed to guide the patient through the treatment process.  
This guideline, formulated on behalf of The Netherlands Association of Hepato-
gastroenterologists, The Netherlands Association of Internal Medicine and The Dutch 
Association for the Study of Liver Disease, serves as a manual for physicians for the 
management and treatment of acute and chronic hepatitis C virus monoinfection in adults. 
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 Introduction  
Hepatitis C virus (HCV) infection resulting in chronic liver disease is highly prevalent in Eu-
rope.(1) With the introduction of interferon therapy, later combined with ribavirin, 
eradication of HCV infection became reality. The last innovation in this field came a decade 
ago with the introduction of pegylated interferon α (peg-IFNα). Further advances in the 
therapy of HCV infection were in most part restricted to  refinements of the existing dual 
therapy with peg-IFNα and ribavirin (combination abbreviated to PR).  
The watershed in the field came with the clinical introduction of two direct-acting antiviral 
agents (DAAs) boceprevir (Victrelis®) and telaprevir (Incivo®). From 2012 these two DAAs have 
been allowed on the market in The Netherlands and are reimbursed by the health insurance 
companies for the treatment of chronic HCV genotype 1 infection in adults with compensated 
liver disease (including cirrhosis). Phase 3 studies, including more than 2700 patients, have 
documented the high antiviral potency of these agents against HCV genotype 1.(2-6) 
Accordingly, the treatment of chronic HCV genotype 1 infected patients has changed and led 
to the introduction of new national guidelines in several countries, and an update of the EASL 
and AASLD guidelines.(7-9) The last Dutch guideline on treatment of HCV infection stems from 
2008.(10) In order to guide the clinician through the changed therapeutic environment we 
provide the reader with a completely revised guideline with concise recommendations for the 
management and treatment of HCV monoinfection in adults. For the complete guideline we 
refer to www.mdl.nl.  
 
Background 
The clinical progression of chronic HCV infection varies among patients. Some have only 
minimal structural hepatic changes even after prolonged infection, while others rapidly 
develop complications such as cirrhosis and hepatocellular carcinoma (HCC).(11, 12) The 
progression of histological deterioration is independent of HCV genotype and the 
concentration of HCV RNA in plasma (viral load), but is related to host factors such as gender, 
obesity, presence of concomitant liver disease, life style aspects (e.g. alcohol use), and the 
existence of an untreated co-infection with hepatitis B virus (HBV) or human 
immunodeficiency virus (HIV).(13-15)   
The overall mortality is increased due to cirrhosis and HCC, but also due to an increased risk 
of extrahepatic manifestations such as cardiovascular and renal diseases.(16, 17) In contrast, 
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 curing HCV infection with antiviral therapy diminishes the risk of cirrhosis and HCC and 
consequently improves survival compared to patients with persistent viremia.(18, 19)  
There are at least 6 distinct HCV genotypes. In The Netherlands, ~50% of chronic hepatitis C 
is caused by genotype 1a and 1b, ~30% by genotype 3, whereas genotype 2 and 4 both account 
for ~10% of chronic HCV infected patients. Genotype 5 and 6 are uncommon in The 
Netherlands.(20, 21)  
Table 1. Treatment responses 
 
The primary goal of therapy is to eliminate HCV infection which is defined as undetectable 
plasma HCV RNA 24 weeks after termination of treatment defined as sustained virological 
response (SVR) (see Table 1 for abbreviations). With PR given for 24 or 48 weeks, SVR can be 
achieved in 40-60% in HCV genotype 1 or 4 infected patients and in 70-80% of patients infected 
with HCV genotype 2 or 3.(9, 22, 23)  
 
 
Category Characteristics 
 
Rapid Viral Response 
(RVR) 
 
HCV RNA undetectable at week 4 
 
Extended Rapid Viral 
Response (eRVR) 
 
HCV RNA undetectable at week 4 and week 12 
 
Early Viral Response 
(EVR) 
 
HCV RNA undetectable at week 12 or a decrease by > 2 log 
 
Delayed Viral Response 
(DVR) 
 
> 2 log decrease but detectable at week 12, undetectable at 
week 24 
 
End of Treatment 
Response (ETR) 
 
HCV RNA undetectable at end of treatment 
 
Sustained Viral Response 
(SVR) 
 
HCV RNA undetectable after 24 weeks of follow-up 
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 Natural history 
In Europe, the incidence of acute HCV infection is around 1 per 100.000 persons per year. This 
probably underestimates the true incidence because acute HCV infection is asymptomatic in 
approximately 80% of cases.(9) After infection, formation of HCV antibodies can take months, 
which implies that plasma HCV RNA analysis should be used to diagnose acute HCV 
infection.(24)  
Spontaneous clearance of HCV infection occurs in 20-30%. Spontaneous clearance is unlikely 
to happen 12 weeks after infection and treatment should subsequently be initiated to prevent 
development of chronic HCV infection.(25, 26)  
Persistence of plasma HCV RNA for more than 6 months constitutes a chronic HCV infection. 
It is thought that chronic hepatitis C affects ~ 3% of the world population, i.e. 170 million 
individuals.(27) The prevalence in The Netherlands varies between 0.1-0.4%.(28, 29) European 
prevalence rates are higher (0.4-4%).(30) Chronic hepatitis C progresses slowly, over a time 
frame of 15-50 years. Cohort studies suggest that 10-20% of all infected patients will 
eventually develop end-stage liver disease, typically after two to three decades.(12, 31) In 
cirrhotic patients, the annual rate of HCC is 1-4% and chronic hepatitis C induced HCC accounts 
for one-third of all HCCs.(11)  
 
Initial evaluation 
As of 2012 treatment of hepatitis C in The Netherlands is preferably restricted to one of the 
40 certified and specialized viral hepatitis treatment centers.(32)  
The initial evaluation of a chronic hepatitis C patient consists of a detailed medical history 
evaluation, which includes assessment of the source of the HCV infection, presence of current 
or past alcohol abuse, and use of concomitant medication. Evaluation includes physical 
examination with special attention to signs of chronic liver disease, cirrhosis and liver failure 
(e.g. spider nevi, palmar erythema, gynecomastia, ascites). Laboratory tests should include 
full blood count, liver enzymes and function, thyroid and kidney function, and plasma HCV 
RNA and genotype.(10) Current guidelines recommend vaccination against hepatitis A and 
hepatitis B for those who are seronegative.(9, 33)  
Pretreatment assessment of liver fibrosis or cirrhosis can be important as this may influence 
indication, strategy and success of treatment.(9, 11, 34) Abdominal ultrasound, liver biopsy 
or elastography are therefore part of the work-up. Liver biopsy remains the gold standard for 
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 fibrosis assessment. Non-invasive tests such as transient elastography (FibroScan®) or the use 
of biomarkers may be useful to identify or exclude cirrhosis. However, the ability of 
Fibroscan® to discriminate between fibrosis stage F1 and F3 is limited.(35, 36)  
Positive predictors of SVR with PR therapy can be classified as pretreatment or on-treatment 
factors. In general, the most important positive pretreatment predictors for SVR are: response 
to previous PR based treatment, e.g. naive patients and patients who relapsed to previous 
therapy respond better than partial and null responders (see Table 2 for classification of 
patients categories), interleukin (IL) 28B CC polymorphism (exclusively HCV genotype 1) and 
low stage of fibrosis. Other predictors are low baseline viral load (< 600.000 IU/ml), genotype 
non-1, non-HIV co-infection, age under 40 years, and non-black race.(37-39) The most 
important on-treatment positive predictive factor for achieving SVR is attaining a rapid viral 
response (RVR) (see Table 1).(40, 41) Other known on-treatment factors are  
 decline in hemoglobin concentration during PR therapy in hepatitis C genotype 1, ribavirin 
plasma concentrations and treatment adherence.(42-44) With the use of  DAAs, the predictive 
value of IL28B polymorphism is limited.(45) In addition, DAAs are more effective in genotype 
1b than in genotype 1a patients.(3, 4, 46)  
Table 2. Treatment categories according to the host response during previous  
treatment         
 
Category Characteristics  
 
Naive patients 
 
 
No previous treatment 
 
Relapsers 
 
 
HCV undetectable at end of treatment, but detectable after 24 
weeks of follow-up 
 
Partial responders 
 
 
> 2 log HCV RNA decline at week 12, but detectable HCV RNA 
at week 24 
 
Null responders 
 
< 2 log HCV RNA decline at week 12 
 
 
Non-responders 
 
 
Null response or partial response 
 
Viral breakthrough 
 
 
Detectable HCV RNA at any time during treatment after 
previous undetectable HCV RNA during antiviral therapy 
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 On-treatment laboratory testing should occur regularly, and should include HCV RNA (at the 
selected time points), hemoglobin, total leucocytes, neutrophils, thrombocytes and liver 
enzymes. 
 
Indications and contraindications for antiviral therapy  
Treatment should be considered in all patients who do not have contraindications, especially 
in those with METAVIR F3 and F4 and should be strongly considered in patients with METAVIR 
F2 fibrosis. In patients with METAVIR ≤F2 alternatively, therapy can be postponed until more 
DAAs have become available, allowing interferon free regimens.(9, 11, 34) There are 
subgroups with limited benefits from chronic hepatitis C treatment. First, elderly patients 
(age > 70 years) or patients with (longstanding) asymptomatic disease and low stage of fibrosis 
(METAVIR ≤ F2).(47) Second, absolute contraindications (such as decompensated cirrhosis or 
uncontrolled depression, psychosis, epilepsy, pregnancy or desire to have children, severe 
other medical diseases) and relative contraindications (such as thrombocytopenia < 90 x 109/l, 
neutrophil count < 1.5 x 109/l, anemia (hemoglobin < 8 mmol/l), renal insufficiency (GFR < 30 
mL/min), or ongoing alcohol or drug abuse) may preclude therapy. In patients with relative 
contraindications benefits of treatment should be balanced carefully against the increased 
risk of side effects.(9, 48) Patients with concomitant HIV or HBV infection or other liver 
diseases and those with contraindications listed above, have been excluded from the phase 3 
studies with boceprevir or telaprevir. As a consequence, treatment strategies formulated 
below cannot be applied to these patients. Finally, patients with virological failure on 
boceprevir or telaprevir therapy create a cohort of non-responders. Given the extensive cross 
resistance that can develop in patients failing either boceprevir or telaprevir retreatment 
with the other drug is not advisable.  
If treatment is postponed, patients should be monitored yearly. Cirrhotic patients should be 
subjected to abdominal ultrasound for HCC screening once or twice a year.(49) 
 
Antiviral therapy 
Acute hepatitis C 
Patients with acute HCV monoinfection should be treated if HCV RNA is still positive at 3 
months after exposure, because spontaneous clearance is unlikely to happen at this stage.(26, 
50) Therapy consists of peg-IFNα monotherapy (peg-IFNα-2a: 180 µg/week, peg-IFNα-2b: 1,5 
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 µg/kg/week) for the duration of 24 weeks. With peg-IFNα monotherapy, SVR rates are more 
than 90%. The addition of ribavirin has no proven benefit.(26, 51)  
Acute HCV infection is frequently reported in HIV co-infected male homosexual patients and 
for management the reader is referred to appropriate guidelines.(52, 53)  
Chronic hepatitis C  
Patients with HCV genotype 1 
Both boceprevir and telaprevir can only be used in combination with PR for treatment of adult 
chronic HCV genotype 1 infected patients with compensated liver disease. Peg-IFNα and 
ribavirin dosage instructions are either peg-IFNα-2a 180 µg/week in combination with ribavirin 
1000 mg (< 75 kg) or 1200 mg (≥ 75 kg) or peg-IFNα-2b 1,5 µg/kg in combination with ribavirin 
800-1400 mg (< 65 kg: 800 mg, 65-80 kg: 1000 mg, 81-105 kg: 1200 mg, and > 105 kg: 1400 
mg). Both peg-IFNα 2a or 2b, can be prescribed with either boceprevir or telaprevir.(54, 55)  
Boceprevir and telaprevir both should be taken orally three times a day with eight hour 
intervals (boceprevir 800 mg three times daily, telaprevir 750 mg three times daily). 
Telaprevir should be taken with food (preferably containing at least 20 gram of fat) and 
boceprevir with a small meal to increase bioavailability.(56, 57)  
There are no head-to-head studies that compare boceprevir and telaprevir, which makes it 
difficult to compare their relative efficacy.(58, 59) SVR rates are assumed to be comparable 
for both DAAs. The main differences are related to the side effect profiles, the use of a 4-
week lead-in period with boceprevir, and the duration of DAA treatment.  
With the new DAAs SVR rates have increased to 65-75% in treatment naive patients.(2-4, 60) 
Some 70-90% of patients who relapsed after PR treatment achieved SVR with boceprevir or 
telaprevir triple therapy compared to 25-30% in PR control arms. Partial responders obtained 
SVR in 40-60% with triple therapy compared to 7-15% with PR alone. Null responders achieved 
SVR in about 30% with telaprevir therapy in combination with PR, compared to 5% treated 
with PR alone (Figure 1 and 2).(5, 6)  
significant proportion of naive patients (44-65%) in phase 3 studies with boceprevir or 
telaprevir in combination with PR met the criteria for response guided therapy (RGT) and can 
be treated for a shorter period (see ’Treatment strategies’). Success rates are very high in 
these patients (>90%).(2, 4) The main advantages of RGT are that it allows shortening of 
treatment and prevents unnecessary exposure to side effects.(61)  
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Figure 1. SVR rates in 
treatment naive patients with 
HCV genotype 1 
 
 
 
 
 
 
 
 
 
Figure 2. SVR rates in 
treatment 
experienced patients 
with HCV genotype 1 
 
 
 
 
Treatment strategies 
Depending on the host response during previous treatment and the presence of cirrhosis the 
optimal treatment strategy for both DAAs follows from figure 3 and 4. Important 
considerations about the implementation of these strategies are described here. First, 
regarding the stopping rules alternative time points and tolerated levels of viral load are used 
in DAA regimens. Second, the concept of RGT is dissimilar with respect to its duration and 
eligibility of patients. RGT can be applied for non-cirrhotic treatment naive patients 
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 (boceprevir and telaprevir) and previous relapsers (telaprevir).(2, 4, 62) In these cases 
duration of treatment can be limited to 24 weeks (telaprevir) or 28 weeks (boceprevir) (Figure 
3 and 4). Accurate quantitative and qualitative plasma HCV RNA measurement is crucial for 
choosing the right treatment strategy as this is the indicator for treatment success.(2-6) There 
are several test characteristics that need to be fulfilled: a lower limit of quantification of 25 
IU/ml and a lower limit of detection of 10-15 IU/ml are mandatory in the DAA era. In this 
respect, RGT can only be applied when HCV RNA is undetectable at selected time points.(56, 
57) It is important that a ‘detectable but below the limit of quantification’ HCV RNA result 
does not equal an ‘undetectable’ HCV RNA result.(63) A small proportion of naive chronic HCV 
genotype 1 patients with a RVR and favourable prognostic factors (low viral load < 600.000 
IU/ml, ≤ F2 fibrosis, IL28B CC genotype) do not have added benefit from DAAs and can be 
treated with PR protecting them from DAA side effects.(64) In case RVR is not achieved, 
introduction of boceprevir at week 4 is recommended.(2) On the other hand, retreatment 
with DAAs in cirrhotic null responders should carefully be discussed considering the low SVR 
rates (~14%), the lack of alternatives, and likelihood of adverse events.(65)  
Figure 3. Boceprevir treatment strategies 
 
 
 
 
 
 
*with a 
lower limit 
of detection 
of 10-15 
iU/ml 
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 Figure 4. Telaprevir treatment strategies 
 
 
 
 
* with a 
lower limit 
of detection 
of 10-15 
iU/ml 
 
 
Patients with HCV genotype 2 and 3 
Boceprevir and telaprevir are not registered for treatment of chronic HCV genotype 2 and 3 
infected patients.(66) Current treatment is 24 weeks of peg-IFNα-2a 180 µg/week or peg-
IFNα-2b 1,5 µg/kg/week with ribavirin 800 mg. If there are baseline factors associated with a 
poor response ribavirin should be dosed weight based.(9) SVR rates are around 70-80% in these 
patients.(9, 67)  
In case of intolerability for peg-IFNα dosage can be adjusted (peg-IFNα-2a 135 µg/week or 
peg-IFNα-2b 1,0 µg/kg/week) without compromising SVR rates. Sixteen weeks of treatment 
with peg-IFNα and weight based ribavirin can be applied to patients with a RVR, who cannot 
complete 24 weeks of treatment because of severe side effects. This strategy is only 
applicable for patients with favorable baseline factors (low viral load, fibrosis ≤ F2). However, 
with shortened therapy there is a slight increased risk of viral relapse in genotype 3 
patients.(64, 68, 69). 
In patients with chronic HCV genotype 2 and 3 infection without RVR and concomitant 
advanced liver fibrosis or cirrhosis or failure on previous treatment, a 48-week treatment 
strategy may be followed.(34, 67) 
Patients with HCV genotype 4, 5 and 6 
For genotype 4, 5 and 6 current PR consists of 48 weeks peg-IFNα with weight based ribavirin 
(see section ‘antiviral therapy of HCV genotype 1 infection’ for peg-IFNα and ribavirin dosage). 
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 SVR rates range between 43-70%.(70) Naive genotype 4 patients with positive prognostic 
factors (≤ F2 fibrosis, low baseline viral load and a RVR) are eligible for shortened therapy of 
24 weeks.(71, 72)  
 
Viral resistance 
Both boceprevir and telaprevir are highly specific inhibitors of the viral NS3/4A serine 
protease. The nucleoside sequence of the NS3/4A protease varies among HCV genotypes. As 
a result, the antiviral activity of the protease inhibitors differs between the HCV genotypes. 
Both DAAs were specifically designed for HCV genotype 1 and have limited activity against 
other genotypes.(66, 73, 74) 
The high mutation rate results in a large diversity in the viral population, which may lead to 
the selection of protease inhibitor cross resistant variants, resulting in treatment failure. 
Therefore, both DAAs cannot be used as monotherapy and can only be prescribed in 
combination with PR to prevent the emergence of viral resistant strains.(75-77) 
 
Drug-drug interactions 
Boceprevir and telaprevir are substrates for CYP3A and P-glycoproteine (PgP).(56, 57) 
Compared to boceprevir, telaprevir is a stronger inhibitor of CYP3A and PgP. Drug interactions 
can be expected when both DAAs are used in combination with other drugs which are also 
CYP3A or PgP inhibitors or inductors enhancing the risk at drug toxicity or a decreased efficacy 
of the involved drugs. Because of the somewhat different profiles, interactions may vary 
between both agents. Therefore information and advice cannot be implemented equally for 
both boceprevir and telaprevir. Before treatment initiation with DAA-combination therapy we 
recommend to check for all possible interactions on http://www.hep-druginteractions.org/, 
the Dutch handbook for drug interactions with anti-HCV infection agents, and/or consult a 
pharmacist.(78, 79) 
Some practical examples, the use of boceprevir and telaprevir leads to impaired efficacy of 
oral estrogen containing contraceptives, due to low estrogen concentrations. Therefore, the 
use of two nonhormonal containing contraceptives is recommended during and at least 2 
months after cessation of boceprevir or telaprevir. (80, 81) Also, the use of both DAAs with 
simvastatin should be avoided as concomitant use results in increased drug levels of 
294
Chapter 6
 simvastatin putting the patient at risk for rhabdomyolysis.(82, 83) Furthermore, drug levels 
of escitalopram, a frequent used selective serotonin reuptake inhibitor (SSRI), are lowered 
during boceprevir and telaprevir usage.(83) 
Table 3 summarizes the most important interactions that should be avoided or interactions 
that require caution. If information on possible interactions is lacking, consider temporary 
discontinuation of the drug.  
Table 3. Overview of drug-drug interactions with most frequently used co-medications in 
HCV-infected patients.[79] 
Interacting agent* 
Anti-HCV 
agent ** 
CI 
Management (M) 
Alternative (A) 
Alprazolam (ALP) BOC, TVR  M: monitor for toxicity ALP 
A: oxazepam 
Amlodipine (AML) TVR  M: monitor for toxicity AML; start with 5 mg of AML 
A: BOC 
Atorvastatin (ATO) TVR Yes A: pravastatin 
BOC  M: monitor for toxicity ATO, max of 20 mg ATO/day 
A: pravastatin 
Budesonide (BUD) 
inhalation, intranasally 
BOC, TVR Yes A: beclomethasone 
Carbamazepin (CAR) BOC, TVR Yes A: valproic acid, lamotrigine, levetiracetam 
Ciclosporin (CIC) TVR  M: reduce CIC dose and/or extend dose interval; 
monitor CIC levels 
A: boceprevir and monitor CIC levels 
Clarithromycin (CLA) BOC, TVR  M: monitor for toxicity CLA and TVR 
A: azithromycine 
Dexamethasone (DEX) BOC, TVR  M: monitor for efficacy HCV PI 
Diltiazem (DIL) BOC, TVR  M: monitor for toxicity DIL 
A: low-dose amlodipine 
Domperidone (DOM) BOC, TVR Yes A: metoclopramide 
Erythromycin (ERY) BOC, TVR  M: monitor for toxicity ERY and TVR 
A: azithromycine 
Escitalopram (ESC) TVR  M: monitor for efficacy ESC, increase ESC dose if 
needed 
A: BOC 
Ethinylestradiol (EE) BOC, TVR Yes M: use two non-hormonal types of contraception 
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 Felodipine (FEL) BOC, TVR  M: monitor for toxicity FEL 
A; low-dose amlodipine 
Fluticasone (FLU) 
inhalation, intranasally 
BOC, TVR Yes A: beclamethasone 
Itraconazole (ITR) BOC, TVR  M: monitor for toxicity ITR and HCV PI; maximum of 
200 mg ITR/day 
A: fluconazole 
Ketoconazole (KET) BOC, TVR  M: monitor for toxicity KET and HCV PI; maximum 200 
mg KET/day 
A: fluconazole 
Methadone (MET) BOC, TVR  M: monitor for efficacy MET 
IFN  M: monitor for toxicity MET 
Midazolam (MID), PO BOC, TVR Yes A: temazepam or lorazepam or parenteral midazolam 
Midazolam (MID), IV BOC, TVR  M: reduce IV dose with 50% 
Nicardipine (NIC) BOC, TVR  M: monitor for toxicity NIC 
A: low-dose amlodipine 
Nifedipine (NIF) BOC, TVR  M: monitor for toxicity NIF 
A: low-dose amlodipine 
Nisoldipine (NIS) BOC, TVR  M: monitor for toxicity NIS 
A: low-dose amlodipine 
Pimozide (PIM) BOC, TVR Yes  
Prednisone (PRE) BOC, TVR Yes  
Salmeterol (SAL) BOC, TVR Yes A: formoterol 
Sildenafil (SIL) BOC, TVR  M: maximum of 25 mg SIL/48 h  
Simvastatine (SIM) BOC, TVR Yes A: pravastatin or BOC with low-dose atorvastatin 
Sirolimus (SIR) BOC, TVR Yes  
St Janskruid (SJK) BOC, TVR Yes  
Tacrolimus (TAC) TVR Yes  
BOC  M: reduce TAC dose and/or extend dose interval; 
monitor TAC levels 
A: ciclosporin 
Tadalafil (TAD) BOC, TVR  M: maximum of 10 mg TAD/72 h 
Trazodone (TRA) BOC, TVR  M: monitor for toxicity TRA, start with low-dose TRA 
Triazolam (TRI) BOC, TVR Yes A: temazepam of lorazepam 
Vardenafil (VAR) TVR  M: maximum of 2.5 mg VAR/72 h 
BOC  M: maximum of 2.5 mg VAR/24 h 
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 Verapamil (VER) BOC, TVR  M: monitor for toxicity VER 
A: low-dose amlodipine 
Zolpidem (ZOL) TVR  M: monitor for efficacy ZOL 
* HIV medications are not listed 
** BOC, boceprevir; TVR, telaprevir; RBV, ribavirin; IFN, interferon 
Other abbreviations: CI, contraindicated;; IV, intravenous; HCV PI, hepatitis C virus protease inhibitor; 
INR, international normalized ratio 
 
Side effects  
PR treatment is frequently accompanied by side effects, such as flu-like symptoms, anemia, 
neutropenia, thrombocytopenia, and depression. These side effects influence quality of life 
and may result in dosage reduction or premature treatment discontinuation. This can be 
prevented by close monitoring and management of side effects.(42, 84)  
With the addition of boceprevir and telaprevir to PR new side effects have emerged while 
other side effects may be aggravated.(85) For example, rash and (anal) pruritus affects ~50% 
of patients taking telaprevir while dysgeusia occurs in 40% of patients treated with 
boceprevir.(2-6) The most important side effects and their management strategies are 
discussed below  
Anemia  
Phase 3 trials have clearly shown that PR with boceprevir, but especially with telaprevir 
results in a higher frequency of anemia than PR alone.(2-6) Ribavirin dose reduction in patients 
treated with boceprevir or telaprevir does not compromise efficacy and is the first step of 
choice.(86, 87) Ribavirin should be reduced with 200 mg per step. During treatment ribavirin 
can be up titrated again when hemoglobin levels are acceptable (≥ 7.0 mmol/l). Dose 
reduction of ribavirin as opposed to dose maintenance supported by erythropoietin in patients 
with triple therapy is equally effective in terms of achieving SVR.(88) If used, erythropoietin 
agents should be discontinued when hemoglobin reaches the threshold of 7.5 mmol/l.(89) 
Blood transfusion should be saved for exceptional cases. For patients treated with PR (i.e. 
non genotype 1 patients) PR dose reduction should be postponed as long as possible as this 
negatively influences chance of SVR.(42) When interference is necessary, ribavirin or peg-IFNα 
dose reduction, use of erythropoietin agents or blood transfusions can be considered. No 
recommendation can be given for the preferred strategy. 
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 Neutropenia  
The incidence of neutropenia is higher in patients treated with PR in combination with a DAA. 
Although there is little evidence that neutropenia puts the patient at risk for an infection, 
current recommendations stipulate peg-IFNα reduction when neutrophil count falls below 0.75 
x 109/l. Furthermore, (temporary) discontinuation of peg-IFNα should be performed when 
neutrophil count drops further (< 0.5 x 109/l).(9, 90) There is no room for granulocyte colony 
stimulating factor because of unclear benefit and high costs.(91)  
Thrombocytopenia 
Thrombocytopenia < 90 x 109/l is a relative contraindication for treatment of chronic HCV 
infection.(9, 92). Peg-IFNα reduction is recommended when platelet count drops below 50 x 
109/l and should be discontinued when platelet count declines below 25 x 109/l. When platelet 
count increases again peg-IFNα can be restarted at a reduced dosage.(9) 
Rash management 
Rash is a common side effect of PR and occurs even more frequently with telaprevir. Moreover, 
4-7% of patients in phase 3 trials assigned to telaprevir had to discontinue all antiviral therapy 
due to dermatological side effects. (3, 4, 6) It develops typically on the trunk, extremities 
and friction sites, it is mostly mild of nature and can be treated with local cooling ointment 
(unguentum emolliens) or with local corticosteroid therapy (class 3) and antihistamines. 
Patients with rash grade 2 to 4 need to be referred to a dermatologist without delay. (93) 
Severe rash (grade 3) is defined as involvement of more than 50% of body surface or if systemic 
symptoms occur (fever, lymphadenopathy, arthralgia, or rise in creatinine or ALT). In this 
case, telaprevir has to be discontinued and if there is no improvement within 1 week PR also 
needs to be discontinued.(94) Generally, rash will disappear within a couple of weeks after 
stopping telaprevir. Rare events with telaprevir are the Drug Reaction with Eosinophilia and 
Systemic Symptoms (DRESS), Stevens - Johnson syndrome (SJS) or Toxic Epidermal Necrolysis 
(TEN). All treatment should be stopped immediately, a dermatologist should be consulted 
immediately, and glucocorticoids should be considered.(94) 
Psychiatric side effects 
Psychiatric side effects such as depression, agitation, irritability, insomnia, lack of 
concentration and emotional instability puts the patient at risk for PR dose reduction, lower 
treatment adherence and premature treatment cessation resulting in lower SVR rates.(42, 95) 
Prophylactic treatment with a SSRI should be considered in all patients with a history of 
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 depression or signs of depression at baseline. (96) Apart from pretreatment evaluation of 
feasibility of treatment and possible drug interactions, consider to consult a psychiatrist 
and/or a specialist in addiction medicine to ensure safety and drug compliance.  
 
Follow-up after antiviral therapy 
HCV RNA should be tested 24 weeks after the end of treatment. In case HCV RNA is negative, 
SVR is achieved and the patient can be considered to be cured from chronic HCV infection 
with only a minimal risk of viral recurrence.(97) Recent data suggest that negative HCV RNA 
12 weeks post treatment is probably sufficient to confirm SVR, although this needs further 
evaluation.(98)  
Hypothyroidism can arise during but also after termination of treatment. Consequently, 
thyroid function should also be assessed during the first 2 years after treatment.(84) Cirrhotic 
patients should be followed-up preferably in a specialized Dutch viral hepatitis center, 
because they still remain at risk for cirrhosis related complications. As per guidelines, 
abdominal ultrasound has been advised in the follow-up of these patients to screen for HCC 
and endoscopic assessment for esophageal varices.(49, 99)  
 
The future 
With the introduction of boceprevir and telaprevir the development of novel DAAs and immune 
modulatory therapy with less side effects than Peg-IFNα does not stop. There is intense 
interest for novel agents that avoid the use of peg-IFNα. Indeed, several HCV polymerase 
inhibitors are in advanced stages of clinical development. Without doubt therapeutic options 
will expand to other genotypes. In addition, efforts to design better options for difficult to 
treat patients (for example with HBV or HIV coinfections) will be necessary.   
Furthermore, a new group of DAA non-responders will emerge. How and when these patients 
will be eligible for anti-HCV infection therapy is uncertain. Consequently, these patients will 
probably be excluded from upcoming trials with second generation DAAs, which means that 
at this time, treatment options for this group are limited. 
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Chapter 7
 Part 1a 
This thesis deals with clinical decision making in the therapeutic management of patients with 
a number of liver diseases. We have focused on infectious and non-infectious liver diseases 
where there is uncertainty or controversy with respect to medical treatment. We explored 
therapeutic options in autoimmune hepatitis, hepatitis delta, and hepatitis C infection. As a 
method we used the model of a systematic review for analyses of medical literature. We 
followed the Cochrane method in two of the four performed reviews. A Cochrane review is 
defined as a scientific endeavor with pre-planned methods section and assembly of original 
studies (predominantly randomized clinical trials, clinical controlled trials, and when there is 
no other evidence available observational studies) as their ‘subjects’. The results of these 
multiple primary investigations are synthesized strategies limiting bias and random error. 
These strategies include a comprehensive search of all potentially relevant studies and the 
use of explicit, reproducible criteria in the selection of trials for review. A Cochrane review 
appraises primary research designs, study characteristics, data synthesis, and interpretation 
of results. This will yield information that facilitates medical decision making and will also 
identify knowledge gaps. Based on the experience of performing the Cochrane reviews, we 
provide the reader with recommendations on how to design new clinical trials in this field in 
the future.  
 
Answers to questions addressed in this thesis: 
Autoimmune hepatitis 
What is the optimal induction and subsequent maintenance therapy for autoimmune 
hepatitis?  
We performed a systematic review and examined all eleven randomized clinical trials for 
treatment of autoimmune hepatitis published from 1950 until July 2009 to answer this 
question. On the basis of these data we performed a descriptive analysis of the published 
randomized clinical trials.  
The available randomized clinical trials show that both predniso(lo)ne monotherapy and 
predniso(lo)ne plus azathioprine combination therapy are able to induce a remission in 
autoimmune hepatitis. This strategy is equally effective in both treatment naive and relapsing 
patients and lead to lower mortality rate compared with azathioprine monotherapy. 
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 We found that predniso(lo)ne plus azathioprine and azathioprine monotherapy are superior to 
predniso(lo)ne monotherapy in maintaining remission in autoimmune hepatitis. Mortality was 
absent in patients who were subjected to any of all three options.  
These conclusions have some marginal notes. First, there was no standardized, universally 
accepted definition of remission before 1999. All included articles were published in or prior 
to 1999, and could consequently not match the overall definition and thus resulted in 
variations of used outcome measures between trials. Furthermore, the early randomized 
clinical trials in the 1970s included more severely affected patients. These trials contained 
more patients with cirrhosis, which led to worse treatment outcomes and a lower survival 
rate. Patients with less severe disease probably have not been included in the trials but are 
currently being treated in daily clinical practice. This hampers the generalizability of these 
trials.[1] There is a lack of data on mild autoimmune hepatitis, which could be due to 
publication bias.  
Current literature indicates remission rates of 65–80% with conventional therapy.[2] We found 
much lower percentages of remission. Similarly, it has been shown recently that the 
application of the 2010 response criteria of the AASLD practice guidelines [3] compared with 
the 2002 criteria [4] lead to a lower remission rate (from 73% to 26%).[5, 6] Therefore, based 
on our review we conclude that either predniso(lo)ne monotherapy or predniso(lo)ne plus 
azathioprine combination therapy can be used in order to achieve remission. In patients that 
are in need for maintenance therapy, predniso(lo)ne plus azathioprine or azathioprine 
monotherapy are equally effective. However, these therapeutic options are far from ideal and 
the search for immunosuppressive agents with a favorable risk–benefit ratio continues. 
 
Hepatitis delta  
What is the available evidence for interferon-alpha in hepatitis delta therapy? 
To address this question we performed a systematic review and examined all nine randomized 
clinical trials that used interferon-alpha-based treatment of hepatitis delta published from 
1970 until January 2011.  
Results from our analysis show that 1-year high dose interferon-alpha monotherapy is superior 
to 1-year pegylated interferon-alpha (peg interferon-alpha) in achieving undetectable levels 
or hepatitis delta virus ribonucleic acid (RNA - HDV RNA) and normal levels of alanine 
transaminase (ALT). The efficacy was not complete as only approximately 30% of hepatitis 
delta virus infected patients reached predefined endpoints.  
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 Only, 48% of patients treated with high dose interferon-alpha monotherapy reached 
undetectable levels of HDV RNA after 1 year of treatment. This was considerably lower with 
peg interferon-alpha based treatment (22%). Similar results were achieved regarding reaching 
normal ALT levels. Fifty percent of patients on 1-year high-dose interferon-alpha therapy 
attained normal ALT levels. Again, this was superior to treatment with peg interferon-alpha 
therapy (31%).  
In spite of our abovementioned results, we do not recommend to use high dose interferon-
alpha in hepatitis delta infection. We advise to use peg interferon alpha therapy. The basis of 
this recommendation comes from the current use of peg interferon-alpha in hepatitis B and 
hepatitis C virus infection. In the last 15 years, peg interferon alpha has been developed 
especially for these two indications.[7-10] Science and drug development has progressed since 
the last trials with conventional interferon-alpha have finished. Unfortunately, no head-to-
head trials have been performed and only indirect comparisons are possible for hepatitis delta 
infected patients. Furthermore, a major caveat in the earlier performed hepatitis delta trials 
has been identified. These earlier trials with interferon-alpha have used less sensitive HDV 
RNA assays and may have overestimated virological response rates compared with more recent 
trials with peg interferon-alpha treatment. All in all and also because of ease of use, it is 
reasonable to prefer peg interferon-alpha above conventional interferon-alpha.  
 
Chronic hepatitis C 
Is the administration or addition of aminoadamantanes in chronic hepatitis C 
treatment beneficial?  
We performed two Cochrane systematic reviews with meta-analyses aimed at assessing 
benefits and harms of aminoadamantanes for chronic hepatitis C. We compared amantadine 
with placebo or no intervention. The second comparison was amantadine versus other antiviral 
drugs in the treatment of chronic hepatitis C infected patients. Both Cochrane systematic 
reviews did not demonstrate any significant effects of amantadine on all-cause mortality or 
liver-related morbidity in patients with chronic hepatitis C virus infection. We also assessed 
the effect on a secondary endpoint sustained virological response (SVR), but failed to 
demonstrate an advantage. However, subgroup analyses demonstrated that triple therapy 
with amantadine plus interferon-alpha and ribavirin compared with placebo or no intervention 
plus interferon-alpha and ribavirin increased the likelihood for SVR. On the contrary, we also 
compared amantadine with ribavirin with both the same additional therapy. Meta-analysis 
demonstrated that amantadine decreased the number of patients achieving SVR.  
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 Since the introduction of amantadine, a wave of new therapies with direct-acting antiviral 
agents has emerged. These drugs hold the promise of higher efficacy, a better safety profile, 
and shorter treatment duration. Given this developing wave, it is better to wait for the results 
of trials that test these new therapeutic compounds, especially for patients who are not in 
immediate need for treatment. There are a number of direct-acting antivirals that target the 
specific sites of the hepatitis C protein such as the nonstructural (NS) NS3/4A protease, the 
NS5A protein, and the NS5B polymerase. Apart from the development of the two protease 
inhibitors (boceprevir and telaprevir) there are more than 40 new NS3/4A, NS5A, or NS5B 
inhibitors in the development pipeline.   
Because of these new therapeutic modalities, we wrote a new Dutch guideline for hepatitis C 
virus infection. This guideline that brings recommendations for the management and 
treatment of hepatitis C infection became necessary with the introduction of boceprevir and 
telaprevir. These protease inhibitors entered the market in the Netherlands in 2012 as an 
adjunct to the standard of care for the treatment of chronic hepatitis C genotype 1 infected 
patients. Since the place of these drugs was unclear, it was needed to provide prescribing 
clinicians with a new updated guideline. The guideline is presented in Chapter 6. 
Current literature shows that the safety profile for both boceprevir and telaprevir in a real-
life setting is relatively poor.[11] This was especially evident in a subset of patients that had 
not been exposed to these drugs in the realm of randomized clinical trials that led up to the 
registration of these drugs. An observational real-life study, the so-called CUPIC cohort, in 
patients with advanced liver disease registered multiple complications and even mortality 
with these two new drugs.[11] Recommendations reproduced in our guideline are based on 
randomized clinical trials. Certain patient populations, for example patients with 
decompensated cirrhosis, were kept outside (whether intentionally) phase III randomized 
clinical trials. Randomized clinical trials preserve internal validity by strict inclusion and 
exclusion criteria, which may result in limited external validity. This leads to differences in 
treatment results and appearance of adverse events between patients included in clinical 
trials and the general practice.[11, 12] 
After completion of our guideline the results from the phase III clinical trials with drugs such 
as ledipasvir, daclatasvir, and sofosbuvir have reached the journals.[13-15] These agents can 
achieve very high cure rates when combined with peg interferon-alpha and ribavirin, but have 
also started to provide promising results when combined in interferon-alpha-free, all-oral 
combinations. This development will make boceprevir and telaprevir superfluous given their 
poor safety profile as abovementioned.[11, 12] 
314
Chapter 7
 What are the conclusions that we are able to draw? Based on our Cochrane systematic review 
we cannot support amantadine for clinical use in chronic hepatitis C infected patients. 
Boceprevir and telaprevir have improved treatment success in chronic hepatitis C, but also 
have safety issues. In case a patient is not in immediate need for treatment, i.e. patients with 
METAVIR ≤F2, therapy can be postponed until more direct-acting antiviral agents have become 
available with higher efficacy rates and a favorable safety profile. 
 
Part 1b 
Treatment has become possible for a wide spectrum of liver diseases. The evidence for these 
treatment options is highly variable. For some disorders the evidence is elaborate, for 
example chronic hepatitis C infection, while this is limited for other diseases such as hepatitis 
delta. This is not only due to the prevalence of the disorder, but is probably also related to 
the therapeutic targets. There is abundance of clinical trials in hepatology. However, the 
distribution is uneven and focused on those hepatological disorders where therapeutic targets 
are readily available. The purpose of the studies in this thesis was to reflect on the evidence 
obtained through these clinical trials using the (Cochrane) systematic review as research 
model. Therefore, we systematically reviewed and explored the evidence for some 
therapeutic targets for autoimmune hepatitis, hepatitis delta, and hepatitis C infection. This 
information allows us to provide the clinician with clear recommendations for therapy. 
Moreover, based on the explored information of the performed Cochrane systematic reviews, 
we obtained information to provide recommendations on how to design new clinical trials in 
this field in the future.  
 
Systematic reviews 
By performing systematic reviews we gained an overview of the quantity and the quality of 
the randomized controlled trials in the field of autoimmune hepatitis, hepatitis delta, and 
hepatitis C virus infection. There is a surprising variety in the number of randomized clinical 
trials describing the clinical efficacy of different treatment strategies among the studied 
hepatological disorders. The proportion of well executed clinical trials in autoimmune 
hepatitis patients is low. We found only 11 randomized clinical trials published between 1950 
and July 2009. Furthermore, we detected a lack of randomized clinical trials describing the 
clinical efficacy of different treatment strategies in hepatitis delta treatment. Our search 
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 yielded 13 randomized clinical trials published between 1970 and January 2011. Only two of 
them evaluated the efficacy of peg interferon-alpha. This is in sharp contrast to the situation 
in hepatitis C virus. There the number of randomized clinical trials describing the clinical 
efficacy of different treatment strategies in hepatitis C infected patients is very high 
compared to the situation in autoimmune hepatitis and hepatitis delta. We found more than 
1600 randomized clinical trials published between 1950 and December 2013. Some, 44 
randomized clinical trials described the clinical efficacy of aminoadamantanes. This uneven 
representation of clinical trials in different hepatological disorders is among others a result 
of the differences in prevalence and so in physical and economic burden of the disorders. 
There are more hepatitis C infected patients worldwide (around 170 million individuals 
worldwide) than there are patients with hepatitis delta and autoimmune hepatitis.[16-18] 
Vaccination against hepatitis B virus infection subsequently reduces the number of hepatitis 
delta infections because hepatitis delta only occur in individuals who are also infected with 
hepatitis B.[19, 20] Also, funding is an important element that determines which research 
topics are explored. Adequate funding, allows the design and execution of randomized clinical 
trials. Most funding goes to the development of promising drugs for highly prevalent or 
incident diseases. This leads to more randomized clinical trials performed in hepatitis C 
patients, than are in patients with hepatitis delta or autoimmune hepatitis. These hepatitis C 
trials generates more knowledge, more money, and this generates funding again to invest in 
new hepatitis C drug developments and trials. The development remains lagging in other 
areas.  
Apart from differences in quantity of the clinical trials we also detected quality differences 
among trials for the described disorders. Most of the executed trials treating autoimmune 
hepatitis and hepatitis delta included only few patients. They were performed decades apart, 
with an evolving set of diagnostic criteria for autoimmune hepatitis. A definition for remission 
for autoimmune hepatitis is accepted since 1999. However, all trials were published in or prior 
to the determination of the definition of remission. Likewise, there is no standardized, 
universally accepted definition of remission in hepatitis delta. In both autoimmune hepatitis 
and hepatitis delta each included randomized clinical trial used their own end points. This 
makes it difficult to compare the included trials in a meta-analysis. Moreover, various doses 
of trial-treatment were used in the different trials, which also makes it difficult to compare 
the included trials with a meta-analysis. Follow-up duration was short in most trials. Longer 
follow-up will yield more information on treatment success, overall mortality, and liver 
related morbidity. 
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 Evidence based medicine and Cochrane systematic review 
To be a good physician, one should practice following evidence based medicine. Evidence 
based medicine is the conscientious, explicit, and judicious use of current best evidence in 
making decisions about the care of individual patients. The practice of evidence based 
medicine means integrating individual clinical expertise with the best available external 
clinical evidence from systematic research.[21] Best external evidence comes from systematic 
reviews of high-quality randomized clinical trials. These trials include homogeneous patient 
groups, with clear inclusion- and exclusion criteria, and uniform outcome measures. They are 
more likely to provide unbiased information than other study designs.  
The Cochrane systematical review method is one of the methods to perform a systematic 
review. The Cochrane Collaboration recommends a domain-based evaluation tool for assessing 
risk of bias. With this tool critical assessments of internal validity (‘quality assessment’) are 
made separately for different domains. This relates to whether it answers its research 
question correctly. The used domains are: sequence generation, allocation concealment, 
blinding of participants and outcome assessors, incomplete outcome data, selective outcome 
reporting, and other sources of bias. The extent to which potential sources of bias have been 
avoided influences the reliability of the results of a randomized trial.[22] In case the method 
of each domain is correctly described this indicates low risk of bias. When the method is not 
described or the method was not adequately performed, it suggests high risk of bias.  
Another dimension is whether the trial is asking an appropriate question. This is part of 
‘external validity’ and its assessment depends on the purpose for which the trial is used. 
External validity is closely connected with the generalizability or applicability of trials’ 
findings.  
Systematic reviews ask a specific clinical question, perform a comprehensive literature 
search, eliminate the poorly performed randomized clinical trials, and attempt to make 
practice recommendations based on the well-executed randomized clinical trials.[21] In case 
of no randomized clinical trials, this means no evidence based medicine. Treatment according 
to one randomized trial could mean no evidence based medicine. However, it is better to 
have one well-performed trial with a large population than more poorly-executed trials.    
To achieve well-executed randomized clinical trials, quality criteria for performing these 
trials have been formulated in the recent years. Any new trial ought to be designed according 
to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. 
These guidelines where developed in 2013 and followed the development of the CONSORT 
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 statement. This statement, updated in 2010, is a minimum set of recommendations for 
reporting randomized clinical trials.[23-25] These CONSORT recommendations have 
contributed to the suboptimal improvement of the quality of randomized clinical trials.[26-
28] These last few years witnessed an ongoing improvement of the quality of randomized 
clinical trials. The use of the CONSORT recommendations has resulted in some improvement 
of trials during the past 10 years. Without any doubt, the recent development of the SPIRIT 
guidelines, will similarly contribute to quality of performed trials 
The Cochrane Collaboration also advises to design any further trial according to the SPIRIT 
guidelines and to conduct and report according to the CONSORT statement.[23-25] There are 
more than 8260 systematic reviews available that have been performed according to the 
Cochrane method. Twenty-four of the Cochrane reviews are discussing hepatitis C therapy. 
We select our two executed hepatitis C virus infection Cochrane reviews as format to describe 
the quality, the differences, and recommendations for improvement of uniformity. 
 
Quality of included trials 
What were the results in terms of quality of the included trials in our two Cochrane reviews 
about aminoadamantanes for chronic hepatitis C? In other words, did these researchers 
perform their trials correctly according to the different domains of the Cochrane method, in 
a way that is free from bias?  
The generation of the allocation sequence was adequately described in 48% of the included 
trials in both systematic Cochrane reviews about aminadamantanes for chronic hepatitis C. 
One trial (= 2%) was judged as high risk of bias and the remaining 50% of trials were described 
as randomized but the method for random sequence generation was not described. The 
method used to conceal allocation was adequately described in 36% of trials. The method for 
allocation concealment was judged as unclear in 59% and as high risk of bias in two trials (5%). 
The method of blinding of participants and personnel (performance bias) was adequately 
described in only 20%. Eighty percent of included trials were considered as high risk of bias 
concerning blinding of participants and personnel. Three trials (7%) adequately described the 
method of blinding of outcome assessment (detection bias). Thus, 93% of trials were judged 
as high risk of bias. Only two trials (5%) had low risk of bias according to both blinding of 
participants and personnel and blinding of outcome assessments. 
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 Incomplete data (attrition bias) were addressed adequately in 39% of included trials. In 61% 
of trials there were risks of incomplete outcome data.  
Pre-defined clinically relevant and reasonably expected primary and secondary outcomes 
were adequately assessed in only 14% of included trials. Accordingly, there were risks of 
selective reporting (reporting bias) of outcomes in 86% of included trials. Following the 
Cochrane Collaboration methods trials are judged low risk of bias relating to selective 
outcome reporting in case 1. The study protocol is available and all of the study’s pre-specified 
(primary and secondary) outcomes that are of interest in the review have been reported in 
the pre-specified way; 2. The study protocol is not available but it is clear that the published 
reports include all expected outcomes, including those that were pre-specified. This means, 
when a protocol is not present, the reviewers make a pre-specified list of expected outcome 
measures following the Cochrane Collaboration. In our both aminoadamantanes Cochrane 
reviews we included all our pre-defined primary and secondary outcome measures as expected 
outcome measures in case the study protocol was not available. This means we considered a 
trial as high risk of bias regarding reporting bias in case a protocol was not present and the 
trial did not report on all our included primary and secondary outcome measures (for example 
all-cause mortality, serious adverse events, SVR, etc.).  
Six trials (14%) did not receive funding and were deemed to be of low risk of bias regarding 
vested interests. Forty-one percent of included trials received funding from the medical 
industry. It was unclear if trials received funding from medical industry in 45%. We considered 
these last 38 trials (86%) as having high risk of bias because industrial sponsorship could 
introduce bias. 
Assessment of risk of bias is important as this may influence the reliability of the results. We 
found that none of the included trials had low risk of bias on all seven domains. Does this 
mean the results are not reliable? We do not think so. For example, what is the importance 
of blinding participants and outcome assessors with respect to SVR? Blinding is of importance 
for outcomes like quality of life. However, when measuring SVR, blinding of outcome assessors 
cannot influence the biomarker. The Cochrane systematic approach assesses clinical trials 
with a predefined analysis plan with list of expected outcomes. In case a protocol is not 
present and trials do not exactly report these pre-defined outcomes, these trials are judged 
as high risk of bias. The larger the list of predefined outcomes the more likely that there is a 
mismatch with outcomes reported in a particular clinical trial and the higher the chance that 
this trial will be marked with ‘high risk of bias’’.   
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 As such use of stringent criteria bears the risk that we lose important information that is 
contained in these clinical trials. Many trials included in our reviews are rated as high risk of 
bias, partly because of poor reporting, partly because blinding was not applied. The 
introduction of the CONSORT statement should help to improve issues of poor reporting.[25] 
 
Comparability of patients 
Apart from assessing potential sources of bias, which could influence the reliability of the 
results, it is important to consider the population that has been allowed in the trials. The 
selection criteria should be sufficiently broad to encompass the likely diversity of trials, but 
sufficiently narrow to ensure that a meaningful answer can be obtained when trials are 
considered in aggregate.  
The participants included in our both reviews met the pre-specified eligibility criteria: The 
diagnosis was based on presence of serum HCV RNA plus elevated transaminases for more than 
six months, or chronic hepatitis documented on liver biopsy. We also included patients 
diagnosed with ’non-A, non-B’ chronic hepatitis as some trials may have been conducted 
before HCV RNA analyses were widely available. We excluded patients who had undergone a 
liver transplantation.  
A total of 6384 patients with chronic hepatitis C were randomized to an amantadine arm or a 
control arm in the 44 clinical trials. Of the included patients more than 64% were males. All 
trials included adult patients, except for one trial which included children of one year old or 
more. Only one trial included human immunodeficiency virus co-infected patients. None of 
the trials included patients co-infected with hepatitis B virus infection. 
Based on the existence of and response to previous antiviral treatment, the included patients 
were classified as naive (not previously treated with antivirals), relapsers (patients with a 
transient serological viral response to previous treatment with antivirals), or non-responders 
(patients without a serological viral response to previous treatment with antivirals). Most 
trials included naive or non-responder patients. However, heterogeneity can be introduced 
because of different definitions of non-responders were used in the different trials, like non-
responder to previous interferon-alpha therapy alone or non-responder to combination 
therapy of interferon-alpha with ribavirin. Also, there could be heterogeneity among trials 
due to disease severity of patients at entry and differences according to genotype, which both 
can affect outcome measures. 
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 Comparability of outcomes 
The outcome measures in the included trials also preferably should be homogeneous. All 
included randomized trials in both Cochrane reviews about aminoadamantanes for chronic 
hepatitis C measured SVR as primary outcome measure. In general, the majority of 
randomized clinical trials in hepatitis C field assesses primarily SVR. However, SVR is a 
surrogate marker, why not determine outcomes which might be of more interest for patients 
and clinicians, such as all-cause mortality, liver-related morbidity, progression to 
hepatocellular carcinoma, and quality of life.[29] Recent large cohort studies showed a 
positive correlation between the presence of viremia and mortality.[30, 31] However, SVR is 
still only a putative (unvalidated) surrogate outcome for the patient-relevant intervention 
effect of antivirals according to current literature.[29, 32] Because randomized clinical trials 
need to inform clinical practice, clinical outcomes such as the risk of liver failure, 
hepatocellular carcinoma, mortality, and quality of life would be of greater interest to 
patients and clinicians. Most of these measures nevertheless require a follow-up of maybe up 
to five years. Currently, no randomized clinical trials assessing antiviral therapy are of such 
long duration. As a consequence, it is questionable whether for example all-cause mortality 
or risk of hepatocellular carcinoma, although highly relevant, are feasible as outcome 
measures in randomized clinical trials.  
For quality of life it is possible to measure this in a shorter period than the abovementioned 
five years. Only six trials reported on quality of life out of the 44 included trials in both our 
aminoadamantanes Cochrane reviews. Three different questionnaires were used in these six 
trials. This indicates that there is no homogeneity considering measurement of quality of life. 
It is important that the field agrees on the instruments to assess quality of life, for example 
which questionnaire should be used.  
Another interesting development is that recent data suggest that negative HCV RNA 12 weeks 
post-treatment is probably sufficient to confirm SVR.[33, 34] On the contrary, other data show 
that 12 weeks post-treatment using TaqMan polymerase chain reaction is less suitable for 
predicting persistent virological response.[35] This indicates there is conflicting and 
insufficient information, which suggests that further evaluation is necessary. Early 
determination of post-treatment response status in hepatitis C infected patients can help 
make decisions for the individual patients and might allow relapse patients to begin 
alternative therapy earlier. It is well established that low baseline viral load is associated with 
higher SVR rates.[36, 37] When negative HCV RNA 12 weeks post-treatment is sufficient to 
confirm SVR, this could mean that patients not achieving HCV RNA 12 weeks post-treatment 
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 might benefit from early retreatment with different regimens or from inclusion in randomized 
clinical trials evaluating new antiviral drugs. 
 
Advice regarding uniformity 
By summarizing all the information about uniformity, we can make recommendations for new 
trials/research. 
First regarding assessing risk of bias, which could influence the reliability of the results. After 
working with the domains for judging risk of bias, there are some considerations and 
recommendations.  
Blinding is of importance for outcomes like quality of life. However, when measuring SVR, 
blinding of personnel cannot influence the laboratorial marker, blinding of personnel could be 
left out of the assessment of risk of bias. Concerning selective outcome reporting, it is 
important to mention the same outcome measures in the review as are presented in the 
protocol. For new trials we advise to report all data, also the negative outcomes. With the 
introduction of the SPIRIT and with the CONSORT statement this should be improved in new 
trials.[23-26] 
Secondly, which type of patients should be included in the trials? An ideally executed trial 
include only adult patients or only children. Large number of patients are included in this 
ideal trial. Subgroups can be made, but also then the power of the subgroup should be large 
enough. With regard to gender, both can be included. However, again it is important to 
perform subgroup analysis and mention this in the paper of the trial. Furthermore, it includes 
only naive patients, only relapsers, or non-responders. Or it includes more than one of these 
groups, but then the results in the different subgroups are separately mentioned in the report 
of the trial. The same applies for differences in genotypes and differences in disease severity. 
Concerning genotype mention all the genotypes separately, not only genotype 1 infected 
patients or genotype non-1 infected patients, but genotype 1, genotype 2, genotype 3 infected 
patients, etc. Also considering disease severity it is of ideally divided into fibrosis grade 0, 
grade 1, grade 2, etc. Furthermore, again it is important to describe the subgroups, what 
were outcome measures in the subgroup with fibrosis grade 0 versus fibrosis grade 1, etc.  
Third, regarding the outcome measures. It is important to make agreements for new trials 
about which outcome measures to assess. We think SVR should be the primary outcome 
measure. Also because a positive correlation between the presence of viremia and mortality 
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 has been shown.[30, 31] However, mortality should be a second outcome measure, which 
yield a longer follow-up. Trials should include this longer follow-up period. Other clinical 
outcomes such as (serious) adverse events, the risk of liver failure, hepatocellular carcinoma, 
and quality of life are also important, which should be included in new trials. For quality of 
life it is important to make general agreements about which questionnaire should be used to 
measure quality of life and which time is needed to measure this.  
 
Reflection 
All in all, the Cochrane method is only one of the possible methods to perform a systematic 
review. Cochrane reviews focuses particularly on randomized clinical trials. The advantage of 
the Cochrane method is that they are well validated and robust. As such the Cochrane reviews 
are comparable and the quality of the evidence is immediately clear. On the other hand, the 
Cochrane method is really useful in those circumstances when the clinical trials that serve as 
input meet with the minimum (but already high) quality standards for risk of bias.  
A different approach consists of the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) method.[38, 39] The GRADE system finds the quality of the available 
scientific research of importance when preparing a good guideline with recommendations. 
Usually a hierarchy of study design is used. Studies with low risk of bias and large size, such 
as meta-analyses and randomized trials, usually weight heavier than uncontrolled small 
studies, which could introduce higher risks of bias.[38] However, evidence is only one aspect 
necessary to draft recommendations. GRADE also takes into account the importance of the 
demonstrated effect for the patient. To make decisions on treatment some effects for 
patients are essential, other effects do not really matter.[40] To gather most essential 
evidence we think it is important to include a longer follow-up in new randomized trials. This 
will yield more information on treatment success, overall mortality, and liver related 
morbidity. 
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 English Summary 
We explored therapeutic options in autoimmune hepatitis, hepatitis delta, and hepatitis C 
infection. As a method we used the model of (Cochrane) systematic review for analysis of 
medical literature. This yield information that facilitates medical decision making but also 
identified knowledge gaps.  
Chapter 1, ‘the General Introduction’, provides background information (epidemiology, 
pathogenesis, and therapeutic options) regarding autoimmune hepatitis, hepatitis delta, and 
hepatitis C infection. We also provide the model of systematic review that we applied to 
address our research questions.  
In Chapter 2 we describe the results of our systematic review of the optimal induction and 
subsequent maintenance therapy for autoimmune hepatitis. We examined all eleven 
randomized clinical trials for treatment of autoimmune hepatitis that were published from 
1950 until July 2009. Seven trials evaluated induction therapy. These trials demonstrate that 
both predniso(lo)ne monotherapy and predniso(lo)ne plus azathioprine combination therapy 
are able to induce a remission in naive or relapsing patients with autoimmune hepatitis. Both 
treatment strategies lead to a lower mortality rate than treatment with azathioprine 
monotherapy. Four trials assessed maintenance therapy. They found that predniso(lo)ne plus 
azathioprine and azathioprine monotherapy maintained remission more often than 
predniso(lo)ne monotherapy in autoimmune hepatitis. Mortality was absent in patients who 
were subjected to any of three indicated options.  
Chapter 3 presents the evidence for interferon-alpha in hepatitis delta infection that we 
systematically reviewed. We examined all nine randomized clinical trials that evaluated 
treatment with interferon-alpha for hepatitis delta. They were published before February 
2011. Seven trials evaluated the treatment with interferon-alpha. The remaining two trials 
evaluated treatment with pegylated interferon-alpha (peg interferon-alpha). Results from our 
analysis show that 1-year high-dose interferon-alpha monotherapy is more effective than 1-
year peg interferon-alpha in achieving undetectable levels of hepatitis delta virus ribonucleic 
acid (HDV RNA) and normal levels of alanine aminotransferase (ALT).  
Next, we delineate treatment with aminoadamantanes versus placebo or no intervention for 
chronic hepatitis C infection in Chapter 4 according to the Cochrane systematical review 
method. Chapter 5 also follows the Cochrane systematic method and focuses on treatment 
with aminoadamantanes for chronic hepatitis C infection, but in this case compared with other 
antiviral drugs. Both Cochrane systematic reviews did not demonstrate any significant effects 
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 of amantadine on all-cause mortality or liver-related morbidity or on achieving a sustained 
virological response (SVR) in patients with chronic hepatitis C virus infection. However, 
subgroup analyses demonstrate that triple therapy with amantadine plus interferon-alpha and 
ribavirin compared with placebo or no intervention plus interferon-alpha and ribavirin 
increased the likelihood for obtaining a sustained virological response. We also compared 
amantadine with ribavirin with both the same additional therapy. Meta-analysis demonstrates 
that amantadine decreased the number of patients achieving SVR. 
Since the introduction of amantadine, a wave of new therapies with direct-acting antiviral 
agents has emerged. Because of these new therapeutic modalities, we wrote a new Dutch 
guideline for hepatitis C virus infection. Chapter 6 describes the current treatment guideline 
of chronic hepatitis C infection. This guideline that brings recommendations for the 
management and treatment of hepatitis C infection became necessary with the introduction 
of boceprevir and telaprevir, which entered the market in the Netherlands in 2012 as an add-
on to the standard of care (peg interferon-alpha and ribavirin).  
We complete this thesis by a General Discussion (Chapter 7) that summarizes and discusses 
the main findings of this thesis. Furthermore, based on the experience of performing the 
(Cochrane) reviews, we provide the reader with recommendations on how to design new 
clinical trials in this field in the future. 
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In dit proefschrift hebben we de therapeutische opties voor auto-immuun hepatitis, hepatitis 
delta en chronische hepatitis C infectie onderzocht. Voor een grondige analyse van de 
medische literatuur hebben we het model van een systematische review gebruikt. Dit levert 
nuttige informatie voor de medische besluitvorming en het vergemakkelijkt tevens het 
identificeren van leemtes in onze kennis. 
Hoofdstuk 1, 'de algemene inleiding', geeft achtergrondinformatie (epidemiologie, 
pathogenese en therapeutische opties) met betrekking tot auto-immuun hepatitis, hepatitis 
delta en chronische hepatitis C infectie. Wij tonen ook het model dat we hebben toegepast 
om onze onderzoeksvragen te beantwoorden. Dit model, de (Cochrane) systematische review, 
volgt een nauwgezet pad om de literatuur te analyseren en is de huidige standaard op dit 
gebied. 
In Hoofdstuk 2 beschrijven we de resultaten van onze systematische review over de optimale 
inductie en verdere onderhoudsbehandeling voor auto-immuun hepatitis. Wij hebben alle elf 
gerandomiseerde klinische studies onderzocht die behandeling van auto-immuun hepatitis 
hebben bestudeerd en gepubliceerd vanaf 1950 tot juli 2009. Zeven studies hebben een 
inductie therapie geëvalueerd. Deze studies tonen aan dat zowel prednison monotherapie als 
prednison plus azathioprine combinatietherapie in staat is om een remissie te induceren bij 
patiënten met auto-immuun hepatitis die niet eerder zijn behandeld of die een relapse 
hebben doorgemaakt. Beide behandelingsstrategieën leiden tot een lager sterftecijfer dan de 
behandeling met azathioprine monotherapie. Vier studies hebben onderhoudstherapie 
onderzocht. Deze tonen aan dat prednison plus azathioprine en azathioprine monotherapie 
vaker remissie induceren dan prednison monotherapie. Mortaliteit was afwezig bij patiënten 
die werden behandeld volgens een van de drie opties. 
Hoofdstuk 3 toont het bewijs voor behandeling met interferon-alfa bij patiënten geïnfecteerd 
met hepatitis delta. We hebben de analyse verricht met een systematische review. Alle negen 
gerandomiseerde klinische studies die behandeling met interferon-alfa voor hepatitis delta 
hebben geëvalueerd, hebben wij onderzocht. Alle negen studies zijn vóór februari 2011 
gepubliceerd. Zeven studies onderzochten behandeling met interferon-alfa. De overige twee 
studies evalueerden behandeling met gepegyleerd interferon-alfa (peg interferon-alfa). 
Resultaten van de analyse tonen aan dat 1-jaar behandeling met alleen hoge dosis interferon-
alfa effectiever is dan 1 jaar peg interferon-alfa in het bereiken van ondetecteerbare waarden 
van hepatitis delta RNA virus en normale waarden van alanine aminotransferase (ALAT). 
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 We beschrijven de behandeling met aminoadamantanes vergeleken met placebo of geen 
interventie voor chronische hepatitis C infectie in Hoofdstuk 4. Dit onderzoek is uitgevoerd 
door middel van een systematische review volgens de Cochrane methode. Hoofdstuk 5 volgt 
ook de Cochrane methode voor systematische review en richt zich eveneens op behandeling 
met aminoadamantanes voor chronische hepatitis C infectie, maar dan vergeleken met andere 
antivirale middelen. Beide systematische reviews tonen aan dat amantadine, een 
aminoadamantane, geen positieve invloed heeft op sterfte, op lever gerelateerde morbiditeit 
en op het bereiken van een ‘sustained virologic response’ (SVR). Dit is klaring van hepatitis C 
RNA virus uit het bloed zes maanden na het stoppen van de behandeling, bij patiënten met 
een aangetoonde chronische hepatitis C infectie. Echter, subgroep analyse toont aan dat 
behandeling met amantadine, interferon-alfa en ribavirine in vergelijking met placebo of geen 
interventie gecombineerd met interferon-alfa en ribavirine een verhoogde kans geeft op het 
behalen van een ‘sustained virologic response’. Ook hebben we behandeling met ribavirine 
vergeleken met behandeling met amantadine, beiden met dezelfde aanvullende therapie 
(bijvoorbeeld interferon-alfa). Meta-analyse toont aan dat het aantal patiënten dat een SVR 
behaalt met behandeling met amantadine lager is dan met behandeling met ribavirine. 
Sinds de introductie van amantadine zijn er nieuwe therapieën in ontwikkeling gekomen. 
Gelet op deze nieuwe therapeutische mogelijkheden, hebben wij een nieuwe Nederlandse 
richtlijn geschreven voor hepatitis C infectie. Hoofdstuk 6 beschrijft de huidige 
behandelingsrichtlijn van chronische hepatitis C infectie. Deze richtlijn geeft aanbevelingen 
voor management en behandeling van hepatitis C infectie, in het licht van de introductie van 
boceprevir en telaprevir. Deze twee proteaseremmers zijn in Nederland in 2012 op de markt 
gekomen als een aanvulling op de standaard behandeling (peg-interferon-alfa en ribavirine). 
Dit proefschrift wordt afgesloten door een algemene discussie in Hoofdstuk 7 waarin de 
belangrijkste resultaten worden samengevat en bediscussieerd. Bovendien bieden wij de lezer 
aanbevelingen, gebaseerd op de ervaring opgedaan bij het uitvoeren van de (Cochrane) 
reviews, hoe nieuwe klinische onderzoeken op dit gebied in de toekomst te ontwerpen en uit 
te voeren. 
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 Dankwoord 
En ineens is dan toch het moment aangebroken dat ik mijn dankwoord van mijn proefschrift 
kan en mag schrijven! Heerlijk gevoel! Ik heb er een aantal jaar met veel plezier aan gewerkt, 
maar de laatste loodjes wegen wel echt het zwaarst, ik heb het geweten..! Desalniettemin 
het ik het toch kunnen volbrengen, iets wat zeker niet gelukt was zonder hulp, steun en 
vertrouwen van anderen die ik hieronder zal benoemen. 
Beste prof. dr. Drenth, beste Joost, als eerste wil ik jou ontzettend bedanken voor het 
blijvende vertrouwen in mijn capaciteiten, waar ik zelf toch regelmatig aan heb getwijfeld. 
Onze gesprekken om mij verder op weg te helpen met mijn onderzoek, in andere richtingen 
te laten denken en jouw altijd snelle reacties op mijn per email verstuurde concept-artikelen, 
waardoor ik nagenoeg direct weer door kon met de verbeterslag. Uiteraard heeft jouw 
ervaring in het onderzoeksveld en het beschrijven ervan, ertoe bij gedragen dat ik veel heb 
geleerd. Even heb je misschien gedacht, ze maakt haar promotie niet af, maar hier is dan 
toch het eindresultaat. Bedankt voor al je hulp, zonder jou was dat zeker niet gelukt! 
Dear dr. Gluud, dear Christian, dear Dimitrinka Nikolova, thank you for all your effort to help 
me work on and finish my Cochrane reviews. It was sometimes difficult and time-consuming, 
but I have learned a lot from it. I also had a great time in Copenhagen. Many thanks for the 
both of you! Furthermore, I want to thank all the other colleagues of the Copenhagen Trial 
Unit for their support.   
Ook wil ik de leden van de manuscriptcommissie, prof. dr. D.M. Burger, prof. dr. B. van Hoek 
en prof. dr. C.J.H.M. van Laarhoven bedanken voor hun bijdrage aan het kritisch bekijken van 
mijn proefschrift. Tevens wil ik de leden van de corona bedanken voor het zitting nemen in 
de oppositie.   
Wietske, jou wil ik bedanken voor het sparren, voor de ondersteuning en voor het opofferen 
van je vrije dagen, om met mij van gedachten te wisselen!  
Ik wil alle co-auteurs bedanken voor hun bijdrage aan het tot stand komen van mijn 
proefschrift. 
Mijn vroegere collega’s van de kelder, de buitenhoek en de flex-ruimten, in het bijzonder 
Mark B. voor onze prettige samenwerking tijdens het schrijven van onze gezamenlijke 
artikelen! Serena, bedankt voor de fijne en gezellige samenwerking bij de klinische trials. 
Floor, het was fijn om de klinische trials en patiënten aan jou over te dragen, jammer dat we 
niet samen hebben kunnen werken! Karin v. H., wat hebben we veel besproken tijdens onze 
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 autoritjes naar o.a. het Dekkerswald. Het was een fijne tijd en gaf afleiding van alle hectiek 
van het promoveren!! Datzelfde geldt voor mijn ‘roommate’ Melissa! Een extra dankjewel 
voor jou en Merel voor jullie hulp bij de laatste loodjes! Dan wil ik Tom, Mark L., Polat, Merel, 
Robin, Ria, Lauranne, Manoe, Wybrich, Evelyn, Loes, Geert, Karin K, Martijn en Leo bedanken 
voor de leerzame tijd, de tips en trics, de gezelligheid op het werk, maar ook voor de 
gezelligheid tijdens feestjes, borrels en congressen. Ook wil ik mijn overige oud-collega’s van 
het lab: Wilbert, Hennie, René, Jody bedanken voor de ondersteuning bij mijn 
laboratoriumwerkzaamheden. Als laatste wil ik mijn andere collega’s van de maag-, darm- en 
leverafdeling, in het bijzonder Wim en Astrid, maar ook alle andere stafleden en AIOS 
bedanken voor de prettige werksfeer en leerzame tijd. 
Cariline en Sanne, een dankjewel voor de geweldige hulp bij de trials en hepatitispoli. Maar 
ook voor de gezellige avonden en feestjes die we samen met Melissa hebben gehad, even met 
mijn gedachten ergens anders. Datzelfde geldt voor Lauranne en de rest van mijn 
voetbalteam! Regelmatig was ik het laatste jaar afwezig in de derde helft of tijdens de 
training, maar vanaf nu wordt dat weer beter! 
Mijn huidige collega’s van mijn opleiding, fijn dat ik met jullie aan een nieuwe uitdaging ben 
begonnen en dat wij samen leuke dingen ondernemen!  
Mijn lieve vrienden en vriendinnen! Zonder jullie interesse, geduld en begrip voor mijn 
beperkte tijd, had ik het niet gered. Alles kon ik bij jullie kwijt. De fijne momenten van 
afleiding en relaxen door middel van leuke uitjes, etentjes, lunches, vakanties, sanadoompjes 
hebben me goed gedaan en er volgen er nog veel meer!  
In het bijzonder wil ik mijn vriendinnen en paranimfen Susanne en Leonie extra bedanken 
voor jullie hulp en mental support bij de laatste loodjes!  
Als een na laatste wil ik ons pap en mam, Martien en Willemien, en Marco, Thijs en Chantal 
bedanken, ik was niet altijd gezellig door de stress. Hopelijk wordt dat nu beter! Bedankt 
voor jullie onvoorwaardelijke interesse, geduld en steun. Pap en mam extra bedankt dat jullie 
mij hebben geleerd om door te zetten, ook als het even tegen zit. Jan en Ria, Janneke en 
Erwin, Sarah en Roel, bedankt voor jullie altijd aanwezige interesse!  
En Mathijs, jou wil ik als laatste super bedanken voor jouw nuchtere en rustige kijk op zaken, 
relativeren gaat daardoor een stuk beter. Af en toe kon ik even lekker bij je uithuilen, maar 
gelukkig zijn het vooral gezellige en fijne momenten die we samen hebben. Regelmatig vond 
ik het vervelend dat ik minder tijd voor je had, gelukkig heb je daar nooit over geklaagd en 
kunnen we dat nu gaan inhalen. Dank je wel voor alles!  
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